

---

# **CANCER INCIDENCE IN MASSACHUSETTS 2016 – 2020:**

## **CITY AND TOWN SUPPLEMENT**

---

Maura Healey, Governor  
Kim Driscoll, Lieutenant Governor  
Kate Walsh, Secretary of Health and Human Services  
Robert Goldstein, Commissioner of Public Health  
Sai Cherala, Assistant Commissioner and Director,  
Office of Population Health

---

Office of Population Health

Massachusetts Department of Public Health

*January 2025*



## ACKNOWLEDGMENTS

This report was prepared by Richard Knowlton, epidemiologist for the Massachusetts Cancer Registry and Massachusetts Cancer Registry staff. Special thanks are given to Braden Miller of the Bureau of Climate and Environmental Health for his geocoding assistance and to Brenda Netreba and Virginia Liu of the same bureau for their quality assurance work with the data. Thanks are given as well to Victoria Nielson of the Office of Population Health for her quality assurance work. The MCR would also like to thank all the hardworking dedicated Oncology Data Specialists throughout the state whose knowledge and skills contribute to our efforts in public health cancer surveillance.

### **Massachusetts Cancer Registry Staff**

Amarilis Cora, *Cancer Registry Coordinator*  
Nancy Donovan, MA, ODS-C, *Quality Control Coordinator*  
Heatha Gomes, ODS-C, *Tumor Registrar*  
Nancy Klein, BS, ODS-C, *Operations Manager*

Richard Knowlton, MS, *Epidemiologist*  
Georgette Santilli, ODS-C, *Education Coordinator*  
Stacie Sullivan, ODS-C, *Tumor Registrar*  
Hung Tran, *Software Developer*

### **Massachusetts Cancer Registry Advisory Committee**

Lindsay Frazier, MD, ScM (*Chair*)  
Martie Carnie, Community Representative  
Deborah Dillon, MD  
Joanna Haas, MD  
Michael Hassett, MD, MPH  
Joseph Jacobson, MD  
Benjamin C. James, MD, MS, FACS  
Nancy Keating, MD, MPH  
Carol Lowenstein, CTR, MBA

Larissa Nekhlyudov, MD, MPH  
Al Ozonoff, MA, PhD  
Sigalle Reiss, MPH, RS/REHS  
Paul C. Shroy, MD, MPH  
Ingrid Stendhal, CTR  
Susan Sturgeon, DrPH, MPH  
Michelle A. Williams, MS, SM, ScD  
Torunn Yock, MD, MCH

The data in this report are intended for public use and may be reproduced without permission. Proper acknowledgement of the source is requested.

For further information, please visit the following:

- Massachusetts Cancer Registry: [mass.gov/massachusetts-cancer-registry](https://mass.gov/massachusetts-cancer-registry)
- Occupational Health Surveillance: [mass.gov/orgs/occupational-health-surveillance-program](https://mass.gov/orgs/occupational-health-surveillance-program)
- Bureau of Climate and Environmental Health: [mass.gov/bceh](https://mass.gov/bceh)
- Comprehensive Cancer Control Program: [mass.gov/comprehensive-cancer-control-program](https://mass.gov/comprehensive-cancer-control-program)
- Massachusetts Department of Public Health: [mass.gov/dph](https://mass.gov/dph)

We acknowledge the Centers for Disease Control and Prevention for its support of the staff under cooperative agreement 1NU58DP007092-02-00 and the National Cancer Institute under contract HHSN2612018000081 awarded to the Massachusetts Department of Public Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention nor the National Cancer Institute.

# CONTENTS

	<u>Page</u>
<b>INTRODUCTION AND METHODS</b>	
<b>Introduction</b> .....	1
Content .....	1
Comparison with Previous Reports .....	1
<b>Methods</b> .....	2
Data Sources .....	2
Presentation of Data .....	3
Observed and Expected Case Counts .....	3
Standardized Incidence Ratios .....	4
Statistical Significance and Interpretation of SIRs .....	4
Example of Calculation of an SIR and Its Significance .....	5
Notes about Data Interpretation .....	6
Data Limitations .....	6
Cases Diagnosed in Non-Hospital Settings .....	7
Melanoma Cases .....	7
COVID-19 .....	7
City/Town Misassignment .....	7
Small Numbers of Cases .....	8
<b>TABLES</b>	
Observed and Expected Counts, with Standardized Incidence Ratios, by Sex, for 351 Cities and Towns, 2016-2020 .....	9
<b>APPENDICES</b>	
<b>APPENDIX I</b>	
Selected Resources for Information on Cancer .....	361
<b>APPENDIX II</b>	
Massachusetts Department of Public Health (MDPH) Cancer Prevention and Control Initiatives .....	363

## INTRODUCTION

### Content

This report provides estimates of cancer incidence for each of the 351 cities and towns of Massachusetts for the five years 2016 through 2020. For each city and town, Standardized Incidence Ratios (SIRs) are presented for twenty-three types of invasive cancer and all invasive cancer types combined. The SIR is explained in detail in the section on Standardized Incidence Ratios. The report is organized into the following sections:

**METHODS** provides a detailed explanation of this report's data collection, processing, and statistical techniques.

**TABLES** present data for selected types of cancer by city/town and sex.

**APPENDIX I** provides selected resources for cancer information.

**APPENDIX II** describes the Massachusetts Department of Public Health's current cancer control initiatives and provides links to bureaus within the department that address some aspect of cancer. It also provides links to publication resources.

### Comparison with Previous Reports

This report updates previous reports published by the Massachusetts Cancer Registry (MCR). It is available online at <http://www.mass.gov/dph/mcr>. For questions about the report, contact the MCR at:

Massachusetts Cancer Registry  
  
Office of Population Health  
Massachusetts Department of Public Health  
250 Washington Street, 6<sup>th</sup> floor  
Boston, MA 02108-4619  
telephone 781-964-2482

A preceding report, *Cancer Incidence in Massachusetts 2011-2015: City and Town Supplement*, included data for diagnosis years 2011 through 2015. This report contains data for the diagnosis years 2016 through 2020. There have been no changes in this report's format from the previous report.



## METHODS

### Data Sources

Massachusetts General Law Chapter 111, Section 111B mandates the reporting of cancer and benign central nervous tumors to the Massachusetts Cancer Registry (MCR). The MCR collects reports of newly diagnosed cancer cases from Massachusetts health care facilities and practitioners. Facilities that reported the 2016-2020 diagnoses that comprise this report include Massachusetts acute care hospitals, independent laboratories, surgical centers, radiation/oncology centers, medical practice associations, endoscopy centers, and private practice physicians. The MCR signed the modified National Data Exchange Agreement on March 28, 2013. This single agreement allows participating states to exchange data on cases diagnosed or treated in other areas. As a result of this agreement, the MCR now has reciprocal reporting with 44 states, the District of Columbia, the Virgin Islands, Puerto Rico, and Guam to obtain data on Massachusetts residents diagnosed out-of-state. Currently, the MCR collects information on *in situ* and invasive cancers and benign brain and central nervous system tumors. The MCR does not collect information on basal and squamous cell carcinomas of the skin or *in situ* cervical cancer.

The MCR reviews death certificate data to improve completeness to identify previously unreported cancer cases. Sometimes, the MCR obtains additional information on these cases through follow-up activities with hospitals, nursing homes, hospice residences, and physicians' offices. In other instances, a cancer-related cause of death recorded on a Massachusetts death certificate is the only source of information for a cancer case. These "death certificate only" cancer diagnoses are poorly documented and have not been confirmed by a review of clinical and pathological information. Such cases are included in this report but comprise less than 3% of all cancer cases.

All case reports that provided the basis for this report were coded following the SEER Site Recode ICD-O-3/WHO 2008 Definition. These are primary site codes based on the *International Classification of Diseases for Oncology, Third Edition* (ICD-O-3). Please refer to this website for a definition of the recodes: [https://seer.cancer.gov/siterecode/icdo3\\_dwhohome/index.html](https://seer.cancer.gov/siterecode/icdo3_dwhohome/index.html)

Each year, the North American Association of Central Cancer Registries (NAACCR) reviews cancer registry data for quality, completeness, and timeliness. For 2016-2018 and 2020, NAACCR estimated the MCR's annual case count to be more than 95% complete for each year (gold certification), and for 2019, it was estimated to be more than 90% complete (silver certification).

The Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among Massachusetts residents during 2016-2020 and reported to the MCR as of June 1, 2024. The numbers presented in this report may change slightly in future reports, reflecting late reported cases or corrections based on subsequent details from the reporting facilities.

Diagnoses reported here include invasive cancers only (except for cancer of the urinary bladder, for which *in situ* cancers are also included). While invasive cancers have spread beyond the layer of cells where they started and have the potential to spread to other parts of the body, *in situ* cancers are at the earliest stage when they are limited to a small number of cells and have not invaded the organ itself. Typically, published incidence rates do not combine invasive and *in situ* cancers due to differences in the biological significance, survival prognosis, and types of treatments of the tumors. The only exception is cancer of the urinary bladder due to the specific nature of the diagnostic techniques and treatment patterns.

## Presentation of Data

Each city and town in Massachusetts is listed alphabetically in the **TABLES** section. The observed number of cases, the expected number of cases, the standardized incidence ratios, and 95% confidence intervals are presented for twenty-three main cancer types and all cancer types combined. The “all cancers combined” category includes the twenty-three main types presented in this report and all other malignant neoplasms. This category provides a summary of the total cancer experience in a community. As different cancers have different risk factors, this category does not reflect any specific risk factors.

### *Observed and Expected Case Counts*

The *observed* case count (**Obs**) for a particular type of cancer in a city/town is the number of newly diagnosed cases among residents of that city/town during a given time period. In this report, the time period covers the five years 2016-2020.

A city/town’s *expected* case count (**Exp**) for a certain type of cancer is a calculated number based on that city/town’s population distribution (by sex and among eighteen age groups) and the corresponding statewide average annual age-specific incidence rates (again, for 2016-2020). Population estimates used for this report were developed by the University of Massachusetts Donahue Institute (UMDI).

### *Standardized Incidence Ratios*

A Standardized Incidence Ratio (SIR) describes how a city/town’s cancer experience compares with that of the state as a whole in a given time period.

- An SIR of *exactly 100* indicates that a city/town’s incidence of a certain type of cancer is *equal to that expected* based on statewide average age-specific incidence rates.
- An SIR of *more than 100* indicates that a city/town’s incidence of a certain type of cancer is *higher than expected* based on statewide average age-specific incidence rates. For example, a SIR of 105 indicates that a city/town’s cancer incidence is 5% higher than expected based on statewide average annual age-specific incidence rates.
- An SIR of *less than 100* indicates that a city/town’s incidence of a certain type of cancer is *lower than expected* based on statewide average age-specific incidence rates. For example, a SIR of 85 indicates that a city/town’s cancer incidence is 15% lower than expected based on statewide average annual age-specific incidence rates.

### *Statistical Significance and Interpretation of SIRs*

The interpretation of an SIR depends on both how large it is and how stable it is. Stability in this context refers to how much the SIR changes when small increases or decreases in the observed or expected number of cases occur. Two SIRs may have the same size but not the same stability. For example, a SIR of 150 may represent six observed cases and four expected cases, or 600 observed cases and 400 expected cases. Both represent a 50 percent excess of observed cases. However, in the first instance, one or two fewer cases would greatly change the SIR. In contrast, in the second instance, the SIR would only change minimally, even if there were several fewer

cases. When the observed and expected numbers of cases are relatively small, their ratio is easily affected by one or two cases. Conversely, when the observed and expected numbers of cases are relatively large, the value of the SIR is stable.

A 95 percent confidence interval (CI) has been presented for each SIR in this report (when the observed number of cases is at least 5) to indicate if the observed number of cases is statistically significantly different from the expected number or if the difference may be due to chance. A confidence interval is a range of values around a measurement that indicates the precision of the measurement. In this report, the 95% confidence interval is the range of estimated SIR values with a 95% probability of including the true SIR for a specific city or town. If the 95% confidence interval range *does not* include the value 100.0, then the number of observed cases significantly differs from the expected number of cases. “Statistically significantly different” means there is at most a 5% chance that the difference between the number of observed and expected cancer cases is due solely to chance alone. If the confidence interval does contain the value 100.0, the observed and expected numbers are not statistically significantly different. Statistically, the interval's width reflects the population's size and the number of events; smaller populations and smaller observed numbers of cases yield less precise estimates with wider confidence intervals. Wide confidence intervals indicate instability, meaning that small changes in the observed or expected number of cases would greatly change the SIR.

Examples:

- SIR = 137.0; 95% CI (101.6 - 180.6) – the confidence interval does not include 100.0, and the interval is above 100.0, indicating that the number of observed cases is *statistically significantly higher* than expected.
- SIR = 71.0; 95% CI (56.2 – 88.4) – the confidence interval does not include 100.0, and the interval is below 100.0, indicating that the number of observed cases is *statistically significantly lower* than expected.
- SIR = 108.8 95% CI (71.0-159.4) – the confidence interval DOES include 100.0, indicating that the number of observed cases is *NOT statistically significantly different* from what is expected, and the difference may be due to chance. When the interval includes 100.0, then the true SIR may be 100.0.

#### ***Example of Calculation of an SIR and Its Significance***

$$\text{SIR} = \frac{\text{OBSERVED CASES}}{\text{EXPECTED CASES}} \times 100$$

The following example illustrates the method of calculation for a hypothetical town for one type of cancer and one sex for a five year period:

Age Group	<u>Town X</u> Population	<u>State</u> Age-Specific Incidence Rate	<u>Town X</u> Expected Cases	<u>Town X</u> Observed Cases
	(A)	(B)	(C) = (A) x (B)	(D)
<b>00-04</b>	74,657	0.0001	7.47	11
<b>05-09</b>	134,957	0.0002	26.99	25
<b>10-14</b>	54,463	0.0005	27.23	30
<b>15-19</b>	25,136	0.0015	37.70	40
<b>20-24</b>	17,012	0.0018	30.62	30
<b>UP TO</b>				
<b>85+</b>	6,337	0.0010	6.34	8

**Total: 136.35      144**

$$\text{SIR} = \frac{\text{Observed Cases}}{\text{Expected Cases}} \times 100 = \frac{(\text{column D total})}{(\text{column C total})} \times 100 = \frac{144}{136.35} \times 100 \approx 106$$

The SIR for this type of cancer in Town X is 106, indicating that the incidence of this cancer type in Town X is 6% higher than the corresponding statewide average incidence. However, the range for the 95% confidence interval (89.1-124.3) (calculation not shown) indicates that the true value may be as low as 89.1 or as high as 124.3. Since the range includes the value 100, it means that the observed number of cases is *not statistically significantly higher or lower* than what is was expected. significance. The SIR is neither calculated nor tested for statistical significance whenever the number of observed cases is less than five. This is indicated with an (nc) (“not calculated”). However, the number of observed and expected cases is shown in these circumstances. The 95% confidence interval for the SIR is calculated with this formula.

$$95\% \text{ CI} = \frac{(\sqrt{\text{Observed}} \pm 1.96/2)^2}{\text{Expected}}$$

### Notes about Data Interpretation

The SIR is a useful indication of how the cancer experience of a given community compares with that of the state as a whole. SIRs, however, should be interpreted with care. Depending on the situation, they may provide a starting point for further research and investigation into a possible health problem, but they do not by themselves confirm or deny the existence of a particular health problem. Many factors may contribute to a higher or lower SIR, including demographic factors, changes in diagnostic techniques, screening rates, and changes in data collection or recording methods over time, as well as the natural variation in disease occurrence.

When reviewing the data tables, it is important to remember that an SIR compares the observed cancer incidence in a particular community with the expected incidence based on statewide average age-specific incidence rates. This means that valid comparisons can only be made between a community and the state as a whole. Comparisons between the two communities would be valid only if there were no differences in the age and sex distributions of the two communities' populations.

**SIRs for different cities and towns CANNOT and SHOULD NOT be compared to each other.**

It is essential to understand that there are a large number of statistical tests being performed in this report. For each of the 351 cities and towns, we evaluate 18 types of cancer that can occur in both males and females, 3 types that occur only in females, and two types that occur only in males, resulting in 41 gender/cancer categories. This results in 14,391 possible calculations (351 cities and towns x 41 gender/cancer categories). Note that gender/cancer categories with less than five observed cases are not evaluated for statistical significance, so the actual numbers of tests will be fewer. When multiple significance tests are performed, some will result in a significant finding due to random chance alone. Using a 95% confidence interval, we would expect 5% (or 720) of the statistically significant findings to be due to chance alone. Roughly half would be expected to be significant excesses, and half would be significant deficits. Statistical techniques can be used to reduce this number; however, their use can lead to the opposite problem – true statistically significant differences that may be missed. We choose to err on the side of caution and identify more significant results, knowing that some may be due to chance alone.

## **Data Limitations**

Apparent increases or decreases in cancer incidence over time might reflect changes in diagnostic methods or case reporting rather than true changes in cancer incidence. Additional limitations must be considered when interpreting cancer incidence data for Massachusetts cities and towns: under-reporting in areas close to neighboring states; under-reporting for cancers that may not be diagnosed in hospitals; cases being assigned to incorrect cities/towns; and standardized incidence ratios based on small numbers of cases.

### ***Cases Diagnosed in Non-Hospital Settings***

During the period covered by this report, the MCR's primary information source for most newly diagnosed cancer cases was hospitals. The MCR also collected information from reporting hospitals on cases diagnosed and treated in staff physician offices when this information was available. Other reporting sources include dermatologists and dermatopathology laboratories, urologists' offices, and general laboratories. Some types of cancer in this report may be under-reported because they are diagnosed primarily by private physicians, private laboratories, health maintenance organizations, or radiotherapy centers that escape identification systems used by hospitals. The most common types of cancer diagnosed or treated outside of the hospital include melanoma and prostate cancer.

### ***Melanoma Cases***

The incidence counts for invasive melanoma of the skin for 2018-2020 are incomplete due to issues related to pathology laboratory data reporting. Consequently, there was a drop in invasive melanoma of the skin incidence counts and rates. MCR is working on pathology laboratory data for invasive melanoma of the skin, which is anticipated to improve the 2017-2021 cancer incidence data, adjusting the counts and incidence rates. As a result of these factors, the melanoma numbers reported in this report are underestimated in terms of the actual value. It is anticipated that most of these backlogged data will be added to future city and town reports.

### ***COVID-19***

The 2016-2020 data includes new cancer cases diagnosed in 2020, the first year of the COVID-19 pandemic. The COVID-19 pandemic disrupted health services, leading to delays and reductions in cancer screenings and diagnoses. This may have contributed to the decline in new cases for many cancer types in 2020. Please refer to the Massachusetts statewide report for 2016-2020 for more details on the number of cases by individual year. Please refer to the Massachusetts statewide report for 2016-2020 for more details on the number of cases by individual year: <https://www.mass.gov/doc/cancer-incidence-and-mortality-in-massachusetts-2016-2020-statewide-report/download>

### ***City/Town Misassignment***

In accordance with standard MCR procedures, each case reported to the MCR is assigned to the city/town in which the patient lived at the time of diagnosis based on the address provided by the reporting hospital. An automated geocoding software performs city/town case assignments. Limitations occur when a patient may provide their post office box located outside the patient's city/town of residence, a business address; or a temporary address (e.g., the patient is staying with a relative while receiving treatment and reports the relative's address as his/her own); or a locality or post office name (e.g., "Chestnut Hill" rather than "Boston," "Brookline," or "Newton"). Sometimes, a hospital may inadvertently report the patient's current address if a patient has moved since being diagnosed. Attempts are made to accurately assign each record, in some cases manually, to a specific city/town. In rare instances, the city/town is left unassigned.

### ***Small Numbers of Cases***

Standardized incidence ratios based on small numbers of cases result in estimates that are very unstable. This situation is common when the population of a city or town is small or if the particular cancer type is rare. SIRs and statistical significance are not calculated when the number of observed cases is less than five. *only. The* observed and expected cases are presented in the tables for qualitative comparison only in these instances.

# **TABLES**

# Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	15.4	117.1	(69.3-185.0)	Male	10	11.3	88.3	(42.3-162.5)
Female	7	5.6	124.3	(49.8-256.0)	Female	10	9.2	108.1	(51.8-198.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.8	130.8	(42.2-305.3)	Male	3	3.9	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	14	10.5	133.0	(72.6-223.1)
Female	91	76.3	119.3	(96.0-146.4)	Female	12	8.7	137.3	(70.9-239.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.6	nc	(nc-nc)	Male	7	9.2	76.2	(30.5-156.9)
<b><u>Colon / Rectum</u></b>					Female	2	3.7	nc	(nc-nc)
Male	21	16.7	125.8	(77.8-192.3)	<b><u>Ovary</u></b>				
Female	13	15.4	84.5	(45.0-144.6)	Female	5	5.5	90.7	(29.2-211.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	4.3	187.6	(80.8-369.6)	Male	7	7.4	94.2	(37.7-194.2)
Female	3	1.2	nc	(nc-nc)	Female	9	6.8	132.8	(60.6-252.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	69	59.4	116.2	(90.4-147.0)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.0	nc	(nc-nc)
Male	8	10.5	76.2	(32.8-150.1)	Female	0	2.4	nc	(nc-nc)
Female	5	5.8	85.9	(27.7-200.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.5	nc	(nc-nc)
Male	7	2.4	287.3	(115.1-592.1)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	8	4.4	181.4	(78.1-357.4)
<b><u>Leukemia</u></b>					Female	4	11.9	nc	(nc-nc)
Male	4	7.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	5.4	92.0	(29.6-214.7)	Female	11	17.5	62.9	(31.3-112.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.9	72.4	(23.3-169.0)	Male	251	227.6	110.3	(97.1-124.8)
Female	2	2.6	nc	(nc-nc)	Female	258	241.0	107.1	(94.4-121.0)
<b><u>Lung and Bronchus</u></b>									
Male	30	27.9	107.4	(72.5-153.4)					
Female	57	33.5	170.2	(128.9-220.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Acton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	24.1	66.4	(37.9-107.8)	Male	14	17.1	81.9	(44.7-137.4)
Female	11	8.1	135.9	(67.8-243.2)	Female	10	12.8	78.3	(37.5-144.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.5	91.5	(29.5-213.5)	Male	5	5.9	84.3	(27.2-196.6)
Female	4	4.2	nc	(nc-nc)	Female	6	4.4	137.0	(50.0-298.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	16	15.8	101.1	(57.7-164.2)
Female	106	106.8	99.2	(81.2-120.0)	Female	6	12.3	48.9	(17.9-106.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	3.5	nc	(nc-nc)	Male	13	13.6	95.5	(50.8-163.3)
<b><u>Colon / Rectum</u></b>					Female	6	5.2	114.5	(41.8-249.2)
Male	23	25.3	91.0	(57.7-136.6)	<b><u>Ovary</u></b>				
Female	24	22.1	108.4	(69.4-161.2)	Female	8	7.7	104.2	(44.9-205.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	6.5	nc	(nc-nc)	Male	5	11.4	43.9	(14.2-102.5)
Female	2	1.8	nc	(nc-nc)	Female	7	9.7	72.0	(28.9-148.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	73	88.0	83.0	(65.0-104.3)
Female	1	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	6.0	99.2	(36.2-215.9)
Male	11	15.5	70.7	(35.3-126.6)	Female	2	3.4	nc	(nc-nc)
Female	9	8.1	110.5	(50.4-209.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.8	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	8	6.0	132.4	(57.0-261.0)
<b><u>Leukemia</u></b>					Female	18	15.6	115.6	(68.5-182.8)
Male	12	11.4	105.1	(54.3-183.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	7.7	117.3	(53.5-222.6)	Female	23	24.2	94.9	(60.1-142.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	10.3	nc	(nc-nc)	Male	260	341.4	76.2	(67.2-86.0)
Female	3	3.6	nc	(nc-nc)	Female	304	337.6	90.0	(80.2-100.8)
<b><u>Lung and Bronchus</u></b>									
Male	22	42.9	51.3	(32.1-77.7)					
Female	31	47.2	65.7	(44.6-93.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	12.5	48.0	(17.5-104.4)	Male	4	8.6	nc	(nc-nc)
Female	2	4.3	nc	(nc-nc)	Female	5	6.3	79.0	(25.4-184.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	6	3.0	197.2	(72.0-429.2)
Female	5	2.0	251.7	(81.1-587.4)	Female	1	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	15	8.0	188.4	(105.4-310.8)
Female	50	51.8	96.5	(71.6-127.2)	Female	9	6.3	142.6	(65.1-270.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	6	6.7	90.1	(32.9-196.2)
<b><u>Colon / Rectum</u></b>					Female	0	2.7	nc	(nc-nc)
Male	10	12.4	80.4	(38.5-148.0)	<b><u>Ovary</u></b>				
Female	9	11.4	79.0	(36.1-150.1)	Female	1	3.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	6	5.8	103.2	(37.7-224.6)
Female	0	0.9	nc	(nc-nc)	Female	10	5.2	192.8	(92.3-354.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	68	45.0	151.3	(117.5-191.8)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.0	nc	(nc-nc)
Male	8	7.6	104.8	(45.1-206.5)	Female	1	1.7	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.4	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	5	2.9	171.9	(55.4-401.1)
<b><u>Leukemia</u></b>					Female	10	7.1	140.9	(67.4-259.1)
Male	2	5.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.9	nc	(nc-nc)	Female	10	12.0	83.2	(39.8-153.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	5.2	134.0	(53.7-276.0)	Male	215	172.9	124.4	(108.3-142.2)
Female	1	1.9	nc	(nc-nc)	Female	156	169.7	92.0	(78.1-107.6)
<b><u>Lung and Bronchus</u></b>									
Male	42	22.3	188.1	(135.5-254.2)					
Female	21	25.0	84.0	(52.0-128.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	10.9	64.4	(25.8-132.7)	Male	6	7.3	82.7	(30.2-179.9)
Female	1	3.8	nc	(nc-nc)	Female	6	5.3	113.2	(41.3-246.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	6.6	120.9	(52.1-238.2)
Female	51	42.6	119.7	(89.1-157.4)	Female	8	5.4	148.2	(63.8-292.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	2	5.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.3	nc	(nc-nc)
Male	12	10.2	117.4	(60.6-205.2)	<b><u>Ovary</u></b>				
Female	7	9.7	72.1	(28.9-148.6)	Female	1	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	0.7	nc	(nc-nc)	Male	47	36.5	128.8	(94.6-171.3)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.5	nc	(nc-nc)
Male	10	6.2	162.4	(77.7-298.6)	Female	1	1.5	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.1	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.7	nc	(nc-nc)
Male	8	4.8	168.0	(72.3-331.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.4	147.9	(47.7-345.2)	Female	7	10.0	69.8	(28.0-143.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	4.3	nc	(nc-nc)	Male	148	143.2	103.3	(87.4-121.4)
Female	0	1.6	nc	(nc-nc)	Female	140	143.0	97.9	(82.4-115.5)
<b><u>Lung and Bronchus</u></b>									
Male	22	18.9	116.5	(73.0-176.4)					
Female	19	21.8	87.3	(52.5-136.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	38.0	73.8	(49.0-106.6)	Male	21	25.2	83.3	(51.5-127.3)
Female	12	14.2	84.3	(43.5-147.3)	Female	18	19.2	93.9	(55.6-148.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	7.3	82.4	(30.1-179.3)	Male	6	8.8	68.5	(25.0-149.2)
Female	7	5.9	117.9	(47.2-243.0)	Female	4	7.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	18	22.9	78.5	(46.5-124.1)
Female	147	152.4	96.5	(81.5-113.4)	Female	15	19.7	76.0	(42.5-125.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.5	nc	(nc-nc)	Male	13	18.3	70.9	(37.7-121.3)
<b><u>Colon / Rectum</u></b>					Female	14	8.2	170.8	(93.3-286.5)
Male	43	35.8	120.2	(87.0-161.9)	<b><u>Ovary</u></b>				
Female	29	36.4	79.7	(53.4-114.5)	Female	11	11.4	96.1	(47.9-172.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	9.5	84.1	(36.2-165.7)	Male	17	17.1	99.5	(57.9-159.3)
Female	2	3.0	nc	(nc-nc)	Female	21	16.9	124.3	(76.9-190.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	106	125.1	84.7	(69.4-102.5)
Female	1	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	8.9	101.7	(46.4-193.0)
Male	34	21.3	159.8	(110.6-223.3)	Female	5	5.5	90.5	(29.2-211.1)
Female	16	12.5	128.5	(73.4-208.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	3.6	nc	(nc-nc)
Male	11	5.1	214.2	(106.8-383.3)	<b><u>Thyroid</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	4	7.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	19.6	45.9	(20.9-87.0)
Male	12	16.5	72.7	(37.5-127.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	18	12.5	144.4	(85.6-228.3)	Female	43	35.6	120.7	(87.4-162.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	14.8	74.5	(37.1-133.3)	Male	465	495.3	93.9	(85.5-102.8)
Female	5	6.0	83.6	(26.9-195.0)	Female	517	518.4	99.7	(91.3-108.7)
<b><u>Lung and Bronchus</u></b>									
Male	69	65.3	105.6	(82.2-133.7)					
Female	96	79.1	121.4	(98.3-148.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Alford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	11	13.4	82.0	(40.9-146.8)
Female	1	0.2	nc	(nc-nc)	Female	4	12.4	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.9	nc	(nc-nc)					
Female	0	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	16.3	110.2	(65.3-174.1)	Male	12	11.8	101.4	(52.3-177.1)
Female	5	6.4	78.0	(25.1-182.0)	Female	8	9.9	80.9	(34.8-159.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.8	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	6	3.4	175.2	(64.0-381.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	9	11.0	82.0	(37.4-155.6)
Female	103	81.6	126.2	(103.0-153.1)	Female	8	9.6	83.6	(36.0-164.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.6	nc	(nc-nc)	Male	11	9.7	113.9	(56.8-203.8)
<b><u>Colon / Rectum</u></b>					Female	3	4.1	nc	(nc-nc)
Male	14	17.4	80.7	(44.1-135.3)	<b><u>Ovary</u></b>				
Female	16	17.3	92.7	(52.9-150.5)	Female	5	5.9	84.1	(27.1-196.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.5	110.3	(35.5-257.4)	Male	10	7.9	126.9	(60.8-233.4)
Female	2	1.4	nc	(nc-nc)	Female	8	7.7	104.4	(44.9-205.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	58	63.5	91.4	(69.4-118.2)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.2	nc	(nc-nc)
Male	16	10.9	146.4	(83.6-237.8)	Female	3	2.6	nc	(nc-nc)
Female	5	6.3	78.8	(25.4-183.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.2	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	6	4.4	136.7	(49.9-297.5)
<b><u>Leukemia</u></b>					Female	11	11.7	93.9	(46.8-168.0)
Male	7	7.9	89.1	(35.7-183.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	6.0	134.2	(57.8-264.5)	Female	29	18.9	153.3	(102.7-220.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	7.3	81.7	(29.8-177.9)	Male	238	239.4	99.4	(87.2-112.9)
Female	3	2.9	nc	(nc-nc)	Female	278	261.6	106.3	(94.2-119.5)
<b><u>Lung and Bronchus</u></b>									
Male	30	29.7	100.9	(68.1-144.0)					
Female	33	37.2	88.7	(61.1-124.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Amherst

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	21.8	82.5	(48.9-130.4)	Male	9	14.7	61.1	(27.9-115.9)
Female	10	8.1	123.3	(59.0-226.7)	Female	6	12.6	47.8	(17.4-104.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	5.6	nc	(nc-nc)	Male	5	5.0	100.7	(32.4-235.0)
Female	4	4.7	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	9	14.7	61.3	(28.0-116.3)
Female	78	88.0	88.6	(70.0-110.6)	Female	12	12.2	98.5	(50.8-172.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.8	nc	(nc-nc)	Male	10	10.3	97.5	(46.7-179.3)
<b><u>Colon / Rectum</u></b>					Female	2	5.0	nc	(nc-nc)
Male	17	20.6	82.5	(48.1-132.2)	<b><u>Ovary</u></b>				
Female	23	21.3	108.0	(68.4-162.1)	Female	7	7.4	94.1	(37.7-193.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	5.4	112.0	(40.9-243.7)	Male	11	9.7	113.7	(56.7-203.5)
Female	3	1.7	nc	(nc-nc)	Female	10	9.6	104.7	(50.1-192.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	4.1	nc	(nc-nc)	Male	57	70.1	81.3	(61.6-105.3)
Female	1	3.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	5.1	nc	(nc-nc)
Male	5	12.2	41.0	(13.2-95.6)	Female	0	3.3	nc	(nc-nc)
Female	8	7.3	108.9	(46.9-214.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	6.4	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	6.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	17.5	62.8	(31.3-112.3)
Male	10	11.0	90.9	(43.5-167.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	8.2	110.0	(50.2-208.7)	Female	27	20.4	132.1	(87.1-192.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	8.4	nc	(nc-nc)	Male	194	296.9	65.3	(56.5-75.2)
Female	3	3.5	nc	(nc-nc)	Female	284	314.7	90.2	(80.0-101.4)
<b><u>Lung and Bronchus</u></b>									
Male	11	37.3	29.5	(14.7-52.8)					
Female	31	45.5	68.2	(46.3-96.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Andover

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	37.0	92.0	(63.7-128.5)	Male	35	25.9	135.0	(94.1-187.8)
Female	10	13.4	74.7	(35.8-137.4)	Female	23	20.1	114.7	(72.7-172.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	8.2	97.3	(41.9-191.7)	Male	6	9.0	66.3	(24.2-144.4)
Female	2	6.5	nc	(nc-nc)	Female	4	7.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	22	24.0	91.8	(57.5-139.0)
Female	198	163.5	121.1	(104.8-139.2)	Female	13	19.7	66.0	(35.1-112.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	5.3	nc	(nc-nc)	Male	18	20.3	88.8	(52.6-140.4)
<b><u>Colon / Rectum</u></b>					Female	8	8.3	96.2	(41.4-189.5)
Male	23	37.7	61.0	(38.6-91.5)	<b><u>Ovary</u></b>				
Female	24	36.0	66.7	(42.7-99.3)	Female	16	12.0	133.6	(76.3-217.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	9.9	81.1	(34.9-159.9)	Male	14	17.3	80.9	(44.2-135.8)
Female	2	2.9	nc	(nc-nc)	Female	11	16.0	68.8	(34.3-123.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	135	133.6	101.0	(84.7-119.6)
Female	3	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	9.2	98.2	(44.8-186.5)
Male	17	23.3	73.1	(42.5-117.0)	Female	5	5.5	91.7	(29.5-213.9)
Female	8	12.8	62.5	(26.9-123.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	4.3	116.8	(37.6-272.5)
Male	3	5.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	11	9.0	122.5	(61.1-219.2)
<b><u>Leukemia</u></b>					Female	34	23.5	145.0	(100.4-202.6)
Male	21	17.4	121.0	(74.8-184.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	12.5	64.1	(27.6-126.4)	Female	29	37.1	78.1	(52.3-112.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	15.7	57.4	(26.2-109.1)	Male	443	517.9	85.5	(77.8-93.9)
Female	2	5.9	nc	(nc-nc)	Female	491	531.6	92.4	(84.4-100.9)
<b><u>Lung and Bronchus</u></b>									
Male	31	65.9	47.1	(32.0-66.8)					
Female	58	76.2	76.1	(57.8-98.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	4.8	124.9	(45.6-271.9)
Female	0	0.1	nc	(nc-nc)	Female	8	5.2	153.3	(66.0-302.1)
<b><u>Lung and Bronchus</u></b>									
Male	1	0.6	nc	(nc-nc)					
Female	1	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	50	47.9	104.4	(77.5-137.6)	Male	29	33.3	87.2	(58.4-125.2)
Female	21	18.8	111.8	(69.2-170.9)	Female	26	27.6	94.1	(61.5-137.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	10.3	77.9	(33.5-153.5)	Male	11	11.4	96.2	(48.0-172.2)
Female	10	8.8	113.5	(54.4-208.8)	Female	7	9.7	72.3	(29.0-149.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	38	30.4	125.0	(88.5-171.6)
Female	258	223.0	115.7	(102.0-130.7)	Female	18	27.3	65.9	(39.0-104.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	7.3	nc	(nc-nc)	Male	21	25.0	84.1	(52.1-128.6)
<b><u>Colon / Rectum</u></b>					Female	8	11.5	69.9	(30.1-137.7)
Male	44	48.1	91.4	(66.4-122.7)	<b><u>Ovary</u></b>				
Female	39	49.9	78.2	(55.6-106.9)	Female	20	16.3	122.6	(74.8-189.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	12.3	64.8	(27.9-127.7)	Male	20	22.0	90.8	(55.4-140.2)
Female	2	4.0	nc	(nc-nc)	Female	23	22.4	102.7	(65.1-154.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	3.5	173.4	(63.3-377.4)	Male	169	163.0	103.7	(88.7-120.6)
Female	0	3.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	11.6	77.4	(35.3-147.0)
Male	26	29.0	89.8	(58.6-131.5)	Female	9	7.6	118.6	(54.1-225.2)
Female	16	17.6	90.9	(51.9-147.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	5.8	120.1	(48.1-247.5)
Male	1	6.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.9	nc	(nc-nc)	Male	19	11.4	166.8	(100.4-260.6)
<b><u>Leukemia</u></b>					Female	30	32.2	93.1	(62.8-132.9)
Male	17	22.0	77.4	(45.1-123.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	17.2	87.0	(48.7-143.5)	Female	39	50.4	77.3	(55.0-105.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	19.4	51.6	(24.7-94.9)	Male	591	650.8	90.8	(83.6-98.4)
Female	6	8.1	73.8	(26.9-160.6)	Female	684	732.2	93.4	(86.5-100.7)
<b><u>Lung and Bronchus</u></b>									
Male	56	83.1	67.4	(50.9-87.5)					
Female	91	106.0	85.8	(69.1-105.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	6.5	92.7	(33.9-201.8)	Male	8	4.7	171.6	(73.9-338.2)
Female	0	1.8	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	4.4	206.8	(94.3-392.5)
Female	34	26.4	128.6	(89.0-179.7)	Female	4	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	6	3.9	154.7	(56.5-336.7)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	10	6.9	145.7	(69.8-268.0)	<b><u>Ovary</u></b>				
Female	4	5.1	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	22	25.8	85.1	(53.3-128.9)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.7	nc	(nc-nc)
Male	6	4.4	137.4	(50.2-299.0)	Female	0	0.8	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	4.0	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.8	nc	(nc-nc)	Female	8	6.1	130.4	(56.1-256.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	103	95.8	107.6	(87.8-130.5)
Female	1	0.9	nc	(nc-nc)	Female	90	81.6	110.3	(88.7-135.5)
<b><u>Lung and Bronchus</u></b>									
Male	8	12.0	66.9	(28.8-131.9)					
Female	17	11.2	152.5	(88.8-244.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	3.6	137.0	(44.2-319.7)	Male	2	2.6	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	17	14.6	116.1	(67.6-186.0)	Female	1	1.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.7	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.8	nc	(nc-nc)	Female	5	1.1	476.0	(153.4-1110.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	14	14.7	95.3	(52.1-160.0)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.9	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	2.2	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	5	3.4	146.2	(47.1-341.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	45	54.1	83.2	(60.7-111.3)
Female	1	0.5	nc	(nc-nc)	Female	55	45.4	121.1	(91.2-157.6)
<b><u>Lung and Bronchus</u></b>									
Male	6	6.7	89.0	(32.5-193.7)					
Female	9	6.3	143.9	(65.7-273.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	7	10.0	69.9	(28.0-144.1)	Female	1	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.5	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	10.4	47.9	(15.5-111.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	21	37.4	56.2	(34.8-85.9)
Female	0	0.4	nc	(nc-nc)	Female	26	32.8	79.3	(51.8-116.2)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.9	nc	(nc-nc)					
Female	3	5.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashland

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	17.0	82.4	(45.0-138.3)	Male	11	12.5	88.2	(44.0-157.9)
Female	7	6.1	115.2	(46.1-237.3)	Female	9	9.9	90.5	(41.3-171.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.2	119.2	(38.4-278.3)	Male	4	4.3	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	15	11.6	129.8	(72.6-214.0)
Female	76	82.2	92.5	(72.9-115.8)	Female	9	9.4	95.7	(43.7-181.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.9	nc	(nc-nc)	Male	7	10.0	69.8	(28.0-143.9)
<b><u>Colon / Rectum</u></b>					Female	3	4.0	nc	(nc-nc)
Male	17	18.4	92.4	(53.8-148.0)	<b><u>Ovary</u></b>				
Female	26	16.7	156.0	(101.9-228.6)	Female	8	5.9	135.3	(58.2-266.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	4.7	192.3	(87.7-365.0)	Male	10	8.2	122.5	(58.7-225.4)
Female	0	1.3	nc	(nc-nc)	Female	4	7.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	88	64.6	136.2	(109.2-167.8)
Female	2	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.4	nc	(nc-nc)
Male	7	11.5	61.1	(24.5-125.8)	Female	3	2.6	nc	(nc-nc)
Female	2	6.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.7	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	8	4.8	166.6	(71.7-328.2)
<b><u>Leukemia</u></b>					Female	14	12.8	109.8	(60.0-184.2)
Male	5	8.4	59.7	(19.2-139.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	5.9	169.2	(81.0-311.3)	Female	15	18.7	80.3	(44.9-132.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	7.5	66.3	(21.4-154.8)	Male	259	249.4	103.9	(91.6-117.3)
Female	1	2.8	nc	(nc-nc)	Female	247	259.4	95.2	(83.7-107.9)
<b><u>Lung and Bronchus</u></b>									
Male	25	30.7	81.5	(52.8-120.4)					
Female	26	35.9	72.5	(47.3-106.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	13.1	175.0	(110.9-262.6)	Male	4	9.1	nc	(nc-nc)
Female	5	4.5	110.8	(35.7-258.5)	Female	7	6.7	105.1	(42.1-216.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	10	8.4	119.5	(57.2-219.7)
Female	51	53.6	95.1	(70.8-125.1)	Female	6	6.6	91.4	(33.4-198.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	1.7	289.2	(93.2-674.9)	Male	15	6.9	216.3	(121.0-356.8)
<b><u>Colon / Rectum</u></b>					Female	2	2.8	nc	(nc-nc)
Male	11	13.0	84.5	(42.1-151.2)	<b><u>Ovary</u></b>				
Female	22	12.0	183.9	(115.2-278.4)	Female	2	4.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	6	6.1	98.5	(36.0-214.4)
Female	1	1.0	nc	(nc-nc)	Female	5	5.4	93.0	(30.0-217.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	53	46.7	113.5	(85.0-148.4)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	3.2	nc	(nc-nc)
Male	7	8.0	87.5	(35.1-180.3)	Female	3	1.8	nc	(nc-nc)
Female	11	4.3	257.6	(128.4-460.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.6	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	7.7	nc	(nc-nc)
Male	7	6.0	115.8	(46.4-238.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.2	119.9	(38.6-279.7)	Female	22	12.4	177.5	(111.2-268.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.5	91.5	(29.5-213.6)	Male	210	181.2	115.9	(100.8-132.7)
Female	0	2.0	nc	(nc-nc)	Female	216	176.6	122.3	(106.6-139.8)
<b><u>Lung and Bronchus</u></b>									
Male	35	23.2	150.6	(104.9-209.5)					
Female	38	25.6	148.6	(105.1-203.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Attleboro

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	55	44.8	122.8	(92.5-159.8)	Male	31	32.1	96.6	(65.7-137.2)
Female	24	16.0	149.8	(96.0-222.9)	Female	25	24.9	100.2	(64.9-148.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	10.3	96.7	(46.3-177.8)	Male	9	11.0	81.8	(37.3-155.3)
Female	7	8.1	86.4	(34.6-178.0)	Female	10	8.5	118.1	(56.5-217.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	31	29.6	104.8	(71.2-148.8)
Female	187	201.3	92.9	(80.1-107.2)	Female	21	24.0	87.5	(54.1-133.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	11	6.8	160.8	(80.1-287.7)	Male	35	25.1	139.6	(97.2-194.1)
<b><u>Colon / Rectum</u></b>					Female	5	10.2	49.1	(15.8-114.6)
Male	68	46.9	144.9	(112.5-183.7)	<b><u>Ovary</u></b>				
Female	50	43.3	115.5	(85.7-152.3)	Female	23	14.7	156.0	(98.8-234.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	14	12.0	116.6	(63.7-195.7)	Male	20	21.1	94.8	(57.9-146.5)
Female	4	3.5	nc	(nc-nc)	Female	21	19.2	109.6	(67.8-167.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	186	162.0	114.8	(98.9-132.5)
Female	2	3.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	11.2	97.8	(48.8-175.1)
Male	26	28.8	90.4	(59.0-132.4)	Female	10	6.6	151.9	(72.7-279.3)
Female	22	15.7	140.2	(87.8-212.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	6.2	96.1	(35.1-209.1)
Male	14	6.8	207.0	(113.1-347.3)	<b><u>Thyroid</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	8	11.7	68.6	(29.5-135.1)
<b><u>Leukemia</u></b>					Female	32	30.7	104.3	(71.3-147.3)
Male	30	21.4	140.5	(94.8-200.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	18	15.2	118.8	(70.4-187.8)	Female	46	45.9	100.2	(73.4-133.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	19.1	67.9	(36.1-116.2)	Male	733	635.1	115.4	(107.2-124.1)
Female	6	7.1	84.4	(30.8-183.7)	Female	688	651.5	105.6	(97.9-113.8)
<b><u>Lung and Bronchus</u></b>									
Male	94	79.5	118.2	(95.5-144.6)					
Female	109	92.0	118.4	(97.3-142.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Auburn

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	22.0	104.6	(66.3-157.0)	Male	25	14.5	172.1	(111.4-254.1)
Female	14	7.3	192.2	(105.0-322.5)	Female	19	10.2	185.6	(111.7-289.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.2	119.9	(38.6-279.8)	Male	4	5.0	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	10	13.2	76.0	(36.4-139.9)
Female	79	81.9	96.4	(76.3-120.2)	Female	11	10.3	106.4	(53.1-190.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	9	10.3	87.5	(39.9-166.1)
<b><u>Colon / Rectum</u></b>					Female	0	4.3	nc	(nc-nc)
Male	22	20.6	106.9	(67.0-161.8)	<b><u>Ovary</u></b>				
Female	16	19.0	84.4	(48.2-137.0)	Female	8	6.1	131.8	(56.8-259.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	5.4	148.2	(63.8-292.1)	Male	9	9.8	92.0	(42.0-174.7)
Female	2	1.5	nc	(nc-nc)	Female	15	8.7	173.0	(96.7-285.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	73	69.3	105.3	(82.6-132.4)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	5.1	118.5	(43.3-257.8)
Male	13	12.0	108.1	(57.5-184.8)	Female	0	2.9	nc	(nc-nc)
Female	7	6.6	106.5	(42.7-219.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.1	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	18	11.2	160.7	(95.2-254.0)
Male	11	9.5	115.5	(57.6-206.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	6.5	138.2	(63.0-262.3)	Female	25	18.8	133.0	(86.1-196.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	8.3	144.4	(74.6-252.3)	Male	297	281.4	105.5	(93.9-118.3)
Female	5	3.1	161.3	(52.0-376.3)	Female	321	274.0	117.2	(104.7-130.7)
<b><u>Lung and Bronchus</u></b>									
Male	39	37.2	104.7	(74.5-143.2)					
Female	59	40.8	144.5	(110.0-186.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Avon

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.1	118.7	(43.3-258.4)	Male	10	3.5	282.5	(135.3-519.6)
Female	6	1.9	320.3	(117.0-697.2)	Female	3	2.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	22	22.2	99.1	(62.1-150.1)	Female	3	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.1	nc	(nc-nc)
Male	6	5.1	116.5	(42.6-253.6)	<b><u>Ovary</u></b>				
Female	3	4.9	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	6	2.2	268.8	(98.1-585.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	15	18.0	83.3	(46.6-137.5)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.2	nc	(nc-nc)
Male	5	3.1	159.3	(51.3-371.8)	Female	1	0.7	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.6	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.0	nc	(nc-nc)
Male	5	2.3	215.1	(69.3-502.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.7	nc	(nc-nc)	Female	6	5.1	116.7	(42.6-254.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	76	70.1	108.3	(85.4-135.6)
Female	0	0.8	nc	(nc-nc)	Female	86	72.7	118.3	(94.6-146.1)
<b><u>Lung and Bronchus</u></b>									
Male	11	8.9	123.3	(61.5-220.6)					
Female	13	10.8	120.7	(64.2-206.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	7.0	185.8	(98.8-317.8)	Male	6	5.2	115.3	(42.1-251.0)
Female	3	2.5	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	11	4.9	226.3	(112.8-405.0)
Female	26	33.0	78.9	(51.5-115.6)	Female	4	3.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.6	nc	(nc-nc)
Male	12	7.7	155.5	(80.3-271.7)	<b><u>Ovary</u></b>				
Female	11	6.8	160.7	(80.1-287.6)	Female	4	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	2.0	255.9	(82.5-597.1)	Male	3	3.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	5	3.0	167.4	(53.9-390.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	28	27.0	103.7	(68.9-149.8)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.8	nc	(nc-nc)
Male	6	4.8	124.2	(45.4-270.3)	Female	1	1.0	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	5.1	136.1	(54.5-280.4)
Male	5	3.5	142.5	(45.9-332.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.4	nc	(nc-nc)	Female	7	7.5	93.1	(37.3-191.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.2	nc	(nc-nc)	Male	126	104.4	120.7	(100.6-143.8)
Female	2	1.1	nc	(nc-nc)	Female	118	105.0	112.4	(93.0-134.6)
<b><u>Lung and Bronchus</u></b>									
Male	13	12.7	102.1	(54.3-174.6)					
Female	18	14.6	123.7	(73.3-195.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	82	71.5	114.6	(91.2-142.3)	Male	58	46.6	124.5	(94.5-160.9)
Female	23	23.1	99.4	(63.0-149.2)	Female	45	31.6	142.4	(103.9-190.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	13.0	107.5	(58.7-180.3)	Male	25	16.6	150.5	(97.4-222.2)
Female	11	9.8	111.7	(55.7-199.9)	Female	10	12.0	83.0	(39.7-152.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	50	42.4	117.9	(87.5-155.5)
Female	302	258.8	116.7	(103.9-130.6)	Female	37	32.7	113.0	(79.6-155.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	7.3	68.8	(22.2-160.6)	Male	54	33.8	159.5	(119.8-208.2)
<b><u>Colon / Rectum</u></b>					Female	11	13.6	80.7	(40.2-144.3)
Male	65	64.9	100.2	(77.3-127.7)	<b><u>Ovary</u></b>				
Female	73	57.5	127.0	(99.5-159.7)	Female	32	19.2	166.5	(113.9-235.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	23	18.0	127.7	(81.0-191.7)	Male	20	32.1	62.2	(38.0-96.1)
Female	6	4.9	121.4	(44.3-264.2)	Female	16	27.6	58.0	(33.1-94.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.9	nc	(nc-nc)	Male	267	240.7	110.9	(98.0-125.1)
Female	3	3.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	16.5	48.6	(20.9-95.7)
Male	33	39.3	84.0	(57.8-118.0)	Female	7	8.9	78.7	(31.5-162.2)
Female	24	21.0	114.3	(73.2-170.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	5.3	93.5	(30.1-218.1)
Male	11	9.5	115.3	(57.5-206.3)	<b><u>Thyroid</u></b>				
Female	3	2.3	nc	(nc-nc)	Male	10	13.6	73.7	(35.3-135.5)
<b><u>Leukemia</u></b>					Female	23	32.0	71.9	(45.5-107.8)
Male	41	30.4	135.1	(96.9-183.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	20	20.3	98.7	(60.3-152.5)	Female	57	62.3	91.5	(69.3-118.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	29	28.0	103.7	(69.4-148.9)	Male	987	927.9	106.4	(99.8-113.2)
Female	7	10.1	69.4	(27.8-143.0)	Female	922	866.4	106.4	(99.7-113.5)
<b><u>Lung and Bronchus</u></b>									
Male	120	124.9	96.0	(79.6-114.9)					
Female	140	135.3	103.5	(87.0-122.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Barre

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	6.2	96.2	(35.1-209.5)	Male	4	4.3	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.0	124.0	(40.0-289.5)
Female	25	23.7	105.5	(68.3-155.8)	Female	1	2.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	5	3.4	144.9	(46.7-338.3)
<b><u>Colon / Rectum</u></b>					Female	1	1.2	nc	(nc-nc)
Male	5	6.2	80.2	(25.8-187.1)	<b><u>Ovary</u></b>				
Female	4	5.0	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	1.7	296.1	(95.4-691.0)	Male	4	3.0	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	26	23.7	109.6	(71.6-160.5)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.5	nc	(nc-nc)
Male	0	3.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	3.5	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.7	nc	(nc-nc)	Female	11	5.5	199.4	(99.4-356.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	82	88.6	92.5	(73.6-114.9)
Female	1	0.8	nc	(nc-nc)	Female	67	76.1	88.0	(68.2-111.8)
<b><u>Lung and Bronchus</u></b>									
Male	10	11.3	88.4	(42.3-162.5)					
Female	6	10.7	56.0	(20.4-121.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	13	9.8	132.4	(70.4-226.3)	Female	0	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	13	10.8	120.6	(64.1-206.2)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.3	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.7	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	43	38.9	110.5	(79.9-148.8)
Female	1	0.4	nc	(nc-nc)	Female	22	31.6	69.7	(43.7-105.5)
<b><u>Lung and Bronchus</u></b>									
Male	11	5.1	216.8	(108.1-388.0)					
Female	1	4.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bedford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	21.7	82.8	(49.0-130.9)	Male	12	14.1	85.1	(43.9-148.6)
Female	2	5.9	nc	(nc-nc)	Female	8	8.5	94.6	(40.7-186.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.9	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	6	12.7	47.3	(17.3-103.0)
Female	79	68.0	116.2	(92.0-144.8)	Female	7	8.5	82.5	(33.0-169.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	8	9.8	82.0	(35.3-161.6)
<b><u>Colon / Rectum</u></b>					Female	4	3.5	nc	(nc-nc)
Male	11	19.9	55.2	(27.5-98.7)	<b><u>Ovary</u></b>				
Female	12	15.5	77.2	(39.9-134.9)	Female	6	5.0	119.6	(43.7-260.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	5.2	nc	(nc-nc)	Male	7	9.5	73.3	(29.4-151.1)
Female	2	1.3	nc	(nc-nc)	Female	10	7.0	141.9	(67.9-260.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	48	65.8	73.0	(53.8-96.8)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.9	nc	(nc-nc)
Male	6	11.4	52.6	(19.2-114.5)	Female	2	2.4	nc	(nc-nc)
Female	3	5.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.8	nc	(nc-nc)
Male	0	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	9.4	95.3	(43.5-180.9)
Male	8	9.3	86.4	(37.2-170.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.4	111.8	(40.8-243.3)	Female	8	15.5	51.5	(22.2-101.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	8.0	113.0	(51.6-214.5)	Male	185	271.0	68.3	(58.8-78.9)
Female	1	2.5	nc	(nc-nc)	Female	216	225.8	95.7	(83.3-109.3)
<b><u>Lung and Bronchus</u></b>									
Male	14	36.1	38.7	(21.2-65.0)					
Female	31	33.2	93.2	(63.3-132.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	15.8	88.4	(48.3-148.3)	Male	10	11.3	88.5	(42.4-162.8)
Female	3	5.6	nc	(nc-nc)	Female	6	8.9	67.8	(24.8-147.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.7	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	16	10.6	151.6	(86.6-246.1)
Female	60	74.5	80.5	(61.4-103.6)	Female	7	8.6	81.6	(32.7-168.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.3	nc	(nc-nc)	Male	11	9.3	118.0	(58.8-211.2)
<b><u>Colon / Rectum</u></b>					Female	0	3.7	nc	(nc-nc)
Male	10	16.6	60.3	(28.9-111.0)	<b><u>Ovary</u></b>				
Female	17	14.9	114.4	(66.6-183.1)	Female	7	5.4	129.4	(51.8-266.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	4.4	nc	(nc-nc)	Male	6	7.7	78.4	(28.6-170.7)
Female	0	1.2	nc	(nc-nc)	Female	6	6.7	89.2	(32.6-194.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	42	62.9	66.8	(48.1-90.3)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.0	nc	(nc-nc)
Male	13	10.6	123.2	(65.5-210.7)	Female	3	2.3	nc	(nc-nc)
Female	5	5.7	87.1	(28.1-203.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.9	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	10.6	nc	(nc-nc)
Male	8	7.5	106.1	(45.7-209.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	5.3	nc	(nc-nc)	Female	24	17.7	135.9	(87.1-202.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	7.1	112.2	(48.3-221.0)	Male	195	232.5	83.9	(72.5-96.5)
Female	0	2.6	nc	(nc-nc)	Female	199	235.9	84.4	(73.0-96.9)
<b><u>Lung and Bronchus</u></b>									
Male	24	29.2	82.3	(52.7-122.4)					
Female	29	33.9	85.6	(57.3-123.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	16.2	117.0	(70.4-182.8)	Male	7	11.9	59.0	(23.6-121.5)
Female	5	5.9	84.8	(27.3-197.8)	Female	4	9.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.9	128.1	(41.3-299.0)	Male	2	4.1	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	7	3.2	219.4	(87.9-452.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	17	11.0	154.9	(90.2-248.0)
Female	75	77.3	97.0	(76.3-121.6)	Female	13	9.0	144.3	(76.8-246.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	12	9.5	126.0	(65.0-220.2)
<b><u>Colon / Rectum</u></b>					Female	3	3.8	nc	(nc-nc)
Male	15	17.5	85.9	(48.0-141.7)	<b><u>Ovary</u></b>				
Female	19	16.1	118.3	(71.2-184.7)	Female	4	5.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	4.5	224.1	(107.3-412.2)	Male	5	7.8	64.4	(20.8-150.3)
Female	1	1.3	nc	(nc-nc)	Female	6	7.1	84.7	(30.9-184.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	81	60.9	132.9	(105.5-165.2)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	4.2	143.8	(52.5-313.1)
Male	12	10.9	110.6	(57.1-193.2)	Female	3	2.5	nc	(nc-nc)
Female	6	5.9	100.9	(36.8-219.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.4	nc	(nc-nc)
Male	6	2.5	236.5	(86.4-514.8)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	13	11.8	110.3	(58.6-188.5)
Male	8	7.9	101.3	(43.6-199.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	5.6	88.5	(28.5-206.6)	Female	18	17.5	102.8	(60.9-162.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	7.2	111.6	(48.0-219.8)	Male	282	236.3	119.3	(105.8-134.1)
Female	1	2.7	nc	(nc-nc)	Female	259	246.5	105.1	(92.7-118.7)
<b><u>Lung and Bronchus</u></b>									
Male	40	29.2	136.8	(97.7-186.3)					
Female	54	34.6	156.1	(117.2-203.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Belmont

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	28.9	121.1	(84.3-168.4)	Male	17	19.7	86.3	(50.2-138.1)
Female	12	10.0	120.3	(62.1-210.2)	Female	16	15.0	106.3	(60.7-172.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.1	82.1	(26.5-191.6)	Male	3	6.8	nc	(nc-nc)
Female	8	4.9	161.9	(69.7-319.1)	Female	8	5.2	153.3	(66.0-302.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	17	18.0	94.2	(54.9-150.9)
Female	138	122.1	113.0	(95.0-133.6)	Female	20	14.8	135.6	(82.8-209.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.1	nc	(nc-nc)	Male	11	14.5	76.0	(37.9-136.0)
<b><u>Colon / Rectum</u></b>					Female	2	6.2	nc	(nc-nc)
Male	34	28.3	120.0	(83.1-167.7)	<b><u>Ovary</u></b>				
Female	23	26.6	86.5	(54.8-129.8)	Female	12	8.9	134.6	(69.5-235.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	7.3	nc	(nc-nc)	Male	11	13.1	83.7	(41.7-149.8)
Female	1	2.1	nc	(nc-nc)	Female	14	11.9	117.5	(64.2-197.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	2.0	243.9	(78.6-569.2)	Male	97	96.0	101.1	(81.9-123.3)
Female	0	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	6.9	nc	(nc-nc)
Male	15	17.0	88.3	(49.4-145.7)	Female	2	4.1	nc	(nc-nc)
Female	6	9.6	62.8	(22.9-136.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.3	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	10	6.5	153.3	(73.4-282.0)
<b><u>Leukemia</u></b>					Female	19	18.1	105.0	(63.2-163.9)
Male	8	13.2	60.6	(26.1-119.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	9.4	53.5	(17.2-124.8)	Female	20	27.6	72.3	(44.2-111.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	11.4	nc	(nc-nc)	Male	327	385.7	84.8	(75.8-94.5)
Female	2	4.4	nc	(nc-nc)	Female	370	397.6	93.1	(83.8-103.0)
<b><u>Lung and Bronchus</u></b>									
Male	18	49.9	36.1	(21.4-57.0)					
Female	27	57.1	47.3	(31.2-68.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	6.2	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	36	29.2	123.2	(86.3-170.6)	Female	0	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.4	nc	(nc-nc)
Male	6	6.8	87.6	(32.0-190.7)	<b><u>Ovary</u></b>				
Female	7	5.6	124.0	(49.7-255.5)	Female	3	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	7	3.0	230.1	(92.2-474.1)
Female	1	0.5	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	31	25.3	122.6	(83.3-174.0)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.6	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	4.5	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.0	nc	(nc-nc)	Female	12	6.7	178.5	(92.1-311.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.9	nc	(nc-nc)	Male	92	93.9	98.0	(79.0-120.2)
Female	0	0.9	nc	(nc-nc)	Female	91	90.1	101.0	(81.3-124.0)
<b><u>Lung and Bronchus</u></b>									
Male	12	11.5	104.6	(54.0-182.8)					
Female	10	12.2	82.0	(39.3-150.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	4.8	103.6	(33.4-241.8)	Male	3	3.2	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	2.9	173.6	(55.9-405.0)
Female	19	18.2	104.5	(62.9-163.2)	Female	1	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	4.0	151.4	(55.3-329.6)	Female	1	1.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	25	16.0	155.8	(100.8-230.1)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.1	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	2.3	264.6	(96.6-575.9)
Male	0	2.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	7	4.3	161.0	(64.5-331.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	66	62.7	105.3	(81.4-134.0)
Female	0	0.7	nc	(nc-nc)	Female	56	60.3	92.8	(70.1-120.6)
<b><u>Lung and Bronchus</u></b>									
Male	8	8.4	95.4	(41.1-187.9)					
Female	5	9.4	53.2	(17.2-124.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	3.5	231.5	(99.7-456.1)	Male	3	2.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	11	11.0	100.1	(49.9-179.2)	Female	0	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.6	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	11.9	59.0	(23.7-121.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.8	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	8	1.5	545.5	(234.9-1075.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.8	nc	(nc-nc)	Female	5	2.6	189.3	(61.0-441.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	46	45.3	101.6	(74.4-135.5)
Female	0	0.4	nc	(nc-nc)	Female	42	36.0	116.7	(84.1-157.8)
<b><u>Lung and Bronchus</u></b>									
Male	3	6.1	nc	(nc-nc)					
Female	10	5.5	181.7	(87.0-334.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	62	44.5	139.3	(106.8-178.6)	Male	36	30.4	118.2	(82.8-163.7)
Female	25	15.7	158.9	(102.8-234.6)	Female	40	23.5	170.5	(121.8-232.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	9.4	74.6	(29.9-153.6)	Male	12	10.6	113.4	(58.5-198.1)
Female	9	7.6	119.0	(54.3-225.9)	Female	6	8.2	73.0	(26.7-158.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	28	28.0	99.9	(66.4-144.4)
Female	217	187.7	115.6	(100.7-132.0)	Female	25	23.1	108.2	(70.0-159.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	6.0	82.7	(26.6-192.9)	Male	24	22.9	104.8	(67.1-155.9)
<b><u>Colon / Rectum</u></b>					Female	12	9.7	123.7	(63.8-216.0)
Male	41	43.4	94.4	(67.7-128.0)	<b><u>Ovary</u></b>				
Female	41	41.2	99.6	(71.5-135.2)	Female	9	14.0	64.5	(29.4-122.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	14	11.5	121.5	(66.3-203.8)	Male	20	20.5	97.8	(59.7-151.0)
Female	4	3.4	nc	(nc-nc)	Female	16	18.8	85.2	(48.7-138.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	146	155.2	94.1	(79.4-110.6)
Female	6	2.9	203.8	(74.4-443.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	10.7	74.8	(32.2-147.5)
Male	23	26.5	87.0	(55.1-130.5)	Female	9	6.3	142.7	(65.1-270.9)
Female	7	14.9	47.0	(18.8-96.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	5.5	182.8	(87.5-336.2)
Male	11	6.3	174.4	(86.9-312.1)	<b><u>Thyroid</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	9	10.3	87.7	(40.0-166.5)
<b><u>Leukemia</u></b>					Female	28	27.7	101.2	(67.2-146.2)
Male	15	20.2	74.1	(41.4-122.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	14.5	103.2	(57.7-170.2)	Female	58	43.6	133.0	(101.0-172.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	18.2	82.6	(46.2-136.2)	Male	624	605.6	103.0	(95.1-111.5)
Female	9	6.9	130.0	(59.3-246.7)	Female	720	619.3	116.3	(107.9-125.1)
<b><u>Lung and Bronchus</u></b>									
Male	85	78.2	108.7	(86.8-134.4)					
Female	121	90.6	133.5	(110.8-159.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# BillERICA

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	43	43.8	98.3	(71.1-132.4)	Male	35	31.3	111.7	(77.8-155.4)
Female	17	14.8	115.1	(67.0-184.3)	Female	20	23.1	86.7	(52.9-133.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	10.1	89.1	(40.7-169.2)	Male	11	10.8	101.4	(50.5-181.4)
Female	4	7.4	nc	(nc-nc)	Female	8	7.9	100.7	(43.4-198.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	29	29.0	100.1	(67.0-143.7)
Female	208	188.9	110.1	(95.7-126.1)	Female	24	22.3	107.5	(68.9-160.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	6.3	142.8	(65.2-271.2)	Male	21	24.7	85.0	(52.6-130.0)
<b><u>Colon / Rectum</u></b>					Female	9	9.5	95.0	(43.3-180.3)
Male	47	45.7	102.8	(75.5-136.7)	<b><u>Ovary</u></b>				
Female	45	39.7	113.4	(82.7-151.8)	Female	13	13.7	94.7	(50.4-161.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	16	11.8	135.3	(77.3-219.7)	Male	24	20.7	116.1	(74.3-172.7)
Female	6	3.2	187.2	(68.4-407.5)	Female	11	17.7	62.2	(31.0-111.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.6	nc	(nc-nc)	Male	122	161.2	75.7	(62.8-90.3)
Female	3	2.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	18	11.0	163.0	(96.6-257.7)
Male	28	28.4	98.7	(65.6-142.6)	Female	6	6.1	99.1	(36.2-215.7)
Female	21	14.7	143.0	(88.5-218.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	6.0	99.4	(36.3-216.3)
Male	6	6.7	90.0	(32.9-195.8)	<b><u>Thyroid</u></b>				
Female	3	1.6	nc	(nc-nc)	Male	13	11.4	113.9	(60.6-194.7)
<b><u>Leukemia</u></b>					Female	23	28.2	81.6	(51.7-122.5)
Male	15	20.8	72.1	(40.3-118.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	13.9	72.0	(34.5-132.4)	Female	56	43.2	129.5	(97.8-168.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	18.9	89.9	(52.4-144.0)	Male	609	624.7	97.5	(89.9-105.5)
Female	13	6.6	196.1	(104.3-335.4)	Female	678	606.9	111.7	(103.5-120.5)
<b><u>Lung and Bronchus</u></b>									
Male	94	78.5	119.8	(96.8-146.5)					
Female	117	86.7	135.0	(111.6-161.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	8.5	105.8	(48.3-200.9)	Male	8	6.2	128.7	(55.4-253.6)
Female	2	3.2	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
Female	41	40.5	101.2	(72.6-137.3)	Female	5	4.8	104.7	(33.7-244.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	5	5.1	98.0	(31.6-228.8)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	8	9.2	87.1	(37.5-171.6)	<b><u>Ovary</u></b>				
Female	7	8.6	81.2	(32.5-167.3)	Female	2	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	2.4	211.1	(68.0-492.7)	Male	6	4.1	146.1	(53.4-318.0)
Female	0	0.7	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	37	32.9	112.5	(79.2-155.0)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.2	nc	(nc-nc)
Male	11	5.7	191.4	(95.4-342.5)	Female	1	1.3	nc	(nc-nc)
Female	7	3.2	221.8	(88.8-456.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	6.1	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.0	nc	(nc-nc)	Female	13	9.3	140.0	(74.4-239.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.8	nc	(nc-nc)	Male	137	125.1	109.5	(92.0-129.5)
Female	1	1.4	nc	(nc-nc)	Female	130	130.3	99.8	(83.3-118.4)
<b><u>Lung and Bronchus</u></b>									
Male	22	15.4	142.4	(89.2-215.7)					
Female	23	18.3	125.8	(79.7-188.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	3	5.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	11	7.1	153.9	(76.7-275.4)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.8	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	22	26.9	81.8	(51.2-123.8)
Female	0	0.2	nc	(nc-nc)	Female	12	18.3	65.6	(33.9-114.6)
<b><u>Lung and Bronchus</u></b>									
Male	3	3.6	nc	(nc-nc)					
Female	0	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	5.0	179.6	(82.0-341.0)	Male	2	3.7	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	31	23.3	133.0	(90.3-188.7)	Female	1	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.1	nc	(nc-nc)
Male	1	5.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	4.7	106.3	(34.3-248.2)	Female	1	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.5	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	25	20.8	120.3	(77.8-177.5)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.3	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	3.3	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.6	nc	(nc-nc)	Female	8	5.4	146.9	(63.2-289.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	2.4	nc	(nc-nc)	Male	79	76.2	103.7	(82.1-129.2)
Female	1	0.8	nc	(nc-nc)	Female	70	72.6	96.5	(75.2-121.9)
<b><u>Lung and Bronchus</u></b>									
Male	6	9.4	64.0	(23.4-139.3)					
Female	4	9.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	351	482.3	72.8	(65.4-80.8)	Male	262	357.8	73.2	(64.6-82.7)
Female	122	180.9	67.4	(56.0-80.5)	Female	244	308.7	79.1	(69.4-89.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	98	126.3	77.6	(63.0-94.6)	Male	145	118.6	122.2	(103.1-143.8)
Female	83	104.6	79.3	(63.2-98.4)	Female	149	95.4	156.2	(132.1-183.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	22	20.2	109.0	(68.3-165.0)	Male	303	332.7	91.1	(81.1-101.9)
Female	2066	2337.8	88.4	(84.6-92.3)	Female	255	283.0	90.1	(79.4-101.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	101	93.0	108.6	(88.4-131.9)	Male	262	269.8	97.1	(85.7-109.6)
<b><u>Colon / Rectum</u></b>					Female	114	118.8	96.0	(79.2-115.3)
Male	464	515.9	89.9	(81.9-98.5)	<b><u>Ovary</u></b>				
Female	444	499.8	88.8	(80.8-97.5)	Female	176	175.4	100.4	(86.1-116.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	108	128.2	84.2	(69.1-101.7)	Male	231	226.7	101.9	(89.2-115.9)
Female	32	38.8	82.5	(56.4-116.4)	Female	226	217.2	104.0	(90.9-118.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	48	57.4	83.7	(61.7-110.9)	Male	1863	1716.1	108.6	(103.7-113.6)
Female	39	52.0	75.1	(53.4-102.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	158	122.7	128.7	(109.4-150.4)
Male	253	316.0	80.1	(70.5-90.6)	Female	116	76.6	151.5	(125.2-181.8)
Female	170	181.2	93.8	(80.3-109.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	89	115.7	76.9	(61.7-94.6)
Male	82	71.7	114.4	(91.0-142.1)	<b><u>Thyroid</u></b>				
Female	26	18.9	137.6	(89.9-201.6)	Male	123	149.0	82.5	(68.6-98.5)
<b><u>Leukemia</u></b>					Female	348	440.4	79.0	(70.9-87.8)
Male	239	242.5	98.6	(86.5-111.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	161	180.8	89.1	(75.8-103.9)	Female	478	518.6	92.2	(84.1-100.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	253	204.9	123.5	(108.8-139.7)	Male	6728	6984.6	96.3	(94.0-98.7)
Female	109	81.1	134.4	(110.3-162.1)	Female	6966	7659.3	90.9	(88.8-93.1)
<b><u>Lung and Bronchus</u></b>									
Male	818	850.2	96.2	(89.7-103.0)					
Female	905	1037.4	87.2	(81.6-93.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bourne

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	42	29.2	143.8	(103.6-194.3)	Male	31	19.3	160.6	(109.1-228.0)
Female	15	9.9	151.6	(84.8-250.0)	Female	17	13.3	128.0	(74.5-205.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	5.7	176.1	(84.3-323.9)	Male	5	6.9	72.6	(23.4-169.5)
Female	6	4.1	146.3	(53.4-318.4)	Female	5	5.1	98.2	(31.6-229.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	25	17.8	140.4	(90.8-207.2)
Female	114	107.7	105.8	(87.3-127.2)	Female	17	13.8	122.8	(71.5-196.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	15	14.3	104.9	(58.7-173.1)
<b><u>Colon / Rectum</u></b>					Female	7	5.8	121.7	(48.8-250.8)
Male	24	27.0	88.7	(56.8-132.0)	<b><u>Ovary</u></b>				
Female	37	24.6	150.4	(105.9-207.3)	Female	8	8.1	99.3	(42.7-195.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	7.5	93.5	(37.5-192.7)	Male	10	13.3	75.4	(36.1-138.7)
Female	2	2.1	nc	(nc-nc)	Female	14	11.8	118.8	(64.9-199.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	144	101.3	142.1	(119.9-167.3)
Female	3	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	6.8	131.6	(60.0-249.8)
Male	13	16.6	78.4	(41.7-134.0)	Female	3	3.8	nc	(nc-nc)
Female	15	8.8	170.6	(95.4-281.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.9	nc	(nc-nc)
Male	7	4.0	174.9	(70.1-360.4)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	1	6.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	16	13.2	121.6	(69.4-197.4)
Male	13	12.8	102.0	(54.2-174.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	8.6	nc	(nc-nc)	Female	26	25.9	100.6	(65.7-147.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	11.7	119.8	(65.4-201.0)	Male	464	388.4	119.5	(108.8-130.8)
Female	4	4.3	nc	(nc-nc)	Female	427	364.3	117.2	(106.4-128.9)
<b><u>Lung and Bronchus</u></b>									
Male	61	51.6	118.1	(90.3-151.7)					
Female	70	57.2	122.4	(95.4-154.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	5.4	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	25	23.3	107.3	(69.4-158.4)	Female	2	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.2	nc	(nc-nc)
Male	5	5.8	86.0	(27.7-200.7)	<b><u>Ovary</u></b>				
Female	2	4.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	21	21.3	98.7	(61.1-150.9)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.4	nc	(nc-nc)
Male	0	3.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	3.4	147.8	(47.6-344.9)
Male	1	2.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.6	nc	(nc-nc)	Female	4	5.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	59	79.8	74.0	(56.3-95.4)
Female	0	0.8	nc	(nc-nc)	Female	55	73.0	75.4	(56.8-98.1)
<b><u>Lung and Bronchus</u></b>									
Male	8	9.9	81.1	(34.9-159.8)					
Female	4	10.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	10.2	98.1	(47.0-180.5)	Male	12	7.0	172.5	(89.0-301.4)
Female	2	3.0	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.4	93.6	(34.2-203.7)
Female	39	38.9	100.2	(71.2-136.9)	Female	8	4.5	176.2	(75.9-347.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	3	5.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.9	nc	(nc-nc)
Male	4	10.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	8.1	62.0	(20.0-144.6)	Female	2	2.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	36	37.8	95.3	(66.7-131.9)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.5	nc	(nc-nc)
Male	2	6.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.8	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	5.3	132.4	(53.0-272.8)
Male	3	4.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.8	nc	(nc-nc)	Female	9	9.2	97.6	(44.6-185.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.4	nc	(nc-nc)	Male	116	141.3	82.1	(67.8-98.5)
Female	2	1.4	nc	(nc-nc)	Female	107	124.4	86.0	(70.5-103.9)
<b><u>Lung and Bronchus</u></b>									
Male	11	18.4	59.9	(29.9-107.3)					
Female	11	18.0	61.1	(30.4-109.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	5.0	nc	(nc-nc)	Male	9	3.5	255.1	(116.4-484.2)
Female	1	1.8	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	20	22.4	89.1	(54.4-137.6)	Female	2	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.1	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	4.7	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	25	19.1	131.1	(84.8-193.6)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	1.3	476.0	(173.8-1036.0)
Male	5	3.2	154.5	(49.8-360.5)	Female	1	0.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	3.2	156.2	(50.4-364.6)
Male	1	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	1.7	nc	(nc-nc)	Female	7	5.2	133.5	(53.5-275.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	84	71.6	117.4	(93.6-145.3)
Female	0	0.8	nc	(nc-nc)	Female	66	72.3	91.3	(70.6-116.1)
<b><u>Lung and Bronchus</u></b>									
Male	10	9.0	110.5	(52.9-203.2)					
Female	9	10.4	86.5	(39.4-164.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	41.7	81.6	(56.5-114.1)	Male	48	28.6	167.8	(123.7-222.5)
Female	13	15.8	82.1	(43.6-140.3)	Female	32	22.9	140.0	(95.7-197.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	8.8	79.7	(31.9-164.3)	Male	10	9.8	102.0	(48.8-187.6)
Female	8	7.3	109.1	(47.0-215.0)	Female	12	8.1	149.0	(76.9-260.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	28	26.1	107.1	(71.1-154.8)
Female	195	182.9	106.6	(92.2-122.7)	Female	17	22.8	74.6	(43.5-119.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	6.0	nc	(nc-nc)	Male	21	21.1	99.3	(61.5-151.8)
<b><u>Colon / Rectum</u></b>					Female	11	9.5	116.0	(57.8-207.5)
Male	53	41.3	128.2	(96.0-167.7)	<b><u>Ovary</u></b>				
Female	45	42.0	107.2	(78.2-143.4)	Female	15	13.4	111.5	(62.4-184.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	10.6	56.7	(20.7-123.5)	Male	25	19.0	131.7	(85.2-194.5)
Female	3	3.4	nc	(nc-nc)	Female	15	18.9	79.5	(44.5-131.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	141	138.0	102.1	(86.0-120.5)
Female	2	2.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	10.0	70.1	(28.1-144.5)
Male	25	24.6	101.6	(65.7-150.0)	Female	8	6.4	125.9	(54.2-248.0)
Female	13	14.5	89.4	(47.6-152.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	4.9	103.0	(33.2-240.4)
Male	6	5.8	103.5	(37.8-225.4)	<b><u>Thyroid</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	10	9.6	104.7	(50.1-192.5)
<b><u>Leukemia</u></b>					Female	27	26.3	102.7	(67.7-149.4)
Male	27	19.0	142.0	(93.6-206.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	14.5	96.6	(52.8-162.1)	Female	44	41.1	107.1	(77.8-143.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	16.5	108.9	(64.5-172.1)	Male	617	557.3	110.7	(102.1-119.8)
Female	3	6.8	nc	(nc-nc)	Female	641	606.6	105.7	(97.6-114.2)
<b><u>Lung and Bronchus</u></b>									
Male	73	71.6	101.9	(79.9-128.2)					
Female	101	88.3	114.4	(93.1-139.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	21.8	78.1	(45.5-125.0)	Male	24	13.3	180.1	(115.4-268.0)
Female	4	7.2	nc	(nc-nc)	Female	13	8.8	148.2	(78.8-253.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	16	12.0	133.1	(76.0-216.2)
Female	79	70.6	112.0	(88.6-139.6)	Female	10	9.6	104.0	(49.8-191.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.7	nc	(nc-nc)	Male	8	9.1	88.0	(37.9-173.5)
<b><u>Colon / Rectum</u></b>					Female	4	3.9	nc	(nc-nc)
Male	20	18.0	110.9	(67.7-171.2)	<b><u>Ovary</u></b>				
Female	14	17.3	81.1	(44.3-136.1)	Female	9	5.4	167.5	(76.4-317.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	7	9.5	73.8	(29.6-152.1)
Female	0	1.5	nc	(nc-nc)	Female	5	8.6	58.4	(18.8-136.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	72	69.0	104.3	(81.6-131.3)
Female	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.7	nc	(nc-nc)
Male	8	10.7	74.8	(32.2-147.5)	Female	0	2.7	nc	(nc-nc)
Female	1	6.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.9	nc	(nc-nc)
Male	4	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	7.3	nc	(nc-nc)
Male	7	8.6	81.5	(32.6-167.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	6.0	99.6	(36.4-216.9)	Female	12	17.4	69.1	(35.7-120.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	7.9	nc	(nc-nc)	Male	251	265.6	94.5	(83.2-106.9)
Female	1	3.0	nc	(nc-nc)	Female	219	247.6	88.5	(77.1-101.0)
<b><u>Lung and Bronchus</u></b>									
Male	24	37.3	64.3	(41.2-95.7)					
Female	22	40.8	53.9	(33.7-81.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	26.9	104.1	(69.2-150.5)	Male	21	19.4	108.4	(67.1-165.7)
Female	9	7.9	114.1	(52.1-216.6)	Female	17	12.7	134.2	(78.1-214.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	6.4	125.0	(53.8-246.4)	Male	9	6.7	134.1	(61.2-254.6)
Female	10	4.2	235.7	(112.8-433.5)	Female	6	4.2	141.3	(51.6-307.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	16	18.1	88.5	(50.6-143.7)
Female	109	101.7	107.2	(88.0-129.3)	Female	12	12.1	99.2	(51.2-173.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	3.4	nc	(nc-nc)	Male	16	15.5	103.5	(59.1-168.0)
<b><u>Colon / Rectum</u></b>					Female	4	5.1	nc	(nc-nc)
Male	24	28.5	84.3	(54.0-125.5)	<b><u>Ovary</u></b>				
Female	24	21.4	112.3	(71.9-167.1)	Female	12	7.6	158.2	(81.7-276.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	7.3	137.0	(65.6-251.9)	Male	9	12.8	70.3	(32.1-133.4)
Female	0	1.7	nc	(nc-nc)	Female	12	9.4	127.3	(65.7-222.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	88	100.7	87.4	(70.1-107.7)
Female	1	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	6.9	73.0	(23.5-170.3)
Male	14	17.8	78.8	(43.1-132.3)	Female	3	3.3	nc	(nc-nc)
Female	12	7.9	152.0	(78.5-265.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	4.3	138.5	(50.6-301.4)
Male	7	4.1	169.0	(67.7-348.3)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	9	7.4	122.2	(55.8-232.0)
<b><u>Leukemia</u></b>					Female	16	16.3	98.5	(56.2-159.9)
Male	14	12.9	108.4	(59.2-181.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	7.6	131.1	(62.7-241.0)	Female	25	23.4	106.7	(69.1-157.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	11.7	94.0	(46.9-168.2)	Male	381	389.1	97.9	(88.3-108.3)
Female	2	3.6	nc	(nc-nc)	Female	375	328.8	114.1	(102.8-126.2)
<b><u>Lung and Bronchus</u></b>									
Male	55	48.3	113.8	(85.7-148.2)					
Female	56	46.2	121.1	(91.5-157.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	4.6	152.1	(61.0-313.5)	Male	3	3.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	17	19.4	87.4	(50.9-140.0)	Female	3	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.0	nc	(nc-nc)
Male	2	4.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	9	4.0	226.7	(103.5-430.4)	Female	2	1.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	1.8	274.6	(88.5-640.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	23	17.8	129.4	(82.0-194.2)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.2	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.6	nc	(nc-nc)
Male	4	2.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	1.4	nc	(nc-nc)	Female	6	4.6	130.7	(47.7-284.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	65	65.9	98.6	(76.1-125.7)
Female	0	0.7	nc	(nc-nc)	Female	74	61.9	119.5	(93.8-150.1)
<b><u>Lung and Bronchus</u></b>									
Male	9	8.4	106.9	(48.8-202.9)					
Female	13	9.1	143.3	(76.2-245.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	71	83.1	85.4	(66.7-107.7)	Male	35	59.9	58.5	(40.7-81.3)
Female	18	30.7	58.7	(34.7-92.7)	Female	16	49.1	32.6	(18.6-52.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	16	20.2	79.1	(45.2-128.5)	Male	33	20.5	161.2	(111.0-226.4)
Female	22	16.6	132.9	(83.2-201.2)	Female	33	16.4	201.6	(138.7-283.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	3.5	nc	(nc-nc)	Male	55	55.6	99.0	(74.6-128.8)
Female	384	396.4	96.9	(87.4-107.1)	Female	43	46.8	91.8	(66.4-123.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	22	13.8	159.2	(99.7-241.0)	Male	46	46.6	98.6	(72.2-131.5)
<b><u>Colon / Rectum</u></b>					Female	27	19.8	136.1	(89.7-198.1)
Male	109	87.6	124.4	(102.2-150.1)	<b><u>Ovary</u></b>				
Female	99	83.6	118.4	(96.2-144.1)	Female	36	29.0	124.3	(87.1-172.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	29	22.2	130.6	(87.5-187.6)	Male	39	39.2	99.6	(70.8-136.1)
Female	6	6.6	90.3	(33.0-196.6)	Female	44	36.8	119.6	(86.9-160.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	12	7.6	158.6	(81.8-277.0)	Male	314	300.0	104.7	(93.4-116.9)
Female	9	6.6	135.8	(61.9-257.7)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	42	20.9	200.6	(144.6-271.2)
Male	73	53.9	135.4	(106.1-170.2)	Female	20	12.8	156.7	(95.7-242.1)
Female	39	30.7	126.9	(90.2-173.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	13.1	84.0	(41.9-150.3)
Male	11	12.5	88.1	(43.9-157.6)	<b><u>Thyroid</u></b>				
Female	5	3.3	152.4	(49.1-355.7)	Male	23	22.5	102.2	(64.8-153.4)
<b><u>Leukemia</u></b>					Female	62	62.9	98.5	(75.5-126.3)
Male	36	40.9	87.9	(61.6-121.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	24	30.1	79.8	(51.1-118.8)	Female	90	89.3	100.8	(81.0-123.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	41	35.5	115.4	(82.8-156.6)	Male	1306	1186.7	110.1	(104.2-116.2)
Female	20	13.8	145.0	(88.5-223.9)	Female	1341	1276.1	105.1	(99.5-110.9)
<b><u>Lung and Bronchus</u></b>									
Male	199	147.1	135.2	(117.1-155.4)					
Female	198	177.9	111.3	(96.3-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brookfield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	4.6	130.1	(47.5-283.2)	Male	3	3.2	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	6	3.0	203.4	(74.3-442.7)
Female	11	17.9	61.3	(30.5-109.7)	Female	2	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	6	0.9	655.1	(239.2-1425.8)
Male	1	4.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	3.8	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	10	17.7	56.5	(27.1-103.9)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.1	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	2.4	248.1	(90.6-540.1)
Male	2	2.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	1.3	nc	(nc-nc)	Female	5	4.2	118.7	(38.3-277.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	52	65.3	79.6	(59.5-104.4)
Female	0	0.7	nc	(nc-nc)	Female	62	58.6	105.8	(81.1-135.6)
<b><u>Lung and Bronchus</u></b>									
Male	3	8.5	nc	(nc-nc)					
Female	11	8.9	123.7	(61.7-221.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	48	55.9	85.9	(63.3-113.9)	Male	39	38.2	102.1	(72.6-139.5)
Female	19	20.3	93.8	(56.4-146.5)	Female	42	31.9	131.5	(94.8-177.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	12.2	89.8	(44.8-160.8)	Male	16	13.0	123.1	(70.3-200.0)
Female	10	10.7	93.5	(44.8-172.0)	Female	16	10.4	153.2	(87.5-248.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	58	35.1	165.2	(125.4-213.5)
Female	282	242.8	116.2	(103.0-130.5)	Female	35	30.5	114.8	(80.0-159.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	9.0	nc	(nc-nc)	Male	24	26.9	89.4	(57.2-133.0)
<b><u>Colon / Rectum</u></b>					Female	9	12.6	71.5	(32.6-135.7)
Male	29	53.8	53.9	(36.1-77.4)	<b><u>Ovary</u></b>				
Female	42	53.9	77.9	(56.2-105.3)	Female	19	18.3	103.8	(62.4-162.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	13.9	72.0	(34.5-132.4)	Male	35	25.0	139.8	(97.4-194.5)
Female	5	4.3	117.1	(37.7-273.3)	Female	41	24.2	169.1	(121.3-229.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	4.9	nc	(nc-nc)	Male	196	179.3	109.3	(94.5-125.7)
Female	4	5.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	13.2	38.0	(12.2-88.6)
Male	24	32.0	75.0	(48.0-111.6)	Female	9	8.3	108.5	(49.5-205.9)
Female	11	19.2	57.3	(28.6-102.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	9.1	55.1	(17.8-128.6)
Male	5	7.4	67.7	(21.8-157.9)	<b><u>Thyroid</u></b>				
Female	0	2.0	nc	(nc-nc)	Male	17	13.4	126.5	(73.6-202.5)
<b><u>Leukemia</u></b>					Female	44	42.5	103.5	(75.2-138.9)
Male	29	25.8	112.5	(75.3-161.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	19.6	107.4	(66.4-164.1)	Female	44	54.3	81.0	(58.9-108.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	21.5	32.6	(13.0-67.1)	Male	672	739.9	90.8	(84.1-98.0)
Female	5	8.9	56.3	(18.2-131.5)	Female	806	811.9	99.3	(92.5-106.4)
<b><u>Lung and Bronchus</u></b>									
Male	49	95.6	51.3	(37.9-67.8)					
Female	78	115.5	67.5	(53.4-84.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	2.6	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	12	10.7	112.0	(57.8-195.7)	Female	1	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.6	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	2.3	220.1	(70.9-513.7)	Female	0	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	9.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	4	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	5	2.6	193.3	(62.3-451.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	23	35.9	64.0	(40.6-96.0)
Female	0	0.4	nc	(nc-nc)	Female	35	35.3	99.2	(69.1-138.0)
<b><u>Lung and Bronchus</u></b>									
Male	5	4.7	107.0	(34.5-249.7)					
Female	3	5.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	37	31.5	117.6	(82.8-162.1)	Male	26	21.4	121.7	(79.5-178.3)
Female	15	11.1	135.2	(75.6-223.0)	Female	21	15.8	132.5	(82.0-202.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	6.4	140.0	(63.9-265.8)	Male	11	7.3	150.6	(75.1-269.5)
Female	9	5.0	178.3	(81.4-338.5)	Female	5	5.6	88.7	(28.6-207.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	17	19.4	87.5	(51.0-140.2)
Female	119	126.0	94.5	(78.2-113.0)	Female	18	15.9	113.3	(67.1-179.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.1	nc	(nc-nc)	Male	16	15.4	103.6	(59.2-168.3)
<b><u>Colon / Rectum</u></b>					Female	6	6.6	91.0	(33.2-198.0)
Male	21	30.5	68.9	(42.6-105.4)	<b><u>Ovary</u></b>				
Female	19	29.0	65.5	(39.4-102.2)	Female	6	9.3	64.6	(23.6-140.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	7.9	76.2	(27.8-165.9)	Male	18	14.2	126.9	(75.2-200.6)
Female	3	2.3	nc	(nc-nc)	Female	14	13.2	106.0	(57.9-177.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	89	101.9	87.3	(70.1-107.5)
Female	6	1.8	328.9	(120.1-715.9)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	7.4	nc	(nc-nc)
Male	12	18.0	66.5	(34.3-116.2)	Female	8	4.4	180.9	(77.9-356.5)
Female	10	10.1	99.1	(47.4-182.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	3.7	163.8	(59.8-356.6)
Male	3	4.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	7	7.0	100.3	(40.2-206.8)
<b><u>Leukemia</u></b>					Female	17	18.1	94.1	(54.8-150.7)
Male	10	14.1	70.9	(33.9-130.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	10.1	69.5	(27.9-143.3)	Female	21	28.5	73.8	(45.6-112.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	12.3	65.3	(28.1-128.7)	Male	376	414.0	90.8	(81.9-100.5)
Female	6	4.7	126.7	(46.3-275.7)	Female	391	421.0	92.9	(83.9-102.5)
<b><u>Lung and Bronchus</u></b>									
Male	38	53.7	70.7	(50.0-97.1)					
Female	52	62.2	83.6	(62.4-109.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	62	75.6	82.0	(62.8-105.1)	Male	42	55.5	75.7	(54.5-102.3)
Female	22	27.2	81.0	(50.7-122.6)	Female	53	47.5	111.6	(83.6-146.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	15	19.8	75.7	(42.4-124.9)	Male	24	18.2	132.1	(84.6-196.6)
Female	13	16.2	80.3	(42.7-137.4)	Female	8	14.2	56.3	(24.3-111.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	3.1	nc	(nc-nc)	Male	41	51.7	79.3	(56.9-107.6)
Female	344	346.0	99.4	(89.2-110.5)	Female	42	43.0	97.6	(70.3-131.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	14.8	nc	(nc-nc)	Male	18	39.2	45.9	(27.2-72.5)
<b><u>Colon / Rectum</u></b>					Female	15	17.7	84.8	(47.4-139.8)
Male	66	78.0	84.6	(65.5-107.7)	<b><u>Ovary</u></b>				
Female	56	74.0	75.7	(57.2-98.3)	Female	30	26.4	113.8	(76.7-162.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	19.3	51.7	(24.8-95.1)	Male	24	34.7	69.2	(44.3-103.0)
Female	3	5.7	nc	(nc-nc)	Female	27	32.7	82.6	(54.4-120.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	10.2	59.0	(21.5-128.4)	Male	273	253.5	107.7	(95.3-121.3)
Female	7	9.1	77.1	(30.9-158.9)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	17	18.7	90.7	(52.8-145.2)
Male	35	47.2	74.1	(51.6-103.1)	Female	10	11.5	87.1	(41.7-160.2)
Female	18	26.9	66.8	(39.6-105.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	20	21.8	91.9	(56.1-141.9)
Male	5	10.5	47.8	(15.4-111.7)	<b><u>Thyroid</u></b>				
Female	2	2.7	nc	(nc-nc)	Male	29	23.9	121.3	(81.2-174.2)
<b><u>Leukemia</u></b>					Female	63	71.9	87.6	(67.3-112.1)
Male	35	37.5	93.4	(65.0-129.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	22	27.4	80.4	(50.3-121.7)	Female	70	75.8	92.4	(72.0-116.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	30.5	59.1	(35.0-93.4)	Male	931	1067.2	87.2	(81.7-93.0)
Female	14	12.2	115.0	(62.8-193.0)	Female	1015	1153.0	88.0	(82.7-93.6)
<b><u>Lung and Bronchus</u></b>									
Male	101	131.0	77.1	(62.8-93.7)					
Female	105	156.9	66.9	(54.7-81.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	27.6	86.9	(55.7-129.3)	Male	21	18.5	113.7	(70.4-173.8)
Female	10	10.0	99.7	(47.7-183.3)	Female	19	14.1	134.5	(80.9-210.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	5.5	nc	(nc-nc)	Male	2	6.3	nc	(nc-nc)
Female	4	4.5	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	18	16.8	107.2	(63.5-169.4)
Female	110	112.9	97.4	(80.1-117.4)	Female	12	14.2	84.6	(43.6-147.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.6	nc	(nc-nc)	Male	18	13.3	135.4	(80.2-213.9)
<b><u>Colon / Rectum</u></b>					Female	10	5.9	168.9	(80.9-310.7)
Male	29	26.3	110.3	(73.8-158.4)	<b><u>Ovary</u></b>				
Female	32	26.5	120.8	(82.6-170.6)	Female	5	8.4	59.8	(19.3-139.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.9	116.6	(50.2-229.7)	Male	12	12.4	96.9	(50.0-169.3)
Female	2	2.1	nc	(nc-nc)	Female	10	11.9	83.8	(40.1-154.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	105	89.0	118.0	(96.5-142.9)
Female	0	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	6.4	nc	(nc-nc)
Male	10	15.5	64.6	(30.9-118.7)	Female	4	4.0	nc	(nc-nc)
Female	11	9.0	121.8	(60.7-217.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.8	176.7	(57.0-412.4)
Male	4	3.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	5	5.8	86.2	(27.8-201.0)
<b><u>Leukemia</u></b>					Female	13	15.6	83.2	(44.2-142.2)
Male	20	12.2	163.7	(100.0-252.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	9.1	77.2	(30.9-159.0)	Female	16	25.6	62.6	(35.7-101.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	10.6	131.6	(71.9-220.8)	Male	379	359.4	105.5	(95.1-116.6)
Female	2	4.2	nc	(nc-nc)	Female	362	377.1	96.0	(86.4-106.4)
<b><u>Lung and Bronchus</u></b>									
Male	41	47.0	87.1	(62.5-118.2)					
Female	48	55.3	86.8	(64.0-115.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Carlisle

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	6.9	101.5	(40.7-209.2)	Male	3	4.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.3	185.6	(79.9-365.7)
Female	20	23.9	83.7	(51.1-129.2)	Female	4	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.2	nc	(nc-nc)
Male	4	6.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	4.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	30	25.4	118.1	(79.7-168.6)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.7	nc	(nc-nc)
Male	6	4.2	143.6	(52.4-312.6)	Female	0	0.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.2	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.6	nc	(nc-nc)	Female	7	5.8	120.6	(48.3-248.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	89	95.0	93.6	(75.2-115.2)
Female	1	0.8	nc	(nc-nc)	Female	61	75.0	81.3	(62.2-104.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	12.4	nc	(nc-nc)					
Female	5	10.9	45.7	(14.7-106.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	14.5	152.0	(95.2-230.1)	Male	7	10.0	70.2	(28.1-144.7)
Female	8	5.1	157.1	(67.7-309.6)	Female	13	7.4	175.2	(93.2-299.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.1	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	15	9.2	162.8	(91.1-268.5)
Female	67	62.2	107.6	(83.4-136.7)	Female	10	7.5	133.5	(63.9-245.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.8	nc	(nc-nc)	Male	20	7.8	257.1	(157.0-397.2)
<b><u>Colon / Rectum</u></b>					Female	8	3.2	253.5	(109.2-499.5)
Male	22	14.3	154.4	(96.7-233.7)	<b><u>Ovary</u></b>				
Female	17	12.9	131.7	(76.7-210.9)	Female	5	4.5	109.9	(35.4-256.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.9	nc	(nc-nc)	Male	13	6.8	191.8	(102.0-327.9)
Female	1	1.1	nc	(nc-nc)	Female	6	6.1	98.5	(36.0-214.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	37	53.7	68.9	(48.5-94.9)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.5	nc	(nc-nc)
Male	12	9.0	133.9	(69.1-233.9)	Female	3	2.0	nc	(nc-nc)
Female	8	4.9	163.6	(70.4-322.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.5	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	14	8.2	170.5	(93.1-286.1)
Male	11	6.6	167.4	(83.4-299.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	4.6	173.1	(74.5-341.0)	Female	15	14.8	101.0	(56.5-166.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	6.1	113.9	(45.6-234.7)	Male	244	202.1	120.7	(106.1-136.9)
Female	4	2.3	nc	(nc-nc)	Female	258	202.0	127.7	(112.6-144.3)
<b><u>Lung and Bronchus</u></b>									
Male	34	26.2	129.7	(89.8-181.3)					
Female	44	30.5	144.1	(104.7-193.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlemont

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	6	6.6	90.6	(33.1-197.3)	Female	3	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	5	1.9	268.4	(86.5-626.3)	<b><u>Ovary</u></b>				
Female	0	1.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.5	nc	(nc-nc)
Male	3	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.8	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	38	26.9	141.0	(99.8-193.6)
Female	0	0.2	nc	(nc-nc)	Female	24	21.6	110.9	(71.0-165.0)
<b><u>Lung and Bronchus</u></b>									
Male	9	3.6	247.3	(112.9-469.5)					
Female	6	3.3	180.4	(65.9-392.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Charlton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	16.6	72.4	(37.3-126.4)	Male	19	11.3	168.1	(101.2-262.6)
Female	7	5.6	124.5	(49.9-256.5)	Female	11	8.1	135.5	(67.5-242.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	3.3	269.0	(122.8-510.8)	Male	4	3.8	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	8	10.3	77.9	(33.5-153.4)
Female	56	64.8	86.4	(65.3-112.2)	Female	7	8.0	87.1	(34.9-179.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	10	8.4	119.3	(57.1-219.4)
<b><u>Colon / Rectum</u></b>					Female	3	3.4	nc	(nc-nc)
Male	15	16.4	91.3	(51.0-150.6)	<b><u>Ovary</u></b>				
Female	12	15.1	79.3	(40.9-138.5)	Female	6	4.8	124.8	(45.6-271.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.2	nc	(nc-nc)	Male	9	7.5	119.4	(54.5-226.6)
Female	1	1.2	nc	(nc-nc)	Female	3	6.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	65	54.2	119.8	(92.5-152.7)
Female	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	3.9	177.6	(71.1-365.9)
Male	8	9.6	83.3	(35.9-164.2)	Female	0	2.3	nc	(nc-nc)
Female	5	5.2	97.1	(31.3-226.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.7	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.5	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	9.1	120.3	(60.0-215.3)
Male	6	7.4	80.9	(29.5-176.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.1	117.7	(43.0-256.2)	Female	15	14.7	102.2	(57.2-168.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	6.5	nc	(nc-nc)	Male	228	219.5	103.9	(90.8-118.3)
Female	2	2.4	nc	(nc-nc)	Female	205	214.7	95.5	(82.9-109.5)
<b><u>Lung and Bronchus</u></b>									
Male	29	28.2	102.8	(68.8-147.7)					
Female	39	30.8	126.5	(89.9-172.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	15.9	150.7	(96.5-224.3)	Male	16	9.5	168.4	(96.2-273.5)
Female	3	5.0	nc	(nc-nc)	Female	15	5.8	259.2	(145.0-427.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	11	8.5	129.8	(64.7-232.2)
Female	48	46.2	104.0	(76.7-137.9)	Female	3	6.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	2	6.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.6	nc	(nc-nc)
Male	11	12.6	87.0	(43.4-155.6)	<b><u>Ovary</u></b>				
Female	13	11.6	111.6	(59.4-190.9)	Female	4	3.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	3.7	nc	(nc-nc)	Male	11	6.7	163.7	(81.6-292.9)
Female	0	1.0	nc	(nc-nc)	Female	6	5.9	101.2	(37.0-220.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	63	46.0	137.1	(105.3-175.4)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	3.3	nc	(nc-nc)
Male	9	7.2	124.5	(56.8-236.3)	Female	2	1.8	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.5	nc	(nc-nc)
Male	5	6.1	82.2	(26.5-191.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.1	147.7	(53.9-321.5)	Female	13	11.2	115.7	(61.5-197.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.4	92.5	(29.8-215.8)	Male	202	184.5	109.5	(94.9-125.7)
Female	1	2.1	nc	(nc-nc)	Female	157	165.4	94.9	(80.6-111.0)
<b><u>Lung and Bronchus</u></b>									
Male	14	26.6	52.6	(28.7-88.3)					
Female	19	28.4	67.0	(40.3-104.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	46	43.3	106.3	(77.8-141.8)	Male	23	29.4	78.2	(49.6-117.4)
Female	20	15.3	130.9	(80.0-202.2)	Female	23	21.8	105.3	(66.7-158.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	8.8	125.3	(62.5-224.2)	Male	11	10.2	108.1	(53.9-193.5)
Female	8	6.9	116.0	(50.0-228.7)	Female	8	7.9	101.8	(43.8-200.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	21	26.8	78.4	(48.5-119.8)
Female	192	176.4	108.8	(94.0-125.4)	Female	24	21.9	109.4	(70.1-162.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	5.6	90.0	(29.0-210.1)	Male	18	21.7	82.8	(49.1-130.9)
<b><u>Colon / Rectum</u></b>					Female	14	9.2	152.7	(83.4-256.3)
Male	45	42.0	107.0	(78.1-143.2)	<b><u>Ovary</u></b>				
Female	36	40.0	90.1	(63.1-124.7)	Female	11	13.0	84.7	(42.2-151.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	11.0	45.4	(14.6-106.1)	Male	22	19.7	111.9	(70.1-169.4)
Female	5	3.2	154.0	(49.6-359.4)	Female	17	18.2	93.4	(54.4-149.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	140	144.4	97.0	(81.6-114.4)
Female	5	2.4	210.5	(67.8-491.3)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	10.3	97.1	(46.5-178.5)
Male	23	25.2	91.4	(57.9-137.2)	Female	8	6.1	131.7	(56.7-259.6)
Female	9	14.1	64.0	(29.2-121.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	4.4	180.0	(77.5-354.8)
Male	5	6.0	83.4	(26.9-194.5)	<b><u>Thyroid</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	9	9.5	95.2	(43.5-180.8)
<b><u>Leukemia</u></b>					Female	42	24.3	173.0	(124.7-233.9)
Male	22	19.4	113.4	(71.0-171.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	13.8	101.7	(55.5-170.6)	Female	48	40.4	118.7	(87.5-157.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	17.2	98.8	(57.5-158.2)	Male	558	575.4	97.0	(89.1-105.4)
Female	9	6.6	136.9	(62.5-260.0)	Female	638	584.3	109.2	(100.9-118.0)
<b><u>Lung and Bronchus</u></b>									
Male	73	74.8	97.6	(76.5-122.7)					
Female	81	86.6	93.6	(74.3-116.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Chelsea

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	24.0	108.3	(70.8-158.8)	Male	2	19.0	nc	(nc-nc)
Female	10	8.5	117.5	(56.2-216.0)	Female	5	15.0	33.4	(10.8-77.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	7.2	nc	(nc-nc)	Male	7	6.2	112.9	(45.2-232.6)
Female	7	5.2	133.4	(53.5-274.9)	Female	3	4.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	20	17.7	112.7	(68.8-174.1)
Female	78	116.7	66.8	(52.8-83.4)	Female	16	13.5	118.3	(67.6-192.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	13	4.7	274.0	(145.8-468.6)	Male	11	15.0	73.1	(36.5-130.9)
<b><u>Colon / Rectum</u></b>					Female	6	5.7	104.5	(38.2-227.4)
Male	38	28.5	133.4	(94.4-183.2)	<b><u>Ovary</u></b>				
Female	20	24.6	81.4	(49.7-125.7)	Female	9	8.5	105.5	(48.2-200.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.7	120.3	(51.8-237.0)	Male	12	11.7	102.8	(53.0-179.5)
Female	0	1.8	nc	(nc-nc)	Female	13	10.2	127.1	(67.6-217.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	3.1	nc	(nc-nc)	Male	69	89.4	77.1	(60.0-97.6)
Female	2	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	6.5	230.5	(128.9-380.1)
Male	17	17.6	96.5	(56.2-154.5)	Female	5	3.7	134.4	(43.3-313.7)
Female	11	8.9	123.9	(61.8-221.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	6.5	nc	(nc-nc)
Male	7	3.9	181.4	(72.7-373.7)	<b><u>Thyroid</u></b>				
Female	3	0.9	nc	(nc-nc)	Male	6	8.7	68.9	(25.2-150.1)
<b><u>Leukemia</u></b>					Female	29	21.8	132.8	(89.0-190.8)
Male	5	13.1	38.1	(12.3-89.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	8.9	nc	(nc-nc)	Female	38	25.0	151.8	(107.4-208.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	20	10.8	185.1	(113.0-285.9)	Male	350	368.9	94.9	(85.2-105.4)
Female	4	3.8	nc	(nc-nc)	Female	365	372.5	98.0	(88.2-108.6)
<b><u>Lung and Bronchus</u></b>									
Male	55	42.7	128.8	(97.1-167.7)					
Female	52	47.9	108.6	(81.1-142.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	4.4	157.8	(63.2-325.2)	Male	2	3.0	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	17	15.9	106.8	(62.2-171.1)	Female	0	1.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.4	211.5	(68.2-493.5)
<b><u>Colon / Rectum</u></b>					Female	0	0.8	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	7	3.4	208.9	(83.7-430.4)	Female	0	1.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	1.2	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	20	16.5	121.3	(74.1-187.3)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.1	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.1	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.2	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	72	61.4	117.3	(91.7-147.7)
Female	2	0.6	nc	(nc-nc)	Female	57	51.5	110.8	(83.9-143.5)
<b><u>Lung and Bronchus</u></b>									
Male	7	8.0	87.3	(35.0-179.8)					
Female	7	7.7	91.4	(36.6-188.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	9	6.4	140.0	(63.9-265.8)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	7	7.0	100.0	(40.1-206.1)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.9	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.5	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	25	26.3	95.2	(61.6-140.5)
Female	0	0.2	nc	(nc-nc)	Female	19	20.5	92.5	(55.7-144.5)
<b><u>Lung and Bronchus</u></b>									
Male	3	3.5	nc	(nc-nc)					
Female	4	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	6.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	6.5	76.4	(24.6-178.2)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.8	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	19	24.1	78.9	(47.5-123.2)
Female	0	0.2	nc	(nc-nc)	Female	12	19.9	60.2	(31.0-105.1)
<b><u>Lung and Bronchus</u></b>									
Male	6	3.1	192.1	(70.2-418.2)					
Female	3	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	54	60.3	89.6	(67.3-116.9)	Male	28	41.5	67.4	(44.8-97.4)
Female	21	22.2	94.5	(58.5-144.5)	Female	18	32.6	55.3	(32.7-87.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	13.0	61.7	(26.6-121.6)	Male	15	14.5	103.6	(58.0-170.9)
Female	12	10.5	114.5	(59.1-200.0)	Female	16	11.6	138.4	(79.1-224.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	6	2.4	247.7	(90.5-539.3)	Male	34	38.3	88.8	(61.5-124.1)
Female	235	260.8	90.1	(79.0-102.4)	Female	34	32.4	105.0	(72.7-146.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	8.3	95.9	(41.3-189.0)	Male	43	31.5	136.4	(98.7-183.7)
<b><u>Colon / Rectum</u></b>					Female	10	13.6	73.7	(35.3-135.6)
Male	70	59.3	118.1	(92.1-149.2)	<b><u>Ovary</u></b>				
Female	56	57.5	97.3	(73.5-126.4)	Female	16	19.4	82.6	(47.2-134.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	15.8	63.4	(30.4-116.6)	Male	31	27.9	111.3	(75.6-157.9)
Female	2	4.8	nc	(nc-nc)	Female	32	26.5	120.7	(82.6-170.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	4.5	132.0	(48.2-287.4)	Male	167	213.8	78.1	(66.7-90.9)
Female	5	3.9	128.0	(41.2-298.7)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	14.6	102.7	(57.5-169.4)
Male	44	36.4	120.8	(87.8-162.2)	Female	7	8.8	79.1	(31.7-163.0)
Female	23	20.8	110.5	(70.0-165.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	13	7.5	174.1	(92.6-297.8)
Male	15	8.7	173.2	(96.9-285.7)	<b><u>Thyroid</u></b>				
Female	3	2.2	nc	(nc-nc)	Male	10	14.2	70.5	(33.7-129.6)
<b><u>Leukemia</u></b>					Female	24	37.7	63.7	(40.8-94.8)
Male	21	27.7	75.8	(46.9-115.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	20.4	73.6	(41.2-121.4)	Female	68	60.7	112.0	(87.0-142.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	36	25.0	144.2	(101.0-199.6)	Male	833	828.7	100.5	(93.8-107.6)
Female	11	9.7	112.9	(56.3-202.0)	Female	864	864.6	99.9	(93.4-106.8)
<b><u>Lung and Bronchus</u></b>									
Male	143	106.7	134.0	(113.0-157.9)					
Female	161	128.1	125.7	(107.0-146.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	11	5.1	213.6	(106.5-382.3)	Female	2	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	6.0	82.8	(26.7-193.3)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	0.6	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	0.4	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	25	24.3	103.0	(66.6-152.0)
Female	0	0.2	nc	(nc-nc)	Female	27	17.3	156.0	(102.8-227.0)
<b><u>Lung and Bronchus</u></b>									
Male	3	3.4	nc	(nc-nc)					
Female	4	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	10	8.1	123.1	(58.9-226.4)	Female	3	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.4	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	7	8.5	82.7	(33.1-170.5)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	4	1.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.1	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	28	32.5	86.3	(57.3-124.7)
Female	0	0.3	nc	(nc-nc)	Female	34	26.3	129.1	(89.4-180.3)
<b><u>Lung and Bronchus</u></b>									
Male	4	4.3	nc	(nc-nc)					
Female	5	4.0	125.7	(40.5-293.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Clinton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	13.2	136.6	(80.9-215.9)	Male	10	9.6	104.6	(50.1-192.4)
Female	6	4.8	125.7	(45.9-273.5)	Female	5	7.6	65.6	(21.1-153.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.1	nc	(nc-nc)	Male	5	3.3	151.9	(49.0-354.5)
Female	1	2.5	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	8.9	nc	(nc-nc)
Female	54	62.0	87.1	(65.4-113.6)	Female	7	7.3	96.4	(38.6-198.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	11	7.7	143.5	(71.6-256.9)
<b><u>Colon / Rectum</u></b>					Female	4	3.1	nc	(nc-nc)
Male	15	14.0	107.4	(60.1-177.2)	<b><u>Ovary</u></b>				
Female	15	13.0	115.4	(64.5-190.3)	Female	3	4.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.6	nc	(nc-nc)	Male	6	6.3	95.2	(34.8-207.3)
Female	3	1.0	nc	(nc-nc)	Female	6	5.7	105.0	(38.3-228.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	48	49.9	96.1	(70.9-127.4)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.4	nc	(nc-nc)
Male	9	8.7	103.3	(47.1-196.1)	Female	2	2.0	nc	(nc-nc)
Female	9	4.8	187.9	(85.7-356.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.0	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	8	3.6	223.2	(96.1-439.8)
<b><u>Leukemia</u></b>					Female	7	9.6	73.2	(29.3-150.9)
Male	14	6.4	218.8	(119.5-367.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	4.5	nc	(nc-nc)	Female	21	14.2	147.6	(91.3-225.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	5.8	188.3	(93.9-336.9)	Male	217	191.7	113.2	(98.6-129.3)
Female	2	2.2	nc	(nc-nc)	Female	211	198.6	106.2	(92.4-121.6)
<b><u>Lung and Bronchus</u></b>									
Male	30	23.8	126.2	(85.1-180.1)					
Female	42	27.8	151.3	(109.0-204.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	9.4	96.1	(43.8-182.4)	Male	15	6.3	236.6	(132.3-390.2)
Female	1	3.3	nc	(nc-nc)	Female	7	4.5	154.5	(61.9-318.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	5	1.4	346.6	(111.7-808.7)	Female	1	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	1	5.8	nc	(nc-nc)
Female	46	36.9	124.6	(91.2-166.3)	Female	3	4.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	5	4.8	104.4	(33.6-243.6)
<b><u>Colon / Rectum</u></b>					Female	1	1.9	nc	(nc-nc)
Male	9	9.2	98.3	(44.8-186.5)	<b><u>Ovary</u></b>				
Female	10	8.7	115.5	(55.3-212.4)	Female	3	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.4	nc	(nc-nc)	Male	5	4.3	116.6	(37.6-272.1)
Female	0	0.7	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	37	31.9	115.9	(81.6-159.8)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.2	nc	(nc-nc)
Male	2	5.5	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.8	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.7	106.6	(34.4-248.8)
Male	10	4.2	236.7	(113.3-435.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.9	nc	(nc-nc)	Female	6	8.5	70.5	(25.8-153.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.8	nc	(nc-nc)	Male	133	125.4	106.0	(88.8-125.7)
Female	1	1.4	nc	(nc-nc)	Female	128	122.8	104.3	(87.0-124.0)
<b><u>Lung and Bronchus</u></b>									
Male	10	16.3	61.5	(29.4-113.0)					
Female	16	18.2	88.0	(50.2-142.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	7	8.0	87.2	(34.9-179.6)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.7	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	9.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.1	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	24	34.1	70.4	(45.1-104.7)
Female	0	0.3	nc	(nc-nc)	Female	30	26.2	114.7	(77.4-163.7)
<b><u>Lung and Bronchus</u></b>									
Male	4	4.4	nc	(nc-nc)					
Female	5	3.9	128.3	(41.4-299.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	28.6	66.5	(40.0-103.9)	Male	21	18.8	112.0	(69.3-171.2)
Female	3	10.2	nc	(nc-nc)	Female	21	12.6	166.4	(103.0-254.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	5.2	153.0	(65.9-301.4)	Male	5	6.4	78.1	(25.2-182.2)
Female	4	3.9	nc	(nc-nc)	Female	3	4.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	22	16.9	130.5	(81.7-197.6)
Female	99	99.7	99.2	(80.7-120.8)	Female	11	13.5	81.7	(40.7-146.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.7	nc	(nc-nc)	Male	5	13.1	38.1	(12.3-89.0)
<b><u>Colon / Rectum</u></b>					Female	5	5.5	90.4	(29.1-211.0)
Male	17	26.6	63.9	(37.2-102.4)	<b><u>Ovary</u></b>				
Female	18	25.6	70.2	(41.6-110.9)	Female	12	7.6	158.8	(81.9-277.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	6.9	nc	(nc-nc)	Male	8	12.6	63.4	(27.3-124.8)
Female	0	2.1	nc	(nc-nc)	Female	7	12.0	58.3	(23.4-120.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	80	87.7	91.3	(72.4-113.6)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	6.5	76.6	(24.7-178.8)
Male	12	15.3	78.4	(40.5-137.0)	Female	1	3.9	nc	(nc-nc)
Female	5	8.3	59.9	(19.3-139.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.5	nc	(nc-nc)
Male	0	3.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	10	5.5	180.3	(86.3-331.5)
<b><u>Leukemia</u></b>					Female	16	11.3	141.4	(80.8-229.7)
Male	13	12.1	107.0	(56.9-183.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	8.6	127.2	(63.4-227.7)	Female	14	23.3	60.2	(32.9-101.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	10.6	nc	(nc-nc)	Male	282	360.0	78.3	(69.5-88.0)
Female	2	4.1	nc	(nc-nc)	Female	276	348.3	79.2	(70.2-89.2)
<b><u>Lung and Bronchus</u></b>									
Male	23	47.7	48.2	(30.5-72.3)					
Female	28	54.5	51.4	(34.1-74.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	1.6	303.2	(97.7-707.6)
Female	9	10.7	84.2	(38.4-159.8)	Female	0	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	10.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.6	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	5	1.2	427.8	(137.9-998.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	6	2.6	228.1	(83.3-496.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	35	37.1	94.4	(65.8-131.3)
Female	0	0.4	nc	(nc-nc)	Female	30	33.8	88.8	(59.9-126.7)
<b><u>Lung and Bronchus</u></b>									
Male	6	4.9	123.0	(44.9-267.7)					
Female	3	5.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	6	4.4	137.1	(50.1-298.4)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.9	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	10	4.4	229.1	(109.7-421.4)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	16	16.7	96.0	(54.8-155.9)
Female	0	0.2	nc	(nc-nc)	Female	19	13.9	136.6	(82.2-213.4)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.2	nc	(nc-nc)					
Female	4	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	9.2	97.8	(44.6-185.7)	Male	4	6.0	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	7	4.3	164.7	(66.0-339.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	5.4	147.0	(63.3-289.6)
Female	32	34.0	94.1	(64.4-132.9)	Female	1	4.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	5	4.3	116.6	(37.6-272.1)
<b><u>Colon / Rectum</u></b>					Female	2	1.8	nc	(nc-nc)
Male	10	8.5	118.3	(56.6-217.5)	<b><u>Ovary</u></b>				
Female	19	7.9	239.0	(143.8-373.3)	Female	4	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	12	4.1	292.8	(151.1-511.4)
Female	0	0.7	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	34	29.6	114.7	(79.4-160.3)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.1	nc	(nc-nc)
Male	5	5.0	100.1	(32.3-233.7)	Female	0	1.2	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	4.4	157.8	(63.2-325.2)
Male	3	3.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.7	nc	(nc-nc)	Female	10	8.0	125.6	(60.1-231.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	123	117.8	104.4	(86.8-124.6)
Female	1	1.3	nc	(nc-nc)	Female	124	115.0	107.8	(89.7-128.5)
<b><u>Lung and Bronchus</u></b>									
Male	13	15.7	82.7	(44.0-141.4)					
Female	21	17.6	119.6	(74.0-182.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	35.3	70.8	(45.8-104.5)	Male	27	23.7	114.0	(75.1-165.8)
Female	18	13.4	134.4	(79.6-212.4)	Female	16	18.5	86.4	(49.4-140.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	6.9	144.7	(69.3-266.1)	Male	11	8.2	134.0	(66.8-239.9)
Female	9	5.8	156.0	(71.2-296.1)	Female	6	6.7	89.1	(32.5-193.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	28	21.5	130.0	(86.4-187.9)
Female	138	147.8	93.4	(78.4-110.3)	Female	17	18.8	90.3	(52.6-144.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.5	nc	(nc-nc)	Male	22	17.3	126.9	(79.5-192.2)
<b><u>Colon / Rectum</u></b>					Female	9	7.9	114.5	(52.3-217.4)
Male	25	33.7	74.1	(48.0-109.4)	<b><u>Ovary</u></b>				
Female	47	34.8	135.0	(99.2-179.5)	Female	11	11.0	99.9	(49.8-178.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	8.9	101.4	(46.3-192.5)	Male	20	16.0	125.4	(76.6-193.7)
Female	0	2.8	nc	(nc-nc)	Female	22	15.9	138.6	(86.8-209.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	110	116.2	94.7	(77.8-114.1)
Female	1	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	8.3	120.5	(57.7-221.5)
Male	19	20.1	94.7	(57.0-147.8)	Female	3	5.3	nc	(nc-nc)
Female	9	11.9	75.4	(34.4-143.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.4	148.8	(47.9-347.2)
Male	4	4.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	7	7.4	94.9	(38.0-195.4)
<b><u>Leukemia</u></b>					Female	23	19.8	116.0	(73.5-174.0)
Male	16	15.6	102.9	(58.8-167.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	11.9	50.5	(18.4-110.0)	Female	32	34.1	93.7	(64.1-132.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	23	13.8	166.1	(105.2-249.2)	Male	477	463.2	103.0	(94.0-112.7)
Female	4	5.7	nc	(nc-nc)	Female	494	497.2	99.4	(90.8-108.5)
<b><u>Lung and Bronchus</u></b>									
Male	60	60.7	98.9	(75.5-127.3)					
Female	65	74.2	87.6	(67.6-111.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	41	41.7	98.2	(70.5-133.3)	Male	22	28.0	78.5	(49.2-118.9)
Female	14	14.7	95.4	(52.1-160.1)	Female	12	20.4	58.9	(30.4-102.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	8.5	58.9	(19.0-137.4)	Male	10	9.7	102.9	(49.3-189.2)
Female	6	6.4	93.3	(34.1-203.0)	Female	7	7.4	94.3	(37.8-194.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	22	25.8	85.2	(53.4-129.0)
Female	161	162.0	99.4	(84.6-116.0)	Female	26	20.7	125.4	(81.9-183.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.9	nc	(nc-nc)	Male	17	20.4	83.5	(48.6-133.6)
<b><u>Colon / Rectum</u></b>					Female	4	8.6	nc	(nc-nc)
Male	26	39.8	65.3	(42.7-95.7)	<b><u>Ovary</u></b>				
Female	31	37.8	81.9	(55.6-116.3)	Female	12	12.2	98.7	(50.9-172.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	10.5	85.5	(39.0-162.4)	Male	21	18.8	111.5	(69.0-170.4)
Female	3	3.1	nc	(nc-nc)	Female	12	17.4	68.8	(35.5-120.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	3.3	nc	(nc-nc)	Male	154	138.6	111.1	(94.3-130.1)
Female	4	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	9.8	102.1	(48.9-187.8)
Male	28	23.7	118.0	(78.4-170.6)	Female	9	5.8	156.1	(71.2-296.3)
Female	12	13.1	91.8	(47.4-160.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	5.2	nc	(nc-nc)
Male	3	5.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	11	9.2	119.4	(59.5-213.7)
<b><u>Leukemia</u></b>					Female	24	22.1	108.5	(69.5-161.4)
Male	21	18.6	113.1	(70.0-172.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	18	13.1	137.5	(81.4-217.3)	Female	31	37.5	82.8	(56.2-117.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	16	16.3	98.2	(56.1-159.5)	Male	529	552.4	95.8	(87.8-104.3)
Female	7	6.2	112.3	(45.0-231.4)	Female	511	546.7	93.5	(85.5-101.9)
<b><u>Lung and Bronchus</u></b>									
Male	67	72.2	92.8	(72.0-117.9)					
Female	68	82.3	82.6	(64.1-104.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	33.9	70.9	(45.4-105.5)	Male	28	22.4	124.8	(82.9-180.5)
Female	6	12.9	46.7	(17.0-101.6)	Female	29	17.1	169.7	(113.6-243.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.5	108.0	(43.3-222.6)	Male	7	7.6	92.1	(36.9-189.7)
Female	3	5.3	nc	(nc-nc)	Female	6	6.2	96.8	(35.3-210.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	19	20.2	93.9	(56.5-146.6)
Female	128	132.4	96.7	(80.7-114.9)	Female	23	17.5	131.4	(83.3-197.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	4.1	nc	(nc-nc)	Male	14	15.7	89.3	(48.8-149.8)
<b><u>Colon / Rectum</u></b>					Female	3	7.2	nc	(nc-nc)
Male	25	31.9	78.5	(50.8-115.9)	<b><u>Ovary</u></b>				
Female	33	33.6	98.1	(67.5-137.8)	Female	9	10.0	90.0	(41.1-170.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	8.2	73.2	(26.7-159.3)	Male	14	15.0	93.4	(51.0-156.7)
Female	4	2.7	nc	(nc-nc)	Female	11	15.2	72.3	(36.1-129.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	85	104.1	81.7	(65.2-101.0)
Female	2	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	7.8	nc	(nc-nc)
Male	23	18.4	125.1	(79.3-187.7)	Female	3	5.0	nc	(nc-nc)
Female	11	10.9	101.0	(50.3-180.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	3.5	200.0	(80.1-412.0)
Male	6	4.4	136.2	(49.7-296.5)	<b><u>Thyroid</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	7	6.9	101.4	(40.6-208.9)
<b><u>Leukemia</u></b>					Female	20	17.7	112.9	(68.9-174.4)
Male	13	14.7	88.3	(47.0-151.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	11.3	79.8	(36.4-151.6)	Female	25	29.9	83.6	(54.1-123.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	12.6	79.3	(38.0-145.8)	Male	383	430.3	89.0	(80.3-98.4)
Female	7	5.2	133.9	(53.6-275.9)	Female	446	456.8	97.6	(88.8-107.1)
<b><u>Lung and Bronchus</u></b>									
Male	49	56.6	86.6	(64.1-114.6)					
Female	72	68.2	105.6	(82.6-132.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	6.8	102.8	(41.2-211.9)	Male	4	4.6	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.2	141.3	(51.6-307.6)
Female	29	28.0	103.6	(69.3-148.7)	Female	6	3.4	177.7	(64.9-386.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.4	nc	(nc-nc)
Male	7	6.5	107.4	(43.0-221.2)	<b><u>Ovary</u></b>				
Female	7	5.8	119.7	(47.9-246.6)	Female	4	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	15	24.9	60.3	(33.7-99.4)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.6	nc	(nc-nc)
Male	1	4.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	3.7	nc	(nc-nc)
Male	10	3.0	329.7	(157.8-606.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.1	nc	(nc-nc)	Female	8	6.7	119.1	(51.3-234.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.9	nc	(nc-nc)	Male	82	93.5	87.7	(69.8-108.9)
Female	1	1.0	nc	(nc-nc)	Female	84	91.1	92.2	(73.6-114.2)
<b><u>Lung and Bronchus</u></b>									
Male	7	12.3	57.1	(22.9-117.6)					
Female	8	13.7	58.4	(25.1-115.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	29.7	84.3	(54.5-124.5)	Male	26	18.2	142.9	(93.3-209.4)
Female	16	10.2	156.9	(89.6-254.9)	Female	20	12.3	162.9	(99.4-251.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.6	152.8	(61.2-314.8)	Male	10	6.5	152.7	(73.1-280.9)
Female	9	3.7	243.5	(111.1-462.3)	Female	6	5.1	117.6	(42.9-255.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	10	16.3	61.2	(29.3-112.6)
Female	129	99.3	130.0	(108.5-154.4)	Female	10	13.6	73.4	(35.2-135.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.4	nc	(nc-nc)	Male	24	12.1	198.5	(127.1-295.3)
<b><u>Colon / Rectum</u></b>					Female	5	5.5	90.9	(29.3-212.1)
Male	26	24.5	106.1	(69.3-155.5)	<b><u>Ovary</u></b>				
Female	25	23.9	104.7	(67.7-154.5)	Female	8	7.5	106.6	(45.9-210.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	7.0	156.4	(78.0-279.9)	Male	17	12.8	133.1	(77.5-213.1)
Female	2	2.1	nc	(nc-nc)	Female	19	12.1	156.9	(94.4-245.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	114	90.5	125.9	(103.9-151.3)
Female	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	6.4	nc	(nc-nc)
Male	20	14.4	139.1	(84.9-214.9)	Female	3	3.7	nc	(nc-nc)
Female	13	8.4	154.7	(82.3-264.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.3	nc	(nc-nc)
Male	7	3.6	196.9	(78.9-405.7)	<b><u>Thyroid</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	6	4.4	136.6	(49.9-297.3)
<b><u>Leukemia</u></b>					Female	10	10.2	98.3	(47.1-180.8)
Male	15	11.7	127.8	(71.5-210.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	8.4	106.9	(48.8-202.9)	Female	15	24.3	61.6	(34.5-101.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	10.6	122.3	(65.1-209.2)	Male	423	356.9	118.5	(107.5-130.4)
Female	3	4.3	nc	(nc-nc)	Female	395	348.7	113.3	(102.4-125.0)
<b><u>Lung and Bronchus</u></b>									
Male	50	50.4	99.1	(73.6-130.7)					
Female	48	58.8	81.6	(60.2-108.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	7.9	101.6	(43.7-200.2)	Male	3	5.6	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	5	4.1	123.1	(39.7-287.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.8	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	2	5.2	nc	(nc-nc)
Female	29	33.6	86.2	(57.7-123.8)	Female	4	3.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	7	4.5	157.2	(63.0-323.9)
<b><u>Colon / Rectum</u></b>					Female	2	1.7	nc	(nc-nc)
Male	7	8.3	84.6	(33.9-174.3)	<b><u>Ovary</u></b>				
Female	7	7.0	100.2	(40.2-206.6)	Female	4	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	42	29.1	144.2	(103.9-194.9)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.0	nc	(nc-nc)
Male	5	5.1	97.9	(31.6-228.6)	Female	0	1.1	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.0	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	5.0	99.5	(32.1-232.2)
Male	8	3.8	213.1	(91.7-419.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.4	nc	(nc-nc)	Female	7	7.7	91.2	(36.5-187.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	127	112.4	113.0	(94.2-134.4)
Female	0	1.2	nc	(nc-nc)	Female	108	106.8	101.1	(82.9-122.1)
<b><u>Lung and Bronchus</u></b>									
Male	15	14.1	106.3	(59.5-175.4)					
Female	21	14.9	140.7	(87.0-215.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	8.1	123.8	(59.3-227.6)	Male	9	6.1	146.7	(67.0-278.6)
Female	4	2.5	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.1	236.5	(76.2-551.9)	Male	3	2.2	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	9	5.8	156.0	(71.2-296.1)
Female	37	37.8	97.9	(68.9-135.0)	Female	4	4.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.8	nc	(nc-nc)
Male	7	9.3	75.3	(30.2-155.1)	<b><u>Ovary</u></b>				
Female	10	7.2	138.4	(66.3-254.5)	Female	2	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	2.4	209.0	(67.3-487.6)	Male	9	4.1	221.3	(101.0-420.0)
Female	1	0.6	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	25	34.6	72.2	(46.7-106.5)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.2	nc	(nc-nc)
Male	8	6.0	132.9	(57.2-261.8)	Female	1	1.1	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	6.1	131.9	(56.8-259.9)
Male	4	4.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.5	nc	(nc-nc)	Female	14	8.6	162.1	(88.6-272.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.9	nc	(nc-nc)	Male	137	126.9	108.0	(90.6-127.6)
Female	0	1.2	nc	(nc-nc)	Female	121	114.9	105.3	(87.4-125.8)
<b><u>Lung and Bronchus</u></b>									
Male	16	15.3	104.4	(59.6-169.5)					
Female	15	14.9	100.5	(56.2-165.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dover

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	7.0	170.9	(88.2-298.5)	Male	6	4.8	125.8	(45.9-273.7)
Female	3	1.9	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.4	135.4	(49.4-294.8)
Female	39	25.4	153.8	(109.4-210.3)	Female	4	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	9	6.9	130.9	(59.7-248.6)	<b><u>Ovary</u></b>				
Female	7	5.1	136.1	(54.5-280.5)	Female	1	1.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	30	26.1	114.8	(77.4-163.9)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	7	4.3	162.6	(65.1-335.0)	Female	0	0.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.4	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.8	nc	(nc-nc)	Female	4	6.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	100	97.5	102.5	(83.4-124.7)
Female	1	0.9	nc	(nc-nc)	Female	92	80.1	114.9	(92.6-140.9)
<b><u>Lung and Bronchus</u></b>									
Male	5	12.8	39.2	(12.6-91.5)					
Female	7	11.5	60.7	(24.3-125.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dracut

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	46	32.1	143.4	(105.0-191.3)	Male	13	22.7	57.2	(30.4-97.9)
Female	23	11.0	209.2	(132.6-313.9)	Female	15	17.3	86.6	(48.4-142.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	7.3	82.2	(30.0-179.0)	Male	9	7.9	114.3	(52.2-217.0)
Female	7	5.6	124.6	(49.9-256.8)	Female	6	5.9	101.5	(37.1-220.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	22	21.0	104.8	(65.6-158.7)
Female	157	141.8	110.7	(94.0-129.4)	Female	17	16.7	102.0	(59.4-163.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.7	147.4	(59.1-303.8)	Male	20	17.7	112.9	(69.0-174.4)
<b><u>Colon / Rectum</u></b>					Female	6	7.1	84.6	(30.9-184.1)
Male	33	33.0	99.9	(68.8-140.4)	<b><u>Ovary</u></b>				
Female	42	29.7	141.6	(102.1-191.5)	Female	13	10.3	125.8	(66.9-215.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	8.6	70.0	(25.6-152.4)	Male	17	15.1	112.8	(65.7-180.6)
Female	0	2.4	nc	(nc-nc)	Female	9	13.2	68.3	(31.2-129.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	124	116.6	106.4	(88.5-126.8)
Female	3	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	8.0	62.6	(20.2-146.0)
Male	16	20.4	78.6	(44.9-127.6)	Female	6	4.5	132.4	(48.3-288.2)
Female	15	11.0	136.7	(76.5-225.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	4.4	206.4	(94.2-391.8)
Male	5	4.8	104.5	(33.7-243.9)	<b><u>Thyroid</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	10	8.2	122.3	(58.6-225.0)
<b><u>Leukemia</u></b>					Female	27	21.4	126.3	(83.2-183.7)
Male	13	15.1	85.8	(45.7-146.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	10.4	115.3	(59.5-201.4)	Female	37	32.6	113.7	(80.0-156.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	13.6	80.7	(40.2-144.4)	Male	461	452.9	101.8	(92.7-111.5)
Female	9	5.0	181.7	(82.9-344.9)	Female	542	454.5	119.2	(109.4-129.7)
<b><u>Lung and Bronchus</u></b>									
Male	59	57.1	103.3	(78.6-133.2)					
Female	81	64.3	126.0	(100.1-156.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Dudley

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	11.4	96.8	(48.2-173.2)	Male	4	8.1	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	Female	10	6.0	166.8	(79.9-306.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.7	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	7.6	145.2	(72.4-259.9)
Female	48	49.2	97.6	(72.0-129.4)	Female	4	5.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.6	nc	(nc-nc)	Male	7	6.4	109.5	(43.8-225.5)
<b><u>Colon / Rectum</u></b>					Female	4	2.4	nc	(nc-nc)
Male	18	11.9	151.6	(89.8-239.6)	<b><u>Ovary</u></b>				
Female	11	10.2	107.9	(53.8-193.1)	Female	7	3.6	194.6	(78.0-401.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.1	nc	(nc-nc)	Male	6	5.4	112.0	(40.9-243.7)
Female	0	0.8	nc	(nc-nc)	Female	5	4.5	112.0	(36.1-261.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.1	nc	(nc-nc)	Male	40	41.7	96.0	(68.6-130.7)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.9	nc	(nc-nc)
Male	15	7.3	205.1	(114.7-338.4)	Female	1	1.6	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.7	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	7.6	145.6	(72.6-260.5)
Male	6	5.5	110.0	(40.2-239.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	3.6	167.0	(61.0-363.4)	Female	14	11.3	124.4	(67.9-208.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	4.9	123.0	(44.9-267.6)	Male	185	162.4	113.9	(98.1-131.6)
Female	2	1.7	nc	(nc-nc)	Female	167	156.6	106.6	(91.1-124.1)
<b><u>Lung and Bronchus</u></b>									
Male	21	20.3	103.3	(63.9-157.9)					
Female	23	21.8	105.7	(67.0-158.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	3.4	149.2	(48.1-348.3)	Male	3	2.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	9	15.3	58.9	(26.9-111.9)	Female	0	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.7	nc	(nc-nc)
Male	3	3.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	3.0	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	11	13.9	79.2	(39.5-141.7)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.9	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.2	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	6	3.6	167.0	(61.0-363.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	38	51.0	74.5	(52.7-102.3)
Female	0	0.5	nc	(nc-nc)	Female	37	47.2	78.4	(55.2-108.0)
<b><u>Lung and Bronchus</u></b>									
Male	2	6.3	nc	(nc-nc)					
Female	5	6.5	77.1	(24.9-180.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	21.3	112.5	(72.1-167.4)	Male	32	14.0	228.4	(156.2-322.4)
Female	5	7.3	68.3	(22.0-159.4)	Female	24	9.9	242.0	(155.0-360.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.0	nc	(nc-nc)	Male	7	4.9	141.4	(56.7-291.4)
Female	2	3.1	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	13	12.8	101.6	(54.0-173.8)
Female	103	81.2	126.8	(103.5-153.8)	Female	18	10.2	175.9	(104.2-278.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.3	nc	(nc-nc)	Male	7	10.3	67.8	(27.2-139.8)
<b><u>Colon / Rectum</u></b>					Female	1	4.3	nc	(nc-nc)
Male	12	19.9	60.2	(31.1-105.2)	<b><u>Ovary</u></b>				
Female	16	18.8	85.0	(48.6-138.1)	Female	2	6.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	5.4	111.7	(40.8-243.1)	Male	10	9.6	104.0	(49.8-191.3)
Female	2	1.6	nc	(nc-nc)	Female	8	8.7	91.8	(39.5-180.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	64	71.1	90.0	(69.3-114.9)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	5.0	nc	(nc-nc)
Male	8	11.9	67.0	(28.9-132.1)	Female	0	2.9	nc	(nc-nc)
Female	5	6.5	76.5	(24.7-178.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	10.0	110.0	(54.8-196.8)
Male	12	9.2	129.9	(67.0-226.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	6.5	185.2	(95.6-323.5)	Female	15	19.0	79.0	(44.2-130.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	8.3	60.0	(19.3-140.0)	Male	258	278.0	92.8	(81.8-104.9)
Female	0	3.1	nc	(nc-nc)	Female	291	271.5	107.2	(95.2-120.2)
<b><u>Lung and Bronchus</u></b>									
Male	26	37.0	70.3	(45.9-103.1)					
Female	42	41.3	101.8	(73.4-137.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	15.4	103.6	(59.2-168.2)	Male	10	10.8	92.2	(44.1-169.6)
Female	5	5.4	93.2	(30.0-217.5)	Female	5	8.2	61.3	(19.8-143.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	5	2.9	173.9	(56.0-405.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	7	10.1	69.6	(27.9-143.4)
Female	63	67.2	93.8	(72.1-120.0)	Female	7	8.0	87.4	(35.0-180.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.1	nc	(nc-nc)	Male	11	8.5	129.0	(64.3-230.8)
<b><u>Colon / Rectum</u></b>					Female	1	3.4	nc	(nc-nc)
Male	13	15.7	82.9	(44.1-141.7)	<b><u>Ovary</u></b>				
Female	11	14.1	78.0	(38.9-139.5)	Female	8	4.9	163.1	(70.2-321.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.2	120.1	(38.7-280.3)	Male	10	7.3	137.5	(65.8-253.0)
Female	1	1.2	nc	(nc-nc)	Female	3	6.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	67	57.3	117.0	(90.7-148.6)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	3.8	nc	(nc-nc)
Male	11	9.9	111.6	(55.7-199.8)	Female	2	2.2	nc	(nc-nc)
Female	2	5.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.8	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	6	3.8	157.5	(57.5-342.9)
<b><u>Leukemia</u></b>					Female	9	9.6	93.3	(42.6-177.1)
Male	13	7.2	179.4	(95.4-306.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	5.0	nc	(nc-nc)	Female	17	15.6	109.2	(63.6-174.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	6.6	105.4	(42.2-217.2)	Male	241	218.5	110.3	(96.8-125.1)
Female	1	2.4	nc	(nc-nc)	Female	200	217.1	92.1	(79.8-105.8)
<b><u>Lung and Bronchus</u></b>									
Male	34	27.9	121.9	(84.4-170.3)					
Female	38	31.7	120.0	(84.9-164.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	9	9.6	94.0	(42.9-178.5)	Female	0	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	6	2.6	227.4	(83.0-494.9)	<b><u>Ovary</u></b>				
Female	4	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	15	9.8	152.4	(85.2-251.3)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.4	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.7	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	50	36.9	135.4	(100.5-178.5)
Female	0	0.3	nc	(nc-nc)	Female	34	30.5	111.5	(77.2-155.9)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.7	nc	(nc-nc)					
Female	6	4.3	138.6	(50.6-301.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	23.0	91.4	(56.5-139.7)	Male	14	15.0	93.5	(51.1-156.9)
Female	7	9.0	77.9	(31.2-160.4)	Female	11	11.6	95.1	(47.4-170.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.2	167.4	(67.1-344.9)	Male	6	5.1	117.0	(42.7-254.7)
Female	3	3.6	nc	(nc-nc)	Female	1	4.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	16	13.5	118.5	(67.7-192.5)
Female	97	90.2	107.6	(87.2-131.2)	Female	8	12.1	66.3	(28.5-130.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	9	10.5	85.5	(39.0-162.4)
<b><u>Colon / Rectum</u></b>					Female	5	5.0	100.7	(32.5-235.0)
Male	14	21.2	66.0	(36.0-110.7)	<b><u>Ovary</u></b>				
Female	19	23.2	82.0	(49.4-128.1)	Female	7	6.8	102.5	(41.1-211.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	5.6	89.9	(29.0-209.9)	Male	8	10.2	78.7	(33.9-155.1)
Female	1	1.9	nc	(nc-nc)	Female	9	10.6	84.7	(38.6-160.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	50	71.1	70.4	(52.2-92.8)
Female	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.2	95.8	(30.9-223.5)
Male	5	12.2	40.9	(13.2-95.4)	Female	6	3.5	172.6	(63.0-375.7)
Female	6	7.5	80.3	(29.3-174.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.9	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	7	4.3	161.5	(64.7-332.8)
<b><u>Leukemia</u></b>					Female	6	11.3	52.9	(19.3-115.2)
Male	11	9.8	112.3	(56.0-200.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	7.8	77.1	(28.2-167.8)	Female	17	20.6	82.7	(48.1-132.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	8.5	nc	(nc-nc)	Male	250	289.4	86.4	(76.0-97.8)
Female	2	3.6	nc	(nc-nc)	Female	296	313.4	94.4	(84.0-105.8)
<b><u>Lung and Bronchus</u></b>									
Male	39	38.4	101.4	(72.1-138.7)					
Female	37	47.7	77.5	(54.6-106.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Eastham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	12.3	81.1	(38.8-149.2)	Male	9	7.5	120.8	(55.1-229.3)
Female	7	3.8	181.8	(72.8-374.6)	Female	6	4.7	128.9	(47.1-280.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	6	2.7	221.9	(81.0-483.0)
Female	2	1.4	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	6.7	119.8	(51.6-236.0)
Female	32	38.2	83.7	(57.2-118.2)	Female	1	5.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	0.9	nc	(nc-nc)	Male	5	4.9	102.6	(33.1-239.5)
<b><u>Colon / Rectum</u></b>					Female	4	2.1	nc	(nc-nc)
Male	6	9.9	60.3	(22.0-131.3)	<b><u>Ovary</u></b>				
Female	10	8.9	111.9	(53.5-205.7)	Female	2	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	5	5.3	94.9	(30.6-221.4)
Female	0	0.8	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	34	37.2	91.4	(63.3-127.8)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.6	nc	(nc-nc)
Male	5	5.8	86.4	(27.8-201.7)	Female	0	1.4	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.8	nc	(nc-nc)
Male	1	4.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.2	157.3	(50.7-367.0)	Female	8	9.5	84.0	(36.2-165.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	4.3	nc	(nc-nc)	Male	129	146.2	88.2	(73.7-104.8)
Female	1	1.6	nc	(nc-nc)	Female	127	133.2	95.3	(79.5-113.4)
<b><u>Lung and Bronchus</u></b>									
Male	13	21.0	62.0	(33.0-106.1)					
Female	17	22.6	75.2	(43.8-120.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	19.7	101.3	(61.8-156.4)	Male	15	13.4	111.8	(62.5-184.3)
Female	6	6.9	87.1	(31.8-189.5)	Female	11	10.2	108.4	(54.0-193.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.0	nc	(nc-nc)	Male	6	4.7	127.0	(46.4-276.5)
Female	2	3.2	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	13	12.3	105.8	(56.3-181.0)
Female	73	82.7	88.3	(69.2-111.0)	Female	12	10.1	119.0	(61.4-207.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	10	10.2	98.1	(47.0-180.5)
<b><u>Colon / Rectum</u></b>					Female	6	4.2	141.4	(51.6-307.8)
Male	31	19.1	162.2	(110.2-230.2)	<b><u>Ovary</u></b>				
Female	14	17.8	78.6	(42.9-131.9)	Female	4	6.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	5.1	136.2	(54.6-280.7)	Male	5	9.1	54.8	(17.7-128.0)
Female	1	1.5	nc	(nc-nc)	Female	7	8.2	85.0	(34.1-175.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	72	70.1	102.7	(80.4-129.4)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.7	105.3	(33.9-245.8)
Male	15	11.7	127.8	(71.5-210.8)	Female	1	2.7	nc	(nc-nc)
Female	4	6.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.1	nc	(nc-nc)
Male	4	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	5	0.7	706.2	(227.6-1647.9)	Male	4	4.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	11.6	77.4	(35.3-146.9)
Male	10	8.8	114.0	(54.6-209.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	6.2	nc	(nc-nc)	Female	21	19.4	108.2	(67.0-165.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	8.1	111.2	(50.7-211.0)	Male	287	268.6	106.9	(94.8-120.0)
Female	4	3.1	nc	(nc-nc)	Female	245	270.9	90.4	(79.5-102.5)
<b><u>Lung and Bronchus</u></b>									
Male	35	34.9	100.3	(69.9-139.5)					
Female	35	40.1	87.3	(60.8-121.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	25.3	95.0	(60.8-141.4)	Male	20	17.4	115.2	(70.3-178.0)
Female	10	8.3	120.2	(57.6-221.1)	Female	18	12.8	140.7	(83.3-222.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	5.4	nc	(nc-nc)	Male	11	6.1	179.8	(89.6-321.7)
Female	5	4.2	118.7	(38.3-277.1)	Female	5	4.5	112.3	(36.2-262.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	16	16.1	99.4	(56.8-161.4)
Female	117	104.5	111.9	(92.6-134.2)	Female	23	12.5	184.6	(117.0-277.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.3	nc	(nc-nc)	Male	12	13.4	89.4	(46.1-156.2)
<b><u>Colon / Rectum</u></b>					Female	5	5.3	94.7	(30.5-221.1)
Male	25	25.0	99.9	(64.6-147.4)	<b><u>Ovary</u></b>				
Female	20	22.2	90.3	(55.1-139.4)	Female	7	7.7	90.7	(36.4-187.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	6.7	nc	(nc-nc)	Male	19	11.7	161.9	(97.4-252.8)
Female	3	1.8	nc	(nc-nc)	Female	14	10.0	140.6	(76.8-236.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	109	90.9	119.9	(98.4-144.6)
Female	1	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	6.2	97.5	(35.6-212.1)
Male	9	15.5	58.2	(26.6-110.6)	Female	1	3.4	nc	(nc-nc)
Female	12	8.2	147.2	(76.0-257.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.9	173.9	(56.1-405.9)
Male	1	3.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	5	5.9	85.2	(27.4-198.7)
<b><u>Leukemia</u></b>					Female	19	15.4	123.5	(74.3-192.9)
Male	11	11.6	94.8	(47.3-169.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	7.8	76.6	(28.0-166.7)	Female	30	24.3	123.5	(83.3-176.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	10.5	56.9	(20.8-123.9)	Male	349	349.4	99.9	(89.7-110.9)
Female	2	3.7	nc	(nc-nc)	Female	376	338.3	111.1	(100.2-123.0)
<b><u>Lung and Bronchus</u></b>									
Male	40	45.0	88.9	(63.5-121.0)					
Female	52	48.7	106.8	(79.8-140.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	6.2	112.3	(45.0-231.4)	Male	15	4.2	359.1	(200.8-592.2)
Female	2	1.8	nc	(nc-nc)	Female	5	2.6	191.7	(61.8-447.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	23	22.0	104.6	(66.3-157.0)	Female	2	2.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	6	3.1	193.1	(70.5-420.4)
<b><u>Colon / Rectum</u></b>					Female	1	1.1	nc	(nc-nc)
Male	10	5.9	170.7	(81.7-313.9)	<b><u>Ovary</u></b>				
Female	10	4.4	226.6	(108.5-416.7)	Female	1	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	1.6	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	6	2.1	280.1	(102.3-609.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	0.4	nc	(nc-nc)	Male	24	21.8	110.0	(70.5-163.7)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	1.5	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	3	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	2.9	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.6	nc	(nc-nc)	Female	8	5.3	150.2	(64.7-295.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	2.5	198.3	(63.9-462.7)	Male	122	83.6	145.9	(121.2-174.3)
Female	1	0.8	nc	(nc-nc)	Female	89	71.3	124.9	(100.3-153.7)
<b><u>Lung and Bronchus</u></b>									
Male	13	11.1	117.1	(62.3-200.2)					
Female	11	11.0	100.2	(49.9-179.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	2.4	246.5	(90.0-536.6)	Male	2	1.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	6	7.8	76.8	(28.0-167.1)	Female	2	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.4	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	8.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	0.9	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	21	31.2	67.3	(41.7-102.9)
Female	0	0.3	nc	(nc-nc)	Female	23	26.6	86.4	(54.7-129.6)
<b><u>Lung and Bronchus</u></b>									
Male	2	4.3	nc	(nc-nc)					
Female	3	4.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	10	9.6	104.6	(50.1-192.4)	Female	1	1.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.5	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	5	8.3	59.9	(19.3-139.8)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.7	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	23	31.1	73.9	(46.8-110.9)
Female	0	0.4	nc	(nc-nc)	Female	28	31.2	89.7	(59.6-129.6)
<b><u>Lung and Bronchus</u></b>									
Male	2	3.9	nc	(nc-nc)					
Female	3	4.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Essex

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	4.7	105.4	(34.0-245.9)	Male	2	3.3	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	21	17.1	122.5	(75.8-187.3)	Female	5	2.0	248.2	(80.0-579.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	1	4.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	3.5	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	11	17.4	63.1	(31.4-112.9)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.2	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.4	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	52	65.8	79.1	(59.0-103.7)
Female	0	0.6	nc	(nc-nc)	Female	57	55.0	103.7	(78.5-134.4)
<b><u>Lung and Bronchus</u></b>									
Male	10	8.5	117.8	(56.4-216.6)					
Female	8	8.0	100.4	(43.2-197.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	34.5	66.7	(42.2-100.0)	Male	4	26.2	nc	(nc-nc)
Female	8	12.6	63.6	(27.4-125.3)	Female	5	21.2	23.6	(7.6-55.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	9.4	63.9	(23.3-139.0)	Male	7	8.7	80.3	(32.2-165.5)
Female	8	7.2	110.8	(47.7-218.3)	Female	7	6.7	104.5	(41.9-215.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	21	24.4	86.1	(53.3-131.7)
Female	111	168.0	66.1	(54.4-79.6)	Female	17	19.6	86.7	(50.5-138.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	6.3	110.7	(44.4-228.2)	Male	10	20.6	48.6	(23.3-89.4)
<b><u>Colon / Rectum</u></b>					Female	7	8.3	84.4	(33.8-174.0)
Male	31	38.8	79.9	(54.2-113.4)	<b><u>Ovary</u></b>				
Female	26	35.4	73.4	(47.9-107.6)	Female	8	12.3	65.3	(28.1-128.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	9.4	nc	(nc-nc)	Male	12	16.5	72.6	(37.5-126.8)
Female	4	2.7	nc	(nc-nc)	Female	16	15.1	105.9	(60.5-172.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.9	nc	(nc-nc)	Male	91	126.5	71.9	(57.9-88.3)
Female	5	3.2	156.8	(50.5-366.0)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	9.0	99.5	(45.4-188.8)
Male	22	23.9	92.0	(57.6-139.3)	Female	8	5.4	149.2	(64.3-294.1)
Female	17	12.8	132.8	(77.3-212.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	7.6	92.1	(36.9-189.8)
Male	5	5.4	92.9	(29.9-216.9)	<b><u>Thyroid</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	7	11.0	63.5	(25.5-130.9)
<b><u>Leukemia</u></b>					Female	31	29.1	106.5	(72.3-151.2)
Male	15	17.9	83.9	(46.9-138.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	12.6	87.0	(43.4-155.7)	Female	22	36.8	59.8	(37.5-90.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	15.1	99.0	(55.4-163.3)	Male	386	512.3	75.4	(68.0-83.3)
Female	7	5.6	123.9	(49.6-255.3)	Female	432	537.2	80.4	(73.0-88.4)
<b><u>Lung and Bronchus</u></b>									
Male	64	61.2	104.5	(80.5-133.5)					
Female	68	71.8	94.7	(73.5-120.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fairhaven

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	22.3	98.7	(61.9-149.5)	Male	6	14.8	40.5	(14.8-88.2)
Female	10	8.2	121.5	(58.2-223.4)	Female	9	10.9	82.2	(37.5-156.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.2	164.8	(66.0-339.6)	Male	3	5.2	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	Female	3	4.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	13	13.5	96.5	(51.4-165.1)
Female	90	87.0	103.4	(83.2-127.2)	Female	13	11.3	114.6	(61.0-196.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	14	10.8	129.9	(71.0-218.0)
<b><u>Colon / Rectum</u></b>					Female	7	4.7	149.4	(59.9-307.9)
Male	28	21.0	133.2	(88.5-192.5)	<b><u>Ovary</u></b>				
Female	25	21.0	119.1	(77.1-175.8)	Female	5	6.5	76.8	(24.8-179.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	5.6	125.0	(50.1-257.5)	Male	13	10.0	129.6	(68.9-221.6)
Female	1	1.7	nc	(nc-nc)	Female	6	9.8	61.4	(22.4-133.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	89	73.5	121.1	(97.2-149.0)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	5.2	115.6	(42.2-251.7)
Male	22	12.5	176.2	(110.4-266.8)	Female	2	3.2	nc	(nc-nc)
Female	3	7.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.0	nc	(nc-nc)
Male	5	3.0	165.9	(53.5-387.2)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	5	4.5	110.2	(35.5-257.2)
<b><u>Leukemia</u></b>					Female	12	11.1	108.4	(56.0-189.4)
Male	9	9.6	93.3	(42.6-177.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	7.2	139.9	(67.0-257.2)	Female	19	20.1	94.3	(56.8-147.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	8.7	69.1	(25.2-150.5)	Male	307	290.7	105.6	(94.1-118.1)
Female	2	3.4	nc	(nc-nc)	Female	293	296.9	98.7	(87.7-110.7)
<b><u>Lung and Bronchus</u></b>									
Male	29	38.4	75.5	(50.5-108.4)					
Female	46	45.5	101.0	(74.0-134.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Fall River

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	112	89.3	125.4	(103.3-150.9)	Male	29	62.3	46.5	(31.2-66.8)
Female	38	33.8	112.4	(79.5-154.3)	Female	18	50.0	36.0	(21.3-56.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	19	19.8	95.9	(57.7-149.7)	Male	29	21.5	135.1	(90.5-194.1)
Female	9	16.2	55.5	(25.3-105.4)	Female	16	17.3	92.3	(52.7-149.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	45	57.4	78.5	(57.2-105.0)
Female	364	396.8	91.7	(82.6-101.7)	Female	53	49.2	107.7	(80.7-140.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	19	13.2	144.1	(86.7-225.0)	Male	31	47.0	65.9	(44.8-93.6)
<b><u>Colon / Rectum</u></b>					Female	23	20.6	111.8	(70.9-167.8)
Male	105	89.9	116.7	(95.5-141.3)	<b><u>Ovary</u></b>				
Female	96	89.7	107.0	(86.7-130.7)	Female	21	29.4	71.5	(44.2-109.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	26	23.2	112.0	(73.1-164.1)	Male	43	41.3	104.2	(75.4-140.4)
Female	8	7.2	111.4	(48.0-219.5)	Female	37	40.3	91.8	(64.6-126.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	11	7.1	154.7	(77.1-276.9)	Male	350	310.2	112.8	(101.3-125.3)
Female	8	6.2	129.2	(55.6-254.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	32	21.8	146.8	(100.4-207.2)
Male	59	54.7	107.9	(82.1-139.2)	Female	20	13.6	146.7	(89.6-226.5)
Female	32	31.5	101.6	(69.5-143.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	12.3	48.7	(17.8-106.0)
Male	33	12.8	258.1	(177.7-362.5)	<b><u>Thyroid</u></b>				
Female	2	3.3	nc	(nc-nc)	Male	19	22.0	86.4	(52.0-134.9)
<b><u>Leukemia</u></b>					Female	73	59.3	123.1	(96.5-154.8)
Male	38	41.6	91.3	(64.6-125.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	29	31.4	92.3	(61.8-132.6)	Female	79	89.8	87.9	(69.6-109.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	52	36.6	142.1	(106.1-186.3)	Male	1427	1229.2	116.1	(110.1-122.3)
Female	30	14.6	205.5	(138.6-293.4)	Female	1335	1314.7	101.5	(96.2-107.1)
<b><u>Lung and Bronchus</u></b>									
Male	273	156.5	174.5	(154.4-196.5)					
Female	216	190.3	113.5	(98.8-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	59	57.4	102.7	(78.2-132.5)	Male	61	36.2	168.6	(129.0-216.6)
Female	14	20.2	69.4	(37.9-116.4)	Female	48	25.5	188.2	(138.8-249.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	9.6	146.1	(79.8-245.2)	Male	12	13.0	92.6	(47.8-161.8)
Female	7	7.8	90.1	(36.1-185.7)	Female	11	10.2	108.1	(53.9-193.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	31	32.7	94.8	(64.4-134.5)
Female	238	206.2	115.4	(101.2-131.0)	Female	17	27.5	61.9	(36.1-99.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	5.4	nc	(nc-nc)	Male	22	25.1	87.8	(55.0-132.9)
<b><u>Colon / Rectum</u></b>					Female	15	11.2	133.6	(74.7-220.4)
Male	49	49.5	99.0	(73.3-130.9)	<b><u>Ovary</u></b>				
Female	44	48.8	90.2	(65.6-121.1)	Female	20	15.5	129.2	(78.9-199.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	14.0	92.9	(49.4-158.9)	Male	27	25.2	107.2	(70.6-155.9)
Female	3	4.2	nc	(nc-nc)	Female	20	24.0	83.4	(50.9-128.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	216	183.2	117.9	(102.7-134.8)
Female	3	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	12.8	125.4	(71.6-203.6)
Male	25	29.4	84.9	(54.9-125.3)	Female	10	7.5	132.7	(63.5-244.1)
Female	20	17.2	116.5	(71.1-179.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.2	nc	(nc-nc)
Male	4	7.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	4	9.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	28	23.1	121.3	(80.6-175.3)
Male	15	23.5	63.9	(35.7-105.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	17.0	76.3	(40.6-130.5)	Female	50	49.8	100.4	(74.5-132.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	21.4	70.1	(39.2-115.6)	Male	738	714.7	103.3	(95.9-111.0)
Female	6	8.5	70.5	(25.7-153.4)	Female	738	711.7	103.7	(96.4-111.5)
<b><u>Lung and Bronchus</u></b>									
Male	92	98.9	93.0	(75.0-114.1)					
Female	105	115.7	90.7	(74.2-109.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	35.6	98.2	(68.4-136.6)	Male	21	25.7	81.8	(50.6-125.1)
Female	19	13.1	144.9	(87.2-226.2)	Female	18	20.3	88.5	(52.4-139.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	8.6	nc	(nc-nc)	Male	9	8.8	102.4	(46.7-194.4)
Female	6	6.8	88.3	(32.2-192.1)	Female	10	6.8	146.5	(70.2-269.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	26	23.9	108.8	(71.1-159.5)
Female	127	161.2	78.8	(65.7-93.8)	Female	22	19.6	112.2	(70.3-169.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	13	5.5	235.0	(125.0-401.8)	Male	28	20.0	140.2	(93.1-202.6)
<b><u>Colon / Rectum</u></b>					Female	8	8.3	96.8	(41.7-190.8)
Male	44	37.3	117.9	(85.6-158.2)	<b><u>Ovary</u></b>				
Female	37	35.5	104.1	(73.3-143.5)	Female	15	12.0	125.4	(70.1-206.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	9.6	135.8	(72.3-232.3)	Male	20	16.8	119.1	(72.7-184.0)
Female	5	2.8	177.4	(57.2-413.9)	Female	11	15.7	70.2	(35.0-125.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	118	129.7	91.0	(75.3-109.0)
Female	4	2.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	9.0	122.8	(61.2-219.7)
Male	23	23.0	99.8	(63.3-149.8)	Female	5	5.4	92.6	(29.8-216.1)
Female	16	12.7	126.4	(72.2-205.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	5.9	101.5	(37.1-220.9)
Male	10	5.4	186.3	(89.2-342.6)	<b><u>Thyroid</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	9	9.7	92.8	(42.3-176.1)
<b><u>Leukemia</u></b>					Female	28	25.6	109.5	(72.8-158.3)
Male	23	17.4	131.8	(83.6-197.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	12.6	71.2	(32.5-135.2)	Female	50	36.3	137.7	(102.2-181.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	24	15.3	156.9	(100.5-233.5)	Male	557	510.3	109.2	(100.3-118.6)
Female	7	5.8	121.3	(48.6-250.0)	Female	558	528.4	105.6	(97.0-114.7)
<b><u>Lung and Bronchus</u></b>									
Male	91	63.5	143.3	(115.4-176.0)					
Female	100	74.3	134.6	(109.5-163.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	16	16.3	98.0	(56.0-159.2)
Female	0	0.1	nc	(nc-nc)	Female	3	10.5	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.2	nc	(nc-nc)					
Female	0	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	18.9	127.2	(81.5-189.3)	Male	17	13.3	127.5	(74.2-204.1)
Female	6	6.4	94.5	(34.5-205.6)	Female	12	9.9	121.8	(62.9-212.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.2	118.2	(38.1-275.9)	Male	7	4.6	150.7	(60.4-310.5)
Female	4	3.2	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	15	12.3	121.7	(68.1-200.8)
Female	93	80.5	115.6	(93.3-141.6)	Female	7	9.5	73.3	(29.4-151.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.7	nc	(nc-nc)	Male	10	10.4	95.7	(45.8-176.1)
<b><u>Colon / Rectum</u></b>					Female	4	4.0	nc	(nc-nc)
Male	24	19.4	123.8	(79.3-184.2)	<b><u>Ovary</u></b>				
Female	17	17.0	100.0	(58.2-160.1)	Female	9	5.9	153.3	(69.9-291.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	5.1	177.8	(81.1-337.5)	Male	7	8.9	78.9	(31.6-162.6)
Female	1	1.4	nc	(nc-nc)	Female	4	7.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	67	68.9	97.3	(75.4-123.6)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	4.7	127.6	(46.6-277.7)
Male	7	12.0	58.4	(23.4-120.3)	Female	3	2.6	nc	(nc-nc)
Female	4	6.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.4	nc	(nc-nc)
Male	4	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.7	nc	(nc-nc)	Male	7	4.7	148.8	(59.6-306.6)
<b><u>Leukemia</u></b>					Female	10	11.9	83.8	(40.1-154.1)
Male	5	8.9	56.3	(18.1-131.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	6.0	117.2	(47.0-241.6)	Female	16	18.5	86.6	(49.5-140.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	8.1	86.8	(34.8-178.8)	Male	301	266.3	113.0	(100.6-126.6)
Female	5	2.8	176.1	(56.7-410.9)	Female	278	259.3	107.2	(95.0-120.6)
<b><u>Lung and Bronchus</u></b>									
Male	44	33.8	130.4	(94.7-175.0)					
Female	35	37.1	94.4	(65.8-131.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	62	69.7	89.0	(68.2-114.1)	Male	44	49.1	89.5	(65.1-120.2)
Female	28	25.7	109.1	(72.5-157.7)	Female	41	38.2	107.3	(77.0-145.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	15.8	69.5	(34.6-124.3)	Male	22	16.6	132.4	(83.0-200.5)
Female	13	12.5	104.3	(55.5-178.3)	Female	16	13.0	123.4	(70.5-200.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	48	45.0	106.6	(78.6-141.4)
Female	277	298.9	92.7	(82.1-104.3)	Female	38	37.3	101.9	(72.1-139.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	10.3	68.0	(27.2-140.1)	Male	26	36.4	71.4	(46.7-104.7)
<b><u>Colon / Rectum</u></b>					Female	15	15.6	96.4	(53.9-159.0)
Male	64	70.9	90.2	(69.5-115.2)	<b><u>Ovary</u></b>				
Female	68	69.1	98.4	(76.4-124.8)	Female	24	22.2	107.9	(69.1-160.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	17.9	83.9	(46.9-138.4)	Male	28	32.0	87.5	(58.1-126.5)
Female	4	5.4	nc	(nc-nc)	Female	23	30.5	75.3	(47.7-113.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	5.9	nc	(nc-nc)	Male	261	234.2	111.5	(98.3-125.8)
Female	7	5.0	138.7	(55.6-285.8)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	17.0	70.5	(36.4-123.1)
Male	44	42.6	103.4	(75.1-138.8)	Female	10	10.4	95.8	(45.9-176.3)
Female	26	23.7	109.7	(71.6-160.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	12	10.8	111.1	(57.3-194.0)
Male	8	9.9	81.1	(34.9-159.9)	<b><u>Thyroid</u></b>				
Female	0	2.5	nc	(nc-nc)	Male	24	17.8	135.0	(86.5-200.9)
<b><u>Leukemia</u></b>					Female	39	46.5	83.9	(59.6-114.7)
Male	23	32.9	70.0	(44.4-105.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	23	24.0	95.8	(60.7-143.7)	Female	65	66.6	97.6	(75.3-124.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	30	28.1	106.6	(71.9-152.2)	Male	904	953.7	94.8	(88.7-101.2)
Female	11	11.0	100.4	(50.0-179.6)	Female	919	994.8	92.4	(86.5-98.6)
<b><u>Lung and Bronchus</u></b>									
Male	92	120.3	76.5	(61.7-93.8)					
Female	115	141.4	81.3	(67.1-97.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	28.6	98.0	(65.1-141.6)	Male	20	21.0	95.3	(58.2-147.1)
Female	14	10.2	136.9	(74.8-229.7)	Female	24	16.8	142.8	(91.5-212.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	7.1	nc	(nc-nc)	Male	7	7.2	97.4	(39.0-200.7)
Female	5	5.6	89.7	(28.9-209.3)	Female	5	5.6	89.5	(28.9-209.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	20	19.5	102.4	(62.5-158.1)
Female	152	139.1	109.3	(92.6-128.1)	Female	12	15.8	75.8	(39.1-132.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.7	127.0	(46.4-276.3)	Male	13	17.1	75.9	(40.4-129.9)
<b><u>Colon / Rectum</u></b>					Female	8	6.8	117.1	(50.4-230.8)
Male	35	31.4	111.6	(77.7-155.1)	<b><u>Ovary</u></b>				
Female	31	28.5	108.7	(73.9-154.3)	Female	7	10.1	69.5	(27.8-143.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	7.9	63.5	(20.5-148.2)	Male	12	13.8	87.2	(45.0-152.3)
Female	1	2.3	nc	(nc-nc)	Female	8	12.3	65.2	(28.1-128.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	112	108.1	103.6	(85.3-124.7)
Female	2	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	7.4	148.3	(73.9-265.4)
Male	21	19.4	108.0	(66.8-165.1)	Female	5	4.3	115.7	(37.3-269.9)
Female	4	10.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	4.3	188.2	(81.0-370.9)
Male	2	4.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	9	8.0	112.5	(51.3-213.6)
<b><u>Leukemia</u></b>					Female	12	21.5	55.9	(28.8-97.6)
Male	19	14.2	133.8	(80.5-208.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	10.0	80.1	(34.5-157.8)	Female	36	31.7	113.7	(79.6-157.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	12.7	nc	(nc-nc)	Male	405	419.9	96.4	(87.3-106.3)
Female	7	4.7	149.8	(60.0-308.8)	Female	454	438.0	103.7	(94.3-113.7)
<b><u>Lung and Bronchus</u></b>									
Male	45	51.3	87.8	(64.0-117.5)					
Female	72	59.7	120.6	(94.4-151.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	10.5	123.5	(65.7-211.3)	Male	3	7.4	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	4	5.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	10	6.8	146.2	(70.0-268.9)
Female	33	42.9	77.0	(53.0-108.1)	Female	10	4.9	202.7	(97.1-372.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	1.3	373.9	(120.5-872.4)	Male	3	5.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	2.1	nc	(nc-nc)
Male	10	10.6	93.9	(45.0-172.8)	<b><u>Ovary</u></b>				
Female	14	8.6	163.6	(89.4-274.5)	Female	3	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	2.9	243.4	(97.5-501.6)	Male	8	5.0	160.2	(69.0-315.6)
Female	0	0.7	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	59	40.3	146.6	(111.6-189.1)
Female	2	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.6	nc	(nc-nc)
Male	7	6.7	103.8	(41.6-213.8)	Female	0	1.3	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.2	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	6.0	83.0	(26.7-193.7)
Male	3	4.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	3.0	nc	(nc-nc)	Female	15	10.1	148.9	(83.3-245.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	4.6	130.4	(47.6-283.9)	Male	174	150.2	115.8	(99.2-134.4)
Female	5	1.5	335.1	(108.0-782.1)	Female	137	135.6	101.0	(84.8-119.4)
<b><u>Lung and Bronchus</u></b>									
Male	24	19.2	124.8	(79.9-185.7)					
Female	20	19.6	102.0	(62.3-157.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	22.3	116.6	(76.1-170.8)	Male	16	15.7	101.8	(58.1-165.3)
Female	8	7.7	103.7	(44.7-204.3)	Female	12	11.2	107.5	(55.5-187.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.9	101.0	(32.6-235.8)	Male	3	5.4	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	7	3.9	178.8	(71.6-368.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	19	14.5	131.4	(79.1-205.3)
Female	74	88.6	83.5	(65.6-104.9)	Female	6	11.1	54.3	(19.8-118.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.9	nc	(nc-nc)	Male	9	12.2	73.6	(33.6-139.8)
<b><u>Colon / Rectum</u></b>					Female	9	4.6	194.1	(88.6-368.5)
Male	25	22.8	109.6	(70.9-161.8)	<b><u>Ovary</u></b>				
Female	18	20.4	88.3	(52.3-139.5)	Female	10	6.6	151.8	(72.7-279.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	5.9	152.0	(69.4-288.6)	Male	15	10.4	143.6	(80.3-236.9)
Female	3	1.6	nc	(nc-nc)	Female	12	9.2	130.8	(67.5-228.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	74	80.4	92.1	(72.3-115.6)
Female	4	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	5.5	nc	(nc-nc)
Male	21	14.0	150.3	(93.0-229.7)	Female	1	3.1	nc	(nc-nc)
Female	8	7.1	112.9	(48.6-222.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.9	nc	(nc-nc)
Male	5	3.3	150.4	(48.5-351.0)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	5	5.6	89.9	(29.0-209.8)
<b><u>Leukemia</u></b>					Female	10	12.7	78.6	(37.6-144.6)
Male	10	10.4	96.3	(46.1-177.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	7.0	127.8	(58.3-242.7)	Female	21	20.3	103.5	(64.0-158.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	20	9.4	211.9	(129.4-327.3)	Male	354	312.4	113.3	(101.8-125.8)
Female	2	3.3	nc	(nc-nc)	Female	292	294.9	99.0	(88.0-111.0)
<b><u>Lung and Bronchus</u></b>									
Male	51	39.4	129.3	(96.3-170.0)					
Female	44	42.9	102.5	(74.5-137.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	9.1	164.2	(91.8-270.9)	Male	7	6.5	107.7	(43.2-222.0)
Female	3	2.9	nc	(nc-nc)	Female	6	4.8	125.8	(45.9-273.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.1	237.7	(76.6-554.6)	Male	1	2.3	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.0	nc	(nc-nc)
Female	57	40.3	141.3	(107.0-183.1)	Female	2	4.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	6	5.2	114.6	(41.8-249.4)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	6	9.5	63.4	(23.2-138.1)	<b><u>Ovary</u></b>				
Female	4	7.9	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	6	4.4	137.7	(50.3-299.7)
Female	0	0.7	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	28	35.1	79.8	(53.0-115.3)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.3	nc	(nc-nc)
Male	6	6.0	100.1	(36.6-217.9)	Female	1	1.2	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.1	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	5.9	169.8	(81.3-312.3)
Male	4	4.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.8	nc	(nc-nc)	Female	4	9.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	4.0	nc	(nc-nc)	Male	125	132.0	94.7	(78.8-112.8)
Female	1	1.4	nc	(nc-nc)	Female	129	126.3	102.1	(85.3-121.4)
<b><u>Lung and Bronchus</u></b>									
Male	16	16.7	95.8	(54.7-155.6)					
Female	18	17.9	100.8	(59.7-159.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Gill

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	5	8.6	58.4	(18.8-136.4)	Female	1	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	9.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.1	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	21	32.9	63.9	(39.5-97.6)
Female	2	0.3	nc	(nc-nc)	Female	20	27.5	72.7	(44.4-112.3)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.3	nc	(nc-nc)					
Female	4	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gloucester

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	52	40.8	127.4	(95.1-167.0)	Male	40	27.4	146.0	(104.3-198.9)
Female	17	14.5	117.5	(68.4-188.1)	Female	33	20.0	165.1	(113.6-231.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	8.0	112.8	(51.5-214.2)	Male	5	9.8	51.1	(16.5-119.3)
Female	8	6.2	129.4	(55.7-255.0)	Female	7	7.5	92.8	(37.2-191.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	20	25.1	79.5	(48.6-122.8)
Female	188	164.0	114.6	(98.8-132.2)	Female	21	20.5	102.2	(63.2-156.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.6	129.4	(47.3-281.7)	Male	22	21.1	104.3	(65.4-158.0)
<b><u>Colon / Rectum</u></b>					Female	10	8.6	116.0	(55.5-213.3)
Male	47	38.8	121.0	(88.9-160.9)	<b><u>Ovary</u></b>				
Female	36	36.4	99.0	(69.3-137.1)	Female	8	12.2	65.7	(28.3-129.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	10.7	139.8	(78.2-230.6)	Male	16	18.9	84.7	(48.4-137.6)
Female	4	3.1	nc	(nc-nc)	Female	14	17.2	81.2	(44.4-136.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	122	148.2	82.3	(68.4-98.3)
Female	2	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	9.7	112.8	(56.2-201.9)
Male	30	24.1	124.6	(84.0-177.9)	Female	4	5.6	nc	(nc-nc)
Female	14	13.2	105.7	(57.7-177.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	3.5	202.6	(81.2-417.4)
Male	6	5.9	102.4	(37.4-223.0)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	8	8.6	92.9	(40.0-183.1)
<b><u>Leukemia</u></b>					Female	24	20.5	117.3	(75.1-174.5)
Male	10	17.8	56.0	(26.8-103.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	16	12.7	126.1	(72.0-204.7)	Female	42	39.5	106.4	(76.7-143.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	24	17.0	141.6	(90.7-210.6)	Male	564	555.3	101.6	(93.4-110.3)
Female	4	6.3	nc	(nc-nc)	Female	608	546.2	111.3	(102.6-120.5)
<b><u>Lung and Bronchus</u></b>									
Male	62	73.0	84.9	(65.1-108.8)					
Female	95	84.2	112.8	(91.2-137.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	5.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.0	100.2	(32.3-233.8)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	8	18.3	43.8	(18.8-86.2)
Female	0	0.2	nc	(nc-nc)	Female	7	18.0	38.9	(15.6-80.1)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.3	nc	(nc-nc)					
Female	0	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.1	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	17.8	151.3	(99.7-220.1)	Male	19	13.1	145.1	(87.3-226.6)
Female	6	6.0	99.3	(36.3-216.2)	Female	11	10.0	109.5	(54.6-195.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.4	137.5	(50.2-299.2)	Male	3	4.5	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	13	12.2	107.0	(56.9-183.0)
Female	84	83.7	100.3	(80.0-124.2)	Female	10	9.4	106.1	(50.8-195.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.9	nc	(nc-nc)	Male	21	10.7	196.2	(121.4-300.0)
<b><u>Colon / Rectum</u></b>					Female	5	4.0	123.5	(39.8-288.1)
Male	13	19.5	66.5	(35.4-113.7)	<b><u>Ovary</u></b>				
Female	11	16.9	65.1	(32.4-116.4)	Female	5	6.0	83.4	(26.9-194.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	4.9	nc	(nc-nc)	Male	7	8.6	81.3	(32.6-167.5)
Female	1	1.3	nc	(nc-nc)	Female	3	7.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	79	68.2	115.8	(91.7-144.3)
Female	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.6	nc	(nc-nc)
Male	15	12.2	123.1	(68.8-203.0)	Female	2	2.6	nc	(nc-nc)
Female	5	6.3	79.2	(25.5-184.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	2.5	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	6	5.0	120.6	(44.0-262.5)
<b><u>Leukemia</u></b>					Female	17	13.1	130.0	(75.7-208.2)
Male	7	8.8	79.9	(32.0-164.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	5.9	84.4	(27.2-197.0)	Female	19	18.8	101.0	(60.8-157.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	8.0	100.4	(43.2-197.9)	Male	282	262.6	107.4	(95.2-120.7)
Female	1	2.8	nc	(nc-nc)	Female	257	261.6	98.2	(86.6-111.0)
<b><u>Lung and Bronchus</u></b>									
Male	26	32.3	80.6	(52.6-118.1)					
Female	34	35.5	95.9	(66.4-133.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	7.1	126.2	(57.6-239.6)	Male	2	5.0	nc	(nc-nc)
Female	5	2.3	217.2	(70.0-506.9)	Female	1	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.6	107.9	(34.8-251.9)
Female	25	29.2	85.6	(55.4-126.4)	Female	4	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	8	7.2	110.8	(47.7-218.3)	<b><u>Ovary</u></b>				
Female	7	6.1	115.2	(46.2-237.4)	Female	5	2.1	234.3	(75.5-546.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	5	3.4	147.8	(47.6-344.8)
Female	3	0.5	nc	(nc-nc)	Female	7	2.8	254.2	(101.8-523.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	24	27.2	88.4	(56.6-131.5)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.8	nc	(nc-nc)
Male	2	4.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.8	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.1	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.1	nc	(nc-nc)	Female	8	6.9	116.6	(50.2-229.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.1	nc	(nc-nc)	Male	88	101.6	86.6	(69.5-106.7)
Female	0	1.0	nc	(nc-nc)	Female	102	93.8	108.8	(88.7-132.0)
<b><u>Lung and Bronchus</u></b>									
Male	10	13.0	77.2	(36.9-141.9)					
Female	10	13.6	73.5	(35.2-135.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	14	7.8	180.6	(98.7-303.1)	Female	1	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	1.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	11	7.9	138.4	(69.0-247.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.1	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	33	29.6	111.3	(76.6-156.3)
Female	0	0.3	nc	(nc-nc)	Female	32	24.5	130.7	(89.4-184.6)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.8	nc	(nc-nc)					
Female	5	3.6	139.9	(45.1-326.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	9.5	116.0	(57.8-207.6)	Male	10	6.2	160.1	(76.6-294.4)
Female	5	3.4	147.5	(47.5-344.1)	Female	12	4.6	259.9	(134.1-454.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	5.7	139.8	(60.2-275.6)
Female	51	37.7	135.4	(100.8-178.0)	Female	6	4.8	125.7	(45.9-273.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	13	4.6	283.8	(150.9-485.3)
<b><u>Colon / Rectum</u></b>					Female	1	2.0	nc	(nc-nc)
Male	10	8.8	113.8	(54.5-209.3)	<b><u>Ovary</u></b>				
Female	16	8.4	189.9	(108.5-308.5)	Female	4	2.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	8	4.0	198.2	(85.3-390.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	49	32.2	152.2	(112.6-201.2)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.2	nc	(nc-nc)
Male	3	5.3	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.8	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.7	nc	(nc-nc)
Male	6	4.1	146.7	(53.6-319.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	3.0	269.4	(116.0-530.9)	Female	12	9.1	131.9	(68.1-230.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.7	nc	(nc-nc)	Male	168	124.6	134.9	(115.2-156.9)
Female	1	1.5	nc	(nc-nc)	Female	174	126.5	137.5	(117.9-159.6)
<b><u>Lung and Bronchus</u></b>									
Male	23	16.6	138.6	(87.8-208.0)					
Female	15	19.7	76.2	(42.6-125.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	20.4	88.0	(52.2-139.2)	Male	12	13.9	86.6	(44.7-151.3)
Female	9	8.4	107.5	(49.1-204.2)	Female	8	11.4	69.9	(30.1-137.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	4.2	nc	(nc-nc)	Male	1	4.8	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	1	4.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.8	nc	(nc-nc)	Male	11	12.7	86.7	(43.2-155.2)
Female	94	91.5	102.7	(83.0-125.7)	Female	8	11.7	68.4	(29.4-134.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.8	nc	(nc-nc)	Male	14	10.4	134.7	(73.6-226.1)
<b><u>Colon / Rectum</u></b>					Female	3	4.9	nc	(nc-nc)
Male	21	19.7	106.5	(65.9-162.8)	<b><u>Ovary</u></b>				
Female	17	21.4	79.5	(46.3-127.3)	Female	3	6.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	5.3	nc	(nc-nc)	Male	5	9.4	53.2	(17.2-124.3)
Female	3	1.8	nc	(nc-nc)	Female	15	9.9	150.9	(84.4-248.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	43	71.4	60.2	(43.6-81.1)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	4.9	nc	(nc-nc)
Male	18	12.0	150.5	(89.1-237.8)	Female	1	3.3	nc	(nc-nc)
Female	4	7.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.2	nc	(nc-nc)
Male	0	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	12.1	nc	(nc-nc)
Male	16	9.1	175.5	(100.2-285.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	7.4	94.4	(37.8-194.4)	Female	26	21.3	121.9	(79.6-178.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	8.3	84.4	(33.8-174.0)	Male	250	276.1	90.5	(79.7-102.5)
Female	4	3.6	nc	(nc-nc)	Female	298	309.1	96.4	(85.8-108.0)
<b><u>Lung and Bronchus</u></b>									
Male	46	35.8	128.4	(94.0-171.3)					
Female	55	46.8	117.6	(88.6-153.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Groton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	12.3	56.9	(22.8-117.3)	Male	10	8.8	113.6	(54.4-208.9)
Female	1	4.0	nc	(nc-nc)	Female	7	6.3	110.6	(44.3-227.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	10	8.2	122.7	(58.7-225.6)
Female	54	52.8	102.2	(76.8-133.3)	Female	5	6.0	83.0	(26.7-193.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	5	7.3	68.9	(22.2-160.7)
<b><u>Colon / Rectum</u></b>					Female	2	2.6	nc	(nc-nc)
Male	14	13.0	107.8	(58.9-180.9)	<b><u>Ovary</u></b>				
Female	13	11.0	118.7	(63.1-203.0)	Female	4	3.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	42	47.6	88.3	(63.6-119.4)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	3.1	nc	(nc-nc)
Male	5	8.1	61.8	(19.9-144.1)	Female	0	1.7	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.4	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	7.6	105.1	(45.3-207.1)
Male	3	5.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.8	nc	(nc-nc)	Female	16	12.3	129.7	(74.1-210.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.5	90.7	(29.2-211.7)	Male	150	178.6	84.0	(71.1-98.6)
Female	0	1.8	nc	(nc-nc)	Female	148	166.7	88.8	(75.1-104.3)
<b><u>Lung and Bronchus</u></b>									
Male	15	22.3	67.4	(37.7-111.1)					
Female	12	23.0	52.2	(26.9-91.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	8.2	73.2	(26.7-159.3)	Male	6	5.6	106.9	(39.0-232.6)
Female	2	3.3	nc	(nc-nc)	Female	5	4.5	112.0	(36.1-261.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.1	nc	(nc-nc)
Female	35	36.2	96.6	(67.3-134.3)	Female	6	4.6	130.4	(47.6-283.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	10	4.3	232.1	(111.1-426.8)
<b><u>Colon / Rectum</u></b>					Female	1	1.9	nc	(nc-nc)
Male	8	8.1	99.3	(42.8-195.7)	<b><u>Ovary</u></b>				
Female	6	8.3	72.3	(26.4-157.3)	Female	1	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	24	29.1	82.3	(52.7-122.5)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.0	nc	(nc-nc)
Male	7	4.9	142.2	(57.0-293.1)	Female	1	1.3	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.8	nc	(nc-nc)
Male	4	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.6	108.0	(34.8-252.1)
Male	1	3.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.9	nc	(nc-nc)	Female	10	8.5	117.5	(56.3-216.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	104	112.1	92.8	(75.8-112.5)
Female	0	1.4	nc	(nc-nc)	Female	124	121.5	102.1	(84.9-121.7)
<b><u>Lung and Bronchus</u></b>									
Male	13	14.5	89.8	(47.8-153.6)					
Female	27	18.6	145.2	(95.6-211.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	7.6	79.3	(28.9-172.6)	Male	5	4.9	101.0	(32.6-235.8)
Female	3	3.0	nc	(nc-nc)	Female	2	3.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	4.5	nc	(nc-nc)
Female	28	29.2	96.0	(63.8-138.7)	Female	4	4.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.6	nc	(nc-nc)
Male	6	6.9	87.0	(31.8-189.3)	<b><u>Ovary</u></b>				
Female	7	7.5	93.3	(37.4-192.3)	Female	4	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	6	3.4	176.7	(64.5-384.6)
Female	0	0.6	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	30	25.1	119.4	(80.6-170.5)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	1.7	nc	(nc-nc)
Male	5	4.1	120.6	(38.9-281.5)	Female	1	1.1	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	3.7	nc	(nc-nc)
Male	5	3.3	153.8	(49.6-358.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.5	nc	(nc-nc)	Female	10	6.8	147.1	(70.4-270.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	97	98.2	98.8	(80.1-120.5)
Female	1	1.2	nc	(nc-nc)	Female	88	102.6	85.8	(68.8-105.7)
<b><u>Lung and Bronchus</u></b>									
Male	7	13.1	53.6	(21.5-110.5)					
Female	9	15.9	56.6	(25.8-107.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Halifax

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	8.5	118.0	(56.5-217.0)	Male	9	6.0	151.1	(69.0-286.9)
Female	2	2.9	nc	(nc-nc)	Female	8	4.4	180.2	(77.6-355.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	7	5.5	127.0	(50.9-261.7)
Female	39	37.1	105.3	(74.8-143.9)	Female	5	4.3	116.0	(37.4-270.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	5	4.8	104.7	(33.7-244.3)
<b><u>Colon / Rectum</u></b>					Female	2	1.8	nc	(nc-nc)
Male	13	8.7	150.1	(79.9-256.7)	<b><u>Ovary</u></b>				
Female	7	7.6	92.6	(37.1-190.8)	Female	1	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	7	4.0	174.0	(69.7-358.6)
Female	2	0.6	nc	(nc-nc)	Female	5	3.4	145.6	(46.9-339.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	35	32.1	109.2	(76.1-151.9)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.1	nc	(nc-nc)
Male	5	5.5	91.7	(29.6-214.1)	Female	0	1.2	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.0	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	5.2	114.4	(41.8-248.9)
Male	6	3.9	152.4	(55.7-331.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	2.7	224.9	(82.1-489.5)	Female	13	8.7	148.8	(79.1-254.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.7	nc	(nc-nc)	Male	152	120.7	125.9	(106.7-147.6)
Female	0	1.3	nc	(nc-nc)	Female	147	118.2	124.3	(105.0-146.1)
<b><u>Lung and Bronchus</u></b>									
Male	24	15.3	156.5	(100.3-232.9)					
Female	33	17.1	192.8	(132.7-270.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	8.0	87.6	(35.1-180.5)	Male	12	5.6	214.7	(110.8-375.1)
Female	1	2.6	nc	(nc-nc)	Female	7	4.0	173.2	(69.4-356.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	5	5.2	96.1	(31.0-224.3)
Female	40	33.4	119.8	(85.6-163.2)	Female	1	3.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	9	4.5	200.3	(91.4-380.2)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	14	8.1	173.3	(94.6-290.7)	<b><u>Ovary</u></b>				
Female	6	7.0	85.8	(31.3-186.8)	Female	2	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	30	30.6	98.2	(66.2-140.2)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.0	nc	(nc-nc)
Male	3	5.1	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	4.7	127.6	(46.6-277.7)
Male	5	3.8	133.0	(42.9-310.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.5	nc	(nc-nc)	Female	6	7.9	76.0	(27.8-165.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	115	114.2	100.7	(83.1-120.9)
Female	3	1.2	nc	(nc-nc)	Female	107	107.5	99.6	(81.6-120.3)
<b><u>Lung and Bronchus</u></b>									
Male	7	14.5	48.3	(19.3-99.5)					
Female	10	15.4	64.8	(31.0-119.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.5	nc	(nc-nc)	Male	3	5.0	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	5	1.8	281.7	(90.8-657.3)
Female	2	1.1	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	8	4.6	175.6	(75.6-346.1)
Female	30	28.5	105.3	(71.0-150.3)	Female	2	3.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.5	nc	(nc-nc)
Male	5	7.0	71.6	(23.1-167.0)	<b><u>Ovary</u></b>				
Female	3	6.7	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	23	26.8	85.8	(54.4-128.7)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.8	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.6	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.4	nc	(nc-nc)
Male	8	3.2	247.5	(106.6-487.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.3	nc	(nc-nc)	Female	8	6.8	117.8	(50.7-232.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.1	nc	(nc-nc)	Male	100	100.5	99.5	(81.0-121.1)
Female	1	1.1	nc	(nc-nc)	Female	85	96.5	88.1	(70.3-108.9)
<b><u>Lung and Bronchus</u></b>									
Male	18	13.3	134.9	(79.9-213.2)					
Female	9	15.0	60.1	(27.4-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hancock

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.5	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	7	15.6	44.8	(18.0-92.4)
Female	0	0.1	nc	(nc-nc)	Female	6	12.2	49.3	(18.0-107.3)
<b><u>Lung and Bronchus</u></b>									
Male	0	2.1	nc	(nc-nc)					
Female	0	1.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Hanover

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	15.3	85.2	(45.3-145.7)	Male	11	10.7	103.3	(51.5-184.8)
Female	8	5.5	144.3	(62.1-284.4)	Female	8	8.2	97.3	(41.9-191.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	3	2.7	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	8	9.9	80.9	(34.9-159.5)
Female	74	68.3	108.3	(85.0-136.0)	Female	11	8.2	134.2	(66.9-240.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	5	8.4	59.5	(19.2-138.9)
<b><u>Colon / Rectum</u></b>					Female	2	3.5	nc	(nc-nc)
Male	16	15.5	103.3	(59.0-167.7)	<b><u>Ovary</u></b>				
Female	17	14.5	116.9	(68.0-187.1)	Female	6	5.0	120.5	(44.0-262.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	4.1	170.7	(68.4-351.7)	Male	7	7.2	97.8	(39.2-201.5)
Female	3	1.2	nc	(nc-nc)	Female	4	6.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	69	56.0	123.2	(95.9-155.9)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.8	nc	(nc-nc)
Male	12	9.6	124.7	(64.3-217.8)	Female	2	2.2	nc	(nc-nc)
Female	1	5.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.6	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	9.3	96.3	(44.0-182.9)
Male	7	7.2	97.9	(39.2-201.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	5.1	97.4	(31.4-227.3)	Female	17	15.8	107.4	(62.5-171.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.5	76.7	(24.7-179.0)	Male	213	214.5	99.3	(86.4-113.6)
Female	0	2.5	nc	(nc-nc)	Female	220	221.4	99.4	(86.7-113.4)
<b><u>Lung and Bronchus</u></b>									
Male	21	27.4	76.5	(47.4-117.0)					
Female	28	32.7	85.7	(56.9-123.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hanson

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	10.6	151.2	(86.4-245.5)	Male	6	7.6	78.9	(28.8-171.7)
Female	4	3.4	nc	(nc-nc)	Female	10	5.6	179.9	(86.1-330.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	7	1.9	367.9	(147.4-758.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	9	7.1	126.9	(57.9-240.9)
Female	56	46.7	119.8	(90.5-155.6)	Female	7	5.3	131.8	(52.8-271.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	11	6.2	178.2	(88.8-318.8)
<b><u>Colon / Rectum</u></b>					Female	4	2.3	nc	(nc-nc)
Male	14	11.2	124.9	(68.2-209.6)	<b><u>Ovary</u></b>				
Female	8	9.3	85.8	(36.9-169.0)	Female	6	3.4	178.0	(65.0-387.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	2.9	205.3	(75.0-446.9)	Male	5	5.1	98.5	(31.8-230.0)
Female	0	0.8	nc	(nc-nc)	Female	5	4.1	120.7	(38.9-281.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	44	40.6	108.4	(78.7-145.5)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	2.7	295.5	(127.2-582.3)
Male	7	7.1	99.3	(39.8-204.6)	Female	1	1.4	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.4	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.4	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	6.9	145.2	(69.5-267.1)
Male	9	5.1	176.6	(80.6-335.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.3	nc	(nc-nc)	Female	14	10.8	129.5	(70.7-217.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.7	nc	(nc-nc)	Male	197	154.1	127.9	(110.6-147.0)
Female	1	1.6	nc	(nc-nc)	Female	183	146.9	124.6	(107.2-144.0)
<b><u>Lung and Bronchus</u></b>									
Male	35	19.3	181.5	(126.4-252.4)					
Female	29	20.7	140.4	(94.0-201.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	3.5	171.7	(62.7-373.7)	Male	4	2.4	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	7	13.1	53.3	(21.4-109.8)	Female	1	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.7	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.7	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	6	1.6	367.5	(134.2-799.9)
Female	0	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	14	12.9	108.9	(59.5-182.7)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.9	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.0	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	0.9	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	48	48.9	98.2	(72.4-130.3)
Female	0	0.5	nc	(nc-nc)	Female	48	41.6	115.4	(85.1-153.0)
<b><u>Lung and Bronchus</u></b>									
Male	5	6.3	79.8	(25.7-186.3)					
Female	14	5.8	240.9	(131.6-404.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Harvard

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	6.7	nc	(nc-nc)	Male	5	5.1	97.3	(31.3-227.0)
Female	0	1.9	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.8	125.7	(45.9-273.7)
Female	35	25.2	138.7	(96.6-192.9)	Female	3	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.2	nc	(nc-nc)
Male	3	7.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	5.0	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	26	26.5	98.2	(64.1-143.9)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.8	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	3.4	234.0	(100.8-461.2)
Male	3	3.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.8	nc	(nc-nc)	Female	7	6.0	115.8	(46.4-238.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.1	nc	(nc-nc)	Male	77	102.2	75.3	(59.4-94.1)
Female	1	0.9	nc	(nc-nc)	Female	87	79.2	109.9	(88.0-135.6)
<b><u>Lung and Bronchus</u></b>									
Male	8	12.3	65.0	(28.0-128.1)					
Female	6	11.4	52.8	(19.3-114.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Harwich

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	24.7	137.8	(95.4-192.6)	Male	29	15.4	188.0	(125.9-270.0)
Female	8	8.5	94.5	(40.7-186.2)	Female	10	10.6	94.1	(45.1-173.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.0	nc	(nc-nc)	Male	8	5.6	143.9	(61.9-283.5)
Female	2	3.2	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	17	13.9	122.0	(71.0-195.3)
Female	107	86.5	123.7	(101.4-149.5)	Female	19	11.5	165.0	(99.3-257.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	10	10.7	93.5	(44.8-172.0)
<b><u>Colon / Rectum</u></b>					Female	3	4.7	nc	(nc-nc)
Male	28	21.0	133.1	(88.4-192.4)	<b><u>Ovary</u></b>				
Female	19	20.3	93.7	(56.4-146.3)	Female	4	6.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.0	133.3	(57.4-262.7)	Male	13	10.8	120.0	(63.8-205.2)
Female	2	1.8	nc	(nc-nc)	Female	10	10.1	99.3	(47.5-182.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	89	79.1	112.5	(90.4-138.5)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.5	91.7	(29.5-213.9)
Male	14	12.5	111.7	(61.0-187.5)	Female	2	3.2	nc	(nc-nc)
Female	6	7.2	83.3	(30.4-181.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.3	nc	(nc-nc)
Male	0	3.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	9.4	74.2	(29.7-153.0)
Male	15	10.0	150.3	(84.1-248.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	7.1	98.3	(39.4-202.6)	Female	21	21.0	100.0	(61.9-152.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	9.2	76.3	(30.6-157.2)	Male	345	306.1	112.7	(101.1-125.3)
Female	6	3.6	167.2	(61.1-364.0)	Female	302	298.4	101.2	(90.1-113.3)
<b><u>Lung and Bronchus</u></b>									
Male	29	42.5	68.3	(45.7-98.0)					
Female	45	49.0	91.9	(67.0-123.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	5.1	98.2	(31.7-229.3)	Male	1	3.4	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	18	19.2	93.5	(55.4-147.8)	Female	1	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	0.5	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.0	nc	(nc-nc)
Male	6	4.7	127.6	(46.6-277.7)	<b><u>Ovary</u></b>				
Female	2	4.0	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	6	2.3	258.3	(94.3-562.2)
Female	0	0.3	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	11	17.8	62.0	(30.9-110.9)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.2	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.4	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	56	67.3	83.2	(62.8-108.0)
Female	0	0.7	nc	(nc-nc)	Female	51	62.7	81.4	(60.6-107.0)
<b><u>Lung and Bronchus</u></b>									
Male	8	9.0	89.2	(38.4-175.8)					
Female	7	9.7	72.4	(29.0-149.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Haverhill

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	79	60.4	130.9	(103.6-163.1)	Male	46	43.6	105.5	(77.2-140.7)
Female	26	22.7	114.7	(74.9-168.0)	Female	29	35.4	81.8	(54.8-117.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	19	14.4	132.2	(79.6-206.5)	Male	13	15.0	86.6	(46.1-148.1)
Female	12	11.5	104.1	(53.7-181.9)	Female	13	12.0	108.2	(57.6-185.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	47	40.4	116.3	(85.4-154.7)
Female	242	287.2	84.2	(74.0-95.6)	Female	41	34.0	120.5	(86.4-163.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	9.7	92.6	(42.3-175.9)	Male	40	34.8	115.0	(82.1-156.6)
<b><u>Colon / Rectum</u></b>					Female	13	14.5	89.8	(47.8-153.6)
Male	62	63.9	97.0	(74.3-124.3)	<b><u>Ovary</u></b>				
Female	60	61.4	97.6	(74.5-125.7)	Female	16	21.0	76.1	(43.5-123.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	22	16.4	133.9	(83.9-202.8)	Male	24	28.8	83.4	(53.4-124.2)
Female	2	4.9	nc	(nc-nc)	Female	23	27.1	84.8	(53.7-127.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	5.2	96.8	(31.2-226.0)	Male	194	225.9	85.9	(74.2-98.8)
Female	7	4.4	159.3	(63.8-328.2)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	15.3	104.3	(59.6-169.4)
Male	50	39.7	125.9	(93.4-165.9)	Female	12	9.4	128.3	(66.2-224.1)
Female	21	22.3	94.0	(58.2-143.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	8.9	78.7	(31.5-162.1)
Male	11	9.3	117.9	(58.8-211.0)	<b><u>Thyroid</u></b>				
Female	2	2.4	nc	(nc-nc)	Male	16	16.3	98.3	(56.1-159.6)
<b><u>Leukemia</u></b>					Female	43	43.7	98.3	(71.2-132.5)
Male	30	29.3	102.6	(69.2-146.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	23	21.5	106.8	(67.7-160.3)	Female	75	65.6	114.3	(89.9-143.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	31	26.4	117.3	(79.7-166.5)	Male	908	872.6	104.1	(97.4-111.1)
Female	17	10.1	168.2	(97.9-269.3)	Female	928	926.8	100.1	(93.8-106.8)
<b><u>Lung and Bronchus</u></b>									
Male	124	108.3	114.5	(95.3-136.5)					
Female	171	130.3	131.3	(112.3-152.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	7.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	6	5.7	105.8	(38.6-230.3)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.0	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	8	17.3	46.3	(19.9-91.2)
Female	0	0.2	nc	(nc-nc)	Female	11	12.8	86.1	(42.9-154.0)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.3	nc	(nc-nc)					
Female	2	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	34.6	86.6	(58.4-123.7)	Male	51	22.1	231.3	(172.2-304.1)
Female	13	13.8	94.2	(50.1-161.1)	Female	31	16.9	183.5	(124.7-260.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.0	83.3	(26.9-194.5)	Male	4	7.5	nc	(nc-nc)
Female	7	5.2	134.2	(53.7-276.4)	Female	6	6.5	92.6	(33.8-201.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	18	19.8	91.1	(53.9-143.9)
Female	164	130.3	125.9	(107.4-146.7)	Female	18	18.1	99.4	(58.9-157.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.7	nc	(nc-nc)	Male	19	14.8	128.6	(77.4-200.8)
<b><u>Colon / Rectum</u></b>					Female	3	7.4	nc	(nc-nc)
Male	25	31.1	80.5	(52.1-118.8)	<b><u>Ovary</u></b>				
Female	28	35.2	79.5	(52.8-114.9)	Female	10	9.9	100.8	(48.2-185.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	8.1	61.8	(19.9-144.2)	Male	7	14.9	46.8	(18.8-96.5)
Female	2	2.8	nc	(nc-nc)	Female	8	16.3	49.2	(21.2-96.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	118	99.3	118.8	(98.4-142.3)
Female	0	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	7.7	nc	(nc-nc)
Male	21	17.4	120.4	(74.5-184.1)	Female	3	5.3	nc	(nc-nc)
Female	6	11.0	54.4	(19.9-118.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	2.3	260.7	(95.2-567.5)
Male	1	4.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	8	5.9	135.4	(58.3-266.7)
<b><u>Leukemia</u></b>					Female	13	15.4	84.5	(45.0-144.5)
Male	14	14.5	96.3	(52.6-161.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	11.8	101.5	(52.4-177.3)	Female	24	29.3	81.9	(52.4-121.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	12.2	114.6	(62.6-192.3)	Male	427	419.0	101.9	(92.5-112.0)
Female	1	5.5	nc	(nc-nc)	Female	435	462.9	94.0	(85.3-103.2)
<b><u>Lung and Bronchus</u></b>									
Male	37	56.7	65.2	(45.9-89.9)					
Female	54	72.2	74.8	(56.2-97.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	3.5	141.4	(45.6-330.0)	Male	2	2.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	11	11.9	92.7	(46.2-165.8)	Female	1	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.6	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	14	12.2	114.8	(62.7-192.7)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.8	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.5	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.9	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	1.4	nc	(nc-nc)	Male	46	46.3	99.3	(72.7-132.4)
Female	0	0.5	nc	(nc-nc)	Female	32	39.1	81.8	(56.0-115.5)
<b><u>Lung and Bronchus</u></b>									
Male	6	6.2	96.1	(35.1-209.3)					
Female	4	6.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holbrook

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	11.3	150.0	(87.3-240.2)	Male	5	8.1	62.0	(20.0-144.7)
Female	4	3.9	nc	(nc-nc)	Female	12	6.1	196.2	(101.3-342.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	8	7.4	107.4	(46.2-211.6)
Female	47	49.9	94.1	(69.1-125.1)	Female	9	5.9	152.1	(69.4-288.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.7	nc	(nc-nc)	Male	9	6.4	141.6	(64.6-268.9)
<b><u>Colon / Rectum</u></b>					Female	3	2.5	nc	(nc-nc)
Male	11	11.7	94.0	(46.8-168.2)	<b><u>Ovary</u></b>				
Female	10	10.6	94.0	(45.0-172.9)	Female	1	3.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.1	nc	(nc-nc)	Male	5	5.4	93.5	(30.1-218.1)
Female	0	0.9	nc	(nc-nc)	Female	6	4.7	127.1	(46.4-276.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	34	41.8	81.4	(56.4-113.8)
Female	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.8	nc	(nc-nc)
Male	9	7.3	123.6	(56.4-234.7)	Female	5	1.6	308.2	(99.3-719.2)
Female	4	3.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.5	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	7.4	94.3	(37.8-194.4)
Male	6	5.4	111.6	(40.8-243.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	3.7	188.1	(75.4-387.6)	Female	11	11.5	96.0	(47.8-171.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	4.9	122.4	(44.7-266.5)	Male	176	161.2	109.2	(93.7-126.6)
Female	2	1.8	nc	(nc-nc)	Female	182	160.9	113.1	(97.3-130.8)
<b><u>Lung and Bronchus</u></b>									
Male	30	20.3	148.0	(99.9-211.3)					
Female	28	22.8	122.9	(81.6-177.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	20.5	126.9	(82.9-186.0)	Male	26	14.3	182.5	(119.2-267.3)
Female	10	7.2	139.1	(66.6-255.9)	Female	12	10.7	111.9	(57.7-195.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.4	112.4	(36.2-262.3)	Male	4	5.0	nc	(nc-nc)
Female	5	3.5	143.7	(46.3-335.4)	Female	3	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	4	13.1	nc	(nc-nc)
Female	97	88.1	110.1	(89.3-134.4)	Female	14	10.6	132.4	(72.3-222.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.8	nc	(nc-nc)	Male	13	11.0	118.4	(63.0-202.4)
<b><u>Colon / Rectum</u></b>					Female	6	4.5	134.5	(49.1-292.8)
Male	25	20.6	121.3	(78.5-179.0)	<b><u>Ovary</u></b>				
Female	15	19.1	78.5	(43.9-129.5)	Female	7	6.4	109.0	(43.7-224.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	5.4	129.9	(52.0-267.6)	Male	15	9.5	157.4	(88.0-259.6)
Female	1	1.5	nc	(nc-nc)	Female	6	8.6	69.9	(25.5-152.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	87	72.9	119.4	(95.6-147.3)
Female	2	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	5.0	nc	(nc-nc)
Male	18	12.6	142.3	(84.3-224.9)	Female	2	2.9	nc	(nc-nc)
Female	7	6.9	101.5	(40.7-209.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	2.3	390.8	(178.3-741.9)
Male	2	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	9	4.9	184.9	(84.4-351.1)
<b><u>Leukemia</u></b>					Female	11	12.5	88.0	(43.9-157.4)
Male	14	9.5	147.5	(80.6-247.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	6.7	74.9	(24.1-174.8)	Female	21	20.2	104.1	(64.4-159.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	8.5	70.2	(25.6-152.8)	Male	341	283.4	120.3	(107.9-133.8)
Female	3	3.2	nc	(nc-nc)	Female	284	285.8	99.4	(88.1-111.6)
<b><u>Lung and Bronchus</u></b>									
Male	34	36.2	94.0	(65.1-131.3)					
Female	32	41.3	77.6	(53.0-109.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	3.1	nc	(nc-nc)	Male	5	2.2	224.8	(72.4-524.5)
Female	0	0.8	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	4	11.2	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.5	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	2.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	12.7	62.8	(27.0-123.8)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.8	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.7	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	46	46.1	99.8	(73.0-133.1)
Female	0	0.4	nc	(nc-nc)	Female	34	34.9	97.4	(67.5-136.1)
<b><u>Lung and Bronchus</u></b>									
Male	6	5.9	102.3	(37.4-222.7)					
Female	6	4.9	123.0	(44.9-267.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	15.4	181.6	(120.6-262.5)	Male	16	10.9	147.3	(84.1-239.2)
Female	5	5.2	96.4	(31.1-225.1)	Female	10	7.9	126.8	(60.7-233.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.4	175.3	(64.0-381.5)	Male	5	3.8	131.2	(42.3-306.3)
Female	1	2.6	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	20	10.0	199.3	(121.7-307.9)
Female	79	66.0	119.7	(94.8-149.2)	Female	14	7.7	180.8	(98.8-303.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	11	8.6	127.3	(63.4-227.7)
<b><u>Colon / Rectum</u></b>					Female	3	3.3	nc	(nc-nc)
Male	19	15.8	120.2	(72.3-187.7)	<b><u>Ovary</u></b>				
Female	16	13.7	116.5	(66.5-189.2)	Female	5	4.8	104.4	(33.7-243.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.2	143.7	(52.5-312.9)	Male	6	7.3	82.3	(30.1-179.2)
Female	3	1.1	nc	(nc-nc)	Female	12	6.2	193.2	(99.7-337.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	68	57.5	118.3	(91.8-150.0)
Female	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	3.9	129.7	(41.8-302.6)
Male	8	9.9	81.2	(35.0-160.0)	Female	1	2.1	nc	(nc-nc)
Female	4	5.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.7	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	6	3.8	159.0	(58.1-346.1)
<b><u>Leukemia</u></b>					Female	8	9.1	87.5	(37.7-172.5)
Male	6	7.2	83.1	(30.4-180.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.9	nc	(nc-nc)	Female	13	15.4	84.4	(44.9-144.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	6.7	nc	(nc-nc)	Male	250	218.7	114.3	(100.6-129.4)
Female	6	2.3	256.2	(93.6-557.7)	Female	230	211.4	108.8	(95.2-123.8)
<b><u>Lung and Bronchus</u></b>									
Male	20	27.8	72.0	(44.0-111.3)					
Female	22	30.6	71.9	(45.0-108.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	38.7	69.8	(46.0-101.6)	Male	21	26.5	79.3	(49.1-121.3)
Female	15	14.5	103.7	(58.0-171.1)	Female	11	21.3	51.7	(25.8-92.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	8.4	83.2	(33.3-171.4)	Male	1	9.0	nc	(nc-nc)
Female	7	7.0	99.5	(39.9-205.0)	Female	9	7.3	123.0	(56.1-233.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	21	24.3	86.4	(53.5-132.1)
Female	146	166.9	87.5	(73.9-102.9)	Female	28	20.9	133.7	(88.8-193.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	14	5.7	246.9	(134.8-414.2)	Male	17	19.4	87.6	(51.0-140.2)
<b><u>Colon / Rectum</u></b>					Female	9	8.7	103.1	(47.1-195.8)
Male	61	37.8	161.2	(123.3-207.1)	<b><u>Ovary</u></b>				
Female	32	38.5	83.1	(56.8-117.3)	Female	9	12.4	72.3	(33.0-137.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	9.8	71.6	(28.7-147.5)	Male	11	17.6	62.5	(31.2-111.9)
Female	5	3.1	163.6	(52.7-381.7)	Female	19	17.2	110.3	(66.4-172.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	106	128.9	82.2	(67.3-99.4)
Female	0	2.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	14	9.2	151.6	(82.8-254.5)
Male	22	22.7	97.0	(60.7-146.8)	Female	8	5.9	136.7	(58.9-269.4)
Female	19	13.3	142.5	(85.8-222.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	5.2	nc	(nc-nc)
Male	11	5.3	206.0	(102.7-368.6)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	8	9.0	88.5	(38.1-174.4)
<b><u>Leukemia</u></b>					Female	19	25.5	74.5	(44.8-116.3)
Male	15	17.9	83.6	(46.7-137.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	17	13.6	125.0	(72.8-200.2)	Female	41	37.5	109.3	(78.4-148.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	15.3	117.3	(69.5-185.4)	Male	484	519.0	93.2	(85.1-101.9)
Female	7	6.2	113.0	(45.3-232.8)	Female	528	557.8	94.7	(86.8-103.1)
<b><u>Lung and Bronchus</u></b>									
Male	70	66.6	105.2	(82.0-132.9)					
Female	71	80.2	88.5	(69.1-111.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	6.1	82.6	(26.6-192.7)	Male	4	4.2	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.9	128.2	(41.3-299.1)
Female	23	26.3	87.5	(55.4-131.2)	Female	1	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.3	nc	(nc-nc)
Male	5	6.3	80.0	(25.8-186.7)	<b><u>Ovary</u></b>				
Female	1	5.9	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	8	2.6	309.6	(133.3-610.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	31	21.3	145.5	(98.9-206.6)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.5	nc	(nc-nc)
Male	6	3.8	158.9	(58.0-345.9)	Female	1	0.9	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.8	nc	(nc-nc)
Male	0	2.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.0	nc	(nc-nc)	Female	7	5.9	117.7	(47.1-242.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	84	84.0	100.0	(79.8-123.9)
Female	2	0.9	nc	(nc-nc)	Female	85	85.4	99.5	(79.5-123.0)
<b><u>Lung and Bronchus</u></b>									
Male	10	10.6	94.6	(45.3-174.1)					
Female	23	12.0	191.0	(121.1-286.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	13.8	130.5	(77.3-206.3)	Male	13	10.4	124.9	(66.4-213.6)
Female	4	4.7	nc	(nc-nc)	Female	11	8.2	134.7	(67.2-241.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	9	3.6	249.1	(113.7-472.9)
Female	5	2.7	182.1	(58.7-424.9)	Female	1	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	8	9.8	81.9	(35.3-161.4)
Female	68	69.5	97.9	(76.0-124.1)	Female	11	7.6	145.7	(72.6-260.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.3	nc	(nc-nc)	Male	6	8.9	67.2	(24.5-146.2)
<b><u>Colon / Rectum</u></b>					Female	2	3.3	nc	(nc-nc)
Male	10	15.7	63.7	(30.5-117.2)	<b><u>Ovary</u></b>				
Female	14	13.4	104.3	(57.0-175.0)	Female	7	5.0	140.7	(56.4-290.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	4.0	200.0	(86.1-394.1)	Male	6	6.8	87.6	(32.0-190.7)
Female	0	1.1	nc	(nc-nc)	Female	6	5.7	105.6	(38.5-229.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	81	56.8	142.6	(113.3-177.3)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.7	nc	(nc-nc)
Male	12	10.0	120.0	(61.9-209.6)	Female	0	2.0	nc	(nc-nc)
Female	7	5.2	135.0	(54.1-278.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.1	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.6	nc	(nc-nc)	Male	9	4.1	218.6	(99.7-415.0)
<b><u>Leukemia</u></b>					Female	9	10.6	84.7	(38.6-160.7)
Male	8	7.0	113.6	(48.9-223.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.7	126.6	(46.2-275.5)	Female	11	16.0	68.8	(34.3-123.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	6.6	nc	(nc-nc)	Male	229	212.6	107.7	(94.2-122.6)
Female	1	2.2	nc	(nc-nc)	Female	204	213.1	95.7	(83.1-109.8)
<b><u>Lung and Bronchus</u></b>									
Male	19	25.6	74.1	(44.6-115.7)					
Female	24	28.4	84.4	(54.0-125.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	5.2	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	13	20.3	64.1	(34.1-109.6)	Female	0	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.0	nc	(nc-nc)
Male	11	5.3	205.8	(102.6-368.3)	<b><u>Ovary</u></b>				
Female	6	3.9	154.8	(56.5-336.9)	Female	0	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	20	20.6	97.2	(59.3-150.1)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.3	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.1	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	6	4.8	125.0	(45.6-272.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	82	75.6	108.5	(86.3-134.6)
Female	1	0.7	nc	(nc-nc)	Female	59	62.7	94.0	(71.6-121.3)
<b><u>Lung and Bronchus</u></b>									
Male	8	9.6	83.8	(36.1-165.0)					
Female	8	8.6	93.2	(40.2-183.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	23.2	77.4	(45.9-122.4)	Male	9	16.0	56.1	(25.6-106.5)
Female	9	7.8	115.8	(52.9-219.9)	Female	9	11.7	76.8	(35.0-145.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	5.0	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	1	3.8	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.9	nc	(nc-nc)	Male	11	14.7	74.8	(37.3-133.8)
Female	104	96.8	107.5	(87.8-130.2)	Female	7	11.6	60.4	(24.2-124.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.1	nc	(nc-nc)	Male	18	12.0	149.5	(88.5-236.2)
<b><u>Colon / Rectum</u></b>					Female	2	4.9	nc	(nc-nc)
Male	27	23.0	117.4	(77.3-170.8)	<b><u>Ovary</u></b>				
Female	22	20.3	108.3	(67.8-163.9)	Female	11	7.0	156.5	(78.0-280.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	6.0	165.9	(79.4-305.2)	Male	10	10.7	93.6	(44.8-172.2)
Female	2	1.7	nc	(nc-nc)	Female	4	9.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	78	80.2	97.3	(76.9-121.4)
Female	2	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	5.6	nc	(nc-nc)
Male	16	14.0	114.6	(65.4-186.0)	Female	4	3.1	nc	(nc-nc)
Female	8	7.6	105.7	(45.5-208.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.8	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	6	5.4	110.6	(40.4-240.8)
<b><u>Leukemia</u></b>					Female	15	13.8	108.7	(60.8-179.3)
Male	6	10.6	56.4	(20.6-122.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	7.2	97.2	(38.9-200.2)	Female	19	22.3	85.1	(51.2-132.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	9.5	126.5	(65.3-221.0)	Male	314	316.4	99.3	(88.6-110.9)
Female	2	3.5	nc	(nc-nc)	Female	286	313.0	91.4	(81.1-102.6)
<b><u>Lung and Bronchus</u></b>									
Male	40	40.8	98.1	(70.1-133.6)					
Female	36	46.0	78.3	(54.8-108.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Hull

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	13.1	107.2	(58.5-179.8)	Male	14	9.0	155.4	(84.9-260.7)
Female	7	4.8	147.3	(59.0-303.5)	Female	16	7.1	226.0	(129.1-367.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
Female	5	2.2	230.8	(74.4-538.5)	Female	6	2.6	230.1	(84.0-500.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	14	8.3	168.3	(91.9-282.3)
Female	62	59.8	103.7	(79.5-132.9)	Female	11	7.1	155.9	(77.7-279.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	11	7.3	150.7	(75.1-269.6)
<b><u>Colon / Rectum</u></b>					Female	2	3.0	nc	(nc-nc)
Male	24	12.9	186.3	(119.3-277.2)	<b><u>Ovary</u></b>				
Female	10	12.1	82.5	(39.5-151.7)	Female	4	4.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	3.6	195.2	(78.2-402.2)	Male	10	6.2	160.9	(77.0-295.9)
Female	0	1.1	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	43	51.1	84.2	(61.0-113.5)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.2	nc	(nc-nc)
Male	7	8.2	85.2	(34.1-175.5)	Female	0	1.9	nc	(nc-nc)
Female	10	4.7	212.7	(101.8-391.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.2	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	7	3.0	234.3	(93.9-482.7)
<b><u>Leukemia</u></b>					Female	4	7.7	nc	(nc-nc)
Male	4	5.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	4.2	nc	(nc-nc)	Female	13	14.6	89.2	(47.4-152.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.8	86.7	(28.0-202.4)	Male	216	185.7	116.3	(101.3-132.9)
Female	8	2.2	367.5	(158.2-724.2)	Female	218	192.0	113.5	(99.0-129.7)
<b><u>Lung and Bronchus</u></b>									
Male	27	24.0	112.4	(74.1-163.6)					
Female	35	28.9	121.2	(84.4-168.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	12	9.9	121.5	(62.7-212.2)	Female	1	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	4	2.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	12	9.8	122.8	(63.4-214.5)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.7	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	46	36.1	127.3	(93.2-169.8)
Female	0	0.3	nc	(nc-nc)	Female	31	31.3	99.0	(67.2-140.5)
<b><u>Lung and Bronchus</u></b>									
Male	7	4.5	154.5	(61.9-318.3)					
Female	5	4.4	112.8	(36.4-263.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	19.3	72.4	(39.5-121.5)	Male	17	12.9	132.0	(76.8-211.3)
Female	10	6.8	146.3	(70.1-269.2)	Female	10	9.3	107.4	(51.4-197.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	5	4.6	109.0	(35.1-254.4)
Female	3	2.9	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	11	11.8	93.3	(46.5-166.9)
Female	88	76.1	115.6	(92.7-142.4)	Female	6	9.6	62.4	(22.8-135.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.1	nc	(nc-nc)	Male	9	9.7	92.9	(42.4-176.3)
<b><u>Colon / Rectum</u></b>					Female	2	4.0	nc	(nc-nc)
Male	17	18.2	93.3	(54.3-149.4)	<b><u>Ovary</u></b>				
Female	14	17.3	81.0	(44.2-135.9)	Female	8	5.7	141.6	(61.0-279.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	5.0	nc	(nc-nc)	Male	9	8.8	101.9	(46.5-193.4)
Female	0	1.5	nc	(nc-nc)	Female	7	8.1	86.1	(34.5-177.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	55	67.6	81.3	(61.3-105.8)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.6	nc	(nc-nc)
Male	7	11.1	62.9	(25.2-129.6)	Female	1	2.7	nc	(nc-nc)
Female	4	6.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.6	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.7	nc	(nc-nc)	Male	6	4.0	151.8	(55.4-330.5)
<b><u>Leukemia</u></b>					Female	9	9.4	95.8	(43.7-181.9)
Male	6	8.4	71.4	(26.1-155.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	6.0	nc	(nc-nc)	Female	21	18.1	116.1	(71.8-177.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	7.8	nc	(nc-nc)	Male	220	258.2	85.2	(74.3-97.2)
Female	1	2.9	nc	(nc-nc)	Female	237	254.7	93.0	(81.6-105.7)
<b><u>Lung and Bronchus</u></b>									
Male	28	34.2	81.8	(54.4-118.3)					
Female	25	39.3	63.7	(41.2-94.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	15.0	113.5	(66.1-181.7)	Male	12	10.4	115.4	(59.5-201.5)
Female	6	6.0	99.2	(36.2-215.9)	Female	9	8.4	107.7	(49.2-204.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	6	3.7	163.4	(59.7-355.7)
Female	6	2.6	227.1	(82.9-494.3)	Female	4	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	12	9.6	124.7	(64.4-217.9)
Female	69	66.7	103.4	(80.5-130.9)	Female	4	8.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.0	nc	(nc-nc)	Male	9	8.2	110.3	(50.3-209.4)
<b><u>Colon / Rectum</u></b>					Female	7	3.5	197.6	(79.2-407.2)
Male	13	15.0	86.5	(46.0-147.8)	<b><u>Ovary</u></b>				
Female	16	15.8	101.4	(57.9-164.7)	Female	4	5.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	4.0	nc	(nc-nc)	Male	5	7.0	71.1	(22.9-166.0)
Female	0	1.3	nc	(nc-nc)	Female	4	7.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	41	55.3	74.2	(53.2-100.6)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	3.7	189.6	(76.0-390.7)
Male	11	9.4	117.6	(58.6-210.5)	Female	1	2.4	nc	(nc-nc)
Female	3	5.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.7	nc	(nc-nc)
Male	6	2.2	269.5	(98.4-586.7)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	8.9	90.3	(38.9-178.0)
Male	12	6.9	173.9	(89.8-303.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	5.4	129.1	(51.7-265.9)	Female	18	15.4	116.7	(69.1-184.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.4	78.4	(25.3-183.0)	Male	224	210.0	106.6	(93.1-121.6)
Female	2	2.6	nc	(nc-nc)	Female	235	224.6	104.6	(91.7-118.9)
<b><u>Lung and Bronchus</u></b>									
Male	37	26.9	137.3	(96.7-189.3)					
Female	38	33.5	113.4	(80.3-155.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	12.5	215.6	(142.1-313.7)	Male	10	8.8	113.1	(54.2-208.1)
Female	2	4.0	nc	(nc-nc)	Female	8	6.3	127.6	(55.0-251.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.8	179.6	(57.9-419.2)	Male	5	3.1	159.4	(51.4-372.0)
Female	0	2.0	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	4	8.2	nc	(nc-nc)
Female	55	52.5	104.7	(78.9-136.3)	Female	5	6.1	82.4	(26.6-192.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	6	7.2	83.9	(30.6-182.6)
<b><u>Colon / Rectum</u></b>					Female	4	2.6	nc	(nc-nc)
Male	9	12.8	70.1	(32.0-133.0)	<b><u>Ovary</u></b>				
Female	15	10.7	140.3	(78.5-231.4)	Female	3	3.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	5	6.0	83.8	(27.0-195.4)
Female	0	0.9	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	42	48.2	87.2	(62.8-117.9)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.1	nc	(nc-nc)
Male	7	8.1	86.5	(34.7-178.2)	Female	1	1.6	nc	(nc-nc)
Female	8	4.1	197.5	(85.0-389.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	1.4	359.3	(115.8-838.5)
Male	2	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	7.5	146.8	(73.2-262.8)
Male	2	5.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.8	nc	(nc-nc)	Female	10	12.3	81.4	(38.9-149.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.5	nc	(nc-nc)	Male	190	180.1	105.5	(91.0-121.6)
Female	1	1.8	nc	(nc-nc)	Female	178	166.6	106.8	(91.7-123.7)
<b><u>Lung and Bronchus</u></b>									
Male	31	22.9	135.4	(92.0-192.2)					
Female	33	23.8	138.8	(95.6-195.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	7.7	65.0	(20.9-151.6)	Male	6	5.7	105.0	(38.3-228.5)
Female	6	2.9	206.2	(75.3-448.7)	Female	3	4.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.3	nc	(nc-nc)	Male	9	5.3	169.5	(77.3-321.7)
Female	38	35.1	108.3	(76.6-148.6)	Female	3	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	5	4.4	112.5	(36.2-262.4)
<b><u>Colon / Rectum</u></b>					Female	2	1.8	nc	(nc-nc)
Male	6	8.3	72.6	(26.5-157.9)	<b><u>Ovary</u></b>				
Female	6	7.5	79.7	(29.1-173.5)	Female	4	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	7	3.5	201.1	(80.6-414.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	22	28.1	78.3	(49.0-118.5)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.0	nc	(nc-nc)
Male	3	5.1	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.7	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	4.7	126.8	(46.3-276.0)
Male	2	3.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.6	nc	(nc-nc)	Female	14	8.3	168.9	(92.3-283.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.3	nc	(nc-nc)	Male	94	112.3	83.7	(67.6-102.4)
Female	4	1.3	nc	(nc-nc)	Female	127	114.6	110.8	(92.4-131.9)
<b><u>Lung and Bronchus</u></b>									
Male	8	13.7	58.2	(25.1-114.8)					
Female	15	17.1	88.0	(49.2-145.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.4	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	7	2.0	350.6	(140.4-722.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	15	16.8	89.2	(49.9-147.1)	Female	2	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.9	nc	(nc-nc)
Male	7	4.2	166.9	(66.9-344.0)	<b><u>Ovary</u></b>				
Female	1	3.5	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	15.8	56.8	(25.9-107.9)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.1	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.1	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.2	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	44	59.7	73.7	(53.5-98.9)
Female	0	0.6	nc	(nc-nc)	Female	51	54.5	93.5	(69.6-123.0)
<b><u>Lung and Bronchus</u></b>									
Male	11	7.9	139.8	(69.7-250.1)					
Female	10	8.3	120.8	(57.8-222.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	31	55.4	56.0	(38.0-79.5)	Male	11	42.0	26.2	(13.0-46.8)
Female	12	20.6	58.4	(30.1-102.0)	Female	9	36.0	25.0	(11.4-47.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	20	15.7	127.3	(77.7-196.6)	Male	12	14.1	84.9	(43.8-148.3)
Female	10	12.8	78.2	(37.4-143.8)	Female	9	11.2	80.2	(36.6-152.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	2.4	nc	(nc-nc)	Male	37	39.7	93.3	(65.7-128.6)
Female	220	290.2	75.8	(66.1-86.5)	Female	25	33.0	75.8	(49.0-111.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	12	11.0	109.4	(56.5-191.2)	Male	24	33.7	71.1	(45.5-105.8)
<b><u>Colon / Rectum</u></b>					Female	18	14.1	127.9	(75.8-202.2)
Male	66	62.5	105.6	(81.7-134.4)	<b><u>Ovary</u></b>				
Female	51	58.8	86.8	(64.6-114.1)	Female	16	21.0	76.1	(43.4-123.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	15.3	58.7	(26.8-111.5)	Male	16	26.8	59.7	(34.1-97.0)
Female	5	4.5	111.4	(35.9-260.0)	Female	16	24.7	64.7	(36.9-105.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	10	6.6	150.7	(72.1-277.1)	Male	227	210.4	107.9	(94.3-122.9)
Female	5	5.7	88.0	(28.4-205.4)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	19	14.6	130.0	(78.2-203.0)
Male	22	39.1	56.2	(35.2-85.1)	Female	14	8.9	156.8	(85.7-263.1)
Female	19	21.9	86.6	(52.1-135.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	12.3	nc	(nc-nc)
Male	16	8.8	181.5	(103.7-294.7)	<b><u>Thyroid</u></b>				
Female	1	2.3	nc	(nc-nc)	Male	20	17.9	111.9	(68.3-172.8)
<b><u>Leukemia</u></b>					Female	57	51.1	111.5	(84.5-144.5)
Male	32	29.7	107.7	(73.7-152.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	21.7	46.2	(22.1-84.9)	Female	56	63.5	88.2	(66.6-114.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	31	24.9	124.3	(84.4-176.4)	Male	763	837.4	91.1	(84.8-97.8)
Female	20	9.5	210.6	(128.6-325.3)	Female	730	913.9	79.9	(74.2-85.9)
<b><u>Lung and Bronchus</u></b>									
Male	89	99.6	89.4	(71.8-110.0)					
Female	83	119.8	69.3	(55.2-85.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lee

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	8.2	85.0	(34.1-175.2)	Male	4	5.4	nc	(nc-nc)
Female	5	3.0	165.7	(53.4-386.8)	Female	6	4.0	148.7	(54.3-323.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.0	121.1	(44.2-263.6)
Female	33	32.1	102.7	(70.7-144.3)	Female	4	4.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	9	7.7	117.2	(53.5-222.6)	<b><u>Ovary</u></b>				
Female	7	7.6	92.1	(36.9-189.8)	Female	3	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	25	28.1	89.1	(57.6-131.5)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	4.1	nc	(nc-nc)
Male	5	3.5	141.2	(45.5-329.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	2.6	228.6	(83.5-497.5)	Female	10	7.6	131.4	(62.9-241.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.3	153.5	(49.5-358.2)	Male	101	108.4	93.2	(75.9-113.3)
Female	4	1.3	nc	(nc-nc)	Female	119	109.5	108.7	(90.0-130.0)
<b><u>Lung and Bronchus</u></b>									
Male	10	14.3	69.7	(33.4-128.3)					
Female	23	16.9	136.4	(86.5-204.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	12.4	137.6	(80.1-220.4)	Male	18	8.6	209.5	(124.1-331.1)
Female	7	4.2	166.9	(66.9-343.8)	Female	11	6.3	174.2	(86.8-311.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	5	3.1	163.9	(52.8-382.5)
Female	2	2.0	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	6	8.0	75.4	(27.5-164.1)
Female	60	51.6	116.3	(88.8-149.7)	Female	10	6.2	160.6	(76.9-295.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	2.6	nc	(nc-nc)
Male	7	12.4	56.6	(22.7-116.7)	<b><u>Ovary</u></b>				
Female	10	11.0	90.9	(43.5-167.1)	Female	1	3.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	5	5.0	99.6	(32.1-232.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	48	46.0	104.3	(76.9-138.3)
Female	3	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	3.1	nc	(nc-nc)
Male	7	7.8	90.3	(36.2-186.0)	Female	1	1.7	nc	(nc-nc)
Female	2	4.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.4	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	5	3.0	168.3	(54.2-392.7)
<b><u>Leukemia</u></b>					Female	9	7.4	121.7	(55.5-230.9)
Male	5	5.7	87.7	(28.3-204.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	3.9	155.0	(56.6-337.3)	Female	11	12.0	91.8	(45.8-164.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.3	94.5	(30.4-220.5)	Male	183	174.0	105.2	(90.5-121.6)
Female	2	1.9	nc	(nc-nc)	Female	187	167.9	111.4	(96.0-128.5)
<b><u>Lung and Bronchus</u></b>									
Male	18	22.3	80.8	(47.8-127.7)					
Female	27	24.6	109.8	(72.3-159.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lenox

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	9.1	142.3	(75.7-243.3)	Male	10	5.6	178.3	(85.4-327.9)
Female	3	4.2	nc	(nc-nc)	Female	1	4.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	8	5.0	160.4	(69.1-316.0)
Female	37	34.2	108.3	(76.2-149.3)	Female	3	5.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	2.1	nc	(nc-nc)
Male	11	7.7	143.0	(71.3-255.9)	<b><u>Ovary</u></b>				
Female	14	10.3	135.4	(74.0-227.2)	Female	2	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	33	25.7	128.4	(88.4-180.3)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.9	nc	(nc-nc)
Male	8	4.3	187.4	(80.7-369.2)	Female	0	1.5	nc	(nc-nc)
Female	4	3.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	3.5	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.4	nc	(nc-nc)	Female	11	7.9	139.2	(69.4-249.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	3.1	nc	(nc-nc)	Male	122	106.9	114.1	(94.8-136.3)
Female	3	1.6	nc	(nc-nc)	Female	122	128.4	95.0	(78.9-113.5)
<b><u>Lung and Bronchus</u></b>									
Male	13	14.9	87.2	(46.4-149.1)					
Female	21	20.9	100.6	(62.3-153.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	46	43.4	105.9	(77.5-141.3)	Male	24	30.3	79.1	(50.7-117.7)
Female	19	16.2	117.1	(70.5-182.9)	Female	18	23.7	75.9	(45.0-120.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	9.5	126.0	(65.0-220.1)	Male	11	10.5	104.7	(52.2-187.4)
Female	7	7.6	92.6	(37.1-190.7)	Female	7	8.3	84.1	(33.7-173.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	31	27.9	111.0	(75.4-157.5)
Female	191	189.7	100.7	(86.9-116.0)	Female	22	23.4	93.9	(58.8-142.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.1	98.4	(35.9-214.1)	Male	24	23.4	102.4	(65.6-152.4)
<b><u>Colon / Rectum</u></b>					Female	8	9.8	81.3	(35.0-160.2)
Male	39	43.8	89.0	(63.3-121.6)	<b><u>Ovary</u></b>				
Female	50	42.9	116.5	(86.5-153.6)	Female	17	14.0	121.0	(70.5-193.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	11.5	78.5	(35.8-148.9)	Male	14	20.2	69.2	(37.8-116.1)
Female	5	3.5	144.1	(46.4-336.2)	Female	19	19.3	98.3	(59.1-153.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	119	155.3	76.6	(63.5-91.7)
Female	6	2.8	216.2	(79.0-470.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	10.7	65.6	(26.3-135.1)
Male	32	26.9	119.0	(81.4-168.0)	Female	6	6.5	92.2	(33.7-200.6)
Female	21	15.1	139.4	(86.3-213.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	5.4	149.1	(64.2-293.7)
Male	9	6.4	140.6	(64.2-266.9)	<b><u>Thyroid</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	12	10.5	114.2	(58.9-199.4)
<b><u>Leukemia</u></b>					Female	23	27.3	84.3	(53.4-126.5)
Male	11	20.2	54.5	(27.2-97.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	20	14.8	134.7	(82.3-208.1)	Female	43	43.4	99.0	(71.6-133.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	16	18.2	87.7	(50.1-142.4)	Male	565	603.8	93.6	(86.0-101.6)
Female	7	7.0	100.0	(40.1-206.1)	Female	670	627.4	106.8	(98.9-115.2)
<b><u>Lung and Bronchus</u></b>									
Male	89	76.8	115.8	(93.0-142.5)					
Female	118	91.2	129.4	(107.1-154.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	8	11.8	68.0	(29.3-133.9)	Female	0	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.6	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	12.0	50.1	(18.3-109.2)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.4	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.8	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	26	43.5	59.7	(39.0-87.5)
Female	0	0.4	nc	(nc-nc)	Female	30	38.0	79.0	(53.3-112.8)
<b><u>Lung and Bronchus</u></b>									
Male	3	5.9	nc	(nc-nc)					
Female	4	6.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	45.7	59.1	(38.9-86.0)	Male	24	30.1	79.7	(51.0-118.6)
Female	7	15.4	45.6	(18.3-93.9)	Female	17	21.3	79.8	(46.4-127.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	8.6	115.9	(55.5-213.2)	Male	9	10.5	85.9	(39.2-163.1)
Female	10	6.8	147.8	(70.8-271.8)	Female	9	7.8	114.8	(52.4-218.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	22	27.3	80.5	(50.4-121.9)
Female	173	174.5	99.2	(84.9-115.1)	Female	18	21.8	82.8	(49.0-130.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	5.2	nc	(nc-nc)	Male	9	21.8	41.4	(18.9-78.5)
<b><u>Colon / Rectum</u></b>					Female	7	9.1	77.1	(30.9-158.9)
Male	43	43.0	100.0	(72.4-134.7)	<b><u>Ovary</u></b>				
Female	27	39.9	67.6	(44.5-98.3)	Female	6	12.8	46.8	(17.1-102.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	11.3	70.8	(30.5-139.5)	Male	23	20.4	112.5	(71.3-168.8)
Female	3	3.3	nc	(nc-nc)	Female	10	18.3	54.7	(26.2-100.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.6	nc	(nc-nc)	Male	113	146.4	77.2	(63.6-92.8)
Female	0	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	10.6	94.5	(45.2-173.8)
Male	26	25.3	102.8	(67.1-150.6)	Female	5	6.1	82.4	(26.5-192.3)
Female	10	13.9	71.9	(34.4-132.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	3.5	nc	(nc-nc)
Male	2	6.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	19	8.9	213.0	(128.2-332.6)
<b><u>Leukemia</u></b>					Female	19	22.7	83.8	(50.4-130.8)
Male	25	19.8	126.0	(81.5-186.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	13.8	50.9	(20.4-104.9)	Female	54	40.0	134.9	(101.4-176.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	17.5	57.2	(27.4-105.3)	Male	447	587.6	76.1	(69.2-83.5)
Female	5	6.6	76.2	(24.6-177.8)	Female	455	578.5	78.7	(71.6-86.2)
<b><u>Lung and Bronchus</u></b>									
Male	31	77.8	39.9	(27.1-56.6)					
Female	35	86.4	40.5	(28.2-56.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	3.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	5	14.2	35.2	(11.3-82.1)
Female	0	0.1	nc	(nc-nc)	Female	3	12.1	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.8	nc	(nc-nc)					
Female	0	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lincoln

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	5.9	170.1	(81.4-312.9)	Male	4	4.4	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	5	3.4	145.6	(46.9-339.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	1.6	317.8	(102.4-741.6)	Male	2	1.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.1	172.8	(69.2-356.0)
Female	60	28.1	213.7	(163.0-275.1)	Female	8	3.1	256.2	(110.3-504.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	5	3.3	152.8	(49.2-356.6)
<b><u>Colon / Rectum</u></b>					Female	4	1.3	nc	(nc-nc)
Male	3	6.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	5.6	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	7	2.3	300.1	(120.2-618.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	32	20.1	159.1	(108.8-224.6)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.5	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.1	nc	(nc-nc)
Male	7	3.1	228.9	(91.7-471.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.1	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	102	84.2	121.2	(98.8-147.1)
Female	0	0.9	nc	(nc-nc)	Female	133	87.0	152.9	(128.0-181.2)
<b><u>Lung and Bronchus</u></b>									
Male	3	10.3	nc	(nc-nc)					
Female	17	11.2	152.0	(88.5-243.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Littleton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	11.0	72.8	(31.3-143.4)	Male	9	7.6	117.7	(53.7-223.4)
Female	4	4.0	nc	(nc-nc)	Female	3	5.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	4	7.0	nc	(nc-nc)
Female	52	48.0	108.3	(80.9-142.0)	Female	7	5.8	120.6	(48.3-248.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	5	6.0	83.6	(26.9-195.0)
<b><u>Colon / Rectum</u></b>					Female	5	2.5	202.8	(65.4-473.3)
Male	12	11.1	107.8	(55.6-188.3)	<b><u>Ovary</u></b>				
Female	10	10.6	94.4	(45.2-173.6)	Female	3	3.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	1	5.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	24	39.3	61.1	(39.1-90.9)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.7	nc	(nc-nc)
Male	5	6.8	73.5	(23.7-171.4)	Female	2	1.6	nc	(nc-nc)
Female	2	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.1	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	6.6	136.9	(62.5-260.0)
Male	3	5.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.7	136.8	(44.1-319.3)	Female	8	11.1	71.8	(30.9-141.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.6	nc	(nc-nc)	Male	118	152.2	77.5	(64.2-92.8)
Female	0	1.7	nc	(nc-nc)	Female	146	156.6	93.2	(78.7-109.6)
<b><u>Lung and Bronchus</u></b>									
Male	20	19.4	103.1	(62.9-159.2)					
Female	18	22.8	79.1	(46.8-125.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	21.2	89.5	(53.8-139.7)	Male	11	13.9	79.2	(39.5-141.8)
Female	5	7.7	64.8	(20.9-151.3)	Female	8	10.2	78.4	(33.8-154.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.9	151.9	(55.5-330.7)	Male	5	4.8	103.4	(33.3-241.3)
Female	1	3.2	nc	(nc-nc)	Female	0	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	13	12.6	103.2	(54.9-176.6)
Female	80	81.2	98.6	(78.2-122.7)	Female	12	10.6	113.3	(58.5-198.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.4	nc	(nc-nc)	Male	4	10.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	4.4	nc	(nc-nc)
Male	9	19.7	45.7	(20.9-86.8)	<b><u>Ovary</u></b>				
Female	20	19.9	100.6	(61.4-155.4)	Female	5	6.1	82.0	(26.4-191.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	5.2	nc	(nc-nc)	Male	12	9.5	126.7	(65.4-221.4)
Female	1	1.6	nc	(nc-nc)	Female	14	9.1	153.1	(83.6-256.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	71	68.1	104.3	(81.4-131.5)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.9	nc	(nc-nc)
Male	15	11.6	129.7	(72.5-213.9)	Female	2	3.0	nc	(nc-nc)
Female	2	6.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.6	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	7	4.0	173.0	(69.3-356.6)
<b><u>Leukemia</u></b>					Female	6	10.2	58.6	(21.4-127.6)
Male	8	9.2	87.4	(37.6-172.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	6.8	117.9	(50.8-232.3)	Female	14	18.7	74.9	(40.9-125.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	8.1	nc	(nc-nc)	Male	247	271.8	90.9	(79.9-102.9)
Female	1	3.2	nc	(nc-nc)	Female	244	277.4	88.0	(77.3-99.7)
<b><u>Lung and Bronchus</u></b>									
Male	26	36.2	71.8	(46.9-105.2)					
Female	29	42.2	68.7	(46.0-98.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lowell

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	81	85.1	95.2	(75.6-118.3)	Male	30	63.5	47.2	(31.9-67.4)
Female	34	30.3	112.3	(77.8-157.0)	Female	20	50.5	39.6	(24.2-61.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	27	22.6	119.2	(78.5-173.5)	Male	24	21.4	112.1	(71.8-166.7)
Female	10	17.4	57.5	(27.5-105.7)	Female	15	16.2	92.8	(51.9-153.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	3.6	nc	(nc-nc)	Male	53	59.5	89.1	(66.8-116.6)
Female	363	400.4	90.7	(81.6-100.5)	Female	36	47.1	76.5	(53.5-105.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	19	14.8	128.2	(77.2-200.2)	Male	50	50.2	99.7	(74.0-131.4)
<b><u>Colon / Rectum</u></b>					Female	23	19.9	115.3	(73.1-173.0)
Male	107	93.4	114.6	(93.9-138.5)	<b><u>Ovary</u></b>				
Female	99	84.0	117.8	(95.7-143.4)	Female	35	29.5	118.8	(82.8-165.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	31	23.3	133.3	(90.5-189.2)	Male	35	40.8	85.9	(59.8-119.4)
Female	12	6.6	183.0	(94.5-319.7)	Female	34	36.3	93.6	(64.8-130.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	9.5	62.9	(23.0-136.9)	Male	298	317.6	93.8	(83.5-105.1)
Female	7	7.6	91.7	(36.7-188.9)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	20	22.1	90.6	(55.3-139.9)
Male	49	58.1	84.4	(62.4-111.6)	Female	16	12.8	125.0	(71.4-203.0)
Female	31	30.8	100.6	(68.3-142.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	18	17.9	100.6	(59.6-159.0)
Male	18	13.2	135.9	(80.5-214.8)	<b><u>Thyroid</u></b>				
Female	8	3.3	245.0	(105.5-482.7)	Male	29	26.1	110.9	(74.3-159.3)
<b><u>Leukemia</u></b>					Female	97	68.8	141.1	(114.4-172.1)
Male	39	43.7	89.3	(63.5-122.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	29	30.5	95.1	(63.7-136.6)	Female	89	89.3	99.6	(80.0-122.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	66	37.6	175.7	(135.9-223.6)	Male	1288	1260.6	102.2	(96.7-107.9)
Female	18	13.7	131.4	(77.9-207.7)	Female	1322	1287.6	102.7	(97.2-108.4)
<b><u>Lung and Bronchus</u></b>									
Male	194	152.4	127.3	(110.0-146.5)					
Female	210	174.4	120.4	(104.7-137.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	25.6	101.7	(66.4-149.0)	Male	11	17.6	62.5	(31.2-111.9)
Female	8	9.0	88.5	(38.1-174.4)	Female	5	12.6	39.7	(12.8-92.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	5.3	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	13	16.2	80.5	(42.8-137.6)
Female	105	101.3	103.6	(84.7-125.4)	Female	14	12.8	109.5	(59.8-183.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	13	13.2	98.3	(52.3-168.1)
<b><u>Colon / Rectum</u></b>					Female	7	5.4	130.7	(52.4-269.3)
Male	37	25.2	147.0	(103.5-202.6)	<b><u>Ovary</u></b>				
Female	20	23.3	85.7	(52.3-132.3)	Female	4	7.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	6.6	75.3	(24.3-175.7)	Male	15	11.8	127.6	(71.4-210.5)
Female	1	1.9	nc	(nc-nc)	Female	8	10.7	74.5	(32.1-146.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	62	88.8	69.8	(53.5-89.5)
Female	2	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	6.2	129.6	(55.8-255.4)
Male	24	15.3	156.8	(100.5-233.4)	Female	6	3.5	169.3	(61.8-368.5)
Female	9	8.2	110.0	(50.2-208.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	3.1	193.8	(70.8-421.9)
Male	2	3.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	18	13.3	134.9	(79.9-213.2)
Male	8	11.5	69.4	(29.9-136.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	8.0	74.9	(27.4-163.1)	Female	33	23.7	139.3	(95.9-195.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	10.4	57.5	(21.0-125.3)	Male	325	347.9	93.4	(83.5-104.1)
Female	1	3.9	nc	(nc-nc)	Female	342	339.0	100.9	(90.5-112.2)
<b><u>Lung and Bronchus</u></b>									
Male	56	45.0	124.5	(94.1-161.7)					
Female	51	51.0	99.9	(74.4-131.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	13.0	131.1	(76.3-209.9)	Male	7	9.0	78.1	(31.3-161.0)
Female	2	4.1	nc	(nc-nc)	Female	13	6.2	209.7	(111.5-358.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.8	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	12	8.3	144.9	(74.8-253.1)
Female	47	51.8	90.8	(66.7-120.7)	Female	6	6.1	98.8	(36.1-215.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.6	nc	(nc-nc)	Male	9	7.1	126.9	(57.9-240.8)
<b><u>Colon / Rectum</u></b>					Female	6	2.6	231.1	(84.4-503.0)
Male	16	12.9	124.1	(70.9-201.5)	<b><u>Ovary</u></b>				
Female	8	10.6	75.2	(32.4-148.2)	Female	3	3.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	8	6.1	131.1	(56.5-258.3)
Female	1	0.9	nc	(nc-nc)	Female	3	4.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	50	48.6	102.9	(76.4-135.7)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.2	nc	(nc-nc)
Male	7	8.1	86.5	(34.7-178.3)	Female	4	1.6	nc	(nc-nc)
Female	6	4.0	148.7	(54.3-323.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.3	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	7.2	nc	(nc-nc)
Male	5	5.9	84.4	(27.2-197.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.8	133.3	(42.9-311.0)	Female	12	12.2	98.0	(50.6-171.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	5.6	107.7	(39.3-234.5)	Male	187	182.1	102.7	(88.5-118.5)
Female	6	1.8	325.3	(118.8-708.1)	Female	164	165.8	98.9	(84.3-115.2)
<b><u>Lung and Bronchus</u></b>									
Male	19	23.5	80.9	(48.7-126.4)					
Female	18	24.2	74.5	(44.1-117.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lynn

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	71	77.8	91.3	(71.3-115.2)	Male	38	57.0	66.7	(47.2-91.6)
Female	32	27.8	115.0	(78.7-162.4)	Female	34	45.7	74.4	(51.5-104.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	19.9	55.3	(27.5-98.9)	Male	20	19.3	103.4	(63.1-159.7)
Female	15	15.6	96.1	(53.8-158.6)	Female	11	14.9	73.7	(36.8-131.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	5	3.3	153.0	(49.3-357.1)	Male	48	53.1	90.4	(66.7-119.9)
Female	314	366.5	85.7	(76.5-95.7)	Female	58	43.0	134.7	(102.3-174.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	19	13.3	143.1	(86.1-223.5)	Male	35	44.4	78.9	(54.9-109.7)
<b><u>Colon / Rectum</u></b>					Female	24	18.2	131.8	(84.4-196.2)
Male	91	83.3	109.2	(87.9-134.1)	<b><u>Ovary</u></b>				
Female	89	76.5	116.4	(93.5-143.2)	Female	33	26.8	123.2	(84.8-173.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	26	20.9	124.2	(81.1-182.0)	Male	35	36.8	95.0	(66.2-132.1)
Female	2	6.0	nc	(nc-nc)	Female	45	33.4	134.8	(98.3-180.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	12	7.9	151.5	(78.2-264.7)	Male	279	283.8	98.3	(87.1-110.6)
Female	2	6.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	27	19.8	136.1	(89.7-198.1)
Male	42	51.5	81.5	(58.7-110.2)	Female	24	11.7	205.3	(131.5-305.4)
Female	52	28.2	184.2	(137.6-241.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	10	14.5	69.2	(33.1-127.2)
Male	18	11.8	152.7	(90.4-241.3)	<b><u>Thyroid</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	32	22.5	142.3	(97.3-200.9)
<b><u>Leukemia</u></b>					Female	80	60.8	131.6	(104.3-163.8)
Male	33	39.2	84.1	(57.9-118.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	28	27.7	101.0	(67.1-145.9)	Female	75	82.1	91.4	(71.9-114.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	53	33.6	157.7	(118.1-206.3)	Male	1181	1128.1	104.7	(98.8-110.8)
Female	16	12.6	127.0	(72.5-206.3)	Female	1277	1176.1	108.6	(102.7-114.7)
<b><u>Lung and Bronchus</u></b>									
Male	195	138.2	141.1	(122.0-162.3)					
Female	205	161.5	126.9	(110.1-145.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	14.8	141.9	(87.8-217.0)	Male	16	10.0	160.3	(91.6-260.4)
Female	7	5.1	136.5	(54.7-281.3)	Female	12	7.2	166.5	(85.9-290.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.0	168.3	(54.2-392.7)	Male	5	3.5	142.9	(46.0-333.5)
Female	3	2.3	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	10	9.1	109.4	(52.4-201.2)
Female	77	58.6	131.4	(103.7-164.2)	Female	11	7.3	150.9	(75.2-270.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.8	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	3.1	nc	(nc-nc)
Male	17	14.3	118.7	(69.1-190.1)	<b><u>Ovary</u></b>				
Female	11	13.5	81.8	(40.8-146.3)	Female	1	4.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.8	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	9	6.1	147.7	(67.4-280.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	52	50.0	103.9	(77.6-136.3)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.5	nc	(nc-nc)
Male	10	8.6	115.7	(55.4-212.7)	Female	2	2.0	nc	(nc-nc)
Female	5	4.7	106.9	(34.5-249.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.3	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	7.8	141.8	(70.7-253.8)
Male	7	6.6	105.8	(42.4-218.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	4.6	nc	(nc-nc)	Female	15	13.5	111.2	(62.2-183.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.9	nc	(nc-nc)	Male	201	197.1	102.0	(88.3-117.1)
Female	3	2.2	nc	(nc-nc)	Female	215	194.3	110.7	(96.4-126.5)
<b><u>Lung and Bronchus</u></b>									
Male	14	25.8	54.4	(29.7-91.2)					
Female	19	28.8	66.0	(39.7-103.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	41	51.4	79.7	(57.2-108.2)	Male	13	38.4	33.8	(18.0-57.8)
Female	17	19.2	88.4	(51.5-141.6)	Female	20	32.3	61.9	(37.8-95.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	13.4	67.3	(30.7-127.8)	Male	8	12.9	62.0	(26.7-122.3)
Female	14	10.6	131.6	(71.9-220.9)	Female	5	10.3	48.6	(15.7-113.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	32	35.7	89.7	(61.3-126.6)
Female	226	256.5	88.1	(77.0-100.4)	Female	27	30.0	90.1	(59.3-131.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	11	9.7	114.0	(56.8-203.9)	Male	28	30.0	93.5	(62.1-135.1)
<b><u>Colon / Rectum</u></b>					Female	8	12.7	63.0	(27.1-124.1)
Male	86	56.3	152.7	(122.2-188.6)	<b><u>Ovary</u></b>				
Female	47	53.5	87.9	(64.6-116.9)	Female	15	18.7	80.1	(44.8-132.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	14.0	64.5	(29.4-122.4)	Male	32	24.5	130.6	(89.3-184.4)
Female	3	4.2	nc	(nc-nc)	Female	23	23.1	99.7	(63.2-149.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	5.5	91.2	(29.4-212.8)	Male	151	188.8	80.0	(67.7-93.8)
Female	4	4.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	20	13.3	150.4	(91.8-232.3)
Male	36	34.8	103.4	(72.4-143.2)	Female	9	8.2	110.3	(50.3-209.4)
Female	12	19.6	61.3	(31.6-107.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	10.8	nc	(nc-nc)
Male	11	7.9	138.8	(69.2-248.4)	<b><u>Thyroid</u></b>				
Female	4	2.1	nc	(nc-nc)	Male	16	15.8	101.6	(58.0-164.9)
<b><u>Leukemia</u></b>					Female	37	44.1	83.8	(59.0-115.5)
Male	24	25.9	92.7	(59.4-137.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	18.9	74.2	(40.5-124.5)	Female	54	56.9	94.9	(71.3-123.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	26	22.4	115.9	(75.7-169.9)	Male	732	754.9	97.0	(90.1-104.3)
Female	9	8.7	103.7	(47.3-196.8)	Female	718	819.9	87.6	(81.3-94.2)
<b><u>Lung and Bronchus</u></b>									
Male	122	91.7	133.1	(110.5-158.9)					
Female	112	111.0	100.9	(83.1-121.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	7.5	120.7	(55.1-229.2)	Male	18	4.9	367.5	(217.7-580.9)
Female	1	2.6	nc	(nc-nc)	Female	7	3.5	199.0	(79.7-410.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	43	29.4	146.2	(105.8-197.0)	Female	2	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	3	6.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	6.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	33	25.3	130.3	(89.7-183.0)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	5	4.2	119.1	(38.4-277.9)	Female	2	1.0	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	3.5	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.3	nc	(nc-nc)	Female	5	7.0	71.0	(22.9-165.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	110	97.7	112.6	(92.6-135.8)
Female	1	1.1	nc	(nc-nc)	Female	97	97.2	99.8	(80.9-121.7)
<b><u>Lung and Bronchus</u></b>									
Male	6	13.1	45.9	(16.8-99.9)					
Female	11	15.2	72.5	(36.2-129.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	19.9	105.6	(65.4-161.5)	Male	24	14.8	162.0	(103.7-241.0)
Female	5	7.1	70.1	(22.6-163.6)	Female	18	11.9	151.2	(89.6-239.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	5.1	178.1	(81.3-338.1)	Male	6	5.1	118.1	(43.1-257.1)
Female	4	3.9	nc	(nc-nc)	Female	2	3.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.8	nc	(nc-nc)	Male	10	13.8	72.3	(34.6-132.9)
Female	108	98.4	109.8	(90.1-132.6)	Female	8	11.1	72.1	(31.0-142.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.3	nc	(nc-nc)	Male	11	12.3	89.2	(44.5-159.6)
<b><u>Colon / Rectum</u></b>					Female	4	4.8	nc	(nc-nc)
Male	26	22.2	117.3	(76.6-171.8)	<b><u>Ovary</u></b>				
Female	25	20.1	124.5	(80.5-183.8)	Female	4	7.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	5.6	125.1	(50.1-257.8)	Male	9	9.7	92.8	(42.4-176.2)
Female	0	1.6	nc	(nc-nc)	Female	8	8.6	93.4	(40.2-184.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.9	nc	(nc-nc)	Male	83	77.9	106.5	(84.8-132.1)
Female	3	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	5.2	190.8	(91.3-350.8)
Male	18	13.9	129.3	(76.6-204.3)	Female	4	3.0	nc	(nc-nc)
Female	3	7.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.2	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	5	5.8	86.2	(27.8-201.0)
<b><u>Leukemia</u></b>					Female	21	15.3	137.5	(85.1-210.2)
Male	6	10.0	60.1	(22.0-130.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	7.0	100.4	(40.2-206.8)	Female	18	22.4	80.2	(47.5-126.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	9.1	109.8	(52.5-201.9)	Male	325	298.6	108.8	(97.3-121.4)
Female	3	3.3	nc	(nc-nc)	Female	313	308.5	101.5	(90.5-113.3)
<b><u>Lung and Bronchus</u></b>									
Male	33	36.2	91.2	(62.8-128.1)					
Female	38	41.7	91.1	(64.4-125.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	25.9	115.7	(78.0-165.1)	Male	53	17.3	305.7	(229.0-399.9)
Female	6	9.1	66.1	(24.1-143.9)	Female	24	12.9	185.9	(119.1-276.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	5.1	nc	(nc-nc)	Male	6	6.2	97.1	(35.4-211.3)
Female	7	4.1	171.7	(68.8-353.7)	Female	5	4.8	103.6	(33.4-241.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	23	15.9	144.4	(91.5-216.7)
Female	143	108.0	132.5	(111.6-156.0)	Female	21	13.1	160.0	(99.0-244.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.1	nc	(nc-nc)	Male	8	13.2	60.5	(26.0-119.2)
<b><u>Colon / Rectum</u></b>					Female	6	5.5	108.3	(39.5-235.7)
Male	21	24.7	84.9	(52.5-129.8)	<b><u>Ovary</u></b>				
Female	17	23.2	73.3	(42.7-117.3)	Female	4	7.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.7	118.5	(51.0-233.6)	Male	16	11.9	134.2	(76.6-217.9)
Female	0	2.0	nc	(nc-nc)	Female	7	10.9	64.5	(25.8-132.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	105	91.9	114.3	(93.5-138.4)
Female	0	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	6.2	nc	(nc-nc)
Male	21	15.2	138.3	(85.6-211.5)	Female	4	3.6	nc	(nc-nc)
Female	4	8.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.0	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	9	5.4	168.1	(76.7-319.2)
<b><u>Leukemia</u></b>					Female	12	13.6	88.5	(45.7-154.6)
Male	14	11.4	122.5	(66.9-205.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	8.1	98.4	(42.4-193.8)	Female	29	25.8	112.6	(75.4-161.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	10.6	nc	(nc-nc)	Male	390	349.3	111.7	(100.8-123.3)
Female	3	4.0	nc	(nc-nc)	Female	388	352.8	110.0	(99.3-121.5)
<b><u>Lung and Bronchus</u></b>									
Male	32	46.0	69.6	(47.6-98.2)					
Female	53	53.5	99.1	(74.3-129.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marion

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	7.3	137.9	(66.0-253.6)	Male	13	4.7	277.1	(147.4-473.9)
Female	3	2.7	nc	(nc-nc)	Female	5	3.5	143.4	(46.2-334.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.3	117.5	(37.9-274.2)
Female	42	27.9	150.4	(108.4-203.3)	Female	3	3.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	6	3.4	178.2	(65.1-387.8)
<b><u>Colon / Rectum</u></b>					Female	0	1.5	nc	(nc-nc)
Male	6	6.6	90.8	(33.1-197.6)	<b><u>Ovary</u></b>				
Female	11	6.8	160.7	(80.1-287.6)	Female	5	2.1	238.0	(76.7-555.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	33	23.6	139.8	(96.2-196.4)
Female	2	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.7	nc	(nc-nc)
Male	5	3.9	126.9	(40.9-296.2)	Female	2	1.0	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.5	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	3.3	303.8	(145.4-558.7)
Male	2	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.3	nc	(nc-nc)	Female	1	6.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	110	92.6	118.7	(97.6-143.1)
Female	0	1.1	nc	(nc-nc)	Female	124	96.2	128.9	(107.2-153.7)
<b><u>Lung and Bronchus</u></b>									
Male	5	12.5	40.1	(12.9-93.6)					
Female	15	15.1	99.4	(55.6-164.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	38.6	90.6	(63.1-126.0)	Male	23	28.1	81.8	(51.8-122.7)
Female	12	14.5	82.5	(42.6-144.1)	Female	20	22.2	90.2	(55.1-139.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	9.3	75.2	(30.1-154.9)	Male	14	9.5	147.1	(80.3-246.7)
Female	7	7.2	97.1	(38.9-200.1)	Female	7	7.4	94.0	(37.7-193.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	20	25.9	77.2	(47.1-119.3)
Female	177	175.1	101.1	(86.7-117.1)	Female	24	21.4	112.3	(71.9-167.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	6.1	130.8	(56.3-257.8)	Male	20	21.8	91.9	(56.1-142.0)
<b><u>Colon / Rectum</u></b>					Female	12	9.0	133.6	(69.0-233.4)
Male	38	41.1	92.5	(65.5-127.0)	<b><u>Ovary</u></b>				
Female	27	39.5	68.3	(45.0-99.3)	Female	9	12.9	69.7	(31.8-132.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	16	10.3	155.2	(88.6-252.0)	Male	9	18.2	49.5	(22.6-93.9)
Female	8	3.1	257.3	(110.8-507.0)	Female	20	17.4	115.2	(70.3-177.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	3.5	nc	(nc-nc)	Male	129	138.2	93.3	(77.9-110.9)
Female	5	2.8	177.5	(57.2-414.2)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	9.8	112.5	(56.1-201.3)
Male	32	25.1	127.3	(87.1-179.8)	Female	7	6.0	117.4	(47.0-241.9)
Female	13	13.8	94.4	(50.2-161.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	6.6	76.0	(24.5-177.4)
Male	3	5.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	11	10.7	102.4	(51.0-183.2)
<b><u>Leukemia</u></b>					Female	30	27.3	109.7	(74.0-156.6)
Male	18	18.8	96.0	(56.9-151.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	17	13.7	124.0	(72.2-198.5)	Female	49	39.1	125.5	(92.8-165.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	16.5	109.4	(64.8-172.8)	Male	504	551.4	91.4	(83.6-99.7)
Female	8	6.3	127.4	(54.9-251.0)	Female	593	575.5	103.0	(94.9-111.7)
<b><u>Lung and Bronchus</u></b>									
Male	57	68.2	83.6	(63.3-108.3)					
Female	79	80.8	97.8	(77.4-121.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	31.1	105.9	(72.9-148.8)	Male	46	21.4	214.5	(157.0-286.1)
Female	11	10.4	106.1	(52.9-189.9)	Female	27	15.5	174.0	(114.7-253.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	6.6	121.7	(52.4-239.8)	Male	9	7.7	117.5	(53.6-223.0)
Female	3	5.0	nc	(nc-nc)	Female	10	5.6	177.4	(84.9-326.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	18	19.9	90.6	(53.7-143.3)
Female	145	130.1	111.4	(94.0-131.1)	Female	23	15.4	149.3	(94.6-224.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.9	128.9	(41.5-300.7)	Male	19	16.9	112.2	(67.5-175.3)
<b><u>Colon / Rectum</u></b>					Female	7	6.5	107.1	(42.9-220.7)
Male	32	30.9	103.7	(70.9-146.4)	<b><u>Ovary</u></b>				
Female	33	26.9	122.7	(84.5-172.4)	Female	11	9.5	115.9	(57.8-207.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	8.4	95.4	(41.1-187.9)	Male	12	14.6	82.1	(42.4-143.4)
Female	3	2.3	nc	(nc-nc)	Female	18	12.4	144.7	(85.7-228.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	115	116.3	98.9	(81.7-118.7)
Female	1	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	7.7	65.3	(21.1-152.5)
Male	15	19.4	77.5	(43.3-127.8)	Female	5	4.1	120.8	(38.9-281.8)
Female	6	10.2	59.0	(21.6-128.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.0	165.4	(53.3-385.9)
Male	5	4.6	107.7	(34.7-251.3)	<b><u>Thyroid</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	9	7.1	126.2	(57.6-239.6)
<b><u>Leukemia</u></b>					Female	12	17.4	68.8	(35.5-120.2)
Male	19	14.2	133.8	(80.5-208.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	9.5	73.5	(29.5-151.5)	Female	32	30.9	103.6	(70.9-146.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	13.3	105.0	(57.3-176.1)	Male	464	436.2	106.4	(96.9-116.5)
Female	4	4.7	nc	(nc-nc)	Female	469	418.8	112.0	(102.1-122.6)
<b><u>Lung and Bronchus</u></b>									
Male	51	56.5	90.3	(67.2-118.7)					
Female	74	62.2	119.1	(93.5-149.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	25.2	127.0	(86.9-179.3)	Male	19	16.0	118.6	(71.4-185.2)
Female	12	9.3	129.5	(66.8-226.2)	Female	13	11.9	108.8	(57.9-186.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	4.3	115.1	(37.1-268.5)	Male	4	5.7	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	Female	8	4.7	169.2	(72.9-333.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	15	14.5	103.2	(57.7-170.3)
Female	82	96.8	84.7	(67.4-105.2)	Female	11	12.8	86.1	(42.9-154.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	18	11.1	162.6	(96.3-256.9)
<b><u>Colon / Rectum</u></b>					Female	2	5.3	nc	(nc-nc)
Male	14	21.8	64.1	(35.0-107.5)	<b><u>Ovary</u></b>				
Female	16	22.4	71.4	(40.8-115.9)	Female	7	7.3	96.5	(38.7-198.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	6.2	145.4	(66.4-276.1)	Male	9	11.1	81.4	(37.1-154.4)
Female	2	2.0	nc	(nc-nc)	Female	10	11.0	90.7	(43.4-166.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	1.3	391.3	(126.1-913.2)	Male	94	80.7	116.5	(94.1-142.5)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	5.6	nc	(nc-nc)
Male	13	13.0	99.6	(53.0-170.4)	Female	4	3.5	nc	(nc-nc)
Female	6	8.1	74.4	(27.2-162.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.7	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	5	4.4	114.5	(36.9-267.2)
<b><u>Leukemia</u></b>					Female	9	11.2	80.6	(36.8-153.1)
Male	8	10.4	76.6	(33.0-150.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	7.9	88.2	(35.3-181.8)	Female	22	23.4	94.1	(59.0-142.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	9.5	52.9	(17.0-123.4)	Male	327	316.1	103.4	(92.5-115.3)
Female	1	4.0	nc	(nc-nc)	Female	285	332.3	85.8	(76.1-96.3)
<b><u>Lung and Bronchus</u></b>									
Male	44	43.7	100.8	(73.2-135.3)					
Female	41	54.0	76.0	(54.5-103.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.8	81.7	(35.2-161.0)	Male	11	6.4	172.4	(85.9-308.5)
Female	3	3.0	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	5.8	85.9	(27.7-200.5)
Female	41	34.5	118.8	(85.2-161.1)	Female	4	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	5	4.7	105.7	(34.1-246.6)
<b><u>Colon / Rectum</u></b>					Female	3	1.8	nc	(nc-nc)
Male	8	9.0	89.0	(38.3-175.3)	<b><u>Ovary</u></b>				
Female	10	7.4	135.2	(64.7-248.7)	Female	5	2.5	197.3	(63.6-460.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.5	nc	(nc-nc)	Male	8	4.4	180.4	(77.7-355.5)
Female	0	0.6	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	58	33.6	172.7	(131.2-223.3)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.3	nc	(nc-nc)
Male	7	5.5	128.4	(51.4-264.6)	Female	1	1.1	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	4.1	nc	(nc-nc)
Male	1	4.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.6	nc	(nc-nc)	Female	6	8.3	72.0	(26.3-156.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.9	nc	(nc-nc)	Male	152	128.0	118.7	(100.6-139.2)
Female	1	1.3	nc	(nc-nc)	Female	119	113.7	104.7	(86.7-125.3)
<b><u>Lung and Bronchus</u></b>									
Male	13	17.2	75.7	(40.3-129.5)					
Female	17	17.8	95.7	(55.7-153.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	10.2	127.5	(67.8-218.0)	Male	4	7.4	nc	(nc-nc)
Female	1	3.7	nc	(nc-nc)	Female	3	5.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.4	nc	(nc-nc)	Male	5	2.5	196.2	(63.2-458.0)
Female	2	1.9	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	12	6.8	177.0	(91.4-309.3)
Female	56	48.9	114.5	(86.5-148.7)	Female	4	5.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	6	5.8	102.9	(37.6-224.0)
<b><u>Colon / Rectum</u></b>					Female	1	2.4	nc	(nc-nc)
Male	13	10.7	121.0	(64.4-207.0)	<b><u>Ovary</u></b>				
Female	12	10.1	118.5	(61.2-207.0)	Female	4	3.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	8	4.8	165.1	(71.1-325.3)
Female	2	0.8	nc	(nc-nc)	Female	1	4.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	41	37.8	108.4	(77.8-147.0)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.6	nc	(nc-nc)
Male	9	6.7	134.9	(61.6-256.1)	Female	2	1.6	nc	(nc-nc)
Female	5	3.8	132.4	(42.7-309.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.4	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	7.3	123.0	(56.1-233.6)
Male	5	4.9	102.3	(33.0-238.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	3.6	168.9	(61.7-367.6)	Female	16	11.2	142.3	(81.3-231.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	4.4	nc	(nc-nc)	Male	153	146.4	104.5	(88.6-122.5)
Female	1	1.7	nc	(nc-nc)	Female	176	156.0	112.9	(96.8-130.8)
<b><u>Lung and Bronchus</u></b>									
Male	23	18.3	125.6	(79.6-188.5)					
Female	29	22.0	131.7	(88.2-189.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	12.4	97.0	(50.1-169.5)	Male	6	8.7	69.0	(25.2-150.2)
Female	2	4.2	nc	(nc-nc)	Female	9	6.5	138.8	(63.3-263.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	5	2.1	235.3	(75.8-549.2)	Female	3	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	11	8.1	136.6	(68.1-244.4)
Female	72	54.1	133.2	(104.2-167.7)	Female	10	6.3	158.9	(76.1-292.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	9	7.0	128.4	(58.6-243.8)
<b><u>Colon / Rectum</u></b>					Female	2	2.7	nc	(nc-nc)
Male	13	12.8	101.4	(53.9-173.4)	<b><u>Ovary</u></b>				
Female	9	11.4	78.8	(35.9-149.5)	Female	3	3.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	7	5.9	119.4	(47.8-246.0)
Female	1	0.9	nc	(nc-nc)	Female	5	5.0	99.4	(32.0-231.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	64	46.0	139.1	(107.1-177.7)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	3.1	nc	(nc-nc)
Male	5	7.9	63.2	(20.4-147.4)	Female	2	1.7	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.2	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	3.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	7.6	65.9	(21.2-153.8)
Male	5	5.8	85.9	(27.7-200.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	4.0	nc	(nc-nc)	Female	9	12.5	71.8	(32.8-136.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.4	nc	(nc-nc)	Male	177	175.3	101.0	(86.6-117.0)
Female	3	1.9	nc	(nc-nc)	Female	172	172.6	99.7	(85.3-115.7)
<b><u>Lung and Bronchus</u></b>									
Male	16	22.2	72.2	(41.3-117.3)					
Female	13	24.4	53.3	(28.3-91.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	49	57.9	84.6	(62.6-111.8)	Male	39	40.7	95.7	(68.1-130.9)
Female	26	21.6	120.5	(78.7-176.6)	Female	24	32.4	74.0	(47.4-110.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	13.0	77.2	(36.9-141.9)	Male	14	13.7	102.1	(55.7-171.2)
Female	10	10.4	96.1	(46.0-176.8)	Female	9	11.0	81.8	(37.3-155.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.4	nc	(nc-nc)	Male	42	37.3	112.6	(81.2-152.3)
Female	230	252.9	90.9	(79.6-103.5)	Female	28	31.6	88.5	(58.8-127.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	8.9	67.5	(24.6-146.9)	Male	29	29.9	97.0	(64.9-139.3)
<b><u>Colon / Rectum</u></b>					Female	7	13.2	53.2	(21.3-109.7)
Male	68	58.5	116.3	(90.3-147.5)	<b><u>Ovary</u></b>				
Female	47	57.4	81.9	(60.2-108.9)	Female	17	18.8	90.4	(52.7-144.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	14.8	101.4	(56.7-167.2)	Male	27	26.5	101.8	(67.1-148.1)
Female	4	4.6	nc	(nc-nc)	Female	17	25.7	66.1	(38.5-105.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	7	5.1	138.5	(55.5-285.4)	Male	164	193.9	84.6	(72.1-98.6)
Female	3	4.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	22	14.1	156.3	(97.9-236.7)
Male	42	34.9	120.2	(86.6-162.5)	Female	7	8.7	80.1	(32.1-165.0)
Female	16	20.1	79.7	(45.5-129.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	9.4	95.5	(43.6-181.3)
Male	9	8.1	110.7	(50.5-210.2)	<b><u>Thyroid</u></b>				
Female	1	2.1	nc	(nc-nc)	Male	15	14.8	101.4	(56.7-167.2)
<b><u>Leukemia</u></b>					Female	29	40.1	72.3	(48.4-103.8)
Male	24	26.9	89.1	(57.1-132.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	21	20.0	105.1	(65.0-160.7)	Female	51	56.6	90.1	(67.1-118.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	33	23.2	141.9	(97.7-199.4)	Male	780	789.5	98.8	(92.0-106.0)
Female	11	9.3	118.4	(59.0-211.8)	Female	758	841.6	90.1	(83.8-96.7)
<b><u>Lung and Bronchus</u></b>									
Male	97	99.8	97.2	(78.8-118.6)					
Female	124	120.9	102.5	(85.3-122.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	12.2	172.7	(106.9-264.0)	Male	8	8.9	89.8	(38.7-177.0)
Female	0	4.5	nc	(nc-nc)	Female	9	7.1	127.0	(57.9-241.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.9	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	10	8.3	120.6	(57.8-221.9)
Female	54	58.2	92.8	(69.7-121.1)	Female	10	6.8	147.7	(70.7-271.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	8	7.4	108.4	(46.7-213.6)
<b><u>Colon / Rectum</u></b>					Female	3	2.9	nc	(nc-nc)
Male	15	13.2	113.2	(63.3-186.8)	<b><u>Ovary</u></b>				
Female	17	12.4	137.2	(79.9-219.7)	Female	4	4.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.4	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	8	5.4	149.1	(64.2-293.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	61	47.4	128.6	(98.4-165.2)
Female	2	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.2	nc	(nc-nc)
Male	12	8.3	144.4	(74.5-252.3)	Female	1	1.9	nc	(nc-nc)
Female	6	4.5	133.3	(48.7-290.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.6	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	5	3.3	150.4	(48.5-351.0)
<b><u>Leukemia</u></b>					Female	6	8.6	69.7	(25.5-151.7)
Male	5	6.0	84.0	(27.1-196.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.3	117.2	(37.8-273.5)	Female	8	13.4	59.9	(25.8-117.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.5	90.6	(29.2-211.4)	Male	196	179.9	108.9	(94.2-125.3)
Female	1	2.0	nc	(nc-nc)	Female	176	185.8	94.7	(81.3-109.8)
<b><u>Lung and Bronchus</u></b>									
Male	23	22.2	103.8	(65.8-155.8)					
Female	21	25.8	81.5	(50.4-124.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	30.7	78.2	(50.1-116.4)	Male	20	21.3	94.0	(57.4-145.1)
Female	5	11.9	42.1	(13.6-98.2)	Female	19	17.3	109.5	(65.9-171.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	6.6	90.4	(33.0-196.7)	Male	3	7.4	nc	(nc-nc)
Female	6	5.6	107.8	(39.4-234.6)	Female	6	6.1	97.8	(35.7-212.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	16	19.5	81.9	(46.8-133.0)
Female	142	140.0	101.5	(85.5-119.6)	Female	16	17.2	92.8	(53.0-150.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	4.6	nc	(nc-nc)	Male	16	16.2	99.0	(56.5-160.7)
<b><u>Colon / Rectum</u></b>					Female	10	7.2	139.3	(66.7-256.2)
Male	26	30.7	84.7	(55.3-124.1)	<b><u>Ovary</u></b>				
Female	37	31.2	118.7	(83.6-163.6)	Female	16	10.3	155.7	(89.0-252.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	8.0	nc	(nc-nc)	Male	10	14.2	70.4	(33.7-129.6)
Female	1	2.5	nc	(nc-nc)	Female	6	14.2	42.3	(15.4-92.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	104	107.6	96.6	(78.9-117.1)
Female	2	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	7.5	120.2	(54.8-228.1)
Male	17	18.8	90.6	(52.7-145.0)	Female	1	4.8	nc	(nc-nc)
Female	9	11.1	81.3	(37.1-154.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.6	nc	(nc-nc)
Male	0	4.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	6	7.3	82.1	(30.0-178.7)
<b><u>Leukemia</u></b>					Female	26	20.1	129.5	(84.6-189.8)
Male	6	14.1	42.5	(15.5-92.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	10.9	119.4	(63.5-204.2)	Female	35	31.9	109.7	(76.4-152.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	12.6	87.1	(43.4-155.9)	Male	371	421.6	88.0	(79.3-97.4)
Female	5	5.2	97.1	(31.3-226.5)	Female	461	461.3	99.9	(91.0-109.5)
<b><u>Lung and Bronchus</u></b>									
Male	50	54.1	92.4	(68.6-121.8)					
Female	65	67.6	96.2	(74.2-122.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	6.3	158.7	(76.0-291.9)	Male	6	4.5	133.1	(48.6-289.6)
Female	4	1.9	nc	(nc-nc)	Female	6	3.1	190.5	(69.6-414.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	40	26.7	149.6	(106.8-203.7)	Female	5	3.0	166.3	(53.6-388.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	0.8	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.3	nc	(nc-nc)
Male	5	6.6	75.2	(24.2-175.5)	<b><u>Ovary</u></b>				
Female	6	5.3	113.3	(41.4-246.6)	Female	3	1.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	34	24.7	137.7	(95.4-192.5)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	1.6	nc	(nc-nc)
Male	7	4.2	166.6	(66.7-343.2)	Female	2	0.8	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.8	nc	(nc-nc)
Male	7	3.0	233.3	(93.5-480.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	1.8	nc	(nc-nc)	Female	5	6.2	80.5	(25.9-187.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	109	92.1	118.4	(97.2-142.8)
Female	0	0.9	nc	(nc-nc)	Female	107	83.4	128.3	(105.1-155.0)
<b><u>Lung and Bronchus</u></b>									
Male	11	11.6	95.2	(47.4-170.3)					
Female	9	11.7	77.1	(35.2-146.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.6	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	35	33.0	106.2	(73.9-147.7)	Female	3	3.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.7	nc	(nc-nc)
Male	8	7.7	103.9	(44.7-204.8)	<b><u>Ovary</u></b>				
Female	11	6.8	161.7	(80.6-289.4)	Female	4	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	27	28.7	93.9	(61.9-136.7)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	5	4.8	103.4	(33.3-241.4)	Female	0	1.0	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.8	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	4.5	199.0	(90.8-377.7)
Male	2	3.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.3	nc	(nc-nc)	Female	4	7.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	100	107.6	92.9	(75.6-113.0)
Female	3	1.2	nc	(nc-nc)	Female	102	105.3	96.9	(79.0-117.6)
<b><u>Lung and Bronchus</u></b>									
Male	16	13.8	116.4	(66.5-189.0)					
Female	14	15.3	91.5	(50.0-153.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	69	51.3	134.6	(104.7-170.3)	Male	20	36.0	55.5	(33.9-85.8)
Female	24	19.1	125.7	(80.5-187.1)	Female	11	29.1	37.9	(18.9-67.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	16	11.5	138.6	(79.2-225.2)	Male	12	12.4	96.5	(49.8-168.5)
Female	4	9.5	nc	(nc-nc)	Female	9	10.0	90.1	(41.1-171.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	22	33.2	66.2	(41.5-100.2)
Female	209	234.9	89.0	(77.3-101.9)	Female	27	28.3	95.5	(62.9-138.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	12	7.8	153.9	(79.4-268.9)	Male	27	27.8	97.1	(63.9-141.2)
<b><u>Colon / Rectum</u></b>					Female	20	12.0	167.4	(102.2-258.5)
Male	44	52.2	84.3	(61.3-113.2)	<b><u>Ovary</u></b>				
Female	38	51.2	74.3	(52.6-102.0)	Female	25	17.3	144.9	(93.7-213.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	14	13.5	103.3	(56.4-173.4)	Male	31	23.9	129.5	(88.0-183.9)
Female	6	4.1	145.9	(53.3-317.5)	Female	23	22.8	100.9	(63.9-151.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	4.1	nc	(nc-nc)	Male	186	183.5	101.3	(87.3-117.0)
Female	4	3.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	14	12.7	110.7	(60.4-185.7)
Male	36	32.0	112.4	(78.7-155.6)	Female	5	7.8	64.2	(20.7-149.8)
Female	17	18.4	92.4	(53.8-148.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	6.7	104.1	(41.7-214.5)
Male	7	7.6	92.6	(37.1-190.9)	<b><u>Thyroid</u></b>				
Female	0	2.0	nc	(nc-nc)	Male	13	12.7	102.0	(54.3-174.5)
<b><u>Leukemia</u></b>					Female	43	35.1	122.5	(88.7-165.1)
Male	25	24.1	103.6	(67.0-152.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	28	18.0	155.8	(103.5-225.2)	Female	61	53.5	113.9	(87.1-146.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	21	21.6	97.4	(60.3-148.9)	Male	719	716.3	100.4	(93.2-108.0)
Female	7	8.4	83.2	(33.3-171.4)	Female	724	764.7	94.7	(87.9-101.8)
<b><u>Lung and Bronchus</u></b>									
Male	92	90.6	101.5	(81.8-124.5)					
Female	113	109.0	103.7	(85.4-124.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	43	35.2	122.2	(88.4-164.6)	Male	18	23.3	77.3	(45.8-122.2)
Female	10	11.3	88.5	(42.4-162.8)	Female	18	16.2	111.4	(66.0-176.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	6.8	131.8	(60.2-250.3)	Male	4	8.3	nc	(nc-nc)
Female	7	5.2	135.1	(54.1-278.4)	Female	5	6.0	83.5	(26.9-194.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	11	21.3	51.6	(25.7-92.4)
Female	105	133.1	78.9	(64.5-95.5)	Female	10	16.4	60.9	(29.2-112.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.0	125.6	(40.5-293.0)	Male	19	16.9	112.7	(67.8-176.0)
<b><u>Colon / Rectum</u></b>					Female	4	6.8	nc	(nc-nc)
Male	42	32.7	128.3	(92.5-173.5)	<b><u>Ovary</u></b>				
Female	25	28.5	87.8	(56.8-129.6)	Female	8	9.8	81.8	(35.2-161.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	8.9	101.0	(46.1-191.7)	Male	13	15.8	82.2	(43.7-140.6)
Female	1	2.4	nc	(nc-nc)	Female	10	13.5	73.8	(35.4-135.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	2.1	233.3	(75.2-544.5)	Male	106	117.5	90.2	(73.8-109.1)
Female	1	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	8.2	60.9	(19.6-142.2)
Male	19	19.8	95.8	(57.7-149.6)	Female	3	4.4	nc	(nc-nc)
Female	7	10.6	66.0	(26.4-136.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	3.1	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	1.1	nc	(nc-nc)	Male	11	7.1	154.2	(76.9-276.0)
<b><u>Leukemia</u></b>					Female	22	17.7	124.3	(77.8-188.1)
Male	11	15.4	71.5	(35.6-128.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	19	10.2	186.0	(111.9-290.5)	Female	30	31.4	95.5	(64.5-136.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	13.7	94.6	(50.3-161.7)	Male	427	461.0	92.6	(84.1-101.8)
Female	1	5.0	nc	(nc-nc)	Female	388	438.7	88.4	(79.9-97.7)
<b><u>Lung and Bronchus</u></b>									
Male	58	61.7	94.0	(71.4-121.6)					
Female	72	67.2	107.1	(83.8-134.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middlefield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.2	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	11.4	52.7	(19.2-114.7)
Female	1	0.1	nc	(nc-nc)	Female	7	7.4	95.2	(38.1-196.2)
<b><u>Lung and Bronchus</u></b>									
Male	2	1.5	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	11.9	67.5	(29.1-133.0)	Male	5	8.3	60.2	(19.4-140.5)
Female	1	3.7	nc	(nc-nc)	Female	9	5.4	167.2	(76.3-317.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	11	7.7	143.3	(71.5-256.5)
Female	48	44.2	108.6	(80.0-143.9)	Female	4	5.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	11	6.3	175.9	(87.7-314.7)
<b><u>Colon / Rectum</u></b>					Female	1	2.3	nc	(nc-nc)
Male	11	12.0	91.9	(45.8-164.5)	<b><u>Ovary</u></b>				
Female	9	9.7	92.7	(42.3-176.0)	Female	5	3.2	154.2	(49.7-359.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.1	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	29	41.0	70.7	(47.3-101.6)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.9	nc	(nc-nc)
Male	9	7.3	123.9	(56.6-235.3)	Female	2	1.5	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.7	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	5.9	136.0	(58.6-268.1)
Male	5	5.5	91.2	(29.4-212.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.4	nc	(nc-nc)	Female	11	10.3	106.6	(53.2-190.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	4.9	nc	(nc-nc)	Male	135	163.3	82.7	(69.3-97.8)
Female	0	1.6	nc	(nc-nc)	Female	139	145.0	95.9	(80.6-113.2)
<b><u>Lung and Bronchus</u></b>									
Male	17	20.9	81.4	(47.4-130.4)					
Female	14	21.7	64.7	(35.3-108.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Milford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	40	29.8	134.0	(95.7-182.5)	Male	17	21.1	80.5	(46.9-129.0)
Female	12	9.8	122.9	(63.4-214.7)	Female	10	15.1	66.2	(31.7-121.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	6.8	118.5	(51.0-233.4)	Male	7	7.2	96.9	(38.8-199.7)
Female	3	4.9	nc	(nc-nc)	Female	2	5.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	19	19.4	98.0	(59.0-153.0)
Female	127	121.7	104.3	(87.0-124.1)	Female	9	14.6	61.7	(28.2-117.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.1	nc	(nc-nc)	Male	15	16.1	93.4	(52.2-154.1)
<b><u>Colon / Rectum</u></b>					Female	2	6.2	nc	(nc-nc)
Male	22	30.6	71.9	(45.0-108.9)	<b><u>Ovary</u></b>				
Female	31	26.3	117.7	(80.0-167.1)	Female	9	8.9	100.7	(46.0-191.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	7.8	89.5	(35.8-184.3)	Male	13	13.9	93.6	(49.8-160.1)
Female	6	2.1	285.1	(104.1-620.5)	Female	12	11.7	102.8	(53.0-179.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	2.4	204.6	(65.9-477.5)	Male	108	104.6	103.2	(84.7-124.6)
Female	0	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	7.4	81.4	(29.7-177.2)
Male	15	18.6	80.7	(45.1-133.0)	Female	8	4.0	200.1	(86.2-394.3)
Female	12	9.5	126.4	(65.3-220.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	4.3	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	9	7.6	118.4	(54.0-224.7)
<b><u>Leukemia</u></b>					Female	22	18.5	119.0	(74.5-180.1)
Male	12	14.0	85.4	(44.1-149.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	9.2	86.5	(37.2-170.4)	Female	16	27.7	57.7	(33.0-93.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	12.4	104.9	(55.8-179.5)	Male	396	415.2	95.4	(86.2-105.3)
Female	4	4.3	nc	(nc-nc)	Female	394	395.0	99.7	(90.1-110.1)
<b><u>Lung and Bronchus</u></b>									
Male	47	52.4	89.8	(65.9-119.4)					
Female	59	55.9	105.5	(80.3-136.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	15.3	104.7	(59.8-170.0)	Male	12	10.7	112.3	(58.0-196.2)
Female	10	5.4	186.4	(89.3-342.9)	Female	8	8.0	99.7	(42.9-196.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	6	3.7	160.6	(58.6-349.6)
Female	2	2.6	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	12	9.8	122.2	(63.1-213.5)
Female	65	65.4	99.3	(76.7-126.6)	Female	9	7.9	113.8	(51.9-216.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	10	8.2	121.2	(58.0-222.9)
<b><u>Colon / Rectum</u></b>					Female	1	3.3	nc	(nc-nc)
Male	21	15.4	136.4	(84.4-208.6)	<b><u>Ovary</u></b>				
Female	14	14.1	99.0	(54.1-166.1)	Female	2	4.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	4.1	172.3	(69.0-355.1)	Male	5	7.1	70.2	(22.6-163.9)
Female	0	1.2	nc	(nc-nc)	Female	9	6.4	140.4	(64.1-266.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	50	54.8	91.3	(67.7-120.3)
Female	3	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.8	nc	(nc-nc)
Male	13	9.5	137.0	(72.9-234.4)	Female	0	2.2	nc	(nc-nc)
Female	6	5.1	116.8	(42.6-254.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.8	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.6	nc	(nc-nc)	Male	7	3.7	191.3	(76.6-394.1)
<b><u>Leukemia</u></b>					Female	11	9.4	117.4	(58.5-210.0)
Male	5	7.0	71.2	(22.9-166.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.9	101.3	(32.7-236.4)	Female	25	15.1	166.1	(107.4-245.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	6.4	93.2	(34.0-202.9)	Male	246	212.3	115.8	(101.8-131.3)
Female	3	2.4	nc	(nc-nc)	Female	248	213.1	116.4	(102.3-131.8)
<b><u>Lung and Bronchus</u></b>									
Male	44	27.2	161.6	(117.4-216.9)					
Female	42	31.1	135.1	(97.4-182.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	8.9	124.3	(62.0-222.4)	Male	11	6.3	175.7	(87.6-314.4)
Female	4	2.9	nc	(nc-nc)	Female	6	4.5	133.8	(48.9-291.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	5.8	103.6	(37.8-225.4)
Female	43	37.7	114.1	(82.6-153.7)	Female	1	4.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	7	5.1	138.3	(55.4-285.0)
<b><u>Colon / Rectum</u></b>					Female	3	1.9	nc	(nc-nc)
Male	5	9.1	54.8	(17.7-127.9)	<b><u>Ovary</u></b>				
Female	9	7.6	118.4	(54.0-224.8)	Female	3	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	36	33.7	106.7	(74.8-147.8)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.2	nc	(nc-nc)
Male	10	5.7	174.4	(83.5-320.7)	Female	1	1.2	nc	(nc-nc)
Female	6	2.9	206.7	(75.5-449.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.0	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.4	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.7	nc	(nc-nc)	Female	6	8.8	67.9	(24.8-147.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.9	128.5	(41.4-300.0)	Male	132	126.9	104.0	(87.0-123.3)
Female	2	1.3	nc	(nc-nc)	Female	115	119.4	96.3	(79.5-115.6)
<b><u>Lung and Bronchus</u></b>									
Male	16	16.0	99.7	(57.0-161.9)					
Female	9	17.1	52.6	(24.0-99.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	12	13.9	86.4	(44.6-150.9)	Female	1	1.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.7	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	2.7	182.6	(58.9-426.2)	Female	0	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	10.9	82.2	(37.5-156.1)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.7	nc	(nc-nc)
Male	6	2.0	306.8	(112.0-667.8)	Female	0	0.4	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.5	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.3	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	49	41.0	119.5	(88.4-158.1)
Female	0	0.5	nc	(nc-nc)	Female	42	43.2	97.3	(70.1-131.5)
<b><u>Lung and Bronchus</u></b>									
Male	6	4.8	124.6	(45.5-271.1)					
Female	10	5.8	172.5	(82.6-317.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Milton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	30.9	87.4	(57.6-127.2)	Male	40	20.9	191.8	(137.0-261.2)
Female	14	11.9	117.4	(64.1-197.0)	Female	31	16.8	184.9	(125.6-262.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	6.4	156.6	(74.9-287.9)	Male	4	7.3	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	Female	5	6.1	81.9	(26.4-191.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	14	19.2	72.9	(39.8-122.3)
Female	158	135.8	116.3	(98.9-136.0)	Female	20	17.0	117.6	(71.8-181.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.1	nc	(nc-nc)	Male	16	15.6	102.3	(58.4-166.1)
<b><u>Colon / Rectum</u></b>					Female	8	7.1	112.7	(48.5-222.1)
Male	34	29.9	113.6	(78.7-158.8)	<b><u>Ovary</u></b>				
Female	45	31.0	145.2	(105.9-194.3)	Female	15	10.1	148.9	(83.3-245.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	7.9	63.2	(20.4-147.6)	Male	11	14.1	77.9	(38.8-139.3)
Female	2	2.5	nc	(nc-nc)	Female	9	14.2	63.4	(28.9-120.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	126	105.8	119.1	(99.2-141.8)
Female	2	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	7.3	nc	(nc-nc)
Male	10	18.0	55.5	(26.6-102.1)	Female	5	4.7	106.0	(34.2-247.4)
Female	13	10.9	119.5	(63.6-204.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.2	155.1	(50.0-361.8)
Male	3	4.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	2	6.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	24	18.3	131.5	(84.2-195.6)
Male	16	14.0	114.4	(65.3-185.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	10.8	101.5	(50.6-181.6)	Female	30	31.3	95.8	(64.6-136.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	12.4	48.4	(17.7-105.3)	Male	401	414.7	96.7	(87.5-106.6)
Female	7	5.1	136.5	(54.7-281.3)	Female	493	452.2	109.0	(99.6-119.1)
<b><u>Lung and Bronchus</u></b>									
Male	32	53.7	59.6	(40.7-84.1)					
Female	53	67.4	78.6	(58.9-102.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	9.6	104.3	(49.9-191.9)	Male	8	6.8	117.5	(50.6-231.6)
Female	0	3.2	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.3	79.1	(25.5-184.5)
Female	45	41.7	108.0	(78.8-144.5)	Female	1	4.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	2.1	240.0	(77.3-560.1)
Male	8	9.9	80.7	(34.7-159.0)	<b><u>Ovary</u></b>				
Female	4	8.5	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.7	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	10	3.8	260.0	(124.5-478.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	36	38.2	94.3	(66.0-130.6)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.4	nc	(nc-nc)
Male	5	6.3	79.2	(25.5-184.9)	Female	1	1.3	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.0	nc	(nc-nc)
Male	5	1.5	327.0	(105.4-763.0)	<b><u>Thyroid</u></b>				
Female	2	0.4	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	5.8	nc	(nc-nc)
Male	3	4.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	3.0	nc	(nc-nc)	Female	12	9.9	120.9	(62.4-211.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.3	nc	(nc-nc)	Male	126	140.0	90.0	(75.0-107.2)
Female	1	1.5	nc	(nc-nc)	Female	125	132.7	94.2	(78.4-112.2)
<b><u>Lung and Bronchus</u></b>									
Male	19	17.7	107.3	(64.6-167.6)					
Female	20	19.2	104.2	(63.6-161.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	10.4	86.7	(39.5-164.5)	Male	2	7.1	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	Female	1	5.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
Female	40	42.1	95.1	(67.9-129.5)	Female	8	5.2	152.9	(65.8-301.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	5	5.5	90.8	(29.3-212.0)
<b><u>Colon / Rectum</u></b>					Female	3	2.2	nc	(nc-nc)
Male	15	10.1	147.9	(82.7-243.9)	<b><u>Ovary</u></b>				
Female	8	9.3	85.6	(36.9-168.6)	Female	4	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	2.8	253.6	(101.6-522.4)	Male	7	4.8	144.9	(58.0-298.5)
Female	1	0.8	nc	(nc-nc)	Female	5	4.3	115.3	(37.2-269.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	22	38.1	57.8	(36.2-87.5)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.5	nc	(nc-nc)
Male	4	6.3	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
Female	5	3.4	148.7	(47.9-347.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	5.8	103.2	(37.7-224.5)
Male	3	4.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.3	nc	(nc-nc)	Female	11	9.9	111.0	(55.3-198.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	4.4	nc	(nc-nc)	Male	127	144.1	88.2	(73.5-104.9)
Female	3	1.6	nc	(nc-nc)	Female	157	139.6	112.4	(95.5-131.5)
<b><u>Lung and Bronchus</u></b>									
Male	29	18.7	155.3	(104.0-223.1)					
Female	24	20.8	115.1	(73.8-171.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	8	6.5	123.2	(53.0-242.7)	Female	1	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	6.5	76.5	(24.6-178.4)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	23	25.2	91.3	(57.8-137.0)
Female	0	0.3	nc	(nc-nc)	Female	14	21.6	64.7	(35.4-108.6)
<b><u>Lung and Bronchus</u></b>									
Male	2	3.5	nc	(nc-nc)					
Female	0	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	4.4	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	7	17.2	40.6	(16.3-83.7)
Female	0	0.2	nc	(nc-nc)	Female	5	13.8	36.2	(11.7-84.5)
<b><u>Lung and Bronchus</u></b>									
Male	0	2.2	nc	(nc-nc)					
Female	1	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.5	nc	(nc-nc)					
Female	0	0.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	5.9	117.8	(47.2-242.7)	Male	5	3.8	130.3	(42.0-304.1)
Female	4	1.8	nc	(nc-nc)	Female	7	2.5	283.9	(113.7-585.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	24	20.3	118.2	(75.7-175.9)	Female	1	2.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	1.1	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	4.6	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.5	nc	(nc-nc)	Male	5	2.7	187.0	(60.2-436.3)
Female	0	0.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	20	20.3	98.6	(60.2-152.3)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.4	nc	(nc-nc)
Male	7	3.2	215.5	(86.3-444.0)	Female	0	0.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	4	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	2.4	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.6	nc	(nc-nc)	Female	3	4.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.3	nc	(nc-nc)	Male	87	77.0	113.0	(90.5-139.4)
Female	1	0.8	nc	(nc-nc)	Female	75	67.7	110.7	(87.1-138.8)
<b><u>Lung and Bronchus</u></b>									
Male	12	10.5	114.8	(59.2-200.5)					
Female	14	10.5	133.3	(72.8-223.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	11.8	101.3	(52.3-177.0)	Male	10	8.6	116.8	(55.9-214.9)
Female	4	3.6	nc	(nc-nc)	Female	8	5.8	137.8	(59.3-271.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.8	nc	(nc-nc)	Male	5	2.9	170.3	(54.9-397.4)
Female	1	1.9	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	16	7.9	203.4	(116.2-330.3)
Female	70	47.2	148.3	(115.6-187.4)	Female	3	5.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	1.7	nc	(nc-nc)	Male	8	6.6	120.7	(52.0-237.9)
<b><u>Colon / Rectum</u></b>					Female	1	2.3	nc	(nc-nc)
Male	16	12.5	128.1	(73.2-208.0)	<b><u>Ovary</u></b>				
Female	14	9.8	142.7	(77.9-239.4)	Female	3	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	3.2	nc	(nc-nc)	Male	5	5.6	89.6	(28.9-209.1)
Female	0	0.8	nc	(nc-nc)	Female	6	4.3	139.0	(50.8-302.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	49	42.5	115.2	(85.2-152.3)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.0	nc	(nc-nc)
Male	8	7.7	104.2	(44.9-205.4)	Female	0	1.5	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.8	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	7.4	107.7	(46.4-212.2)
Male	7	5.7	123.7	(49.6-255.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.5	nc	(nc-nc)	Female	12	10.7	111.7	(57.7-195.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	5.0	119.2	(43.5-259.5)	Male	186	168.2	110.6	(95.3-127.7)
Female	2	1.6	nc	(nc-nc)	Female	181	150.9	120.0	(103.1-138.8)
<b><u>Lung and Bronchus</u></b>									
Male	19	21.0	90.7	(54.6-141.6)					
Female	22	20.9	105.1	(65.9-159.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	38	36.8	103.3	(73.1-141.8)	Male	28	25.9	108.1	(71.8-156.2)
Female	8	13.1	61.3	(26.4-120.8)	Female	28	20.1	139.6	(92.7-201.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	8.2	97.6	(42.0-192.2)	Male	5	8.9	56.3	(18.1-131.3)
Female	6	6.5	92.6	(33.8-201.6)	Female	4	6.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	24	23.8	100.8	(64.6-150.0)
Female	185	164.1	112.7	(97.1-130.2)	Female	20	19.5	102.5	(62.6-158.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	5.4	110.5	(40.4-240.5)	Male	16	20.0	79.9	(45.7-129.8)
<b><u>Colon / Rectum</u></b>					Female	8	8.3	96.9	(41.7-190.8)
Male	33	37.7	87.4	(60.2-122.8)	<b><u>Ovary</u></b>				
Female	31	35.0	88.7	(60.2-125.9)	Female	13	11.9	108.9	(57.9-186.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	9.7	113.5	(56.6-203.1)	Male	20	17.2	116.5	(71.1-179.9)
Female	5	2.8	177.0	(57.0-412.9)	Female	14	15.6	89.6	(49.0-150.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	151	130.4	115.8	(98.1-135.8)
Female	2	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	9.1	55.0	(17.7-128.4)
Male	15	23.0	65.3	(36.5-107.6)	Female	5	5.3	93.7	(30.2-218.7)
Female	9	12.8	70.5	(32.2-133.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	4.7	nc	(nc-nc)
Male	5	5.4	91.9	(29.6-214.5)	<b><u>Thyroid</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	8	9.1	87.8	(37.8-173.1)
<b><u>Leukemia</u></b>					Female	27	24.2	111.8	(73.6-162.6)
Male	20	17.3	115.9	(70.8-179.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	12.2	114.4	(62.5-192.0)	Female	46	37.5	122.6	(89.7-163.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	15.4	32.4	(10.5-75.7)	Male	494	512.3	96.4	(88.1-105.3)
Female	2	5.8	nc	(nc-nc)	Female	558	529.4	105.4	(96.8-114.5)
<b><u>Lung and Bronchus</u></b>									
Male	57	64.6	88.2	(66.8-114.3)					
Female	71	75.6	93.9	(73.3-118.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	35.7	84.1	(56.8-120.1)	Male	42	24.0	175.1	(126.2-236.7)
Female	20	12.5	159.6	(97.4-246.5)	Female	26	17.5	148.9	(97.3-218.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	7.2	153.1	(76.3-274.0)	Male	12	8.3	144.8	(74.8-253.0)
Female	6	5.6	106.5	(38.9-231.8)	Female	2	6.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	33	21.9	150.6	(103.7-211.5)
Female	179	142.0	126.1	(108.3-145.9)	Female	17	17.7	96.0	(55.9-153.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	4.3	nc	(nc-nc)	Male	7	17.8	39.3	(15.7-80.9)
<b><u>Colon / Rectum</u></b>					Female	8	7.4	107.5	(46.3-211.9)
Male	33	34.7	95.1	(65.4-133.6)	<b><u>Ovary</u></b>				
Female	28	33.1	84.6	(56.2-122.3)	Female	12	10.5	114.4	(59.0-199.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	9.0	99.9	(45.6-189.7)	Male	18	16.2	111.1	(65.8-175.7)
Female	2	2.7	nc	(nc-nc)	Female	10	14.9	67.2	(32.2-123.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	138	118.4	116.6	(98.0-137.8)
Female	3	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	8.4	59.3	(19.1-138.3)
Male	17	20.6	82.7	(48.1-132.4)	Female	2	5.0	nc	(nc-nc)
Female	10	11.4	87.9	(42.1-161.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.2	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	13	7.5	172.3	(91.6-294.6)
<b><u>Leukemia</u></b>					Female	23	18.6	123.4	(78.2-185.2)
Male	26	16.0	162.7	(106.2-238.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	11.4	61.4	(24.6-126.5)	Female	30	32.5	92.4	(62.3-131.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	14.1	49.8	(19.9-102.6)	Male	489	471.4	103.7	(94.7-113.3)
Female	4	5.3	nc	(nc-nc)	Female	462	471.9	97.9	(89.2-107.3)
<b><u>Lung and Bronchus</u></b>									
Male	34	61.2	55.6	(38.5-77.6)					
Female	46	69.4	66.3	(48.5-88.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	4.1	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.7	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	94	93.6	100.4	(81.2-122.9)	Male	22	65.4	33.6	(21.1-50.9)
Female	38	35.6	106.9	(75.6-146.7)	Female	14	52.7	26.6	(14.5-44.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	19	21.1	89.9	(54.1-140.4)	Male	21	22.4	93.6	(57.9-143.0)
Female	14	17.4	80.5	(44.0-135.1)	Female	17	18.2	93.5	(54.4-149.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	8	3.8	210.3	(90.6-414.4)	Male	55	60.3	91.2	(68.7-118.7)
Female	317	416.1	76.2	(68.0-85.0)	Female	43	51.8	83.0	(60.1-111.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	14	14.0	100.0	(54.6-167.9)	Male	52	49.1	105.8	(79.0-138.8)
<b><u>Colon / Rectum</u></b>					Female	23	21.6	106.4	(67.4-159.7)
Male	107	94.4	113.4	(92.9-137.0)	<b><u>Ovary</u></b>				
Female	91	94.3	96.5	(77.7-118.5)	Female	32	30.9	103.6	(70.8-146.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	31	24.2	127.9	(86.9-181.5)	Male	51	43.2	118.1	(87.9-155.3)
Female	7	7.5	92.7	(37.1-191.1)	Female	54	42.4	127.4	(95.7-166.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	7	7.7	90.5	(36.3-186.5)	Male	386	322.8	119.6	(107.9-132.1)
Female	5	6.7	74.1	(23.9-172.9)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	40	22.8	175.2	(125.1-238.6)
Male	71	57.3	123.9	(96.8-156.3)	Female	14	14.4	97.5	(53.3-163.6)
Female	45	33.1	135.9	(99.1-181.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	13.3	45.2	(16.5-98.4)
Male	15	13.3	112.4	(62.9-185.4)	<b><u>Thyroid</u></b>				
Female	5	3.5	144.3	(46.5-336.7)	Male	12	23.3	51.6	(26.6-90.1)
<b><u>Leukemia</u></b>					Female	82	63.1	130.0	(103.4-161.3)
Male	47	44.2	106.4	(78.2-141.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	34	33.4	101.7	(70.4-142.2)	Female	119	94.0	126.5	(104.8-151.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	58	38.2	151.6	(115.1-196.0)	Male	1422	1287.7	110.4	(104.8-116.3)
Female	20	15.4	130.1	(79.5-201.0)	Female	1320	1383.0	95.4	(90.4-100.7)
<b><u>Lung and Bronchus</u></b>									
Male	238	163.3	145.7	(127.8-165.5)					
Female	224	199.7	112.2	(98.0-127.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	5	4.9	102.7	(33.1-239.6)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.0	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	7	4.4	157.3	(63.0-324.2)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	2	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	16	16.2	98.7	(56.4-160.3)
Female	1	0.2	nc	(nc-nc)	Female	18	15.7	114.8	(68.0-181.4)
<b><u>Lung and Bronchus</u></b>									
Male	0	2.0	nc	(nc-nc)					
Female	3	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	2.8	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	5	9.2	54.1	(17.4-126.3)	Female	3	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	9.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.6	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	23	36.4	63.1	(40.0-94.7)
Female	0	0.4	nc	(nc-nc)	Female	20	30.5	65.5	(40.0-101.1)
<b><u>Lung and Bronchus</u></b>									
Male	1	5.0	nc	(nc-nc)					
Female	0	4.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	8	5.5	146.0	(62.8-287.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	19	19.6	97.0	(58.4-151.4)
Female	0	0.2	nc	(nc-nc)	Female	10	14.8	67.7	(32.4-124.6)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.5	nc	(nc-nc)					
Female	0	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Newbury

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.4	84.8	(36.5-167.0)	Male	6	6.4	93.1	(34.0-202.6)
Female	2	2.8	nc	(nc-nc)	Female	5	4.3	116.9	(37.7-272.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	6.0	83.8	(27.0-195.5)
Female	39	36.2	107.9	(76.7-147.4)	Female	7	4.2	164.8	(66.0-339.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	6	5.2	114.8	(41.9-250.0)
<b><u>Colon / Rectum</u></b>					Female	1	1.8	nc	(nc-nc)
Male	4	9.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	12	7.3	164.2	(84.7-286.8)	Female	3	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.6	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	23	36.9	62.4	(39.5-93.6)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.3	nc	(nc-nc)
Male	4	5.9	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	4.7	127.2	(46.5-276.9)
Male	5	4.2	118.5	(38.2-276.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.6	nc	(nc-nc)	Female	7	8.8	79.6	(31.9-164.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	4.1	120.5	(38.8-281.2)	Male	92	133.5	68.9	(55.5-84.5)
Female	0	1.3	nc	(nc-nc)	Female	113	115.9	97.5	(80.3-117.2)
<b><u>Lung and Bronchus</u></b>									
Male	5	17.4	28.7	(9.2-66.9)					
Female	11	17.3	63.5	(31.6-113.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	23.0	65.2	(36.5-107.6)	Male	18	15.6	115.7	(68.5-182.9)
Female	5	9.0	55.4	(17.9-129.3)	Female	13	12.5	104.0	(55.3-177.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	4.6	173.7	(74.8-342.2)	Male	6	5.5	108.6	(39.6-236.3)
Female	4	3.9	nc	(nc-nc)	Female	6	4.7	128.6	(47.0-279.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	20	14.3	140.2	(85.6-216.5)
Female	118	102.5	115.2	(95.3-137.9)	Female	8	12.8	62.6	(27.0-123.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.9	nc	(nc-nc)	Male	10	11.9	84.3	(40.3-155.0)
<b><u>Colon / Rectum</u></b>					Female	6	5.4	111.7	(40.8-243.0)
Male	26	22.2	117.2	(76.5-171.7)	<b><u>Ovary</u></b>				
Female	20	23.1	86.7	(53.0-134.0)	Female	13	7.6	171.3	(91.1-292.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	6.0	nc	(nc-nc)	Male	6	10.6	56.7	(20.7-123.3)
Female	3	1.9	nc	(nc-nc)	Female	10	10.7	93.1	(44.6-171.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	109	81.7	133.5	(109.6-161.0)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	5.5	126.7	(50.8-261.1)
Male	12	13.7	87.8	(45.3-153.3)	Female	2	3.5	nc	(nc-nc)
Female	8	8.2	97.2	(41.8-191.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.0	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	7	4.9	141.6	(56.7-291.7)
<b><u>Leukemia</u></b>					Female	14	12.9	108.6	(59.3-182.2)
Male	14	10.2	137.2	(74.9-230.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	8.0	75.3	(27.5-163.9)	Female	18	24.3	74.0	(43.8-116.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	9.5	105.7	(50.6-194.4)	Male	328	312.0	105.1	(94.1-117.1)
Female	3	3.9	nc	(nc-nc)	Female	325	340.4	95.5	(85.4-106.4)
<b><u>Lung and Bronchus</u></b>									
Male	35	41.0	85.4	(59.5-118.8)					
Female	30	51.7	58.0	(39.1-82.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	90	101.5	88.6	(71.3-109.0)	Male	78	67.8	115.1	(91.0-143.6)
Female	34	35.6	95.6	(66.2-133.6)	Female	45	51.0	88.2	(64.4-118.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	22	20.5	107.5	(67.3-162.8)	Male	19	23.6	80.5	(48.5-125.8)
Female	16	16.6	96.3	(55.0-156.4)	Female	17	18.3	93.1	(54.2-149.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	9	4.0	225.6	(102.9-428.3)	Male	65	62.2	104.5	(80.6-133.2)
Female	467	409.6	114.0	(103.9-124.8)	Female	41	51.2	80.1	(57.5-108.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	12.7	47.3	(17.3-103.0)	Male	31	49.5	62.7	(42.6-88.9)
<b><u>Colon / Rectum</u></b>					Female	14	21.4	65.5	(35.8-109.9)
Male	83	96.6	85.9	(68.5-106.5)	<b><u>Ovary</u></b>				
Female	88	92.9	94.7	(76.0-116.7)	Female	32	30.5	104.9	(71.8-148.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	18	25.5	70.6	(41.8-111.5)	Male	43	45.8	93.8	(67.9-126.4)
Female	7	7.5	92.8	(37.2-191.2)	Female	34	42.4	80.3	(55.6-112.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	10	7.2	138.3	(66.2-254.3)	Male	347	336.1	103.2	(92.7-114.7)
Female	8	6.3	126.4	(54.4-249.0)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	19	23.8	79.9	(48.1-124.7)
Male	56	57.7	97.1	(73.4-126.1)	Female	21	14.2	148.0	(91.6-226.3)
Female	19	32.6	58.2	(35.0-90.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	10.7	74.8	(32.2-147.5)
Male	5	13.7	36.4	(11.7-84.9)	<b><u>Thyroid</u></b>				
Female	1	3.4	nc	(nc-nc)	Male	23	21.6	106.6	(67.6-160.0)
<b><u>Leukemia</u></b>					Female	57	57.7	98.9	(74.9-128.1)
Male	36	45.3	79.6	(55.7-110.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	42	32.6	128.7	(92.8-174.0)	Female	82	94.1	87.1	(69.3-108.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	31	39.6	78.2	(53.1-111.0)	Male	1174	1336.8	87.8	(82.9-93.0)
Female	14	15.4	91.2	(49.8-153.0)	Female	1282	1362.9	94.1	(89.0-99.4)
<b><u>Lung and Bronchus</u></b>									
Male	103	175.0	58.9	(48.1-71.4)					
Female	129	201.3	64.1	(53.5-76.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Norfolk

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	13.0	61.7	(26.6-121.6)	Male	10	10.1	99.3	(47.5-182.6)
Female	6	2.9	203.6	(74.3-443.1)	Female	4	4.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	3.5	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	11	9.4	117.5	(58.6-210.2)
Female	44	40.3	109.1	(79.3-146.5)	Female	4	4.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	8	8.6	93.5	(40.3-184.2)
<b><u>Colon / Rectum</u></b>					Female	2	2.0	nc	(nc-nc)
Male	9	15.2	59.3	(27.1-112.6)	<b><u>Ovary</u></b>				
Female	10	8.0	125.1	(59.9-230.1)	Female	2	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.8	nc	(nc-nc)	Male	4	6.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	62	53.7	115.4	(88.4-147.9)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.6	nc	(nc-nc)
Male	7	9.7	71.9	(28.8-148.2)	Female	1	1.2	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.4	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	5.9	nc	(nc-nc)
Male	6	6.6	91.4	(33.4-198.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.8	nc	(nc-nc)	Female	6	9.5	63.4	(23.2-138.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.2	80.7	(26.0-188.4)	Male	164	202.8	80.9	(69.0-94.2)
Female	2	1.4	nc	(nc-nc)	Female	130	126.6	102.7	(85.8-121.9)
<b><u>Lung and Bronchus</u></b>									
Male	12	24.2	49.7	(25.6-86.7)					
Female	19	17.8	106.9	(64.3-166.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	14.2	154.5	(96.8-233.9)	Male	5	9.7	51.6	(16.6-120.5)
Female	11	5.3	206.5	(102.9-369.5)	Female	7	7.5	93.3	(37.4-192.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	3.0	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	14	8.9	156.9	(85.7-263.3)
Female	65	58.8	110.5	(85.3-140.8)	Female	9	7.6	118.7	(54.2-225.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	1.8	272.9	(87.9-636.8)	Male	14	7.2	193.6	(105.7-324.8)
<b><u>Colon / Rectum</u></b>					Female	2	3.2	nc	(nc-nc)
Male	16	13.7	116.7	(66.7-189.5)	<b><u>Ovary</u></b>				
Female	17	13.7	124.5	(72.5-199.3)	Female	6	4.5	134.7	(49.2-293.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	3.7	163.2	(59.6-355.3)	Male	10	6.5	153.2	(73.3-281.7)
Female	0	1.1	nc	(nc-nc)	Female	5	6.3	79.0	(25.5-184.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	53	49.6	106.9	(80.0-139.8)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.4	nc	(nc-nc)
Male	7	8.4	83.7	(33.5-172.5)	Female	1	2.1	nc	(nc-nc)
Female	5	4.8	104.2	(33.6-243.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.8	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.5	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	8.4	95.4	(41.1-188.1)
Male	5	6.4	77.6	(25.0-181.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.8	103.6	(33.4-241.7)	Female	10	13.7	72.9	(34.9-134.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	5.8	138.0	(59.4-271.9)	Male	225	192.9	116.6	(101.9-132.9)
Female	0	2.3	nc	(nc-nc)	Female	224	199.7	112.2	(98.0-127.9)
<b><u>Lung and Bronchus</u></b>									
Male	33	25.0	131.8	(90.7-185.1)					
Female	45	30.0	149.9	(109.3-200.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	40	29.6	135.1	(96.5-183.9)	Male	31	20.7	149.5	(101.6-212.2)
Female	8	11.5	69.6	(29.9-137.1)	Female	18	16.9	106.8	(63.3-168.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	6.6	90.7	(33.1-197.3)	Male	6	7.2	83.8	(30.6-182.3)
Female	6	5.5	109.3	(39.9-237.9)	Female	3	5.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	16	19.1	83.6	(47.8-135.8)
Female	134	136.0	98.5	(82.6-116.7)	Female	18	16.6	108.4	(64.2-171.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.4	nc	(nc-nc)	Male	18	16.0	112.3	(66.5-177.5)
<b><u>Colon / Rectum</u></b>					Female	6	7.0	85.6	(31.3-186.3)
Male	28	30.3	92.3	(61.3-133.4)	<b><u>Ovary</u></b>				
Female	24	31.0	77.4	(49.6-115.2)	Female	16	10.0	159.6	(91.2-259.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	7.8	115.7	(52.8-219.6)	Male	9	13.8	65.3	(29.8-123.9)
Female	2	2.5	nc	(nc-nc)	Female	15	13.7	109.4	(61.2-180.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	2.3	259.8	(94.9-565.5)	Male	107	104.5	102.4	(83.9-123.8)
Female	0	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	7.3	95.8	(38.4-197.4)
Male	19	18.5	102.9	(61.9-160.7)	Female	4	4.7	nc	(nc-nc)
Female	18	10.7	167.6	(99.3-264.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	3.6	195.7	(78.4-403.2)
Male	5	4.3	115.0	(37.1-268.3)	<b><u>Thyroid</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	7	7.2	96.8	(38.8-199.5)
<b><u>Leukemia</u></b>					Female	32	19.5	163.8	(112.0-231.2)
Male	17	13.9	122.1	(71.1-195.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	10.7	130.9	(71.5-219.7)	Female	33	30.7	107.5	(74.0-151.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	12.3	105.5	(56.1-180.4)	Male	415	411.2	100.9	(91.5-111.1)
Female	1	4.9	nc	(nc-nc)	Female	419	447.1	93.7	(85.0-103.1)
<b><u>Lung and Bronchus</u></b>									
Male	39	52.0	74.9	(53.3-102.4)					
Female	41	63.8	64.2	(46.1-87.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	26.6	101.4	(66.8-147.5)	Male	32	19.6	163.4	(111.7-230.6)
Female	10	9.4	106.8	(51.1-196.5)	Female	20	15.3	130.4	(79.6-201.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	6.6	121.7	(52.4-239.9)	Male	5	6.8	74.0	(23.8-172.6)
Female	10	5.1	197.5	(94.6-363.3)	Female	6	5.1	118.2	(43.2-257.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	21	18.2	115.2	(71.3-176.1)
Female	126	126.5	99.6	(83.0-118.6)	Female	12	14.5	83.0	(42.8-145.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.4	nc	(nc-nc)	Male	19	15.9	119.2	(71.7-186.1)
<b><u>Colon / Rectum</u></b>					Female	4	6.2	nc	(nc-nc)
Male	36	29.2	123.5	(86.5-170.9)	<b><u>Ovary</u></b>				
Female	29	26.0	111.3	(74.5-159.9)	Female	6	9.1	65.8	(24.0-143.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	7.4	67.7	(21.8-157.9)	Male	14	12.8	109.0	(59.5-182.9)
Female	1	2.1	nc	(nc-nc)	Female	11	11.3	97.7	(48.7-174.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.4	nc	(nc-nc)	Male	116	101.8	113.9	(94.1-136.6)
Female	2	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	6.9	101.3	(40.6-208.7)
Male	18	18.2	98.9	(58.6-156.3)	Female	3	4.0	nc	(nc-nc)
Female	9	9.6	93.6	(42.7-177.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	4.0	nc	(nc-nc)
Male	3	4.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	5	7.5	66.5	(21.4-155.1)
<b><u>Leukemia</u></b>					Female	15	19.8	75.9	(42.5-125.3)
Male	14	13.1	106.7	(58.3-179.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	9.1	164.1	(91.8-270.7)	Female	28	28.4	98.7	(65.5-142.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	11.9	67.3	(29.0-132.6)	Male	429	392.7	109.2	(99.2-120.1)
Female	2	4.2	nc	(nc-nc)	Female	409	399.1	102.5	(92.8-112.9)
<b><u>Lung and Bronchus</u></b>									
Male	53	48.2	109.9	(82.3-143.8)					
Female	63	54.5	115.5	(88.8-147.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	5.3	93.5	(30.1-218.1)	Male	3	3.7	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.5	172.7	(63.1-376.0)
Female	17	20.9	81.4	(47.4-130.4)	Female	4	2.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	0.7	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.1	nc	(nc-nc)
Male	6	5.5	109.5	(40.0-238.4)	<b><u>Ovary</u></b>				
Female	6	4.5	134.2	(49.0-292.2)	Female	0	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	21	20.2	104.0	(64.3-158.9)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.3	nc	(nc-nc)
Male	8	3.4	234.4	(100.9-461.8)	Female	1	0.7	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	3.1	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.6	nc	(nc-nc)	Female	9	4.8	188.1	(85.8-357.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	82	76.1	107.8	(85.7-133.8)
Female	1	0.7	nc	(nc-nc)	Female	76	67.6	112.4	(88.5-140.6)
<b><u>Lung and Bronchus</u></b>									
Male	9	9.7	92.7	(42.3-176.0)					
Female	11	9.7	113.5	(56.6-203.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	16.7	89.9	(50.3-148.3)	Male	14	11.9	117.4	(64.1-197.0)
Female	5	5.6	89.9	(29.0-209.8)	Female	13	8.8	148.3	(78.9-253.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.8	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.7	nc	(nc-nc)	Male	6	11.0	54.5	(19.9-118.5)
Female	94	72.1	130.3	(105.3-159.5)	Female	6	8.4	71.3	(26.0-155.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.4	nc	(nc-nc)	Male	11	9.5	115.5	(57.6-206.7)
<b><u>Colon / Rectum</u></b>					Female	7	3.6	193.9	(77.7-399.6)
Male	22	17.5	125.7	(78.8-190.4)	<b><u>Ovary</u></b>				
Female	15	15.2	99.0	(55.4-163.3)	Female	4	5.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.5	nc	(nc-nc)	Male	5	7.9	63.1	(20.3-147.2)
Female	2	1.2	nc	(nc-nc)	Female	3	6.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	45	62.2	72.3	(52.7-96.7)
Female	1	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.2	nc	(nc-nc)
Male	10	10.8	92.4	(44.2-169.9)	Female	2	2.3	nc	(nc-nc)
Female	5	5.6	89.7	(28.9-209.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.1	nc	(nc-nc)
Male	0	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	7	4.3	163.5	(65.5-337.0)
<b><u>Leukemia</u></b>					Female	7	10.7	65.2	(26.1-134.3)
Male	5	7.9	63.1	(20.4-147.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	5.3	nc	(nc-nc)	Female	17	16.6	102.4	(59.6-163.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	7.3	96.3	(38.6-198.4)	Male	208	238.8	87.1	(75.7-99.8)
Female	4	2.5	nc	(nc-nc)	Female	234	230.3	101.6	(89.0-115.5)
<b><u>Lung and Bronchus</u></b>									
Male	21	29.9	70.1	(43.4-107.2)					
Female	28	32.3	86.7	(57.6-125.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	28	31.1	90.1	(59.8-130.2)	Male	18	21.1	85.2	(50.5-134.7)
Female	14	11.5	121.4	(66.3-203.7)	Female	14	17.2	81.2	(44.4-136.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	6.4	nc	(nc-nc)	Male	8	7.4	107.6	(46.3-212.0)
Female	5	5.6	89.6	(28.9-209.0)	Female	2	6.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	13	19.4	66.9	(35.6-114.5)
Female	132	137.1	96.3	(80.5-114.1)	Female	18	17.0	106.0	(62.8-167.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.3	nc	(nc-nc)	Male	21	15.9	131.8	(81.6-201.5)
<b><u>Colon / Rectum</u></b>					Female	8	7.1	112.1	(48.3-220.8)
Male	30	30.0	100.0	(67.5-142.8)	<b><u>Ovary</u></b>				
Female	19	30.0	63.4	(38.2-99.0)	Female	12	10.3	116.0	(59.9-202.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	8.1	61.7	(19.9-144.1)	Male	14	14.3	97.8	(53.4-164.2)
Female	4	2.5	nc	(nc-nc)	Female	15	13.7	109.2	(61.0-180.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	84	110.1	76.3	(60.8-94.4)
Female	1	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	7.4	nc	(nc-nc)
Male	22	18.4	119.7	(75.0-181.2)	Female	5	4.6	108.2	(34.9-252.6)
Female	7	10.9	64.2	(25.7-132.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	3.5	198.1	(79.3-408.1)
Male	3	4.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	2	7.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	20.5	43.8	(20.0-83.1)
Male	13	13.8	94.0	(50.0-160.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	10.6	131.5	(71.9-220.7)	Female	35	32.3	108.3	(75.4-150.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	12.7	78.8	(37.7-145.0)	Male	347	422.9	82.0	(73.6-91.1)
Female	5	5.1	97.9	(31.5-228.4)	Female	401	454.6	88.2	(79.8-97.3)
<b><u>Lung and Bronchus</u></b>									
Male	42	55.1	76.2	(54.9-103.0)					
Female	42	66.8	62.9	(45.3-85.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	15.4	64.8	(31.0-119.1)	Male	17	10.8	157.1	(91.4-251.5)
Female	4	6.0	nc	(nc-nc)	Female	7	8.5	82.4	(33.0-169.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	6	10.0	60.1	(22.0-130.9)
Female	89	68.9	129.2	(103.8-159.0)	Female	15	8.5	176.4	(98.7-290.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	10	8.5	117.3	(56.2-215.8)
<b><u>Colon / Rectum</u></b>					Female	1	3.6	nc	(nc-nc)
Male	14	15.8	88.5	(48.4-148.6)	<b><u>Ovary</u></b>				
Female	16	15.8	101.4	(57.9-164.7)	Female	3	5.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	4.1	nc	(nc-nc)	Male	7	7.2	96.6	(38.7-199.1)
Female	1	1.3	nc	(nc-nc)	Female	3	7.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	82	56.1	146.1	(116.2-181.4)
Female	4	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.8	nc	(nc-nc)
Male	9	9.7	92.8	(42.3-176.1)	Female	2	2.4	nc	(nc-nc)
Female	3	5.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.7	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	7	3.7	187.8	(75.2-386.9)
<b><u>Leukemia</u></b>					Female	9	9.3	97.0	(44.3-184.1)
Male	10	7.2	139.5	(66.8-256.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	5.4	nc	(nc-nc)	Female	15	15.9	94.6	(52.9-156.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.6	nc	(nc-nc)	Male	236	216.4	109.1	(95.6-123.9)
Female	1	2.6	nc	(nc-nc)	Female	220	227.6	96.7	(84.3-110.3)
<b><u>Lung and Bronchus</u></b>									
Male	20	27.5	72.8	(44.4-112.4)					
Female	22	33.3	66.1	(41.4-100.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	17.1	128.6	(80.6-194.7)	Male	8	12.1	66.2	(28.5-130.5)
Female	7	6.5	108.5	(43.5-223.6)	Female	13	9.7	134.7	(71.6-230.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.8	155.9	(56.9-339.2)	Male	4	4.1	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	5	3.3	150.6	(48.5-351.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	9	11.1	81.1	(37.0-154.0)
Female	76	77.2	98.4	(77.5-123.2)	Female	7	9.4	74.3	(29.7-153.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.6	nc	(nc-nc)	Male	9	9.3	97.1	(44.3-184.3)
<b><u>Colon / Rectum</u></b>					Female	0	4.0	nc	(nc-nc)
Male	15	17.7	84.7	(47.4-139.7)	<b><u>Ovary</u></b>				
Female	12	17.4	68.8	(35.5-120.1)	Female	4	5.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	4.5	134.0	(48.9-291.6)	Male	13	8.0	163.4	(86.9-279.4)
Female	0	1.4	nc	(nc-nc)	Female	5	7.7	65.1	(21.0-151.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	67	59.5	112.7	(87.3-143.1)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	4.2	nc	(nc-nc)
Male	9	10.7	84.4	(38.5-160.2)	Female	1	2.6	nc	(nc-nc)
Female	6	6.1	98.6	(36.0-214.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.2	223.2	(71.9-520.9)
Male	0	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	14	11.4	122.4	(66.8-205.3)
Male	10	8.1	123.8	(59.3-227.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	6.0	99.6	(36.4-216.9)	Female	27	17.5	154.5	(101.8-224.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	7.1	112.8	(48.6-222.3)	Male	252	237.2	106.3	(93.5-120.2)
Female	2	2.8	nc	(nc-nc)	Female	252	253.6	99.4	(87.5-112.4)
<b><u>Lung and Bronchus</u></b>									
Male	32	29.8	107.3	(73.4-151.5)					
Female	44	36.0	122.2	(88.7-164.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	4.3	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	16	15.0	106.7	(61.0-173.3)	Female	5	1.8	279.6	(90.1-652.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	0.8	nc	(nc-nc)
Male	7	4.1	170.6	(68.3-351.5)	<b><u>Ovary</u></b>				
Female	3	3.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	13	15.5	83.7	(44.5-143.1)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.0	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.0	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.1	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	47	58.3	80.6	(59.2-107.1)
Female	0	0.5	nc	(nc-nc)	Female	48	48.5	99.0	(73.0-131.2)
<b><u>Lung and Bronchus</u></b>									
Male	6	7.7	78.2	(28.6-170.3)					
Female	6	7.2	83.9	(30.6-182.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Norton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	18.7	106.8	(65.2-165.0)	Male	7	13.5	52.0	(20.8-107.1)
Female	6	6.8	88.7	(32.4-193.0)	Female	12	10.5	114.4	(59.1-199.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	4.4	182.3	(78.5-359.3)	Male	3	4.7	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	13	12.5	103.6	(55.1-177.3)
Female	88	86.1	102.2	(82.0-125.9)	Female	9	10.2	88.4	(40.4-167.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.7	nc	(nc-nc)	Male	9	10.9	82.8	(37.8-157.2)
<b><u>Colon / Rectum</u></b>					Female	2	4.3	nc	(nc-nc)
Male	24	19.8	121.5	(77.8-180.8)	<b><u>Ovary</u></b>				
Female	18	18.0	100.0	(59.3-158.1)	Female	3	6.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	5.1	194.3	(93.0-357.4)	Male	9	8.9	100.6	(45.9-191.0)
Female	1	1.5	nc	(nc-nc)	Female	7	8.1	86.2	(34.5-177.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	75	71.4	105.0	(82.6-131.6)
Female	4	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.8	nc	(nc-nc)
Male	16	12.4	129.4	(73.9-210.1)	Female	2	2.8	nc	(nc-nc)
Female	10	6.7	149.3	(71.5-274.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.7	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	7	5.0	140.1	(56.1-288.7)
<b><u>Leukemia</u></b>					Female	11	12.6	87.2	(43.5-156.1)
Male	9	9.0	100.4	(45.8-190.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	6.4	125.3	(53.9-246.8)	Female	17	20.1	84.6	(49.3-135.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	8.3	108.8	(49.6-206.6)	Male	294	272.0	108.1	(96.1-121.2)
Female	3	3.1	nc	(nc-nc)	Female	279	277.4	100.6	(89.1-113.1)
<b><u>Lung and Bronchus</u></b>									
Male	39	34.0	114.8	(81.6-157.0)					
Female	42	39.9	105.3	(75.9-142.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Norwell

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	13.2	45.4	(16.6-98.9)	Male	14	8.9	157.5	(86.1-264.3)
Female	6	4.9	122.8	(44.8-267.3)	Female	12	6.7	179.3	(92.5-313.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	9	3.1	287.5	(131.2-545.9)
Female	4	2.1	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.2	110.3	(50.3-209.4)
Female	61	54.2	112.5	(86.1-144.5)	Female	9	6.9	131.2	(59.9-249.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	8	6.8	118.5	(51.0-233.4)
<b><u>Colon / Rectum</u></b>					Female	4	2.9	nc	(nc-nc)
Male	9	12.8	70.2	(32.0-133.3)	<b><u>Ovary</u></b>				
Female	12	12.7	94.1	(48.6-164.4)	Female	2	4.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.4	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	5	5.8	86.1	(27.8-201.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	51	45.7	111.5	(83.0-146.6)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.2	nc	(nc-nc)
Male	9	7.8	115.5	(52.7-219.3)	Female	1	1.9	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.1	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.8	179.4	(57.8-418.6)
<b><u>Leukemia</u></b>					Female	7	6.9	100.8	(40.4-207.8)
Male	6	5.9	101.4	(37.0-220.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	4.4	159.7	(64.0-329.0)	Female	9	12.5	72.2	(32.9-137.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	5.3	112.2	(41.0-244.2)	Male	180	177.4	101.5	(87.2-117.4)
Female	1	2.1	nc	(nc-nc)	Female	178	181.6	98.0	(84.1-113.5)
<b><u>Lung and Bronchus</u></b>									
Male	18	23.2	77.7	(46.0-122.9)					
Female	19	27.2	69.8	(42.0-109.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	34.5	84.1	(56.3-120.8)	Male	34	23.4	145.3	(100.6-203.1)
Female	9	13.1	68.5	(31.3-130.0)	Female	25	18.2	137.2	(88.8-202.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	7.1	98.9	(39.6-203.7)	Male	12	8.0	149.8	(77.3-261.7)
Female	10	5.8	173.4	(83.0-318.9)	Female	10	6.5	153.0	(73.2-281.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	5	1.4	366.9	(118.3-856.3)	Male	25	21.3	117.4	(75.9-173.3)
Female	162	143.0	113.3	(96.5-132.1)	Female	15	18.4	81.4	(45.5-134.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.5	132.1	(48.2-287.4)	Male	24	16.8	142.8	(91.5-212.5)
<b><u>Colon / Rectum</u></b>					Female	4	7.6	nc	(nc-nc)
Male	33	33.2	99.4	(68.4-139.6)	<b><u>Ovary</u></b>				
Female	38	34.3	110.9	(78.5-152.3)	Female	12	10.7	112.2	(57.9-196.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	8.6	127.4	(63.5-228.0)	Male	22	15.5	141.7	(88.8-214.5)
Female	0	2.8	nc	(nc-nc)	Female	14	15.6	89.8	(49.1-150.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	105	112.0	93.7	(76.7-113.5)
Female	0	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	8.1	135.4	(67.5-242.3)
Male	23	19.7	116.9	(74.1-175.4)	Female	3	5.2	nc	(nc-nc)
Female	7	11.6	60.4	(24.2-124.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	4.3	117.2	(37.8-273.4)
Male	3	4.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	8	7.7	103.7	(44.7-204.4)
<b><u>Leukemia</u></b>					Female	25	20.0	125.1	(80.9-184.7)
Male	12	15.5	77.6	(40.1-135.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	11.8	67.9	(29.2-133.8)	Female	39	32.5	119.9	(85.3-164.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	13.4	97.0	(51.6-165.8)	Male	497	454.1	109.4	(100.0-119.5)
Female	1	5.5	nc	(nc-nc)	Female	504	485.0	103.9	(95.0-113.4)
<b><u>Lung and Bronchus</u></b>									
Male	64	59.0	108.4	(83.5-138.5)					
Female	76	72.1	105.4	(83.0-131.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	7.0	115.0	(49.5-226.7)	Male	5	4.7	106.4	(34.3-248.3)
Female	0	2.7	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	21	28.4	73.9	(45.7-113.0)	Female	2	3.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.5	nc	(nc-nc)
Male	6	6.7	90.1	(32.9-196.0)	<b><u>Ovary</u></b>				
Female	10	6.7	149.5	(71.6-275.0)	Female	3	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	23	24.9	92.4	(58.6-138.7)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	4	4.1	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	3.5	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.3	nc	(nc-nc)	Female	4	6.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.9	nc	(nc-nc)	Male	83	94.5	87.8	(69.9-108.9)
Female	1	1.1	nc	(nc-nc)	Female	74	96.9	76.4	(60.0-95.9)
<b><u>Lung and Bronchus</u></b>									
Male	16	12.4	128.7	(73.5-209.1)					
Female	13	15.1	86.2	(45.8-147.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Oakham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	5	1.7	291.3	(93.9-679.8)
Female	1	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	13	9.5	136.2	(72.5-233.0)	Female	1	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.3	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	1.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	11	9.7	113.9	(56.8-203.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.7	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	25	35.3	70.8	(45.8-104.5)
Female	0	0.3	nc	(nc-nc)	Female	37	29.8	124.1	(87.3-171.0)
<b><u>Lung and Bronchus</u></b>									
Male	4	4.5	nc	(nc-nc)					
Female	5	4.2	118.6	(38.2-276.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	8.9	179.7	(102.6-291.8)	Male	2	6.2	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	1	4.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	5.7	87.2	(28.1-203.5)
Female	38	37.4	101.6	(71.9-139.5)	Female	4	4.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.9	nc	(nc-nc)
Male	15	8.8	170.1	(95.1-280.6)	<b><u>Ovary</u></b>				
Female	7	8.0	87.9	(35.2-181.1)	Female	5	2.7	181.9	(58.6-424.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	29	33.9	85.5	(57.3-122.8)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.2	nc	(nc-nc)
Male	12	5.6	214.0	(110.5-373.8)	Female	2	1.2	nc	(nc-nc)
Female	5	3.0	169.1	(54.5-394.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.0	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	5.3	nc	(nc-nc)
Male	7	4.1	170.0	(68.1-350.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.8	nc	(nc-nc)	Female	6	8.8	68.4	(25.0-148.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.9	nc	(nc-nc)	Male	137	126.3	108.4	(91.0-128.2)
Female	0	1.4	nc	(nc-nc)	Female	118	122.3	96.5	(79.9-115.5)
<b><u>Lung and Bronchus</u></b>									
Male	22	16.2	135.8	(85.1-205.7)					
Female	13	18.0	72.1	(38.3-123.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	16.1	93.1	(52.1-153.6)	Male	13	9.6	135.8	(72.2-232.2)
Female	7	5.0	141.1	(56.5-290.8)	Female	19	5.7	333.1	(200.4-520.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.3	220.2	(70.9-513.8)	Male	5	3.5	144.7	(46.6-337.7)
Female	3	1.7	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	13	8.5	152.4	(81.0-260.5)
Female	63	45.6	138.3	(106.2-176.9)	Female	7	6.5	108.0	(43.3-222.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	5	6.0	83.0	(26.7-193.7)
<b><u>Colon / Rectum</u></b>					Female	4	2.6	nc	(nc-nc)
Male	6	12.7	47.3	(17.3-103.0)	<b><u>Ovary</u></b>				
Female	8	11.5	69.6	(30.0-137.2)	Female	5	3.5	144.0	(46.4-336.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.7	nc	(nc-nc)	Male	7	6.8	103.1	(41.3-212.4)
Female	1	1.0	nc	(nc-nc)	Female	2	5.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	62	46.4	133.5	(102.3-171.1)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.4	nc	(nc-nc)
Male	11	7.3	151.5	(75.5-271.1)	Female	1	1.8	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	4.3	nc	(nc-nc)
Male	8	6.1	130.4	(56.1-257.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	4.0	174.0	(69.7-358.6)	Female	11	11.2	98.5	(49.1-176.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	5.5	182.7	(87.5-336.0)	Male	195	186.0	104.8	(90.6-120.6)
Female	4	2.0	nc	(nc-nc)	Female	185	163.6	113.1	(97.3-130.6)
<b><u>Lung and Bronchus</u></b>									
Male	18	26.9	66.9	(39.6-105.7)					
Female	15	28.2	53.2	(29.7-87.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	2.9	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	3	10.6	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	5	2.7	184.9	(59.6-431.5)	<b><u>Ovary</u></b>				
Female	5	2.1	234.9	(75.7-548.2)	Female	0	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	10.3	68.2	(27.3-140.5)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.8	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	34	38.6	88.0	(60.9-122.9)
Female	0	0.4	nc	(nc-nc)	Female	16	34.2	46.7	(26.7-75.9)
<b><u>Lung and Bronchus</u></b>									
Male	7	5.1	136.4	(54.6-281.0)					
Female	3	5.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Oxford

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	13.8	180.9	(117.0-267.0)	Male	17	9.9	171.1	(99.6-274.0)
Female	9	4.7	192.4	(87.8-365.3)	Female	8	7.5	107.0	(46.1-210.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	3.2	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	9	9.3	97.3	(44.4-184.6)
Female	51	62.4	81.8	(60.9-107.5)	Female	13	7.2	181.3	(96.4-310.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.0	nc	(nc-nc)	Male	11	8.1	135.0	(67.3-241.6)
<b><u>Colon / Rectum</u></b>					Female	2	3.1	nc	(nc-nc)
Male	11	14.6	75.2	(37.5-134.5)	<b><u>Ovary</u></b>				
Female	23	12.6	182.3	(115.5-273.6)	Female	3	4.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	3.8	155.9	(56.9-339.3)	Male	11	6.7	165.2	(82.3-295.5)
Female	1	1.0	nc	(nc-nc)	Female	5	5.6	89.1	(28.7-208.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	45	54.0	83.4	(60.8-111.6)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	3.5	nc	(nc-nc)
Male	12	9.2	130.7	(67.4-228.2)	Female	1	1.9	nc	(nc-nc)
Female	4	4.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	1.7	458.6	(197.5-903.7)
Male	2	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	5	3.6	137.8	(44.4-321.5)
<b><u>Leukemia</u></b>					Female	10	9.2	108.7	(52.1-200.0)
Male	12	6.6	181.7	(93.8-317.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	4.4	nc	(nc-nc)	Female	17	14.5	117.2	(68.2-187.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	6.2	nc	(nc-nc)	Male	226	202.3	111.7	(97.6-127.3)
Female	3	2.1	nc	(nc-nc)	Female	207	197.3	104.9	(91.1-120.2)
<b><u>Lung and Bronchus</u></b>									
Male	27	25.3	106.8	(70.3-155.4)					
Female	31	27.9	111.3	(75.6-158.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	13.4	127.1	(74.0-203.5)	Male	7	9.5	73.8	(29.6-152.1)
Female	6	4.6	129.8	(47.4-282.6)	Female	2	6.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	5	3.3	151.3	(48.7-353.0)
Female	2	2.2	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.5	nc	(nc-nc)	Male	11	8.8	125.5	(62.5-224.5)
Female	50	55.1	90.8	(67.4-119.7)	Female	7	6.7	104.1	(41.7-214.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.8	nc	(nc-nc)	Male	5	7.6	66.0	(21.3-154.0)
<b><u>Colon / Rectum</u></b>					Female	6	2.9	210.2	(76.7-457.5)
Male	17	13.8	123.1	(71.7-197.1)	<b><u>Ovary</u></b>				
Female	15	12.2	122.5	(68.5-202.0)	Female	7	4.1	171.5	(68.7-353.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	9	6.3	141.8	(64.7-269.1)
Female	1	1.0	nc	(nc-nc)	Female	4	5.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	42	50.5	83.2	(60.0-112.5)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.4	nc	(nc-nc)
Male	11	8.6	128.2	(63.9-229.5)	Female	2	1.9	nc	(nc-nc)
Female	11	4.4	251.7	(125.5-450.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.7	nc	(nc-nc)
Male	4	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	6	3.4	177.7	(64.9-386.8)
<b><u>Leukemia</u></b>					Female	4	7.9	nc	(nc-nc)
Male	6	6.2	96.0	(35.1-209.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	4.2	142.2	(51.9-309.4)	Female	16	12.8	124.8	(71.3-202.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.8	nc	(nc-nc)	Male	214	191.3	111.8	(97.4-127.9)
Female	0	2.0	nc	(nc-nc)	Female	191	181.0	105.5	(91.1-121.6)
<b><u>Lung and Bronchus</u></b>									
Male	38	24.2	157.2	(111.3-215.8)					
Female	39	26.3	148.6	(105.6-203.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	5.3	93.8	(30.2-219.0)	Male	7	3.7	191.6	(76.8-394.9)
Female	4	1.6	nc	(nc-nc)	Female	5	2.5	203.0	(65.4-473.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	29	20.5	141.2	(94.6-202.8)	Female	2	2.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.0	nc	(nc-nc)
Male	5	5.3	94.7	(30.5-220.9)	<b><u>Ovary</u></b>				
Female	8	4.3	187.3	(80.6-369.0)	Female	1	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	20	18.9	105.5	(64.4-163.0)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.3	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	2.9	nc	(nc-nc)
Male	8	2.5	325.5	(140.1-641.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.5	nc	(nc-nc)	Female	11	4.8	231.1	(115.2-413.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	2.2	nc	(nc-nc)	Male	77	73.4	104.9	(82.8-131.1)
Female	0	0.7	nc	(nc-nc)	Female	85	65.7	129.3	(103.3-159.9)
<b><u>Lung and Bronchus</u></b>									
Male	2	9.4	nc	(nc-nc)					
Female	8	9.4	84.9	(36.6-167.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	81	78.4	103.3	(82.1-128.4)	Male	43	50.7	84.7	(61.3-114.2)
Female	28	29.9	93.7	(62.3-135.5)	Female	40	38.4	104.2	(74.5-141.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	20	14.0	142.9	(87.2-220.6)	Male	14	17.2	81.2	(44.4-136.3)
Female	8	11.7	68.1	(29.3-134.3)	Female	9	14.4	62.6	(28.6-118.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	7	3.0	233.7	(93.6-481.5)	Male	44	45.5	96.7	(70.2-129.8)
Female	326	296.8	109.8	(98.2-122.4)	Female	44	40.2	109.4	(79.5-146.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	8.8	113.5	(54.3-208.7)	Male	39	34.5	113.0	(80.4-154.5)
<b><u>Colon / Rectum</u></b>					Female	19	16.5	115.3	(69.4-180.1)
Male	71	71.4	99.5	(77.7-125.4)	<b><u>Ovary</u></b>				
Female	59	76.2	77.4	(59.0-99.9)	Female	24	22.5	106.5	(68.2-158.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	17	18.6	91.5	(53.3-146.5)	Male	33	34.2	96.5	(66.4-135.5)
Female	15	6.2	242.6	(135.7-400.1)	Female	36	35.3	102.0	(71.5-141.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	7	4.5	155.0	(62.1-319.4)	Male	211	232.4	90.8	(78.9-103.9)
Female	7	3.8	182.8	(73.2-376.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	20	17.6	113.8	(69.5-175.8)
Male	46	40.5	113.5	(83.1-151.4)	Female	10	11.5	87.0	(41.7-160.0)
Female	28	24.8	113.1	(75.1-163.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	6.9	73.0	(23.5-170.3)
Male	10	9.8	101.8	(48.7-187.3)	<b><u>Thyroid</u></b>				
Female	4	2.5	nc	(nc-nc)	Male	14	14.6	96.1	(52.5-161.2)
<b><u>Leukemia</u></b>					Female	48	37.8	126.9	(93.6-168.3)
Male	36	33.0	109.0	(76.3-150.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	22	25.7	85.5	(53.6-129.4)	Female	61	68.0	89.8	(68.7-115.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	28.3	60.1	(35.0-96.3)	Male	948	968.1	97.9	(91.8-104.4)
Female	10	12.1	82.5	(39.5-151.8)	Female	1087	1038.2	104.7	(98.6-111.1)
<b><u>Lung and Bronchus</u></b>									
Male	130	129.6	100.3	(83.8-119.2)					
Female	177	160.1	110.6	(94.9-128.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	7.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	7.1	70.9	(22.8-165.4)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.9	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	16	26.6	60.1	(34.3-97.6)
Female	0	0.3	nc	(nc-nc)	Female	11	23.0	47.9	(23.9-85.7)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.6	nc	(nc-nc)					
Female	1	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Pembroke

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	17.8	129.3	(81.9-194.0)	Male	20	12.9	154.9	(94.5-239.2)
Female	4	6.1	nc	(nc-nc)	Female	15	10.0	150.3	(84.0-247.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	4.2	189.0	(81.4-372.4)	Male	5	4.5	110.8	(35.7-258.6)
Female	4	3.3	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	16	12.0	133.0	(75.9-215.9)
Female	81	83.6	96.9	(76.9-120.4)	Female	9	9.5	94.9	(43.3-180.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.7	nc	(nc-nc)	Male	18	10.6	170.3	(100.9-269.2)
<b><u>Colon / Rectum</u></b>					Female	4	4.1	nc	(nc-nc)
Male	19	19.1	99.7	(60.0-155.6)	<b><u>Ovary</u></b>				
Female	19	16.7	113.6	(68.4-177.5)	Female	3	6.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	5.0	161.2	(69.4-317.7)	Male	6	8.6	70.0	(25.6-152.3)
Female	0	1.4	nc	(nc-nc)	Female	8	7.4	108.5	(46.7-213.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	63	69.0	91.3	(70.1-116.8)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.6	nc	(nc-nc)
Male	21	12.0	175.2	(108.4-267.8)	Female	3	2.5	nc	(nc-nc)
Female	6	6.4	94.2	(34.4-205.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.3	nc	(nc-nc)
Male	6	2.8	211.8	(77.4-461.1)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	8	4.8	167.3	(72.0-329.7)
<b><u>Leukemia</u></b>					Female	11	12.4	88.8	(44.2-158.8)
Male	8	8.6	92.7	(39.9-182.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	5.9	85.2	(27.4-198.8)	Female	11	19.4	56.7	(28.2-101.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	8.0	112.5	(51.3-213.6)	Male	320	261.4	122.4	(109.4-136.6)
Female	4	2.8	nc	(nc-nc)	Female	267	262.6	101.7	(89.9-114.6)
<b><u>Lung and Bronchus</u></b>									
Male	50	32.5	153.7	(114.1-202.6)					
Female	45	36.7	122.6	(89.4-164.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	12.7	110.5	(60.4-185.5)	Male	10	9.1	109.7	(52.5-201.8)
Female	6	4.1	147.6	(53.9-321.3)	Female	4	6.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.9	170.3	(54.9-397.3)	Male	2	3.2	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	6	8.5	70.7	(25.8-153.8)
Female	53	55.6	95.4	(71.4-124.8)	Female	4	6.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.8	nc	(nc-nc)	Male	4	7.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	2.7	nc	(nc-nc)
Male	13	13.4	96.9	(51.5-165.7)	<b><u>Ovary</u></b>				
Female	15	10.9	137.2	(76.7-226.2)	Female	7	4.0	173.7	(69.6-357.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	3.6	140.2	(45.2-327.3)	Male	7	6.2	113.6	(45.5-234.1)
Female	1	0.9	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	48	50.9	94.3	(69.5-125.1)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.3	nc	(nc-nc)
Male	6	8.5	70.3	(25.7-153.1)	Female	0	1.7	nc	(nc-nc)
Female	8	4.3	187.8	(80.9-370.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.5	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	8.0	62.2	(20.0-145.1)
Male	7	6.0	115.8	(46.4-238.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.9	nc	(nc-nc)	Female	12	13.2	91.1	(47.0-159.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	5.8	nc	(nc-nc)	Male	176	187.5	93.9	(80.5-108.8)
Female	1	1.9	nc	(nc-nc)	Female	173	174.6	99.1	(84.9-115.0)
<b><u>Lung and Bronchus</u></b>									
Male	29	23.4	124.1	(83.1-178.3)					
Female	26	24.7	105.1	(68.7-154.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	3.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	4.1	122.0	(39.3-284.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.6	nc	(nc-nc)
Male	2	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	12	14.9	80.8	(41.7-141.1)
Female	0	0.1	nc	(nc-nc)	Female	10	11.7	85.3	(40.8-156.9)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.8	nc	(nc-nc)					
Female	2	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	7.0	85.8	(31.3-186.7)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.4	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	6	6.8	87.8	(32.0-191.0)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	0.9	nc	(nc-nc)
Male	3	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	23	25.3	91.0	(57.6-136.5)
Female	1	0.3	nc	(nc-nc)	Female	22	22.5	97.7	(61.2-147.9)
<b><u>Lung and Bronchus</u></b>									
Male	2	3.3	nc	(nc-nc)					
Female	3	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	3	7.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.4	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.4	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	7.2	69.3	(22.3-161.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.5	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.2	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.5	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	18	26.8	67.2	(39.8-106.2)
Female	0	0.2	nc	(nc-nc)	Female	19	22.9	83.1	(50.0-129.8)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.3	nc	(nc-nc)					
Female	1	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	61	55.1	110.8	(84.8-142.3)	Male	30	37.0	81.1	(54.7-115.8)
Female	28	19.2	145.6	(96.7-210.4)	Female	23	27.0	85.2	(54.0-127.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	10.9	73.3	(31.6-144.4)	Male	13	12.9	101.0	(53.7-172.8)
Female	5	8.6	58.3	(18.8-135.9)	Female	5	9.8	50.8	(16.4-118.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	39	33.7	115.6	(82.2-158.0)
Female	190	215.8	88.1	(76.0-101.5)	Female	25	27.4	91.4	(59.1-134.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	6.6	106.1	(42.5-218.7)	Male	41	27.2	150.6	(108.1-204.4)
<b><u>Colon / Rectum</u></b>					Female	11	11.4	96.6	(48.1-172.8)
Male	69	52.4	131.6	(102.4-166.6)	<b><u>Ovary</u></b>				
Female	63	49.4	127.5	(97.9-163.1)	Female	19	16.1	118.1	(71.1-184.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	14	14.0	100.1	(54.7-168.0)	Male	27	25.0	108.1	(71.2-157.3)
Female	6	4.1	146.8	(53.6-319.5)	Female	32	22.9	139.7	(95.5-197.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.6	nc	(nc-nc)	Male	215	185.5	115.9	(100.9-132.4)
Female	4	3.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	18	13.0	138.7	(82.2-219.3)
Male	38	31.5	120.6	(85.3-165.5)	Female	8	7.6	105.9	(45.6-208.7)
Female	12	17.4	68.8	(35.5-120.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	5.6	nc	(nc-nc)
Male	12	7.6	158.4	(81.8-276.7)	<b><u>Thyroid</u></b>				
Female	5	1.9	269.0	(86.7-627.7)	Male	16	11.7	136.6	(78.0-221.8)
<b><u>Leukemia</u></b>					Female	31	29.3	105.7	(71.8-150.1)
Male	25	24.3	102.7	(66.5-151.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	17.3	86.7	(48.5-143.0)	Female	50	50.3	99.4	(73.8-131.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	35	21.9	160.1	(111.5-222.7)	Male	875	729.5	119.9	(112.1-128.2)
Female	9	8.3	108.9	(49.7-206.8)	Female	751	724.4	103.7	(96.4-111.4)
<b><u>Lung and Bronchus</u></b>									
Male	151	95.6	157.9	(133.7-185.2)					
Female	144	109.2	131.9	(111.2-155.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	4	3.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	3	0.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	16	13.7	116.6	(66.6-189.4)
Female	0	0.1	nc	(nc-nc)	Female	11	11.4	96.9	(48.3-173.4)
<b><u>Lung and Bronchus</u></b>									
Male	3	1.8	nc	(nc-nc)					
Female	2	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	8.6	150.4	(80.0-257.2)	Male	11	6.3	175.7	(87.6-314.4)
Female	6	3.3	181.2	(66.2-394.4)	Female	6	5.1	116.5	(42.6-253.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	5.8	137.9	(59.4-271.6)
Female	34	42.2	80.5	(55.8-112.5)	Female	6	5.0	120.1	(43.8-261.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	9	5.0	180.6	(82.4-342.9)
<b><u>Colon / Rectum</u></b>					Female	0	2.1	nc	(nc-nc)
Male	11	9.1	120.7	(60.2-215.9)	<b><u>Ovary</u></b>				
Female	15	8.8	170.0	(95.1-280.4)	Female	4	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	2.4	211.3	(68.1-493.0)	Male	5	4.1	121.4	(39.1-283.4)
Female	0	0.7	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	33	32.5	101.6	(69.9-142.7)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.2	nc	(nc-nc)
Male	9	5.7	157.8	(72.0-299.6)	Female	2	1.3	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	1.3	474.9	(173.4-1033.7)
Male	1	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.4	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	6.3	111.4	(44.6-229.6)
Male	2	4.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.1	nc	(nc-nc)	Female	3	9.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	3.8	nc	(nc-nc)	Male	148	125.2	118.2	(100.0-138.9)
Female	0	1.5	nc	(nc-nc)	Female	139	135.8	102.4	(86.1-120.9)
<b><u>Lung and Bronchus</u></b>									
Male	18	15.6	115.2	(68.2-182.0)					
Female	25	19.5	128.0	(82.8-189.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	97	73.9	131.3	(106.5-160.2)	Male	88	50.7	173.5	(139.2-213.8)
Female	36	26.2	137.2	(96.1-190.0)	Female	52	37.7	137.8	(102.9-180.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	20	15.6	128.3	(78.4-198.2)	Male	19	18.0	105.4	(63.5-164.7)
Female	26	12.0	216.7	(141.5-317.6)	Female	18	13.9	129.7	(76.8-205.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	45	46.8	96.2	(70.2-128.8)
Female	307	312.4	98.3	(87.6-109.9)	Female	34	38.1	89.2	(61.8-124.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	9.4	106.6	(51.0-196.0)	Male	40	38.9	102.9	(73.5-140.1)
<b><u>Colon / Rectum</u></b>					Female	18	16.0	112.8	(66.8-178.4)
Male	84	72.5	115.9	(92.4-143.5)	<b><u>Ovary</u></b>				
Female	66	67.0	98.5	(76.2-125.3)	Female	23	22.9	100.6	(63.7-150.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	26	19.5	133.3	(87.0-195.3)	Male	37	34.3	107.9	(76.0-148.8)
Female	5	5.6	89.0	(28.7-207.6)	Female	33	31.4	105.1	(72.3-147.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	8	5.1	156.4	(67.3-308.2)	Male	278	266.6	104.3	(92.4-117.3)
Female	5	4.0	125.1	(40.3-291.9)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	18.0	89.0	(50.9-144.6)
Male	36	45.1	79.9	(55.9-110.6)	Female	10	10.4	96.3	(46.1-177.2)
Female	28	24.7	113.3	(75.3-163.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	8.1	98.7	(42.5-194.5)
Male	15	10.6	141.0	(78.9-232.6)	<b><u>Thyroid</u></b>				
Female	2	2.7	nc	(nc-nc)	Male	17	17.1	99.4	(57.9-159.2)
<b><u>Leukemia</u></b>					Female	59	41.6	141.9	(108.0-183.1)
Male	46	33.5	137.5	(100.6-183.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	33	23.7	139.2	(95.8-195.5)	Female	91	73.4	123.9	(99.8-152.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	34	30.7	110.6	(76.6-154.5)	Male	1132	1019.0	111.1	(104.7-117.8)
Female	6	11.6	51.7	(18.9-112.5)	Female	1103	1023.3	107.8	(101.5-114.3)
<b><u>Lung and Bronchus</u></b>									
Male	127	132.3	96.0	(80.0-114.2)					
Female	154	154.5	99.7	(84.6-116.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	4.1	171.1	(68.5-352.5)	Male	0	2.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	12	15.0	79.9	(41.3-139.7)	Female	3	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.8	nc	(nc-nc)
Male	3	3.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	3.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	14.8	54.1	(23.3-106.7)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.0	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.0	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.1	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	43	55.7	77.1	(55.8-103.9)
Female	1	0.5	nc	(nc-nc)	Female	40	48.4	82.6	(59.0-112.5)
<b><u>Lung and Bronchus</u></b>									
Male	7	7.4	95.0	(38.1-195.7)					
Female	9	7.3	123.7	(56.5-234.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	4.4	157.4	(63.1-324.4)	Male	4	3.1	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	22	17.4	126.2	(79.0-191.0)	Female	1	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	0.5	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	0.9	nc	(nc-nc)
Male	1	4.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	3.5	144.2	(46.5-336.6)	Female	0	1.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	15	18.5	80.9	(45.2-133.4)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.1	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	2.3	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.2	nc	(nc-nc)	Female	6	4.3	139.6	(51.0-303.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	52	65.4	79.5	(59.3-104.2)
Female	0	0.6	nc	(nc-nc)	Female	58	55.5	104.6	(79.4-135.2)
<b><u>Lung and Bronchus</u></b>									
Male	0	8.4	nc	(nc-nc)					
Female	3	8.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	5.8	86.0	(27.7-200.8)	Male	4	3.9	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	6	1.4	424.3	(154.9-923.6)
Female	1	0.7	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
Female	25	18.5	134.9	(87.3-199.2)	Female	4	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.0	nc	(nc-nc)
Male	3	5.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	3.9	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	24	22.0	108.9	(69.7-162.0)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.4	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.0	nc	(nc-nc)
Male	6	2.5	241.9	(88.3-526.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	1.4	nc	(nc-nc)	Female	1	4.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	85	80.5	105.6	(84.3-130.6)
Female	0	0.7	nc	(nc-nc)	Female	73	61.6	118.5	(92.8-148.9)
<b><u>Lung and Bronchus</u></b>									
Male	10	10.5	95.0	(45.5-174.6)					
Female	13	10.0	129.7	(69.0-221.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	79	98.8	79.9	(63.3-99.6)	Male	60	70.1	85.6	(65.3-110.2)
Female	41	37.6	109.0	(78.2-147.9)	Female	68	56.6	120.2	(93.3-152.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	20	22.4	89.3	(54.5-138.0)	Male	20	23.9	83.8	(51.2-129.4)
Female	14	17.9	78.1	(42.6-131.0)	Female	18	19.3	93.5	(55.4-147.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	4.0	nc	(nc-nc)	Male	60	64.2	93.4	(71.3-120.3)
Female	396	444.6	89.1	(80.5-98.3)	Female	57	55.1	103.5	(78.4-134.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	18	15.4	116.6	(69.1-184.3)	Male	56	52.6	106.4	(80.4-138.2)
<b><u>Colon / Rectum</u></b>					Female	30	23.0	130.5	(88.0-186.2)
Male	110	100.8	109.1	(89.7-131.5)	<b><u>Ovary</u></b>				
Female	129	100.3	128.7	(107.4-152.9)	Female	29	32.9	88.2	(59.0-126.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	35	25.8	135.9	(94.6-189.0)	Male	46	45.8	100.4	(73.5-134.0)
Female	8	8.0	100.1	(43.1-197.2)	Female	68	44.9	151.6	(117.7-192.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	8.3	72.0	(26.3-156.7)	Male	274	343.2	79.8	(70.7-89.9)
Female	2	7.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	36	24.4	147.8	(103.5-204.7)
Male	43	61.3	70.2	(50.8-94.6)	Female	16	15.3	104.9	(59.9-170.4)
Female	42	35.1	119.5	(86.1-161.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	11	15.7	70.1	(35.0-125.5)
Male	17	14.2	119.5	(69.6-191.4)	<b><u>Thyroid</u></b>				
Female	4	3.7	nc	(nc-nc)	Male	23	25.7	89.4	(56.7-134.2)
<b><u>Leukemia</u></b>					Female	78	69.1	112.9	(89.3-140.9)
Male	42	46.2	90.9	(65.5-122.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	33	34.6	95.3	(65.6-133.8)	Female	88	100.1	87.9	(70.5-108.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	76	40.7	186.7	(147.1-233.7)	Male	1334	1370.6	97.3	(92.2-102.7)
Female	13	16.2	80.1	(42.6-137.0)	Female	1511	1471.4	102.7	(97.6-108.0)
<b><u>Lung and Bronchus</u></b>									
Male	203	172.9	117.4	(101.8-134.7)					
Female	241	211.2	114.1	(100.2-129.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	31.9	106.4	(73.7-148.8)	Male	16	22.9	69.7	(39.8-113.2)
Female	13	12.1	107.6	(57.2-183.9)	Female	7	18.9	37.1	(14.9-76.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	7.5	106.3	(45.8-209.5)	Male	13	7.9	164.5	(87.5-281.3)
Female	6	6.1	98.8	(36.1-215.2)	Female	9	6.4	139.7	(63.8-265.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	19	21.2	89.5	(53.9-139.8)
Female	151	153.6	98.3	(83.3-115.3)	Female	26	18.2	143.1	(93.4-209.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	5.2	135.8	(54.4-279.8)	Male	10	18.1	55.3	(26.5-101.7)
<b><u>Colon / Rectum</u></b>					Female	9	7.7	116.4	(53.1-220.9)
Male	43	33.4	128.7	(93.1-173.3)	<b><u>Ovary</u></b>				
Female	30	32.5	92.2	(62.2-131.6)	Female	7	11.2	62.5	(25.0-128.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	8.6	69.7	(25.5-151.8)	Male	14	15.1	92.5	(50.5-155.2)
Female	3	2.6	nc	(nc-nc)	Female	13	14.5	89.8	(47.8-153.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	150	118.2	126.9	(107.4-148.9)
Female	2	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	8.1	185.9	(104.0-306.6)
Male	24	20.8	115.5	(74.0-171.9)	Female	8	5.0	161.2	(69.4-317.6)
Female	9	11.9	75.4	(34.4-143.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	4.8	nc	(nc-nc)
Male	3	4.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	1.3	nc	(nc-nc)	Male	5	8.6	58.5	(18.8-136.5)
<b><u>Leukemia</u></b>					Female	29	23.1	125.5	(84.0-180.2)
Male	13	15.3	84.8	(45.1-145.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	15	11.4	132.0	(73.8-217.8)	Female	34	35.2	96.6	(66.9-135.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	27	13.8	195.3	(128.7-284.2)	Male	514	458.0	112.2	(102.7-122.4)
Female	7	5.4	129.5	(51.9-266.9)	Female	480	494.6	97.1	(88.6-106.1)
<b><u>Lung and Bronchus</u></b>									
Male	57	57.1	99.8	(75.6-129.4)					
Female	52	70.1	74.2	(55.4-97.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	16.2	136.0	(85.2-206.0)	Male	12	11.3	106.7	(55.0-186.3)
Female	9	5.5	162.3	(74.1-308.1)	Female	8	8.4	95.3	(41.1-187.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	3.5	283.8	(135.8-521.9)	Male	3	3.9	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	5	2.9	169.9	(54.7-396.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	17	10.4	163.7	(95.3-262.2)
Female	68	69.1	98.4	(76.4-124.8)	Female	11	8.2	133.8	(66.7-239.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	11	8.7	126.8	(63.2-226.8)
<b><u>Colon / Rectum</u></b>					Female	4	3.5	nc	(nc-nc)
Male	21	16.3	129.1	(79.9-197.4)	<b><u>Ovary</u></b>				
Female	14	14.7	95.1	(51.9-159.5)	Female	3	5.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	4.3	nc	(nc-nc)	Male	5	7.5	66.5	(21.4-155.1)
Female	1	1.2	nc	(nc-nc)	Female	11	6.6	165.5	(82.5-296.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	59	57.7	102.3	(77.8-131.9)
Female	3	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.0	126.0	(40.6-294.1)
Male	8	10.0	80.0	(34.5-157.7)	Female	4	2.2	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.9	nc	(nc-nc)
Male	0	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	16	9.9	162.0	(92.6-263.2)
Male	5	7.5	66.7	(21.5-155.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	5.1	155.4	(66.9-306.3)	Female	10	15.9	63.0	(30.2-115.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	6.8	133.1	(60.7-252.7)	Male	243	224.2	108.4	(95.2-122.9)
Female	4	2.5	nc	(nc-nc)	Female	263	223.0	117.9	(104.1-133.1)
<b><u>Lung and Bronchus</u></b>									
Male	32	28.7	111.4	(76.2-157.3)					
Female	55	32.2	170.8	(128.7-222.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	27.4	124.1	(85.9-173.4)	Male	34	19.2	176.9	(122.5-247.1)
Female	8	9.9	80.5	(34.7-158.6)	Female	14	14.9	93.7	(51.2-157.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.1	114.5	(45.9-236.0)	Male	7	6.6	105.7	(42.4-217.9)
Female	11	4.8	228.2	(113.8-408.4)	Female	4	5.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	21	17.7	118.8	(73.5-181.6)
Female	145	121.0	119.8	(101.1-141.0)	Female	18	14.6	123.3	(73.1-194.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	4.0	nc	(nc-nc)	Male	13	14.8	87.7	(46.7-150.0)
<b><u>Colon / Rectum</u></b>					Female	5	6.2	81.1	(26.1-189.2)
Male	26	27.9	93.1	(60.8-136.4)	<b><u>Ovary</u></b>				
Female	28	26.8	104.7	(69.5-151.3)	Female	8	8.9	90.4	(38.9-178.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	7.2	69.4	(22.4-161.9)	Male	11	12.8	86.1	(42.9-154.1)
Female	1	2.1	nc	(nc-nc)	Female	18	11.9	151.7	(89.9-239.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	2.1	238.6	(76.9-556.8)	Male	115	97.2	118.3	(97.7-142.0)
Female	2	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	6.8	103.7	(41.5-213.7)
Male	13	17.0	76.3	(40.6-130.5)	Female	1	4.1	nc	(nc-nc)
Female	5	9.5	52.6	(16.9-122.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	3.4	205.8	(82.4-424.0)
Male	4	4.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	13	6.7	193.3	(102.8-330.5)
<b><u>Leukemia</u></b>					Female	24	17.7	135.2	(86.6-201.2)
Male	12	12.9	93.2	(48.1-162.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	9.3	75.4	(30.2-155.4)	Female	26	27.4	94.9	(62.0-139.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	11.5	104.7	(54.0-182.9)	Male	403	381.0	105.8	(95.7-116.6)
Female	6	4.3	138.3	(50.5-300.9)	Female	405	394.4	102.7	(92.9-113.2)
<b><u>Lung and Bronchus</u></b>									
Male	29	48.2	60.2	(40.3-86.5)					
Female	46	56.2	81.9	(59.9-109.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	14.8	88.0	(46.8-150.6)	Male	7	10.3	67.8	(27.2-139.7)
Female	7	4.4	158.6	(63.5-326.8)	Female	5	7.0	71.7	(23.1-167.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	3.2	218.6	(87.6-450.5)	Male	3	3.7	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	7	9.6	73.2	(29.3-150.8)
Female	64	59.0	108.5	(83.6-138.6)	Female	6	6.8	88.9	(32.4-193.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.9	nc	(nc-nc)	Male	5	8.3	60.5	(19.5-141.2)
<b><u>Colon / Rectum</u></b>					Female	2	2.9	nc	(nc-nc)
Male	14	15.0	93.5	(51.1-156.9)	<b><u>Ovary</u></b>				
Female	8	11.8	68.0	(29.3-134.0)	Female	4	4.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	4.0	nc	(nc-nc)	Male	10	7.0	143.0	(68.5-263.0)
Female	3	1.0	nc	(nc-nc)	Female	6	5.3	113.2	(41.3-246.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	54	55.8	96.8	(72.7-126.3)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.7	nc	(nc-nc)
Male	10	9.4	106.5	(51.0-195.9)	Female	2	1.8	nc	(nc-nc)
Female	3	4.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.6	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	8.3	96.3	(41.5-189.7)
Male	8	6.8	117.5	(50.6-231.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	4.2	nc	(nc-nc)	Female	11	13.9	79.2	(39.5-141.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	6.4	140.4	(64.1-266.5)	Male	195	209.6	93.0	(80.4-107.1)
Female	5	2.0	245.0	(78.9-571.6)	Female	179	186.0	96.2	(82.6-111.4)
<b><u>Lung and Bronchus</u></b>									
Male	26	26.8	97.1	(63.4-142.3)					
Female	23	26.7	86.2	(54.6-129.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Revere

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	63	58.2	108.2	(83.1-138.4)	Male	29	41.5	69.9	(46.8-100.4)
Female	27	21.0	128.7	(84.8-187.3)	Female	21	31.8	66.0	(40.8-100.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	13.3	45.0	(16.4-97.9)	Male	9	13.9	64.6	(29.5-122.6)
Female	10	10.3	96.9	(46.4-178.2)	Female	6	10.7	55.8	(20.4-121.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	33	37.9	87.0	(59.9-122.2)
Female	193	251.1	76.9	(66.4-88.5)	Female	31	30.8	100.5	(68.3-142.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	11	8.7	125.8	(62.7-225.2)	Male	24	30.9	77.6	(49.7-115.5)
<b><u>Colon / Rectum</u></b>					Female	14	13.0	107.7	(58.8-180.8)
Male	57	60.1	94.9	(71.9-123.0)	<b><u>Ovary</u></b>				
Female	50	56.6	88.3	(65.5-116.4)	Female	13	18.6	69.9	(37.2-119.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	15.1	33.2	(10.7-77.4)	Male	20	26.9	74.3	(45.4-114.8)
Female	0	4.5	nc	(nc-nc)	Female	34	25.0	136.1	(94.2-190.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	5.0	nc	(nc-nc)	Male	128	198.1	64.6	(53.9-76.8)
Female	3	4.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	17	14.3	118.5	(69.0-189.7)
Male	43	36.0	119.5	(86.5-160.9)	Female	11	8.6	128.1	(63.9-229.2)
Female	15	19.9	75.6	(42.3-124.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	9.3	53.9	(17.4-125.7)
Male	11	8.4	131.6	(65.6-235.4)	<b><u>Thyroid</u></b>				
Female	2	2.1	nc	(nc-nc)	Male	13	15.2	85.4	(45.4-146.1)
<b><u>Leukemia</u></b>					Female	42	39.1	107.5	(77.5-145.3)
Male	26	27.5	94.6	(61.8-138.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	24	19.7	121.9	(78.1-181.3)	Female	53	56.5	93.8	(70.2-122.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	35	23.8	147.2	(102.5-204.8)	Male	698	804.1	86.8	(80.5-93.5)
Female	12	9.1	132.1	(68.2-230.7)	Female	794	827.9	95.9	(89.4-102.8)
<b><u>Lung and Bronchus</u></b>									
Male	104	100.8	103.1	(84.3-125.0)					
Female	162	117.1	138.3	(117.9-161.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	7	8.7	80.8	(32.4-166.5)	Female	2	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	1.8	277.2	(89.3-647.0)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	9.8	50.8	(16.4-118.5)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.7	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.0	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	20	37.0	54.1	(33.0-83.5)
Female	0	0.3	nc	(nc-nc)	Female	24	28.5	84.2	(53.9-125.3)
<b><u>Lung and Bronchus</u></b>									
Male	2	5.1	nc	(nc-nc)					
Female	3	4.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	6.8	132.3	(60.4-251.2)	Male	3	4.7	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.5	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.4	137.2	(50.1-298.6)
Female	22	27.0	81.6	(51.1-123.6)	Female	3	3.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	7	3.8	184.4	(73.9-379.9)
<b><u>Colon / Rectum</u></b>					Female	1	1.3	nc	(nc-nc)
Male	5	6.9	72.8	(23.5-169.9)	<b><u>Ovary</u></b>				
Female	3	5.3	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	45	25.7	174.8	(127.5-234.0)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.7	nc	(nc-nc)
Male	5	4.3	115.6	(37.2-269.7)	Female	1	0.8	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	3.7	161.8	(59.1-352.1)
Male	3	3.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	1.9	nc	(nc-nc)	Female	7	6.4	109.5	(43.9-225.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	114	96.2	118.4	(97.7-142.3)
Female	0	0.9	nc	(nc-nc)	Female	73	84.7	86.2	(67.6-108.4)
<b><u>Lung and Bronchus</u></b>									
Male	9	12.3	72.9	(33.3-138.5)					
Female	11	12.2	90.0	(44.9-161.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	17.9	100.5	(59.5-158.9)	Male	21	12.6	166.6	(103.1-254.6)
Female	5	6.7	75.0	(24.2-175.0)	Female	16	10.2	157.5	(90.0-255.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	4.0	248.6	(119.0-457.2)	Male	3	4.4	nc	(nc-nc)
Female	5	3.3	152.7	(49.2-356.4)	Female	4	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	16	11.6	137.6	(78.6-223.4)
Female	77	82.0	93.9	(74.1-117.4)	Female	8	9.9	80.8	(34.8-159.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.7	nc	(nc-nc)	Male	15	9.8	152.6	(85.4-251.7)
<b><u>Colon / Rectum</u></b>					Female	4	4.2	nc	(nc-nc)
Male	18	18.3	98.6	(58.4-155.8)	<b><u>Ovary</u></b>				
Female	21	17.8	118.1	(73.1-180.6)	Female	9	6.0	149.1	(68.0-283.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	3	8.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	5	8.0	62.8	(20.2-146.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	64	65.2	98.1	(75.6-125.3)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.4	nc	(nc-nc)
Male	16	11.3	141.9	(81.1-230.5)	Female	2	2.7	nc	(nc-nc)
Female	8	6.4	124.4	(53.6-245.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.4	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	8	4.5	178.2	(76.7-351.2)
<b><u>Leukemia</u></b>					Female	14	12.2	115.1	(62.9-193.2)
Male	14	8.4	166.5	(91.0-279.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	6.2	160.8	(77.0-295.7)	Female	16	18.9	84.9	(48.5-137.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	7.6	157.5	(81.3-275.2)	Male	294	252.0	116.7	(103.7-130.8)
Female	2	2.9	nc	(nc-nc)	Female	299	267.1	111.9	(99.6-125.4)
<b><u>Lung and Bronchus</u></b>									
Male	37	31.8	116.3	(81.9-160.3)					
Female	56	38.3	146.1	(110.3-189.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	11.5	87.0	(41.7-160.0)	Male	10	7.4	135.6	(64.9-249.4)
Female	6	4.3	140.5	(51.3-305.8)	Female	8	5.5	145.5	(62.7-286.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.0	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	12	6.7	178.3	(92.0-311.5)
Female	49	45.1	108.7	(80.4-143.7)	Female	7	5.9	119.2	(47.8-245.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	6	5.4	110.8	(40.5-241.1)
<b><u>Colon / Rectum</u></b>					Female	4	2.4	nc	(nc-nc)
Male	10	10.2	98.3	(47.1-180.8)	<b><u>Ovary</u></b>				
Female	19	10.3	183.9	(110.7-287.2)	Female	0	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	5	5.2	96.4	(31.1-225.0)
Female	1	0.9	nc	(nc-nc)	Female	9	5.1	177.3	(80.9-336.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	41	40.0	102.6	(73.6-139.2)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.6	nc	(nc-nc)
Male	8	6.3	127.6	(54.9-251.4)	Female	0	1.6	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.7	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	5.0	99.3	(32.0-231.8)
Male	4	4.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.6	nc	(nc-nc)	Female	15	11.0	135.8	(75.9-224.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.5	nc	(nc-nc)	Male	147	149.4	98.4	(83.1-115.6)
Female	0	1.8	nc	(nc-nc)	Female	178	153.6	115.9	(99.5-134.2)
<b><u>Lung and Bronchus</u></b>									
Male	17	20.4	83.5	(48.6-133.7)					
Female	22	24.8	88.8	(55.6-134.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	10.2	68.7	(27.5-141.5)
Female	0	0.1	nc	(nc-nc)	Female	7	7.4	94.0	(37.6-193.6)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.5	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	7.3	nc	(nc-nc)	Male	6	5.1	117.0	(42.7-254.7)
Female	5	2.2	223.5	(72.0-521.6)	Female	1	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.7	126.5	(46.2-275.3)
Female	26	29.3	88.6	(57.9-129.9)	Female	1	3.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	2	7.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	6.0	83.9	(27.1-195.9)	Female	2	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	5	2.7	186.1	(60.0-434.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	28	28.6	97.9	(65.1-141.5)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.8	nc	(nc-nc)
Male	7	4.8	147.1	(59.0-303.2)	Female	0	0.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	4.1	146.5	(53.5-318.9)
Male	3	3.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.1	nc	(nc-nc)	Female	13	7.0	186.6	(99.3-319.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	3.3	nc	(nc-nc)	Male	85	105.2	80.8	(64.5-99.9)
Female	3	1.0	nc	(nc-nc)	Female	92	93.2	98.8	(79.6-121.1)
<b><u>Lung and Bronchus</u></b>									
Male	4	13.3	nc	(nc-nc)					
Female	8	13.4	59.9	(25.8-118.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	1.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	15	6.1	245.9	(137.5-405.6)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	0.3	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	8	7.3	110.2	(47.4-217.1)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.9	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	29	25.6	113.3	(75.9-162.7)
Female	0	0.2	nc	(nc-nc)	Female	29	19.2	151.2	(101.2-217.1)
<b><u>Lung and Bronchus</u></b>									
Male	5	3.3	152.3	(49.1-355.4)					
Female	5	2.8	179.3	(57.8-418.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Russell

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	4	7.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.4	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.2	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	26	25.6	101.6	(66.3-148.8)
Female	1	0.3	nc	(nc-nc)	Female	16	23.6	67.7	(38.7-110.0)
<b><u>Lung and Bronchus</u></b>									
Male	4	3.1	nc	(nc-nc)					
Female	3	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	7.5	106.3	(45.8-209.4)	Male	7	5.6	124.1	(49.7-255.7)
Female	2	2.7	nc	(nc-nc)	Female	9	4.5	200.2	(91.3-380.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	10	5.3	189.7	(90.8-348.9)
Female	27	37.9	71.2	(46.9-103.6)	Female	8	4.2	189.9	(81.8-374.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	8	4.8	168.2	(72.4-331.4)
<b><u>Colon / Rectum</u></b>					Female	1	1.8	nc	(nc-nc)
Male	7	8.5	82.1	(32.9-169.2)	<b><u>Ovary</u></b>				
Female	4	7.5	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	37	30.0	123.2	(86.7-169.8)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.0	nc	(nc-nc)
Male	5	5.4	92.7	(29.9-216.2)	Female	0	1.1	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.1	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	5.8	173.1	(82.9-318.3)
Male	8	3.8	211.0	(90.9-415.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.6	nc	(nc-nc)	Female	10	8.6	115.8	(55.5-213.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	3.5	nc	(nc-nc)	Male	123	114.1	107.8	(89.6-128.6)
Female	1	1.2	nc	(nc-nc)	Female	120	117.6	102.0	(84.6-122.0)
<b><u>Lung and Bronchus</u></b>									
Male	13	13.8	94.2	(50.1-161.0)					
Female	21	16.1	130.8	(80.9-199.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Salem

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	39.5	86.0	(59.5-120.1)	Male	33	28.1	117.3	(80.8-164.8)
Female	25	15.4	162.6	(105.2-240.0)	Female	26	24.1	107.9	(70.5-158.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	9.2	130.1	(67.2-227.3)	Male	8	9.7	82.5	(35.5-162.6)
Female	5	7.9	63.5	(20.5-148.3)	Female	11	8.1	135.2	(67.4-241.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	26	26.1	99.7	(65.1-146.0)
Female	178	191.8	92.8	(79.7-107.5)	Female	24	23.1	103.7	(66.4-154.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	6.5	137.9	(62.9-261.8)	Male	22	21.8	101.1	(63.3-153.1)
<b><u>Colon / Rectum</u></b>					Female	12	9.8	122.8	(63.4-214.6)
Male	45	40.7	110.5	(80.6-147.9)	<b><u>Ovary</u></b>				
Female	29	41.1	70.6	(47.3-101.4)	Female	13	14.2	91.4	(48.6-156.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	10.6	123.2	(65.5-210.7)	Male	23	18.6	124.0	(78.6-186.0)
Female	5	3.3	150.3	(48.4-350.8)	Female	16	18.4	86.9	(49.7-141.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	132	143.5	92.0	(77.0-109.1)
Female	6	3.3	183.6	(67.0-399.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	9.9	121.8	(62.9-212.8)
Male	29	25.1	115.4	(77.3-165.7)	Female	5	6.3	79.5	(25.6-185.6)
Female	19	15.0	126.4	(76.1-197.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	6.2	112.2	(45.0-231.3)
Male	5	5.9	85.2	(27.4-198.7)	<b><u>Thyroid</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	6	10.4	57.6	(21.0-125.3)
<b><u>Leukemia</u></b>					Female	43	30.2	142.2	(102.9-191.6)
Male	25	18.9	132.6	(85.8-195.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	14.6	54.9	(23.6-108.2)	Female	43	44.1	97.6	(70.6-131.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	15	16.8	89.4	(50.0-147.5)	Male	593	560.5	105.8	(97.5-114.7)
Female	6	6.9	87.5	(31.9-190.4)	Female	645	625.7	103.1	(95.3-111.4)
<b><u>Lung and Bronchus</u></b>									
Male	85	70.4	120.7	(96.4-149.2)					
Female	116	89.2	130.1	(107.5-156.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	10.9	137.5	(76.9-226.8)	Male	9	7.6	118.4	(54.0-224.8)
Female	4	3.9	nc	(nc-nc)	Female	7	5.8	121.0	(48.5-249.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.0	128.1	(58.4-243.1)
Female	47	48.3	97.3	(71.5-129.4)	Female	3	5.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	8	6.1	130.7	(56.3-257.6)
<b><u>Colon / Rectum</u></b>					Female	5	2.5	203.9	(65.7-475.8)
Male	7	10.9	64.2	(25.7-132.2)	<b><u>Ovary</u></b>				
Female	4	9.9	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	3.0	167.1	(53.8-390.0)	Male	6	5.2	116.0	(42.4-252.5)
Female	0	0.9	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	46	42.0	109.5	(80.2-146.1)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.7	nc	(nc-nc)
Male	4	6.9	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.1	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	3	0.4	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	6.4	nc	(nc-nc)
Male	8	5.0	160.7	(69.2-316.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.5	nc	(nc-nc)	Female	5	11.7	42.9	(13.8-100.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	4.8	103.9	(33.5-242.6)	Male	173	155.3	111.4	(95.4-129.3)
Female	2	1.8	nc	(nc-nc)	Female	136	156.0	87.2	(73.2-103.1)
<b><u>Lung and Bronchus</u></b>									
Male	26	20.0	130.1	(85.0-190.7)					
Female	24	23.4	102.7	(65.8-152.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	5.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.3	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.6	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	19	27.7	68.5	(41.2-107.0)
Female	0	0.2	nc	(nc-nc)	Female	9	16.2	55.7	(25.4-105.7)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.8	nc	(nc-nc)					
Female	3	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	27.0	111.0	(74.9-158.5)	Male	30	18.3	164.1	(110.7-234.3)
Female	13	9.4	137.9	(73.4-235.9)	Female	15	13.5	111.0	(62.1-183.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	5.5	128.1	(51.3-263.8)	Male	4	6.6	nc	(nc-nc)
Female	6	4.3	139.8	(51.0-304.2)	Female	3	5.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	18	16.9	106.5	(63.1-168.4)
Female	125	112.3	111.3	(92.6-132.6)	Female	13	13.7	94.9	(50.5-162.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.2	nc	(nc-nc)	Male	14	14.3	97.6	(53.3-163.8)
<b><u>Colon / Rectum</u></b>					Female	1	5.8	nc	(nc-nc)
Male	19	26.0	73.1	(44.0-114.2)	<b><u>Ovary</u></b>				
Female	25	23.9	104.7	(67.7-154.6)	Female	9	8.3	108.8	(49.6-206.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	7.2	166.1	(85.7-290.2)	Male	11	12.6	87.2	(43.4-156.0)
Female	2	2.0	nc	(nc-nc)	Female	14	11.3	124.2	(67.9-208.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.7	nc	(nc-nc)	Male	93	101.0	92.0	(74.3-112.8)
Female	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	6.5	nc	(nc-nc)
Male	9	16.4	55.0	(25.1-104.4)	Female	2	3.7	nc	(nc-nc)
Female	9	8.9	100.7	(46.0-191.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	2.3	258.4	(94.4-562.5)
Male	1	4.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	14.4	62.3	(28.4-118.3)
Male	14	12.0	116.2	(63.5-195.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	8.5	82.8	(33.2-170.6)	Female	19	27.0	70.4	(42.4-109.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	11	11.5	95.7	(47.7-171.3)	Male	361	374.2	96.5	(86.8-107.0)
Female	2	4.2	nc	(nc-nc)	Female	351	367.8	95.4	(85.7-105.9)
<b><u>Lung and Bronchus</u></b>									
Male	44	49.0	89.8	(65.2-120.6)					
Female	48	56.0	85.8	(63.2-113.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	33.5	98.4	(67.7-138.2)	Male	19	23.0	82.7	(49.8-129.2)
Female	10	12.1	82.7	(39.6-152.2)	Female	18	17.6	102.5	(60.7-162.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	6.9	144.6	(69.2-266.0)	Male	10	8.0	124.7	(59.7-229.4)
Female	10	5.5	180.2	(86.3-331.4)	Female	5	6.3	79.0	(25.5-184.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	29	21.1	137.8	(92.2-197.8)
Female	153	142.5	107.3	(91.0-125.8)	Female	21	17.6	119.5	(73.9-182.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	8	4.4	179.9	(77.5-354.5)	Male	10	17.3	57.8	(27.7-106.3)
<b><u>Colon / Rectum</u></b>					Female	5	7.4	67.8	(21.9-158.3)
Male	28	32.9	85.1	(56.6-123.1)	<b><u>Ovary</u></b>				
Female	35	31.3	111.7	(77.8-155.3)	Female	10	10.5	95.2	(45.6-175.1)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	8.7	103.4	(47.2-196.3)	Male	22	15.4	142.8	(89.4-216.2)
Female	7	2.6	270.1	(108.2-556.6)	Female	17	14.4	117.8	(68.6-188.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	5	2.3	216.5	(69.8-505.1)	Male	103	116.4	88.5	(72.2-107.3)
Female	4	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	8.1	74.3	(27.1-161.6)
Male	28	20.0	139.9	(92.9-202.2)	Female	4	4.8	nc	(nc-nc)
Female	19	11.3	167.6	(100.9-261.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.7	nc	(nc-nc)
Male	7	4.8	146.7	(58.8-302.3)	<b><u>Thyroid</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	5	7.6	65.9	(21.2-153.8)
<b><u>Leukemia</u></b>					Female	33	19.8	167.0	(114.9-234.5)
Male	23	15.1	152.6	(96.7-229.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	10.9	91.5	(43.8-168.3)	Female	42	33.2	126.7	(91.3-171.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	13.7	65.8	(30.0-124.9)	Male	466	454.7	102.5	(93.4-112.2)
Female	9	5.3	170.1	(77.6-322.9)	Female	557	469.7	118.6	(108.9-128.9)
<b><u>Lung and Bronchus</u></b>									
Male	65	59.0	110.2	(85.0-140.4)					
Female	106	69.9	151.6	(124.1-183.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	10	14.9	67.1	(32.1-123.5)
Female	0	0.1	nc	(nc-nc)	Female	9	10.6	84.7	(38.7-160.8)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.0	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	24.4	123.1	(83.0-175.7)	Male	20	16.3	122.8	(75.0-189.7)
Female	9	8.2	109.2	(49.9-207.4)	Female	19	11.6	163.3	(98.3-255.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	4.7	168.5	(72.5-332.0)	Male	6	5.7	104.6	(38.2-227.7)
Female	4	3.7	nc	(nc-nc)	Female	5	4.3	116.2	(37.4-271.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	16	14.9	107.4	(61.4-174.4)
Female	108	95.8	112.7	(92.5-136.1)	Female	11	11.8	93.1	(46.4-166.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.8	nc	(nc-nc)	Male	10	12.2	81.7	(39.1-150.3)
<b><u>Colon / Rectum</u></b>					Female	5	5.0	100.1	(32.3-233.7)
Male	27	23.3	116.0	(76.4-168.8)	<b><u>Ovary</u></b>				
Female	27	21.3	126.8	(83.6-184.5)	Female	6	7.1	84.8	(31.0-184.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	6.3	95.9	(35.0-208.8)	Male	7	11.1	62.9	(25.2-129.7)
Female	1	1.8	nc	(nc-nc)	Female	7	9.8	71.4	(28.6-147.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	93	83.7	111.1	(89.7-136.1)
Female	5	1.2	426.4	(137.4-995.2)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	5.8	86.7	(28.0-202.4)
Male	18	14.1	128.1	(75.9-202.4)	Female	3	3.2	nc	(nc-nc)
Female	6	7.7	78.3	(28.6-170.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.0	nc	(nc-nc)
Male	1	3.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	5	5.0	100.2	(32.3-233.9)
<b><u>Leukemia</u></b>					Female	9	12.3	73.3	(33.4-139.1)
Male	15	10.7	139.7	(78.1-230.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	7.4	94.8	(38.0-195.3)	Female	25	22.6	110.4	(71.4-163.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	9.8	51.0	(16.4-119.1)	Male	346	324.3	106.7	(95.8-118.6)
Female	3	3.6	nc	(nc-nc)	Female	326	315.9	103.2	(92.3-115.0)
<b><u>Lung and Bronchus</u></b>									
Male	39	42.6	91.5	(65.0-125.1)					
Female	38	47.5	80.0	(56.6-109.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	17.6	102.2	(60.6-161.6)	Male	10	12.1	82.9	(39.7-152.5)
Female	7	5.6	124.0	(49.7-255.5)	Female	10	8.5	117.0	(56.0-215.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	0	2.7	nc	(nc-nc)	Female	5	3.0	164.6	(53.1-384.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	11	11.1	99.5	(49.6-178.0)
Female	76	71.1	106.9	(84.2-133.8)	Female	11	8.4	130.8	(65.2-234.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	6	9.2	65.1	(23.8-141.6)
<b><u>Colon / Rectum</u></b>					Female	3	3.6	nc	(nc-nc)
Male	8	17.3	46.2	(19.9-91.0)	<b><u>Ovary</u></b>				
Female	8	14.9	53.8	(23.2-106.1)	Female	8	5.2	154.6	(66.5-304.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	4.6	108.6	(35.0-253.4)	Male	6	8.1	73.7	(26.9-160.4)
Female	0	1.2	nc	(nc-nc)	Female	10	6.8	148.0	(70.8-272.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	84	62.2	135.0	(107.7-167.1)
Female	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.3	nc	(nc-nc)
Male	10	10.6	94.0	(45.0-172.9)	Female	1	2.3	nc	(nc-nc)
Female	5	5.5	90.2	(29.1-210.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	1.7	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	12	9.9	121.4	(62.7-212.1)
Male	9	7.9	113.8	(51.9-216.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	5.2	134.9	(54.0-278.0)	Female	11	16.6	66.1	(33.0-118.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	7.3	nc	(nc-nc)	Male	226	240.3	94.1	(82.2-107.2)
Female	3	2.5	nc	(nc-nc)	Female	230	228.6	100.6	(88.0-114.5)
<b><u>Lung and Bronchus</u></b>									
Male	28	31.2	89.8	(59.7-129.8)					
Female	32	33.3	96.0	(65.7-135.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	20.3	29.6	(10.8-64.4)	Male	12	14.1	85.0	(43.9-148.5)
Female	5	6.6	75.9	(24.5-177.1)	Female	16	10.2	157.0	(89.7-254.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.4	nc	(nc-nc)	Male	2	5.0	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	5	3.6	140.5	(45.3-328.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	11	13.0	84.6	(42.2-151.3)
Female	100	85.2	117.4	(95.5-142.8)	Female	9	9.9	90.6	(41.4-172.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.8	nc	(nc-nc)	Male	7	11.1	63.0	(25.2-129.7)
<b><u>Colon / Rectum</u></b>					Female	4	4.2	nc	(nc-nc)
Male	18	20.5	87.9	(52.1-138.9)	<b><u>Ovary</u></b>				
Female	9	17.6	51.1	(23.3-97.1)	Female	5	6.2	81.3	(26.2-189.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	5.4	nc	(nc-nc)	Male	3	9.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	9	7.9	113.9	(52.0-216.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.4	nc	(nc-nc)	Male	75	74.3	100.9	(79.3-126.5)
Female	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	5.0	119.8	(43.8-260.8)
Male	21	12.7	165.7	(102.5-253.2)	Female	1	2.7	nc	(nc-nc)
Female	9	6.6	136.7	(62.4-259.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.1	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	13	12.2	106.3	(56.6-181.8)
Male	10	9.4	106.5	(51.0-195.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	6.2	80.4	(25.9-187.6)	Female	16	19.7	81.4	(46.5-132.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	8.6	nc	(nc-nc)	Male	231	283.7	81.4	(71.3-92.6)
Female	2	3.0	nc	(nc-nc)	Female	268	271.6	98.7	(87.2-111.2)
<b><u>Lung and Bronchus</u></b>									
Male	20	36.2	55.2	(33.7-85.3)					
Female	27	38.8	69.6	(45.8-101.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	4.9	164.2	(70.7-323.7)	Male	4	3.3	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	5	2.2	227.0	(73.1-529.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	17	18.0	94.2	(54.9-150.9)	Female	2	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.0	nc	(nc-nc)
Male	9	4.6	195.1	(89.0-370.4)	<b><u>Ovary</u></b>				
Female	7	4.1	172.0	(68.9-354.4)	Female	3	1.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	12	17.5	68.7	(35.5-120.1)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.2	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	2.2	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	61	65.8	92.7	(70.9-119.0)
Female	0	0.7	nc	(nc-nc)	Female	67	60.5	110.7	(85.8-140.5)
<b><u>Lung and Bronchus</u></b>									
Male	5	8.7	57.5	(18.5-134.1)					
Female	11	9.5	116.3	(58.0-208.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	2.7	262.0	(105.0-539.9)	Male	3	1.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	16	10.4	153.5	(87.7-249.3)	Female	3	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	2.3	220.7	(71.1-515.1)	Female	1	0.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	8	9.5	84.4	(36.3-166.3)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.6	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.3	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	38	35.9	105.9	(74.9-145.3)
Female	0	0.4	nc	(nc-nc)	Female	47	34.9	134.8	(99.0-179.2)
<b><u>Lung and Bronchus</u></b>									
Male	9	4.7	189.7	(86.6-360.2)					
Female	6	5.5	109.9	(40.1-239.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	4.9	122.9	(44.9-267.6)	Male	5	3.4	148.6	(47.9-346.7)
Female	0	1.5	nc	(nc-nc)	Female	5	2.3	220.3	(71.0-514.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	29	19.3	150.4	(100.7-216.0)	Female	4	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.0	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	4.0	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	17	17.9	95.2	(55.4-152.4)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.2	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	2.5	197.9	(63.8-461.9)
Male	1	2.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.4	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	49	67.8	72.3	(53.4-95.5)
Female	0	0.7	nc	(nc-nc)	Female	77	61.3	125.5	(99.1-156.9)
<b><u>Lung and Bronchus</u></b>									
Male	2	8.7	nc	(nc-nc)					
Female	10	8.9	112.5	(53.9-206.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shirley

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	7.0	170.3	(87.9-297.5)	Male	9	5.6	160.4	(73.2-304.6)
Female	2	2.1	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	31	29.0	106.8	(72.5-151.6)	Female	4	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	5	4.6	109.6	(35.3-255.7)
<b><u>Colon / Rectum</u></b>					Female	3	1.4	nc	(nc-nc)
Male	6	8.4	71.6	(26.1-155.8)	<b><u>Ovary</u></b>				
Female	6	5.8	103.0	(37.6-224.1)	Female	4	2.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	6	3.5	173.2	(63.2-376.9)
Female	0	0.5	nc	(nc-nc)	Female	6	2.6	233.1	(85.1-507.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	27	27.1	99.5	(65.5-144.7)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.9	nc	(nc-nc)
Male	0	5.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	5	2.2	226.4	(73.0-528.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.8	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.4	nc	(nc-nc)
Male	5	3.7	136.5	(44.0-318.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.0	nc	(nc-nc)	Female	9	6.7	133.9	(61.1-254.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	3.3	153.6	(49.5-358.4)	Male	111	109.0	101.9	(83.8-122.7)
Female	2	1.0	nc	(nc-nc)	Female	104	91.4	113.8	(93.0-137.9)
<b><u>Lung and Bronchus</u></b>									
Male	14	12.7	110.6	(60.4-185.6)					
Female	12	12.7	94.3	(48.7-164.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	38.4	86.0	(59.2-120.8)	Male	43	27.0	159.2	(115.2-214.5)
Female	19	13.5	140.2	(84.4-219.0)	Female	30	20.7	145.1	(97.8-207.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	12	8.6	139.6	(72.0-243.8)	Male	13	9.2	140.7	(74.8-240.6)
Female	8	6.7	118.8	(51.1-234.0)	Female	7	7.0	99.7	(39.9-205.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	26	24.8	104.8	(68.4-153.5)
Female	170	165.6	102.6	(87.8-119.3)	Female	13	20.0	65.0	(34.6-111.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	5.6	nc	(nc-nc)	Male	16	20.5	78.0	(44.6-126.7)
<b><u>Colon / Rectum</u></b>					Female	9	8.4	106.8	(48.7-202.7)
Male	32	39.4	81.2	(55.5-114.7)	<b><u>Ovary</u></b>				
Female	29	36.9	78.6	(52.6-112.9)	Female	10	12.2	82.2	(39.4-151.2)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	10.0	80.2	(34.5-158.0)	Male	14	17.8	78.9	(43.1-132.3)
Female	0	2.9	nc	(nc-nc)	Female	18	16.2	111.2	(65.9-175.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	3.1	nc	(nc-nc)	Male	138	131.8	104.7	(88.0-123.7)
Female	2	2.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	10	9.4	105.8	(50.7-194.6)
Male	27	23.8	113.4	(74.7-165.0)	Female	5	5.6	90.0	(29.0-210.0)
Female	6	12.9	46.4	(16.9-101.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	9	5.1	174.9	(79.8-332.1)
Male	4	5.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	13	9.5	136.3	(72.5-233.0)
<b><u>Leukemia</u></b>					Female	24	25.2	95.2	(61.0-141.7)
Male	24	18.0	133.2	(85.3-198.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	16	12.7	125.6	(71.7-204.0)	Female	44	37.1	118.5	(86.1-159.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	20	15.7	127.1	(77.6-196.3)	Male	559	528.7	105.7	(97.1-114.9)
Female	2	5.9	nc	(nc-nc)	Female	522	540.2	96.6	(88.5-105.3)
<b><u>Lung and Bronchus</u></b>									
Male	52	66.8	77.8	(58.1-102.1)					
Female	58	76.1	76.2	(57.9-98.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	8	9.3	86.2	(37.1-169.9)	Female	0	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.5	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.7	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	8	8.7	91.7	(39.5-180.8)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.3	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	23	31.8	72.4	(45.9-108.7)
Female	0	0.3	nc	(nc-nc)	Female	20	28.9	69.1	(42.2-106.8)
<b><u>Lung and Bronchus</u></b>									
Male	2	4.1	nc	(nc-nc)					
Female	1	4.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Somerset

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	24.8	101.0	(65.3-149.1)	Male	17	16.4	104.0	(60.5-166.5)
Female	10	9.7	102.8	(49.2-189.1)	Female	17	12.6	134.5	(78.3-215.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.7	128.5	(46.9-279.6)	Male	4	5.7	nc	(nc-nc)
Female	6	3.9	154.8	(56.5-336.9)	Female	6	4.7	127.5	(46.6-277.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	16	14.8	108.0	(61.7-175.4)
Female	92	98.9	93.1	(75.0-114.1)	Female	11	13.2	83.5	(41.6-149.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	14	11.6	120.3	(65.7-201.8)
<b><u>Colon / Rectum</u></b>					Female	4	5.4	nc	(nc-nc)
Male	23	23.2	99.3	(62.9-149.0)	<b><u>Ovary</u></b>				
Female	26	25.0	103.8	(67.8-152.2)	Female	7	7.4	94.2	(37.7-194.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.1	131.0	(56.4-258.1)	Male	8	11.0	72.5	(31.2-142.8)
Female	1	2.0	nc	(nc-nc)	Female	10	11.5	86.9	(41.6-159.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.5	nc	(nc-nc)	Male	111	78.8	141.0	(115.9-169.7)
Female	1	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	5.7	157.3	(71.8-298.6)
Male	28	13.6	205.5	(136.5-297.0)	Female	4	3.8	nc	(nc-nc)
Female	7	8.1	86.0	(34.4-177.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.2	nc	(nc-nc)
Male	5	3.3	153.3	(49.4-357.8)	<b><u>Thyroid</u></b>				
Female	2	0.8	nc	(nc-nc)	Male	6	4.9	121.5	(44.4-264.5)
<b><u>Leukemia</u></b>					Female	12	12.6	94.9	(49.0-165.7)
Male	7	10.7	65.5	(26.3-135.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	8.4	130.7	(65.1-233.8)	Female	24	22.4	107.1	(68.6-159.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	9.4	95.7	(43.7-181.7)	Male	393	317.7	123.7	(111.8-136.5)
Female	1	4.0	nc	(nc-nc)	Female	351	342.0	102.6	(92.2-114.0)
<b><u>Lung and Bronchus</u></b>									
Male	62	42.2	147.1	(112.7-188.5)					
Female	61	52.2	116.9	(89.4-150.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Somerville

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	51	49.0	104.1	(77.5-136.9)	Male	34	38.1	89.2	(61.7-124.6)
Female	12	17.8	67.5	(34.8-117.9)	Female	22	32.5	67.7	(42.4-102.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	14.1	63.9	(29.2-121.4)	Male	4	12.3	nc	(nc-nc)
Female	18	10.9	165.6	(98.1-261.8)	Female	8	9.3	85.8	(37.0-169.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.1	nc	(nc-nc)	Male	32	35.4	90.4	(61.8-127.6)
Female	204	238.0	85.7	(74.4-98.3)	Female	24	28.7	83.7	(53.6-124.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	10.7	84.1	(38.4-159.6)	Male	23	28.4	80.9	(51.3-121.4)
<b><u>Colon / Rectum</u></b>					Female	8	11.9	67.1	(28.9-132.2)
Male	53	55.3	95.9	(71.8-125.5)	<b><u>Ovary</u></b>				
Female	44	50.4	87.3	(63.4-117.1)	Female	17	17.8	95.5	(55.6-152.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	13.1	91.4	(47.2-159.7)	Male	28	23.2	120.6	(80.1-174.3)
Female	0	3.8	nc	(nc-nc)	Female	18	21.4	84.0	(49.8-132.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	6.8	nc	(nc-nc)	Male	148	173.8	85.1	(72.0-100.0)
Female	5	6.0	83.4	(26.9-194.6)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	12.9	93.3	(48.1-163.0)
Male	28	33.7	83.0	(55.1-119.9)	Female	11	7.7	141.9	(70.8-254.0)
Female	10	18.1	55.1	(26.4-101.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	12	15.4	77.8	(40.2-135.9)
Male	7	7.4	95.1	(38.1-195.9)	<b><u>Thyroid</u></b>				
Female	3	1.8	nc	(nc-nc)	Male	15	17.7	84.9	(47.5-140.0)
<b><u>Leukemia</u></b>					Female	48	50.8	94.6	(69.7-125.4)
Male	22	25.4	86.6	(54.2-131.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	16	18.1	88.4	(50.5-143.6)	Female	52	50.7	102.5	(76.5-134.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	28	20.9	133.7	(88.8-193.3)	Male	657	729.9	90.0	(83.3-97.2)
Female	8	8.0	100.3	(43.2-197.7)	Female	677	777.4	87.1	(80.6-93.9)
<b><u>Lung and Bronchus</u></b>									
Male	83	86.1	96.4	(76.8-119.5)					
Female	81	100.9	80.3	(63.7-99.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	21.2	94.3	(57.6-145.6)	Male	6	14.0	42.9	(15.6-93.3)
Female	9	7.8	116.1	(53.0-220.4)	Female	16	10.8	147.6	(84.3-239.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	4.0	nc	(nc-nc)	Male	5	4.9	102.5	(33.0-239.2)
Female	2	3.5	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	9	12.7	70.8	(32.3-134.5)
Female	83	83.5	99.4	(79.1-123.2)	Female	10	11.0	90.9	(43.5-167.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	2.6	194.5	(62.7-453.9)	Male	11	10.0	109.7	(54.7-196.3)
<b><u>Colon / Rectum</u></b>					Female	5	4.5	110.0	(35.4-256.7)
Male	12	19.7	60.9	(31.5-106.5)	<b><u>Ovary</u></b>				
Female	32	19.9	160.8	(109.9-226.9)	Female	5	6.4	77.8	(25.1-181.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	5.3	113.6	(41.5-247.2)	Male	13	9.5	137.0	(72.9-234.3)
Female	2	1.6	nc	(nc-nc)	Female	12	9.2	130.7	(67.4-228.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	1.3	nc	(nc-nc)	Male	64	69.0	92.8	(71.5-118.5)
Female	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	4.9	142.9	(57.3-294.5)
Male	11	11.7	94.2	(47.0-168.6)	Female	4	3.0	nc	(nc-nc)
Female	6	6.9	87.5	(32.0-190.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.9	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	1	4.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	12.3	40.8	(13.1-95.2)
Male	8	9.1	87.5	(37.7-172.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	7.0	185.2	(98.5-316.7)	Female	21	19.4	108.3	(67.0-165.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	8.2	nc	(nc-nc)	Male	264	274.0	96.3	(85.1-108.7)
Female	2	3.3	nc	(nc-nc)	Female	304	287.3	105.8	(94.2-118.4)
<b><u>Lung and Bronchus</u></b>									
Male	39	36.5	107.0	(76.1-146.2)					
Female	44	43.3	101.6	(73.8-136.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	7.4	188.1	(102.7-315.6)	Male	5	5.2	96.8	(31.2-225.8)
Female	4	2.4	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	32	30.8	104.1	(71.2-146.9)	Female	2	3.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	0.9	nc	(nc-nc)	Male	7	4.2	165.9	(66.5-341.8)
<b><u>Colon / Rectum</u></b>					Female	2	1.5	nc	(nc-nc)
Male	8	7.5	107.0	(46.1-210.8)	<b><u>Ovary</u></b>				
Female	5	6.2	81.0	(26.1-189.0)	Female	4	2.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	4	2.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	21	29.2	71.8	(44.5-109.8)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	1	4.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	5	4.3	117.6	(37.9-274.5)
Male	1	3.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.2	nc	(nc-nc)	Female	4	7.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	91	106.6	85.3	(68.7-104.8)
Female	0	1.1	nc	(nc-nc)	Female	102	98.3	103.8	(84.6-126.0)
<b><u>Lung and Bronchus</u></b>									
Male	11	13.7	80.3	(40.0-143.7)					
Female	19	14.5	130.9	(78.8-204.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	10.2	78.2	(33.7-154.1)	Male	12	7.4	163.2	(84.2-285.1)
Female	4	3.7	nc	(nc-nc)	Female	8	5.6	142.1	(61.2-280.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.4	nc	(nc-nc)	Male	6	2.6	232.4	(84.9-505.8)
Female	1	1.8	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	9	6.8	131.6	(60.1-249.9)
Female	51	47.2	108.0	(80.4-142.0)	Female	3	5.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	2.4	nc	(nc-nc)
Male	9	10.9	82.9	(37.8-157.5)	<b><u>Ovary</u></b>				
Female	14	9.8	142.3	(77.7-238.8)	Female	4	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	11	4.9	223.6	(111.4-400.0)
Female	1	0.8	nc	(nc-nc)	Female	2	4.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	0.8	nc	(nc-nc)	Male	51	39.7	128.4	(95.6-168.9)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.6	nc	(nc-nc)
Male	7	6.8	102.6	(41.1-211.5)	Female	1	1.5	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.2	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	6.5	93.0	(34.0-202.4)
Male	2	4.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	3.4	233.2	(100.4-459.6)	Female	8	11.0	72.5	(31.2-142.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	4.6	nc	(nc-nc)	Male	164	149.3	109.8	(93.7-128.0)
Female	0	1.7	nc	(nc-nc)	Female	138	150.9	91.5	(76.8-108.1)
<b><u>Lung and Bronchus</u></b>									
Male	16	18.7	85.5	(48.8-138.9)					
Female	9	21.8	41.2	(18.8-78.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	16.3	97.9	(55.9-159.0)	Male	12	11.5	104.4	(53.9-182.4)
Female	9	6.2	146.0	(66.6-277.2)	Female	6	9.2	65.2	(23.8-141.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.7	nc	(nc-nc)	Male	6	3.9	152.1	(55.5-331.1)
Female	1	3.0	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	12	10.6	113.2	(58.4-197.8)
Female	65	73.0	89.0	(68.7-113.4)	Female	6	9.0	66.6	(24.3-145.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.4	nc	(nc-nc)	Male	8	8.8	91.0	(39.2-179.4)
<b><u>Colon / Rectum</u></b>					Female	10	3.8	263.4	(126.1-484.5)
Male	19	16.7	113.9	(68.6-177.9)	<b><u>Ovary</u></b>				
Female	23	16.4	139.8	(88.6-209.8)	Female	7	5.4	128.8	(51.6-265.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	4.3	nc	(nc-nc)	Male	4	7.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	11	7.3	149.8	(74.7-268.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.3	nc	(nc-nc)	Male	66	57.6	114.5	(88.6-145.7)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.0	nc	(nc-nc)
Male	10	10.1	98.5	(47.2-181.2)	Female	2	2.5	nc	(nc-nc)
Female	8	5.8	137.8	(59.4-271.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.3	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	11.0	82.1	(37.5-155.9)
Male	5	7.7	65.0	(20.9-151.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	5.8	104.1	(38.0-226.6)	Female	17	16.7	101.9	(59.3-163.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	6.8	176.6	(91.1-308.5)	Male	266	227.3	117.0	(103.4-132.0)
Female	3	2.7	nc	(nc-nc)	Female	249	241.5	103.1	(90.7-116.7)
<b><u>Lung and Bronchus</u></b>									
Male	56	28.7	194.9	(147.2-253.1)					
Female	41	34.7	118.2	(84.8-160.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	12.3	138.1	(80.4-221.2)	Male	11	8.5	129.4	(64.5-231.6)
Female	3	4.3	nc	(nc-nc)	Female	6	6.1	98.9	(36.1-215.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.6	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	9	7.8	115.1	(52.5-218.6)
Female	45	49.1	91.7	(66.8-122.6)	Female	4	6.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	3	6.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.6	nc	(nc-nc)
Male	13	12.2	106.6	(56.7-182.3)	<b><u>Ovary</u></b>				
Female	11	11.2	98.3	(49.0-176.0)	Female	5	3.6	137.3	(44.2-320.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	3.3	242.4	(104.4-477.6)	Male	5	5.8	86.5	(27.9-201.8)
Female	0	0.9	nc	(nc-nc)	Female	5	5.1	98.1	(31.6-228.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	46	45.9	100.3	(73.4-133.7)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.0	nc	(nc-nc)
Male	6	7.6	78.8	(28.8-171.5)	Female	0	1.7	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.2	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	6.5	138.5	(63.2-262.8)
Male	4	5.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	3.8	235.1	(107.3-446.3)	Female	6	11.5	52.1	(19.0-113.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	5.3	113.5	(41.4-246.9)	Male	187	172.0	108.7	(93.7-125.4)
Female	1	1.9	nc	(nc-nc)	Female	148	163.1	90.7	(76.7-106.6)
<b><u>Lung and Bronchus</u></b>									
Male	23	22.2	103.8	(65.8-155.8)					
Female	25	24.3	102.9	(66.6-151.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	13.8	93.9	(49.9-160.6)	Male	12	9.6	125.3	(64.7-218.9)
Female	4	4.5	nc	(nc-nc)	Female	10	6.7	148.2	(70.9-272.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.0	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	11	8.8	124.4	(62.0-222.6)
Female	56	55.7	100.6	(76.0-130.7)	Female	9	6.7	134.7	(61.5-255.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	5	7.4	67.1	(21.6-156.7)
<b><u>Colon / Rectum</u></b>					Female	3	2.8	nc	(nc-nc)
Male	17	13.8	123.5	(71.9-197.7)	<b><u>Ovary</u></b>				
Female	19	11.8	161.3	(97.1-251.9)	Female	7	4.1	172.1	(68.9-354.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	3.7	135.4	(43.6-316.0)	Male	4	6.5	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)	Female	7	5.4	129.2	(51.8-266.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	62	50.6	122.6	(94.0-157.2)
Female	0	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.4	nc	(nc-nc)
Male	8	8.6	93.6	(40.3-184.4)	Female	1	1.8	nc	(nc-nc)
Female	3	4.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.5	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	7.8	129.0	(61.7-237.2)
Male	4	6.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	4.1	nc	(nc-nc)	Female	20	13.0	153.7	(93.9-237.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.8	nc	(nc-nc)	Male	196	192.7	101.7	(88.0-117.0)
Female	3	2.0	nc	(nc-nc)	Female	218	180.5	120.8	(105.3-137.9)
<b><u>Lung and Bronchus</u></b>									
Male	23	24.9	92.5	(58.6-138.9)					
Female	37	26.6	139.3	(98.1-192.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	103	119.8	86.0	(70.2-104.3)	Male	32	85.7	37.4	(25.5-52.7)
Female	26	44.6	58.3	(38.1-85.5)	Female	24	72.6	33.1	(21.2-49.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	32	29.7	107.9	(73.8-152.3)	Male	29	29.3	98.8	(66.2-141.9)
Female	22	25.0	88.0	(55.2-133.3)	Female	33	23.9	138.3	(95.2-194.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	10	4.9	203.0	(97.2-373.3)	Male	75	80.2	93.5	(73.6-117.2)
Female	524	581.4	90.1	(82.6-98.2)	Female	73	68.8	106.1	(83.2-133.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	39	20.7	188.3	(133.9-257.5)	Male	84	65.8	127.7	(101.9-158.1)
<b><u>Colon / Rectum</u></b>					Female	25	29.0	86.1	(55.7-127.2)
Male	163	123.9	131.5	(112.1-153.4)	<b><u>Ovary</u></b>				
Female	138	121.6	113.5	(95.3-134.1)	Female	34	42.7	79.7	(55.2-111.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	29	31.8	91.2	(61.1-131.0)	Male	62	56.0	110.6	(84.8-141.8)
Female	15	9.6	155.8	(87.2-257.1)	Female	51	53.5	95.4	(71.0-125.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	17	12.2	139.8	(81.4-223.9)	Male	354	429.8	82.4	(74.0-91.4)
Female	9	10.7	84.0	(38.3-159.4)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	38	29.9	127.1	(90.0-174.5)
Male	77	76.5	100.6	(79.4-125.8)	Female	23	18.6	123.6	(78.3-185.5)
Female	69	45.0	153.5	(119.4-194.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	12	21.0	57.3	(29.6-100.0)
Male	24	17.7	135.7	(86.9-202.0)	<b><u>Thyroid</u></b>				
Female	7	4.8	146.5	(58.7-301.9)	Male	23	32.6	70.6	(44.8-106.0)
<b><u>Leukemia</u></b>					Female	78	96.1	81.2	(64.1-101.3)
Male	50	59.5	84.0	(62.3-110.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	46	44.3	103.7	(75.9-138.4)	Female	134	130.5	102.7	(86.1-121.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	94	50.8	185.1	(149.6-226.5)	Male	1698	1705.1	99.6	(94.9-104.4)
Female	27	20.2	133.9	(88.2-194.9)	Female	1837	1873.7	98.0	(93.6-102.6)
<b><u>Lung and Bronchus</u></b>									
Male	245	212.4	115.3	(101.4-130.7)					
Female	300	259.7	115.5	(102.8-129.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	9.6	124.7	(64.4-217.9)	Male	8	6.6	120.6	(51.9-237.7)
Female	1	3.8	nc	(nc-nc)	Female	4	5.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.0	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	7	6.1	114.5	(45.9-235.9)
Female	48	41.9	114.6	(84.5-151.9)	Female	3	5.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.2	nc	(nc-nc)	Male	7	5.3	133.2	(53.4-274.5)
<b><u>Colon / Rectum</u></b>					Female	3	2.2	nc	(nc-nc)
Male	11	9.6	115.1	(57.4-205.9)	<b><u>Ovary</u></b>				
Female	7	9.8	71.3	(28.6-146.9)	Female	3	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	1	4.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	35	35.8	97.7	(68.0-135.8)
Female	3	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.4	nc	(nc-nc)
Male	2	6.0	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.9	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	9	5.3	168.4	(76.8-319.7)
Male	4	4.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	3.3	nc	(nc-nc)	Female	7	9.8	71.4	(28.6-147.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.1	nc	(nc-nc)	Male	117	134.5	87.0	(71.9-104.2)
Female	0	1.6	nc	(nc-nc)	Female	140	140.2	99.9	(84.0-117.8)
<b><u>Lung and Bronchus</u></b>									
Male	6	17.3	34.6	(12.6-75.3)					
Female	20	20.9	95.6	(58.4-147.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	3.4	234.6	(101.0-462.4)	Male	2	2.2	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	8	12.7	63.1	(27.2-124.3)	Female	3	1.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.7	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	2.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	13	12.0	108.6	(57.8-185.8)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.8	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.4	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.0	nc	(nc-nc)	Female	5	3.1	162.7	(52.4-379.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	41	44.5	92.2	(66.2-125.1)
Female	0	0.5	nc	(nc-nc)	Female	40	43.6	91.7	(65.5-124.8)
<b><u>Lung and Bronchus</u></b>									
Male	4	6.1	nc	(nc-nc)					
Female	7	7.2	97.2	(38.9-200.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	28.4	84.5	(54.1-125.7)	Male	16	19.1	83.8	(47.9-136.2)
Female	7	10.6	66.2	(26.5-136.3)	Female	22	14.6	150.2	(94.1-227.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	5.6	nc	(nc-nc)	Male	5	6.6	75.2	(24.2-175.5)
Female	2	4.6	nc	(nc-nc)	Female	2	5.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	12	17.4	69.0	(35.6-120.5)
Female	127	117.4	108.2	(90.2-128.7)	Female	22	14.9	147.4	(92.4-223.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.6	nc	(nc-nc)	Male	20	14.0	142.8	(87.2-220.6)
<b><u>Colon / Rectum</u></b>					Female	9	6.2	145.0	(66.1-275.2)
Male	32	27.2	117.8	(80.6-166.3)	<b><u>Ovary</u></b>				
Female	28	27.2	103.0	(68.4-148.8)	Female	5	8.7	57.3	(18.5-133.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	7.2	nc	(nc-nc)	Male	12	12.9	93.2	(48.1-162.9)
Female	0	2.2	nc	(nc-nc)	Female	11	12.6	87.5	(43.6-156.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	77	95.1	81.0	(63.9-101.2)
Female	0	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	6.7	119.5	(51.5-235.5)
Male	16	16.3	98.2	(56.1-159.5)	Female	4	4.1	nc	(nc-nc)
Female	8	9.5	84.4	(36.3-166.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	2.8	nc	(nc-nc)
Male	5	3.9	128.5	(41.4-299.8)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	6	6.0	99.4	(36.3-216.3)
<b><u>Leukemia</u></b>					Female	18	15.7	115.0	(68.1-181.7)
Male	11	12.5	87.9	(43.8-157.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	12	9.4	128.1	(66.1-223.7)	Female	26	27.3	95.3	(62.2-139.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	11.2	107.1	(55.3-187.0)	Male	336	375.4	89.5	(80.2-99.6)
Female	4	4.5	nc	(nc-nc)	Female	397	394.3	100.7	(91.0-111.1)
<b><u>Lung and Bronchus</u></b>									
Male	38	49.3	77.1	(54.5-105.8)					
Female	57	59.5	95.8	(72.6-124.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	32.1	99.7	(68.2-140.8)	Male	21	22.0	95.5	(59.1-145.9)
Female	16	12.1	132.3	(75.6-214.9)	Female	18	17.3	104.1	(61.7-164.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.7	104.4	(41.8-215.2)	Male	5	7.7	65.3	(21.0-152.4)
Female	2	5.5	nc	(nc-nc)	Female	4	6.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	20	20.2	99.0	(60.5-152.9)
Female	123	140.5	87.5	(72.7-104.4)	Female	18	17.4	103.3	(61.2-163.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	4.3	nc	(nc-nc)	Male	12	16.6	72.2	(37.3-126.2)
<b><u>Colon / Rectum</u></b>					Female	11	7.3	150.9	(75.2-270.0)
Male	45	31.7	142.1	(103.6-190.2)	<b><u>Ovary</u></b>				
Female	47	31.4	149.8	(110.1-199.2)	Female	6	10.3	58.1	(21.2-126.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	11	8.3	132.2	(65.9-236.6)	Male	17	14.8	115.2	(67.1-184.4)
Female	4	2.6	nc	(nc-nc)	Female	11	14.4	76.3	(38.1-136.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	124	111.3	111.4	(92.7-132.9)
Female	7	1.9	374.6	(150.1-771.8)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	7.7	103.4	(44.5-203.8)
Male	19	19.2	98.9	(59.5-154.4)	Female	4	4.8	nc	(nc-nc)
Female	19	11.2	169.7	(102.1-265.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	3.6	168.7	(61.6-367.2)
Male	8	4.6	175.2	(75.5-345.3)	<b><u>Thyroid</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	2	7.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	23	19.1	120.3	(76.3-180.6)
Male	17	14.5	117.0	(68.1-187.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	10.9	91.9	(44.0-169.0)	Female	33	32.5	101.6	(69.9-142.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	12	13.1	91.9	(47.4-160.5)	Male	460	435.8	105.5	(96.1-115.7)
Female	4	5.2	nc	(nc-nc)	Female	468	464.4	100.8	(91.8-110.3)
<b><u>Lung and Bronchus</u></b>									
Male	57	56.3	101.2	(76.6-131.1)					
Female	63	69.3	90.9	(69.8-116.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	8.8	102.8	(46.9-195.2)	Male	8	6.0	133.3	(57.4-262.6)
Female	2	2.7	nc	(nc-nc)	Female	5	4.1	120.8	(38.9-281.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	4	1.3	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.5	nc	(nc-nc)
Female	31	34.9	88.8	(60.3-126.1)	Female	2	4.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.7	nc	(nc-nc)
Male	3	8.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	6	7.2	83.3	(30.4-181.3)	Female	7	2.5	278.4	(111.5-573.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.3	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	5	3.2	154.1	(49.7-359.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	38	29.8	127.6	(90.3-175.2)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.1	nc	(nc-nc)
Male	9	5.2	172.8	(78.8-328.0)	Female	0	1.1	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.8	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	6	4.8	125.7	(45.9-273.6)
Male	6	4.0	151.7	(55.4-330.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	2.5	nc	(nc-nc)	Female	3	8.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	112	117.8	95.1	(78.3-114.4)
Female	2	1.2	nc	(nc-nc)	Female	103	111.1	92.7	(75.7-112.5)
<b><u>Lung and Bronchus</u></b>									
Male	9	15.2	59.3	(27.1-112.7)					
Female	16	16.1	99.7	(56.9-161.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	11.4	140.1	(80.0-227.5)	Male	11	7.9	139.3	(69.5-249.3)
Female	8	3.8	210.9	(90.8-415.6)	Female	3	5.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.5	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	7.3	nc	(nc-nc)
Female	40	47.6	84.0	(60.0-114.4)	Female	6	5.7	106.0	(38.7-230.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	1.5	nc	(nc-nc)	Male	8	6.0	133.0	(57.3-262.1)
<b><u>Colon / Rectum</u></b>					Female	4	2.4	nc	(nc-nc)
Male	24	11.4	211.1	(135.2-314.1)	<b><u>Ovary</u></b>				
Female	13	10.0	129.6	(68.9-221.6)	Female	4	3.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.0	nc	(nc-nc)	Male	6	5.3	113.6	(41.5-247.3)
Female	1	0.8	nc	(nc-nc)	Female	8	4.5	176.2	(75.9-347.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	44	40.2	109.5	(79.5-147.0)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	2.8	nc	(nc-nc)
Male	11	7.0	156.9	(78.2-280.8)	Female	0	1.5	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.2	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	6.8	nc	(nc-nc)
Male	5	5.3	94.5	(30.5-220.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.5	nc	(nc-nc)	Female	17	11.0	155.1	(90.3-248.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	4.7	148.1	(59.3-305.2)	Male	166	156.9	105.8	(90.3-123.2)
Female	2	1.7	nc	(nc-nc)	Female	157	153.5	102.3	(86.9-119.6)
<b><u>Lung and Bronchus</u></b>									
Male	16	20.2	79.1	(45.2-128.4)					
Female	27	22.3	121.2	(79.8-176.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	19.7	91.3	(54.1-144.2)	Male	19	13.8	138.0	(83.1-215.6)
Female	8	6.6	121.2	(52.2-238.9)	Female	13	10.0	130.5	(69.4-223.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.3	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	17	12.7	133.7	(77.9-214.1)
Female	100	83.2	120.3	(97.8-146.3)	Female	12	9.8	123.0	(63.5-214.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	8	10.9	73.1	(31.5-144.0)
<b><u>Colon / Rectum</u></b>					Female	3	4.2	nc	(nc-nc)
Male	19	20.2	93.9	(56.5-146.6)	<b><u>Ovary</u></b>				
Female	15	17.9	83.6	(46.8-137.9)	Female	4	6.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	5.3	nc	(nc-nc)	Male	8	9.3	86.3	(37.2-170.0)
Female	2	1.4	nc	(nc-nc)	Female	11	7.9	139.4	(69.5-249.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	81	71.8	112.7	(89.5-140.1)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	4.9	nc	(nc-nc)
Male	6	12.4	48.3	(17.6-105.1)	Female	2	2.7	nc	(nc-nc)
Female	6	6.4	93.1	(34.0-202.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.9	nc	(nc-nc)
Male	0	3.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	5	4.6	108.0	(34.8-252.1)
<b><u>Leukemia</u></b>					Female	13	11.5	113.5	(60.4-194.0)
Male	10	9.2	108.6	(52.0-199.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	6.2	129.1	(55.6-254.3)	Female	19	19.0	99.8	(60.0-155.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	8.4	59.5	(19.2-139.0)	Male	238	276.3	86.1	(75.5-97.8)
Female	1	2.9	nc	(nc-nc)	Female	263	266.4	98.7	(87.1-111.4)
<b><u>Lung and Bronchus</u></b>									
Male	18	35.1	51.3	(30.4-81.0)					
Female	16	37.8	42.4	(24.2-68.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	3.4	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	8	14.5	55.2	(23.8-108.7)	Female	1	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	0.8	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	3.1	160.0	(51.6-373.4)	Female	1	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	14	12.6	111.0	(60.6-186.3)
Female	1	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.8	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.7	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	2.4	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.1	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	41	48.4	84.8	(60.8-115.0)
Female	1	0.5	nc	(nc-nc)	Female	42	48.3	86.9	(62.6-117.5)
<b><u>Lung and Bronchus</u></b>									
Male	2	6.1	nc	(nc-nc)					
Female	5	7.0	71.8	(23.1-167.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	10.2	68.9	(27.6-142.0)	Male	8	7.2	110.4	(47.5-217.5)
Female	2	3.2	nc	(nc-nc)	Female	8	5.1	156.7	(67.5-308.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
Female	45	43.4	103.6	(75.5-138.6)	Female	4	4.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	9	6.1	148.5	(67.8-281.9)
<b><u>Colon / Rectum</u></b>					Female	2	2.1	nc	(nc-nc)
Male	13	10.7	121.7	(64.8-208.2)	<b><u>Ovary</u></b>				
Female	11	8.6	128.1	(63.9-229.3)	Female	0	3.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	7	4.9	142.1	(56.9-292.9)
Female	1	0.7	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	40	40.8	98.1	(70.1-133.6)
Female	1	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.6	nc	(nc-nc)
Male	5	6.8	73.2	(23.6-170.9)	Female	0	1.3	nc	(nc-nc)
Female	5	3.3	150.9	(48.6-352.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.1	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	6.1	130.6	(56.3-257.4)
Male	5	4.8	104.7	(33.7-244.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.0	nc	(nc-nc)	Female	10	10.3	97.5	(46.7-179.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	4.6	108.4	(34.9-252.9)	Male	139	149.5	93.0	(78.2-109.8)
Female	1	1.5	nc	(nc-nc)	Female	132	135.9	97.1	(81.3-115.2)
<b><u>Lung and Bronchus</u></b>									
Male	15	18.9	79.5	(44.5-131.2)					
Female	13	19.2	67.6	(36.0-115.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	18.4	108.5	(66.3-167.6)	Male	16	12.2	130.8	(74.7-212.4)
Female	10	6.8	147.6	(70.7-271.5)	Female	13	9.3	139.6	(74.2-238.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	6	4.3	140.1	(51.2-304.9)
Female	4	2.9	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	12	11.1	107.7	(55.6-188.1)
Female	91	75.3	120.9	(97.3-148.5)	Female	13	9.5	136.5	(72.6-233.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.2	nc	(nc-nc)	Male	8	9.0	88.8	(38.2-174.9)
<b><u>Colon / Rectum</u></b>					Female	5	4.0	125.3	(40.4-292.5)
Male	18	17.4	103.6	(61.4-163.8)	<b><u>Ovary</u></b>				
Female	15	17.5	85.8	(48.0-141.6)	Female	7	5.6	124.9	(50.1-257.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	4.7	nc	(nc-nc)	Male	9	8.3	108.0	(49.3-205.1)
Female	2	1.4	nc	(nc-nc)	Female	11	8.0	136.8	(68.2-244.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	65	61.7	105.4	(81.3-134.3)
Female	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.3	nc	(nc-nc)
Male	11	10.4	105.6	(52.7-189.0)	Female	2	2.7	nc	(nc-nc)
Female	7	6.1	115.2	(46.1-237.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.5	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	13	9.7	134.0	(71.3-229.1)
Male	9	8.1	111.7	(51.0-212.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	6.0	nc	(nc-nc)	Female	22	17.6	125.0	(78.3-189.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	7.3	nc	(nc-nc)	Male	237	241.8	98.0	(85.9-111.3)
Female	1	2.9	nc	(nc-nc)	Female	291	252.2	115.4	(102.5-129.5)
<b><u>Lung and Bronchus</u></b>									
Male	28	31.9	87.8	(58.3-126.9)					
Female	40	38.0	105.3	(75.2-143.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	20.9	105.5	(66.1-159.7)	Male	10	14.2	70.6	(33.8-129.9)
Female	6	7.2	83.0	(30.3-180.6)	Female	6	10.3	58.5	(21.3-127.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.2	nc	(nc-nc)	Male	7	5.0	140.8	(56.4-290.2)
Female	2	3.2	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	19	13.0	146.6	(88.2-229.0)
Female	75	84.0	89.3	(70.3-112.0)	Female	12	10.4	115.9	(59.8-202.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.6	nc	(nc-nc)	Male	12	10.7	112.1	(57.9-195.8)
<b><u>Colon / Rectum</u></b>					Female	2	4.3	nc	(nc-nc)
Male	14	20.3	69.0	(37.7-115.7)	<b><u>Ovary</u></b>				
Female	18	18.8	95.7	(56.7-151.2)	Female	7	6.2	113.7	(45.5-234.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	5.4	166.6	(76.0-316.2)	Male	13	9.6	135.6	(72.1-231.8)
Female	2	1.5	nc	(nc-nc)	Female	18	8.6	208.7	(123.6-329.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	1.3	nc	(nc-nc)	Male	97	72.6	133.5	(108.3-162.9)
Female	3	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	5.0	nc	(nc-nc)
Male	12	12.3	97.3	(50.2-170.0)	Female	2	2.9	nc	(nc-nc)
Female	6	6.7	90.1	(32.9-196.1)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.0	nc	(nc-nc)
Male	6	2.9	203.5	(74.3-442.9)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	7	4.6	153.1	(61.3-315.4)
<b><u>Leukemia</u></b>					Female	16	11.2	143.1	(81.7-232.3)
Male	14	9.2	151.5	(82.7-254.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	6.5	154.8	(74.1-284.7)	Female	18	19.3	93.0	(55.1-147.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	8.5	153.5	(81.6-262.5)	Male	341	281.5	121.1	(108.6-134.7)
Female	2	3.1	nc	(nc-nc)	Female	272	276.6	98.3	(87.0-110.7)
<b><u>Lung and Bronchus</u></b>									
Male	47	36.7	128.2	(94.2-170.5)					
Female	40	41.2	97.1	(69.4-132.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Taunton

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	81	56.6	143.1	(113.7-177.9)	Male	24	40.0	60.0	(38.5-89.3)
Female	29	21.6	134.4	(90.0-193.0)	Female	26	32.6	79.8	(52.1-116.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	11	12.7	86.3	(43.0-154.4)	Male	17	13.8	123.2	(71.7-197.3)
Female	6	10.5	57.0	(20.8-124.1)	Female	7	11.3	62.1	(24.9-127.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	29	36.8	78.7	(52.7-113.1)
Female	229	262.5	87.2	(76.3-99.3)	Female	35	31.8	109.9	(76.6-152.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	15	8.6	173.5	(97.0-286.1)	Male	40	31.0	129.0	(92.1-175.7)
<b><u>Colon / Rectum</u></b>					Female	12	13.4	89.3	(46.1-156.1)
Male	69	58.0	118.9	(92.5-150.4)	<b><u>Ovary</u></b>				
Female	63	57.6	109.3	(84.0-139.8)	Female	19	19.3	98.4	(59.2-153.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	17	15.0	113.2	(65.9-181.3)	Male	28	26.5	105.8	(70.3-152.9)
Female	4	4.6	nc	(nc-nc)	Female	24	25.8	93.2	(59.7-138.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	4.5	nc	(nc-nc)	Male	192	202.7	94.7	(81.8-109.1)
Female	4	3.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	16	14.0	113.9	(65.1-185.0)
Male	47	35.6	131.9	(96.9-175.4)	Female	7	8.8	79.9	(32.0-164.6)
Female	26	20.6	126.1	(82.4-184.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	7.5	92.9	(37.2-191.5)
Male	13	8.4	154.8	(82.3-264.7)	<b><u>Thyroid</u></b>				
Female	5	2.2	226.8	(73.1-529.2)	Male	13	14.2	91.6	(48.7-156.6)
<b><u>Leukemia</u></b>					Female	34	38.9	87.5	(60.6-122.3)
Male	28	26.7	105.0	(69.8-151.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	26	20.1	129.3	(84.5-189.5)	Female	67	60.0	111.7	(86.6-141.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	29	23.9	121.4	(81.3-174.3)	Male	881	793.1	111.1	(103.9-118.7)
Female	12	9.5	126.8	(65.4-221.5)	Female	863	857.6	100.6	(94.0-107.6)
<b><u>Lung and Bronchus</u></b>									
Male	155	100.2	154.8	(131.4-181.1)					
Female	158	123.1	128.4	(109.1-150.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	10.2	117.2	(60.5-204.7)	Male	2	7.2	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.2	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.7	105.1	(42.1-216.5)
Female	29	37.9	76.5	(51.3-109.9)	Female	5	4.5	110.4	(35.6-257.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	5	5.7	87.2	(28.1-203.4)
<b><u>Colon / Rectum</u></b>					Female	4	1.9	nc	(nc-nc)
Male	11	10.4	105.6	(52.6-188.9)	<b><u>Ovary</u></b>				
Female	12	8.1	148.5	(76.6-259.4)	Female	4	2.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	2.8	215.1	(78.5-468.1)	Male	7	4.8	144.6	(57.9-298.0)
Female	1	0.7	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	26	38.4	67.7	(44.2-99.2)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.6	nc	(nc-nc)
Male	4	6.5	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	6	3.0	203.1	(74.2-442.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.1	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	8	5.5	146.1	(62.9-287.8)
Male	8	4.8	168.0	(72.3-331.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.9	nc	(nc-nc)	Female	13	8.8	148.5	(79.0-254.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.5	nc	(nc-nc)	Male	115	145.4	79.1	(65.3-94.9)
Female	2	1.4	nc	(nc-nc)	Female	128	122.7	104.3	(87.0-124.0)
<b><u>Lung and Bronchus</u></b>									
Male	13	18.6	70.0	(37.2-119.7)					
Female	21	17.7	118.7	(73.5-181.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	44	36.3	121.3	(88.1-162.8)	Male	23	25.0	92.2	(58.4-138.3)
Female	17	12.6	134.8	(78.5-215.9)	Female	20	18.7	107.1	(65.4-165.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	7.6	nc	(nc-nc)	Male	9	8.7	103.4	(47.2-196.3)
Female	9	5.9	152.8	(69.7-290.0)	Female	9	6.6	135.5	(61.8-257.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	28	22.9	122.4	(81.3-176.9)
Female	163	152.3	107.0	(91.2-124.8)	Female	12	18.5	65.0	(33.5-113.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.8	nc	(nc-nc)	Male	22	19.0	115.5	(72.4-174.9)
<b><u>Colon / Rectum</u></b>					Female	8	7.8	102.2	(44.0-201.5)
Male	35	35.8	97.7	(68.1-135.9)	<b><u>Ovary</u></b>				
Female	30	33.2	90.4	(61.0-129.1)	Female	13	11.2	116.0	(61.7-198.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	9.5	52.7	(17.0-123.0)	Male	16	16.8	95.4	(54.5-155.0)
Female	3	2.7	nc	(nc-nc)	Female	13	15.1	86.3	(45.9-147.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	6	2.5	240.9	(88.0-524.3)	Male	123	127.7	96.3	(80.0-114.9)
Female	2	2.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	8.8	68.2	(24.9-148.5)
Male	26	21.9	118.8	(77.6-174.0)	Female	6	5.1	118.3	(43.2-257.5)
Female	10	12.0	83.1	(39.8-152.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	3.9	129.5	(41.7-302.2)
Male	4	5.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	9	8.3	108.8	(49.6-206.5)
<b><u>Leukemia</u></b>					Female	33	21.2	155.3	(106.9-218.1)
Male	16	16.4	97.3	(55.6-158.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	8	11.5	69.5	(29.9-137.0)	Female	29	35.5	81.6	(54.6-117.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	15.0	120.0	(71.1-189.7)	Male	531	495.8	107.1	(98.2-116.6)
Female	3	5.6	nc	(nc-nc)	Female	531	497.6	106.7	(97.8-116.2)
<b><u>Lung and Bronchus</u></b>									
Male	85	64.0	132.8	(106.1-164.2)					
Female	100	72.9	137.1	(111.6-166.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	5.1	97.9	(31.6-228.5)	Male	4	3.5	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	7	2.7	262.9	(105.3-541.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.2	153.9	(49.6-359.1)
Female	21	21.9	96.0	(59.4-146.7)	Female	3	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.1	nc	(nc-nc)
Male	9	5.0	178.3	(81.4-338.5)	<b><u>Ovary</u></b>				
Female	8	4.6	173.7	(74.8-342.3)	Female	1	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	33	19.1	172.4	(118.7-242.1)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.3	nc	(nc-nc)
Male	5	3.2	157.3	(50.7-367.0)	Female	0	0.7	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	3.0	nc	(nc-nc)
Male	4	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.7	nc	(nc-nc)	Female	11	5.2	211.0	(105.2-377.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	97	71.6	135.5	(109.9-165.3)
Female	1	0.8	nc	(nc-nc)	Female	84	71.9	116.8	(93.2-144.6)
<b><u>Lung and Bronchus</u></b>									
Male	8	9.2	86.9	(37.4-171.2)					
Female	12	11.0	109.5	(56.5-191.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.0	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	9.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	5	8.0	62.8	(20.2-146.5)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.3	nc	(nc-nc)					
Female	1	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	8.2	122.1	(58.4-224.5)	Male	9	5.5	163.9	(74.8-311.2)
Female	3	3.0	nc	(nc-nc)	Female	6	4.0	151.7	(55.4-330.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.0	139.2	(55.8-286.8)
Female	52	31.7	164.0	(122.4-215.0)	Female	6	4.1	147.0	(53.7-320.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	6	4.2	143.9	(52.6-313.3)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	4	7.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	7	7.8	90.1	(36.1-185.7)	Female	3	2.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	5	3.5	141.1	(45.5-329.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	25	28.7	87.2	(56.4-128.7)
Female	3	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.9	nc	(nc-nc)
Male	7	4.8	146.8	(58.8-302.6)	Female	0	1.2	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	0.6	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	3.9	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	2.6	nc	(nc-nc)	Female	2	7.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	107	109.9	97.3	(79.8-117.6)
Female	0	1.2	nc	(nc-nc)	Female	120	107.7	111.4	(92.4-133.2)
<b><u>Lung and Bronchus</u></b>									
Male	13	14.4	90.0	(47.9-153.9)					
Female	12	16.2	74.0	(38.2-129.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	9.5	105.2	(50.4-193.6)	Male	3	6.8	nc	(nc-nc)
Female	0	3.0	nc	(nc-nc)	Female	3	4.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.2	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	8	6.3	126.0	(54.3-248.3)
Female	42	41.8	100.5	(72.4-135.9)	Female	6	4.7	128.3	(46.8-279.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	6	2.0	294.7	(107.6-641.4)
Male	12	9.9	120.7	(62.3-210.8)	<b><u>Ovary</u></b>				
Female	8	8.1	98.8	(42.5-194.6)	Female	6	3.0	198.8	(72.6-432.8)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	10	4.6	217.4	(104.1-399.7)
Female	1	0.7	nc	(nc-nc)	Female	5	3.6	138.6	(44.7-323.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	31	37.9	81.7	(55.5-116.0)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	2.4	nc	(nc-nc)
Male	7	6.4	109.9	(44.0-226.4)	Female	0	1.3	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.1	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.4	nc	(nc-nc)	Male	5	2.5	201.6	(65.0-470.4)
<b><u>Leukemia</u></b>					Female	4	6.1	nc	(nc-nc)
Male	5	4.5	110.5	(35.6-257.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.9	nc	(nc-nc)	Female	9	9.9	91.1	(41.5-172.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	4.3	nc	(nc-nc)	Male	143	139.9	102.2	(86.1-120.4)
Female	1	1.4	nc	(nc-nc)	Female	131	130.4	100.5	(84.0-119.2)
<b><u>Lung and Bronchus</u></b>									
Male	19	17.6	108.2	(65.1-169.0)					
Female	25	18.3	136.9	(88.6-202.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Truro

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	4.8	104.1	(33.5-242.9)	Male	3	3.0	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	3	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	5	2.8	180.7	(58.2-421.7)
Female	17	13.9	122.4	(71.3-196.0)	Female	3	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.7	nc	(nc-nc)
Male	3	4.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	2.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	17	16.6	102.3	(59.6-163.8)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.1	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	0.2	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.5	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	1.1	nc	(nc-nc)	Female	5	3.5	142.9	(46.0-333.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	59	61.7	95.6	(72.8-123.4)
Female	1	0.6	nc	(nc-nc)	Female	55	46.7	117.8	(88.8-153.4)
<b><u>Lung and Bronchus</u></b>									
Male	5	8.6	58.1	(18.7-135.6)					
Female	6	7.8	77.4	(28.3-168.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	10.9	109.7	(56.6-191.6)	Male	6	8.2	73.6	(26.9-160.1)
Female	2	3.8	nc	(nc-nc)	Female	2	6.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	5	2.8	175.7	(56.6-410.1)
Female	3	2.1	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.5	nc	(nc-nc)	Male	5	7.6	65.6	(21.2-153.2)
Female	69	53.1	129.9	(101.1-164.4)	Female	11	5.9	185.3	(92.4-331.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	2.6	nc	(nc-nc)
Male	17	12.2	139.9	(81.4-223.9)	<b><u>Ovary</u></b>				
Female	12	10.5	114.3	(59.0-199.7)	Female	5	3.8	130.5	(42.1-304.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	5	4.5	110.4	(35.6-257.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	42	45.0	93.3	(67.3-126.2)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.9	nc	(nc-nc)
Male	11	7.8	141.9	(70.7-253.9)	Female	1	1.6	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.6	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	14	8.1	172.4	(94.2-289.3)
Male	7	5.4	129.5	(51.9-266.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	3.7	191.6	(76.8-394.8)	Female	15	12.3	122.0	(68.2-201.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	5.2	96.7	(31.2-225.7)	Male	182	166.8	109.1	(93.8-126.1)
Female	2	1.8	nc	(nc-nc)	Female	195	165.3	118.0	(102.0-135.7)
<b><u>Lung and Bronchus</u></b>									
Male	34	20.3	167.3	(115.9-233.8)					
Female	22	22.6	97.3	(61.0-147.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	2.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	4	9.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	3	8.1	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	1.3	nc	(nc-nc)					
Female	0	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	8.2	109.8	(50.1-208.4)	Male	8	6.1	132.2	(56.9-260.5)
Female	7	2.9	239.2	(95.8-492.8)	Female	5	4.8	104.7	(33.7-244.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	4	1.6	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.6	159.8	(72.9-303.4)
Female	52	40.3	129.1	(96.4-169.3)	Female	6	4.5	132.0	(48.2-287.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	10	5.1	196.5	(94.1-361.4)
<b><u>Colon / Rectum</u></b>					Female	5	2.0	253.8	(81.8-592.3)
Male	12	9.0	133.3	(68.8-232.9)	<b><u>Ovary</u></b>				
Female	8	7.9	100.9	(43.5-198.8)	Female	4	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	36	32.8	109.6	(76.8-151.8)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.2	nc	(nc-nc)
Male	5	5.7	87.5	(28.2-204.2)	Female	2	1.2	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.1	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	5	2.3	218.1	(70.3-509.0)
<b><u>Leukemia</u></b>					Female	5	5.9	85.0	(27.4-198.5)
Male	4	4.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	2.8	nc	(nc-nc)	Female	2	9.5	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.8	nc	(nc-nc)	Male	129	123.0	104.8	(87.5-124.6)
Female	1	1.4	nc	(nc-nc)	Female	136	126.3	107.7	(90.3-127.4)
<b><u>Lung and Bronchus</u></b>									
Male	11	15.1	72.8	(36.3-130.3)					
Female	14	17.8	78.7	(43.0-132.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	18.1	77.2	(42.2-129.6)	Male	13	12.7	102.6	(54.6-175.5)
Female	0	5.8	nc	(nc-nc)	Female	10	8.7	114.4	(54.8-210.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.9	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	13	11.7	111.6	(59.3-190.8)
Female	78	72.6	107.5	(85.0-134.2)	Female	3	8.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.2	nc	(nc-nc)	Male	8	10.0	79.6	(34.3-156.9)
<b><u>Colon / Rectum</u></b>					Female	2	3.7	nc	(nc-nc)
Male	13	18.3	70.9	(37.7-121.2)	<b><u>Ovary</u></b>				
Female	14	15.1	92.5	(50.5-155.2)	Female	0	5.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	4.9	164.1	(70.7-323.4)	Male	8	8.5	93.6	(40.3-184.5)
Female	1	1.3	nc	(nc-nc)	Female	8	6.9	115.3	(49.6-227.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	59	67.2	87.8	(66.8-113.3)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	4.5	155.8	(62.4-321.0)
Male	11	11.4	96.6	(48.2-172.9)	Female	3	2.3	nc	(nc-nc)
Female	8	5.7	140.6	(60.5-277.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.9	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	5	4.3	116.2	(37.4-271.1)
<b><u>Leukemia</u></b>					Female	5	10.0	50.0	(16.1-116.7)
Male	6	8.3	72.1	(26.3-156.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	5.3	nc	(nc-nc)	Female	21	17.1	123.0	(76.1-188.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	7.8	nc	(nc-nc)	Male	238	254.9	93.4	(81.9-106.0)
Female	2	2.6	nc	(nc-nc)	Female	210	234.2	89.7	(78.0-102.7)
<b><u>Lung and Bronchus</u></b>									
Male	38	32.5	117.0	(82.8-160.6)					
Female	32	34.5	92.7	(63.4-130.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	31	29.3	105.8	(71.9-150.2)	Male	25	20.4	122.7	(79.4-181.1)
Female	11	10.4	106.2	(52.9-190.0)	Female	13	15.6	83.4	(44.4-142.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.3	110.5	(44.3-227.8)	Male	7	7.1	99.0	(39.7-204.0)
Female	9	5.0	180.5	(82.4-342.6)	Female	3	5.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	23	18.7	122.9	(77.9-184.5)
Female	148	127.5	116.1	(98.1-136.4)	Female	14	15.3	91.3	(49.9-153.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.1	nc	(nc-nc)	Male	23	15.5	148.5	(94.1-222.9)
<b><u>Colon / Rectum</u></b>					Female	3	6.5	nc	(nc-nc)
Male	26	29.3	88.7	(57.9-130.0)	<b><u>Ovary</u></b>				
Female	22	27.3	80.6	(50.5-122.0)	Female	8	9.3	85.9	(37.0-169.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	15	7.7	195.4	(109.3-322.3)	Male	13	13.6	95.8	(50.9-163.8)
Female	3	2.2	nc	(nc-nc)	Female	14	12.4	112.9	(61.7-189.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	83	103.2	80.4	(64.1-99.7)
Female	2	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	12	7.1	167.8	(86.6-293.2)
Male	16	17.9	89.4	(51.1-145.3)	Female	2	4.2	nc	(nc-nc)
Female	3	10.0	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	3.6	nc	(nc-nc)
Male	1	4.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	10	7.0	142.4	(68.2-261.8)
<b><u>Leukemia</u></b>					Female	25	18.4	136.1	(88.1-200.9)
Male	12	13.5	89.0	(46.0-155.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	9.6	52.3	(16.8-122.0)	Female	20	29.4	68.1	(41.6-105.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	12.1	66.0	(28.4-130.0)	Male	403	403.6	99.9	(90.3-110.1)
Female	2	4.6	nc	(nc-nc)	Female	382	414.0	92.3	(83.3-102.0)
<b><u>Lung and Bronchus</u></b>									
Male	57	51.7	110.3	(83.5-142.9)					
Female	41	60.2	68.1	(48.9-92.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Wales

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	12	8.2	146.3	(75.5-255.5)	Female	0	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	3	1.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	7	8.8	79.5	(31.9-163.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.6	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	2	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	1.2	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	33	33.8	97.7	(67.3-137.2)
Female	0	0.3	nc	(nc-nc)	Female	35	26.0	134.5	(93.7-187.1)
<b><u>Lung and Bronchus</u></b>									
Male	5	4.4	114.7	(37.0-267.7)					
Female	7	3.7	187.6	(75.2-386.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	28.8	93.8	(61.8-136.4)	Male	24	19.9	120.7	(77.3-179.6)
Female	11	10.2	108.3	(54.0-193.8)	Female	26	14.7	176.6	(115.4-258.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.1	114.5	(45.9-236.0)	Male	5	6.9	73.0	(23.5-170.3)
Female	6	4.7	126.5	(46.2-275.3)	Female	3	5.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	1.2	nc	(nc-nc)	Male	16	18.2	87.7	(50.1-142.4)
Female	130	119.2	109.0	(91.1-129.5)	Female	17	14.7	116.0	(67.6-185.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	3.8	nc	(nc-nc)	Male	10	15.1	66.3	(31.8-122.0)
<b><u>Colon / Rectum</u></b>					Female	3	6.2	nc	(nc-nc)
Male	27	28.9	93.5	(61.6-136.1)	<b><u>Ovary</u></b>				
Female	22	27.0	81.6	(51.1-123.5)	Female	11	8.8	125.3	(62.5-224.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	7.5	nc	(nc-nc)	Male	13	13.3	98.0	(52.1-167.6)
Female	4	2.2	nc	(nc-nc)	Female	7	12.1	57.9	(23.2-119.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	107	99.1	108.0	(88.5-130.5)
Female	0	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	7.0	71.8	(23.1-167.5)
Male	18	17.3	103.8	(61.5-164.0)	Female	2	4.1	nc	(nc-nc)
Female	10	9.5	105.6	(50.6-194.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.2	nc	(nc-nc)
Male	2	4.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	11	6.7	164.8	(82.2-294.9)
<b><u>Leukemia</u></b>					Female	9	16.6	54.1	(24.7-102.7)
Male	10	13.2	75.8	(36.3-139.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	9.3	96.4	(44.0-183.1)	Female	28	27.2	102.9	(68.3-148.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	16	11.7	136.3	(77.9-221.4)	Male	387	391.9	98.8	(89.2-109.1)
Female	8	4.4	182.5	(78.6-359.6)	Female	389	392.7	99.1	(89.5-109.4)
<b><u>Lung and Bronchus</u></b>									
Male	46	50.2	91.7	(67.1-122.3)					
Female	49	57.0	85.9	(63.6-113.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Waltham

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	54	54.2	99.6	(74.8-129.9)	Male	30	39.2	76.5	(51.6-109.2)
Female	19	19.6	97.0	(58.4-151.5)	Female	27	30.8	87.6	(57.7-127.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	13.3	75.2	(36.0-138.3)	Male	10	13.2	75.8	(36.3-139.4)
Female	6	10.2	59.1	(21.6-128.6)	Female	8	10.1	79.2	(34.1-156.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	5	2.2	223.5	(72.0-521.6)	Male	30	36.4	82.3	(55.5-117.5)
Female	248	237.3	104.5	(91.9-118.4)	Female	28	29.4	95.3	(63.3-137.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	8.6	81.0	(32.4-166.9)	Male	28	29.4	95.1	(63.2-137.4)
<b><u>Colon / Rectum</u></b>					Female	7	12.3	57.1	(22.9-117.6)
Male	54	56.3	95.9	(72.1-125.2)	<b><u>Ovary</u></b>				
Female	56	52.7	106.2	(80.2-138.0)	Female	23	17.8	129.2	(81.9-193.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	14.3	63.1	(28.8-119.9)	Male	30	25.3	118.7	(80.1-169.5)
Female	5	4.2	119.7	(38.6-279.4)	Female	30	23.4	128.3	(86.6-183.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	8	6.0	134.1	(57.7-264.2)	Male	173	190.9	90.6	(77.6-105.2)
Female	3	4.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	20	13.5	147.7	(90.2-228.2)
Male	39	34.4	113.4	(80.6-155.0)	Female	8	8.0	99.4	(42.8-195.9)
Female	20	18.7	106.8	(65.2-165.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	11.4	52.7	(19.3-114.8)
Male	4	7.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	2.0	nc	(nc-nc)	Male	17	15.5	109.6	(63.8-175.6)
<b><u>Leukemia</u></b>					Female	42	40.3	104.2	(75.1-140.8)
Male	22	26.4	83.4	(52.3-126.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	20	18.7	106.9	(65.3-165.1)	Female	47	53.3	88.2	(64.8-117.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	27	22.7	119.1	(78.5-173.3)	Male	743	769.4	96.6	(89.8-103.8)
Female	4	8.6	nc	(nc-nc)	Female	776	786.6	98.6	(91.8-105.8)
<b><u>Lung and Bronchus</u></b>									
Male	114	95.3	119.6	(98.7-143.7)					
Female	92	110.6	83.2	(67.0-102.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ware

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	11.5	86.9	(41.6-159.8)	Male	8	7.9	100.6	(43.3-198.3)
Female	3	3.8	nc	(nc-nc)	Female	1	5.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	10	7.3	136.8	(65.5-251.7)
Female	43	46.5	92.4	(66.9-124.5)	Female	6	5.6	106.5	(38.9-231.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	5	6.1	81.7	(26.3-190.7)
<b><u>Colon / Rectum</u></b>					Female	4	2.4	nc	(nc-nc)
Male	10	11.5	87.3	(41.8-160.6)	<b><u>Ovary</u></b>				
Female	13	9.9	131.4	(69.9-224.7)	Female	4	3.4	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	7	5.4	130.6	(52.3-269.2)
Female	1	0.8	nc	(nc-nc)	Female	6	4.6	131.6	(48.0-286.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	39	41.3	94.5	(67.2-129.2)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.8	nc	(nc-nc)
Male	7	7.1	99.1	(39.7-204.3)	Female	0	1.5	nc	(nc-nc)
Female	6	3.7	163.3	(59.6-355.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.3	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	7	6.6	105.7	(42.3-217.8)
Male	4	5.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	3.5	nc	(nc-nc)	Female	12	10.9	110.0	(56.8-192.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	163	159.0	102.5	(87.4-119.6)
Female	0	1.7	nc	(nc-nc)	Female	155	151.9	102.0	(86.6-119.4)
<b><u>Lung and Bronchus</u></b>									
Male	27	20.4	132.5	(87.3-192.8)					
Female	31	22.4	138.7	(94.2-196.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	33	30.8	107.1	(73.7-150.5)	Male	22	20.9	105.4	(66.1-159.6)
Female	8	10.3	77.8	(33.5-153.3)	Female	11	15.0	73.5	(36.7-131.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	6.2	160.9	(77.0-296.0)	Male	7	7.4	94.0	(37.7-193.8)
Female	7	4.7	148.4	(59.4-305.7)	Female	6	5.5	109.9	(40.1-239.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	14	19.2	73.0	(39.9-122.5)
Female	119	123.3	96.5	(79.9-115.5)	Female	18	15.0	119.9	(71.0-189.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.7	135.1	(43.5-315.3)	Male	19	16.0	118.7	(71.5-185.4)
<b><u>Colon / Rectum</u></b>					Female	10	6.3	157.6	(75.4-289.8)
Male	25	29.5	84.8	(54.9-125.2)	<b><u>Ovary</u></b>				
Female	30	26.4	113.7	(76.7-162.4)	Female	5	9.1	55.1	(17.8-128.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	8.1	123.3	(59.0-226.7)	Male	12	14.2	84.2	(43.5-147.1)
Female	3	2.2	nc	(nc-nc)	Female	13	12.3	105.8	(56.3-181.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	121	111.4	108.6	(90.1-129.7)
Female	1	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	7.4	nc	(nc-nc)
Male	26	18.4	141.5	(92.4-207.3)	Female	2	4.1	nc	(nc-nc)
Female	15	9.8	153.1	(85.6-252.6)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	6	2.9	207.1	(75.6-450.7)
Male	8	4.4	180.8	(77.9-356.3)	<b><u>Thyroid</u></b>				
Female	3	1.1	nc	(nc-nc)	Male	3	6.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	14	16.5	85.0	(46.4-142.7)
Male	14	13.7	102.1	(55.7-171.2)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	9.3	97.0	(44.3-184.2)	Female	21	29.3	71.6	(44.3-109.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	12.9	132.3	(77.0-211.8)	Male	500	421.0	118.8	(108.6-129.6)
Female	5	4.6	109.2	(35.2-254.9)	Female	435	403.5	107.8	(97.9-118.4)
<b><u>Lung and Bronchus</u></b>									
Male	86	55.2	155.9	(124.7-192.5)					
Female	93	60.5	153.6	(124.0-188.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	5.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	0	2.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	13	21.5	60.6	(32.2-103.6)	Female	4	2.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.1	nc	(nc-nc)
Male	5	5.5	90.6	(29.2-211.3)	<b><u>Ovary</u></b>				
Female	2	4.3	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.4	nc	(nc-nc)	Male	8	20.0	39.9	(17.2-78.7)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	1.3	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.7	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	3.4	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	1.5	nc	(nc-nc)	Female	5	4.9	101.4	(32.7-236.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.3	nc	(nc-nc)	Male	56	76.0	73.6	(55.6-95.6)
Female	1	0.7	nc	(nc-nc)	Female	56	67.5	82.9	(62.6-107.7)
<b><u>Lung and Bronchus</u></b>									
Male	10	9.5	105.8	(50.7-194.6)					
Female	11	9.2	119.9	(59.8-214.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Warwick

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	3	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	4	4.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	4.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.5	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	11	17.0	64.8	(32.3-115.9)
Female	0	0.2	nc	(nc-nc)	Female	11	13.8	79.8	(39.8-142.8)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.2	nc	(nc-nc)					
Female	3	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	11.7	51.1	(18.7-111.2)
Female	0	0.1	nc	(nc-nc)	Female	5	8.4	59.3	(19.1-138.4)
<b><u>Lung and Bronchus</u></b>									
Male	1	1.6	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	33.4	86.8	(58.1-124.6)	Male	11	23.4	46.9	(23.4-84.0)
Female	13	13.0	99.9	(53.1-170.8)	Female	14	19.7	71.1	(38.8-119.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	7.4	67.6	(21.8-157.7)	Male	7	8.0	87.1	(34.9-179.4)
Female	7	6.3	111.7	(44.7-230.1)	Female	10	6.8	146.9	(70.3-270.1)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	23	21.5	107.0	(67.8-160.6)
Female	168	156.6	107.3	(91.6-124.8)	Female	22	19.3	114.2	(71.5-172.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	5.4	111.7	(40.8-243.2)	Male	14	17.5	80.2	(43.8-134.5)
<b><u>Colon / Rectum</u></b>					Female	5	8.0	62.2	(20.1-145.2)
Male	36	33.5	107.3	(75.2-148.6)	<b><u>Ovary</u></b>				
Female	38	34.0	111.7	(79.1-153.4)	Female	12	11.5	104.1	(53.7-181.9)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	8.7	115.4	(55.2-212.2)	Male	16	15.4	103.8	(59.3-168.5)
Female	4	2.8	nc	(nc-nc)	Female	14	15.6	89.8	(49.1-150.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	4	2.7	nc	(nc-nc)	Male	113	115.6	97.7	(80.5-117.5)
Female	1	2.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	8.2	73.6	(26.9-160.1)
Male	18	20.4	88.2	(52.2-139.4)	Female	8	5.2	152.5	(65.6-300.4)
Female	9	12.4	72.8	(33.2-138.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	5.0	139.0	(55.7-286.5)
Male	8	4.7	168.6	(72.6-332.2)	<b><u>Thyroid</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	16	8.4	189.7	(108.4-308.1)
<b><u>Leukemia</u></b>					Female	29	24.1	120.4	(80.6-173.0)
Male	22	15.4	142.5	(89.3-215.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	12.0	83.5	(40.0-153.5)	Female	39	35.8	109.1	(77.5-149.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	13.7	58.6	(25.2-115.5)	Male	451	459.7	98.1	(89.3-107.6)
Female	8	5.7	139.6	(60.1-275.1)	Female	530	515.9	102.7	(94.2-111.9)
<b><u>Lung and Bronchus</u></b>									
Male	58	58.5	99.1	(75.3-128.1)					
Female	76	75.5	100.7	(79.4-126.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	14	17.9	78.3	(42.8-131.4)	Male	16	11.9	134.2	(76.6-217.9)
Female	10	5.7	175.5	(84.0-322.8)	Female	8	8.1	98.6	(42.4-194.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.5	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	3	0.7	nc	(nc-nc)	Male	12	10.8	110.6	(57.1-193.3)
Female	92	66.7	137.8	(111.1-169.1)	Female	5	8.2	61.2	(19.7-142.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.0	nc	(nc-nc)	Male	3	8.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	5	3.4	145.1	(46.8-338.6)
Male	11	17.0	64.6	(32.2-115.7)	<b><u>Ovary</u></b>				
Female	13	14.9	87.1	(46.3-149.0)	Female	2	4.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	4.5	nc	(nc-nc)	Male	9	8.1	111.2	(50.7-211.1)
Female	0	1.2	nc	(nc-nc)	Female	6	6.8	88.3	(32.2-192.1)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	71	59.5	119.3	(93.2-150.5)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	4.2	nc	(nc-nc)
Male	6	10.1	59.2	(21.6-128.9)	Female	3	2.3	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.5	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	8.8	114.0	(54.6-209.7)
Male	7	7.8	89.2	(35.7-183.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	5.2	nc	(nc-nc)	Female	11	15.5	70.9	(35.4-127.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	7.0	nc	(nc-nc)	Male	214	234.7	91.2	(79.4-104.3)
Female	1	2.5	nc	(nc-nc)	Female	220	219.4	100.3	(87.5-114.5)
<b><u>Lung and Bronchus</u></b>									
Male	18	30.8	58.4	(34.6-92.2)					
Female	21	32.4	64.8	(40.1-99.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Webster

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	19.3	140.1	(92.3-203.8)	Male	24	13.3	180.7	(115.7-268.8)
Female	5	7.1	70.7	(22.8-165.0)	Female	11	10.1	108.8	(54.2-194.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.1	nc	(nc-nc)	Male	6	4.6	130.8	(47.8-284.7)
Female	5	3.2	155.3	(50.0-362.4)	Female	7	3.6	196.4	(78.7-404.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	13	12.2	106.8	(56.8-182.6)
Female	82	80.1	102.4	(81.4-127.1)	Female	6	10.1	59.6	(21.8-129.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	2.5	235.9	(86.1-513.4)	Male	15	10.1	149.1	(83.4-245.9)
<b><u>Colon / Rectum</u></b>					Female	3	4.2	nc	(nc-nc)
Male	14	19.2	73.1	(39.9-122.7)	<b><u>Ovary</u></b>				
Female	25	18.7	133.9	(86.6-197.7)	Female	3	6.0	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	9	5.0	180.2	(82.2-342.1)	Male	4	8.9	nc	(nc-nc)
Female	4	1.5	nc	(nc-nc)	Female	7	8.4	83.3	(33.4-171.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	63	67.0	94.1	(72.3-120.4)
Female	1	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	4.7	nc	(nc-nc)
Male	14	11.6	120.7	(65.9-202.5)	Female	1	2.8	nc	(nc-nc)
Female	7	6.4	108.6	(43.5-223.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.3	217.4	(70.1-507.4)
Male	3	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	2	0.7	nc	(nc-nc)	Male	7	4.5	155.8	(62.4-321.0)
<b><u>Leukemia</u></b>					Female	21	11.4	184.7	(114.3-282.4)
Male	11	8.8	125.4	(62.5-224.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	6.4	93.1	(34.0-202.7)	Female	17	18.3	92.7	(53.9-148.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	7.9	88.8	(35.6-183.0)	Male	302	262.8	114.9	(102.3-128.7)
Female	6	3.0	199.2	(72.8-433.7)	Female	317	267.9	118.3	(105.6-132.1)
<b><u>Lung and Bronchus</u></b>									
Male	47	33.7	139.5	(102.5-185.5)					
Female	63	39.1	161.0	(123.7-206.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wellesley

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	21	28.5	73.8	(45.7-112.8)	Male	25	19.3	129.6	(83.8-191.3)
Female	12	10.4	115.8	(59.7-202.2)	Female	18	15.1	119.1	(70.5-188.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	6.0	149.5	(68.2-283.7)	Male	3	6.8	nc	(nc-nc)
Female	5	5.2	96.9	(31.2-226.2)	Female	6	5.3	112.3	(41.0-244.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.1	nc	(nc-nc)	Male	19	17.9	106.4	(64.0-166.1)
Female	138	120.8	114.2	(96.0-135.0)	Female	14	15.1	92.7	(50.7-155.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.7	nc	(nc-nc)	Male	12	14.6	82.3	(42.5-143.8)
<b><u>Colon / Rectum</u></b>					Female	6	6.3	95.1	(34.7-206.9)
Male	28	27.8	100.7	(66.9-145.6)	<b><u>Ovary</u></b>				
Female	18	27.5	65.5	(38.8-103.5)	Female	12	9.1	131.9	(68.1-230.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	7.3	nc	(nc-nc)	Male	13	13.0	99.8	(53.1-170.6)
Female	0	2.2	nc	(nc-nc)	Female	14	12.3	113.5	(62.0-190.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.1	nc	(nc-nc)	Male	113	97.8	115.5	(95.2-138.9)
Female	3	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	6.8	nc	(nc-nc)
Male	12	16.9	71.1	(36.7-124.1)	Female	6	4.2	144.1	(52.6-313.7)
Female	6	9.7	62.1	(22.7-135.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	5	2.9	173.2	(55.8-404.2)
Male	3	4.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	5	6.3	79.8	(25.7-186.2)
<b><u>Leukemia</u></b>					Female	15	17.6	85.2	(47.7-140.6)
Male	12	13.1	91.4	(47.2-159.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	9.8	50.8	(16.4-118.5)	Female	23	27.6	83.2	(52.7-124.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	11.5	nc	(nc-nc)	Male	349	384.5	90.8	(81.5-100.8)
Female	3	4.5	nc	(nc-nc)	Female	376	402.5	93.4	(84.2-103.4)
<b><u>Lung and Bronchus</u></b>									
Male	29	49.8	58.2	(39.0-83.6)					
Female	41	58.7	69.9	(50.1-94.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	5.9	118.6	(47.5-244.3)	Male	7	3.7	187.7	(75.2-386.7)
Female	5	2.0	250.5	(80.7-584.7)	Female	8	2.5	320.3	(137.9-631.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.0	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	20	20.6	96.9	(59.2-149.7)	Female	2	2.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	7	2.7	261.3	(104.7-538.4)
<b><u>Colon / Rectum</u></b>					Female	1	1.1	nc	(nc-nc)
Male	7	5.1	137.8	(55.2-284.0)	<b><u>Ovary</u></b>				
Female	7	4.7	149.2	(59.8-307.4)	Female	2	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	1.5	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	12	20.2	59.3	(30.6-103.6)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.3	nc	(nc-nc)
Male	1	3.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	2.2	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	1.7	nc	(nc-nc)	Female	1	5.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	75	75.6	99.2	(78.0-124.4)
Female	0	0.9	nc	(nc-nc)	Female	73	70.8	103.1	(80.8-129.6)
<b><u>Lung and Bronchus</u></b>									
Male	5	10.5	47.7	(15.4-111.3)					
Female	16	11.9	135.0	(77.1-219.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	8	4.6	173.5	(74.7-341.9)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	0.9	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.6	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	14	15.5	90.1	(49.2-151.2)
Female	0	0.2	nc	(nc-nc)	Female	20	14.5	137.7	(84.1-212.6)
<b><u>Lung and Bronchus</u></b>									
Male	2	2.1	nc	(nc-nc)					
Female	4	2.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	7	5.0	139.5	(55.9-287.3)	Male	4	3.3	nc	(nc-nc)
Female	7	1.6	426.6	(170.9-879.0)	Female	4	2.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	22	18.6	118.4	(74.2-179.2)	Female	1	2.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.0	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	4.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	12	16.7	71.7	(37.0-125.2)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	1.2	nc	(nc-nc)
Male	4	2.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	2.8	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	1.5	nc	(nc-nc)	Female	6	4.4	137.2	(50.1-298.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	51	66.4	76.8	(57.2-101.0)
Female	1	0.7	nc	(nc-nc)	Female	70	63.1	110.9	(86.5-140.1)
<b><u>Lung and Bronchus</u></b>									
Male	6	8.7	69.0	(25.2-150.2)					
Female	8	9.3	86.3	(37.2-170.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	13.0	38.6	(12.4-90.0)	Male	15	8.7	173.3	(96.9-285.9)
Female	8	3.7	216.9	(93.4-427.5)	Female	8	4.8	166.7	(71.8-328.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	8	7.9	101.9	(43.9-200.8)
Female	42	37.8	111.1	(80.1-150.2)	Female	4	5.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	15	6.4	233.1	(130.3-384.4)
<b><u>Colon / Rectum</u></b>					Female	3	2.1	nc	(nc-nc)
Male	6	12.3	48.6	(17.7-105.8)	<b><u>Ovary</u></b>				
Female	5	9.3	53.5	(17.3-124.9)	Female	1	2.9	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	2	5.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	4.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	37	43.8	84.4	(59.4-116.3)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.0	nc	(nc-nc)
Male	9	7.4	122.0	(55.7-231.7)	Female	0	1.4	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.1	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	4.7	nc	(nc-nc)
Male	6	5.6	107.3	(39.2-233.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	3.2	156.5	(50.4-365.3)	Female	12	8.8	136.6	(70.5-238.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	5.2	nc	(nc-nc)	Male	152	170.9	88.9	(75.4-104.2)
Female	0	1.5	nc	(nc-nc)	Female	128	130.6	98.0	(81.8-116.5)
<b><u>Lung and Bronchus</u></b>									
Male	17	22.5	75.7	(44.1-121.2)					
Female	19	20.2	93.8	(56.5-146.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	9.7	82.1	(35.3-161.8)	Male	8	6.5	122.7	(52.8-241.8)
Female	3	3.1	nc	(nc-nc)	Female	5	4.4	114.6	(36.9-267.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	4	1.4	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	10	5.9	168.1	(80.5-309.2)
Female	37	35.2	105.2	(74.1-145.0)	Female	7	4.4	159.4	(63.8-328.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	3	1.8	nc	(nc-nc)
Male	11	9.3	118.4	(59.0-211.9)	<b><u>Ovary</u></b>				
Female	6	8.2	73.3	(26.8-159.6)	Female	2	2.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	2.5	nc	(nc-nc)	Male	6	4.4	136.2	(49.7-296.5)
Female	1	0.7	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	31	32.4	95.6	(65.0-135.8)
Female	1	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.3	nc	(nc-nc)
Male	6	5.6	107.4	(39.2-233.8)	Female	0	1.2	nc	(nc-nc)
Female	5	2.8	178.8	(57.6-417.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.8	nc	(nc-nc)
Male	5	4.3	116.8	(37.7-272.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	2.8	nc	(nc-nc)	Female	11	8.0	137.1	(68.4-245.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	3.8	nc	(nc-nc)	Male	144	128.3	112.3	(94.7-132.2)
Female	1	1.3	nc	(nc-nc)	Female	139	116.9	118.9	(99.9-140.4)
<b><u>Lung and Bronchus</u></b>									
Male	25	16.9	147.9	(95.7-218.4)					
Female	29	17.2	169.0	(113.1-242.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.4	111.2	(40.6-242.1)	Male	2	3.6	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	26	20.5	126.9	(82.9-186.0)	Female	5	2.6	189.7	(61.1-442.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	1.1	nc	(nc-nc)
Male	4	5.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	4.7	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	17	18.6	91.4	(53.2-146.3)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.3	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	2.6	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	1.6	304.3	(98.1-710.2)	Female	11	4.8	229.2	(114.2-410.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	2.2	nc	(nc-nc)	Male	77	71.4	107.8	(85.1-134.7)
Female	2	0.8	nc	(nc-nc)	Female	82	69.2	118.5	(94.2-147.0)
<b><u>Lung and Bronchus</u></b>									
Male	12	9.5	126.1	(65.1-220.4)					
Female	8	10.7	74.7	(32.2-147.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	5.1	98.4	(31.7-229.6)	Male	9	3.6	253.5	(115.7-481.2)
Female	2	1.6	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	1.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	23	21.4	107.7	(68.3-161.6)	Female	3	2.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	2	1.1	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	4	4.2	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	35	19.6	178.2	(124.1-247.9)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.3	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.5	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	2.8	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	1.5	nc	(nc-nc)	Female	10	5.1	194.3	(93.0-357.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	78	72.7	107.3	(84.8-134.0)
Female	1	0.7	nc	(nc-nc)	Female	72	67.0	107.4	(84.1-135.3)
<b><u>Lung and Bronchus</u></b>									
Male	4	9.3	nc	(nc-nc)					
Female	8	9.7	82.6	(35.6-162.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	31.3	102.4	(70.0-144.6)	Male	16	21.8	73.4	(41.9-119.3)
Female	6	10.8	55.3	(20.2-120.4)	Female	13	16.2	80.4	(42.8-137.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	6.9	131.2	(59.9-249.1)	Male	4	7.6	nc	(nc-nc)
Female	6	5.2	114.8	(41.9-249.8)	Female	2	5.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	24	20.1	119.4	(76.5-177.7)
Female	118	129.3	91.3	(75.6-109.3)	Female	12	15.9	75.5	(39.0-131.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	4.2	165.6	(66.3-341.2)	Male	21	16.8	125.0	(77.3-191.0)
<b><u>Colon / Rectum</u></b>					Female	7	6.7	104.9	(42.0-216.2)
Male	26	31.2	83.2	(54.4-122.0)	<b><u>Ovary</u></b>				
Female	25	28.6	87.6	(56.6-129.3)	Female	9	9.6	94.0	(42.9-178.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	8.3	96.5	(41.5-190.1)	Male	10	14.6	68.6	(32.8-126.2)
Female	1	2.3	nc	(nc-nc)	Female	10	12.9	77.2	(37.0-142.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	2.4	nc	(nc-nc)	Male	71	113.2	62.7	(49.0-79.1)
Female	1	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	7.7	104.3	(44.9-205.5)
Male	23	19.3	119.1	(75.4-178.6)	Female	2	4.4	nc	(nc-nc)
Female	13	10.2	127.1	(67.6-217.4)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	4.0	nc	(nc-nc)
Male	5	4.6	108.9	(35.1-254.2)	<b><u>Thyroid</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	4	7.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	24	19.1	125.9	(80.6-187.3)
Male	19	14.5	131.0	(78.9-204.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	10.0	129.4	(68.8-221.3)	Female	38	29.8	127.5	(90.2-175.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	14	13.2	106.1	(58.0-178.1)	Male	398	436.0	91.3	(82.5-100.7)
Female	2	4.7	nc	(nc-nc)	Female	422	426.1	99.0	(89.8-108.9)
<b><u>Lung and Bronchus</u></b>									
Male	72	55.7	129.2	(101.1-162.7)					
Female	75	62.0	121.0	(95.2-151.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	2.5	237.7	(86.8-517.5)	Male	2	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	5	8.4	59.3	(19.1-138.4)	Female	0	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	8.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.9	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	28	32.1	87.2	(57.9-126.1)
Female	0	0.3	nc	(nc-nc)	Female	22	27.6	79.6	(49.9-120.6)
<b><u>Lung and Bronchus</u></b>									
Male	3	4.4	nc	(nc-nc)					
Female	4	4.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	12	17.7	67.9	(35.1-118.7)	Female	1	2.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	0.9	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	8	3.5	231.8	(99.8-456.8)	Female	0	1.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	1.2	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	17	17.4	97.5	(56.8-156.2)
Female	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	1.1	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	3	2.2	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	1.3	nc	(nc-nc)	Female	5	4.3	115.2	(37.1-268.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	53	63.9	82.9	(62.1-108.4)
Female	0	0.6	nc	(nc-nc)	Female	45	56.6	79.6	(58.0-106.5)
<b><u>Lung and Bronchus</u></b>									
Male	10	8.6	115.6	(55.3-212.6)					
Female	3	8.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	19.4	103.0	(62.9-159.1)	Male	16	13.6	117.8	(67.3-191.3)
Female	5	7.1	70.0	(22.5-163.3)	Female	18	10.5	171.4	(101.5-270.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.3	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
Female	7	3.4	206.2	(82.6-424.9)	Female	7	3.6	194.1	(77.8-400.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	9	12.4	72.3	(33.0-137.3)
Female	92	82.9	111.0	(89.5-136.1)	Female	16	10.3	155.0	(88.6-251.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.8	nc	(nc-nc)	Male	11	10.2	107.8	(53.7-192.9)
<b><u>Colon / Rectum</u></b>					Female	7	4.3	161.9	(64.9-333.6)
Male	20	19.7	101.4	(61.9-156.6)	<b><u>Ovary</u></b>				
Female	17	19.3	88.2	(51.3-141.2)	Female	7	6.1	114.1	(45.7-235.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	5.0	nc	(nc-nc)	Male	7	8.9	78.3	(31.4-161.3)
Female	1	1.5	nc	(nc-nc)	Female	12	8.5	141.3	(72.9-246.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	64	66.1	96.8	(74.5-123.6)
Female	0	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	4.7	nc	(nc-nc)
Male	15	11.9	126.4	(70.7-208.6)	Female	5	2.9	171.8	(55.4-401.0)
Female	5	6.6	76.1	(24.5-177.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.5	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	8	4.8	167.7	(72.2-330.4)
<b><u>Leukemia</u></b>					Female	16	12.5	128.3	(73.3-208.3)
Male	8	9.1	88.2	(38.0-173.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	6.6	90.6	(33.1-197.1)	Female	11	18.5	59.5	(29.7-106.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	7	7.9	88.9	(35.6-183.3)	Male	244	265.5	91.9	(80.7-104.2)
Female	3	3.0	nc	(nc-nc)	Female	292	275.3	106.1	(94.3-119.0)
<b><u>Lung and Bronchus</u></b>									
Male	25	33.7	74.3	(48.1-109.7)					
Female	29	39.2	74.1	(49.6-106.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westfield

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	43.9	77.5	(53.7-108.3)	Male	20	30.2	66.1	(40.4-102.1)
Female	15	15.2	98.9	(55.3-163.1)	Female	15	22.4	67.0	(37.5-110.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	9.5	52.5	(16.9-122.4)	Male	6	10.6	56.6	(20.7-123.1)
Female	12	7.3	164.6	(84.9-287.5)	Female	5	8.0	62.9	(20.3-146.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	14	28.1	49.9	(27.2-83.7)
Female	183	180.7	101.3	(87.1-117.1)	Female	23	22.2	103.6	(65.6-155.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	5.6	nc	(nc-nc)	Male	25	23.3	107.3	(69.4-158.4)
<b><u>Colon / Rectum</u></b>					Female	10	9.3	107.0	(51.2-196.8)
Male	33	43.5	75.9	(52.3-106.7)	<b><u>Ovary</u></b>				
Female	40	39.5	101.2	(72.3-137.8)	Female	9	13.5	66.9	(30.5-127.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	10	11.6	86.3	(41.3-158.8)	Male	24	20.4	117.7	(75.4-175.1)
Female	3	3.3	nc	(nc-nc)	Female	14	18.1	77.3	(42.2-129.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	3.5	nc	(nc-nc)	Male	141	158.3	89.1	(75.0-105.0)
Female	4	2.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	13	10.7	121.7	(64.7-208.1)
Male	37	26.8	137.9	(97.1-190.1)	Female	7	6.1	115.4	(46.2-237.8)
Female	17	14.3	118.5	(69.0-189.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	5.5	nc	(nc-nc)
Male	3	6.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	8	10.4	76.8	(33.1-151.3)
<b><u>Leukemia</u></b>					Female	17	25.9	65.7	(38.2-105.2)
Male	25	20.2	123.5	(79.9-182.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	20	14.0	142.6	(87.1-220.2)	Female	45	42.3	106.4	(77.6-142.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	18.3	43.6	(18.8-85.9)	Male	542	608.8	89.0	(81.7-96.8)
Female	5	6.7	74.7	(24.1-174.3)	Female	591	595.9	99.2	(91.3-107.5)
<b><u>Lung and Bronchus</u></b>									
Male	81	78.2	103.6	(82.3-128.8)					
Female	90	87.7	102.6	(82.5-126.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	22.9	96.0	(60.1-145.3)	Male	23	16.7	137.4	(87.1-206.2)
Female	6	7.5	79.7	(29.1-173.4)	Female	12	12.4	96.9	(50.0-169.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.5	90.8	(29.2-211.8)	Male	7	5.9	119.1	(47.7-245.3)
Female	4	4.0	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	19	15.6	121.6	(73.2-189.9)
Female	110	105.3	104.5	(85.9-125.9)	Female	13	11.8	110.6	(58.8-189.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.4	nc	(nc-nc)	Male	7	14.0	49.8	(20.0-102.7)
<b><u>Colon / Rectum</u></b>					Female	2	5.1	nc	(nc-nc)
Male	26	24.9	104.4	(68.2-153.0)	<b><u>Ovary</u></b>				
Female	14	20.7	67.7	(37.0-113.7)	Female	9	7.5	119.4	(54.5-226.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	6.5	nc	(nc-nc)	Male	11	11.2	98.6	(49.2-176.4)
Female	0	1.7	nc	(nc-nc)	Female	9	9.1	99.2	(45.3-188.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	83	91.4	90.8	(72.3-112.6)
Female	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	6.0	133.8	(57.6-263.6)
Male	13	15.8	82.4	(43.8-140.8)	Female	2	3.2	nc	(nc-nc)
Female	5	8.0	62.7	(20.2-146.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	7	2.8	252.3	(101.1-519.8)
Male	3	3.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	6.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	21	15.3	137.2	(84.9-209.7)
Male	13	11.2	116.1	(61.8-198.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	7.3	124.1	(56.6-235.6)	Female	26	24.4	106.5	(69.5-156.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	10.5	85.4	(39.0-162.1)	Male	304	341.6	89.0	(79.3-99.6)
Female	0	3.5	nc	(nc-nc)	Female	300	327.3	91.7	(81.6-102.6)
<b><u>Lung and Bronchus</u></b>									
Male	23	42.3	54.3	(34.4-81.6)					
Female	30	45.6	65.8	(44.4-93.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	2.2	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	7	8.9	78.4	(31.4-161.5)	Female	1	1.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	8	8.6	93.2	(40.1-183.6)
Female	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	1.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	22	31.4	70.0	(43.8-106.0)
Female	0	0.3	nc	(nc-nc)	Female	22	28.7	76.8	(48.1-116.3)
<b><u>Lung and Bronchus</u></b>									
Male	1	4.0	nc	(nc-nc)					
Female	4	4.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	8.4	154.8	(82.3-264.7)	Male	8	5.9	134.9	(58.1-265.7)
Female	1	2.5	nc	(nc-nc)	Female	6	4.1	148.1	(54.1-322.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	1.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.5	nc	(nc-nc)
Female	33	34.2	96.6	(66.5-135.7)	Female	2	3.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	1.7	nc	(nc-nc)
Male	8	8.6	92.7	(39.9-182.8)	<b><u>Ovary</u></b>				
Female	3	6.8	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	2	3.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	29	32.6	88.9	(59.5-127.6)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	2.1	nc	(nc-nc)
Male	5	5.5	91.3	(29.4-213.2)	Female	1	1.0	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.0	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.3	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	4.9	nc	(nc-nc)
Male	1	3.9	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	2.4	nc	(nc-nc)	Female	5	8.0	62.4	(20.1-145.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.7	nc	(nc-nc)	Male	123	121.3	101.4	(84.3-121.0)
Female	3	1.2	nc	(nc-nc)	Female	102	107.2	95.1	(77.5-115.5)
<b><u>Lung and Bronchus</u></b>									
Male	18	15.4	117.1	(69.4-185.1)					
Female	20	15.0	133.0	(81.2-205.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	16.7	77.8	(41.4-133.0)	Male	14	10.8	130.2	(71.1-218.5)
Female	2	4.9	nc	(nc-nc)	Female	10	6.7	148.7	(71.2-273.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	10	9.7	102.9	(49.2-189.2)
Female	63	54.6	115.5	(88.7-147.7)	Female	9	6.9	130.2	(59.4-247.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	2	7.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	1	2.9	nc	(nc-nc)
Male	7	15.1	46.3	(18.5-95.4)	<b><u>Ovary</u></b>				
Female	18	12.8	140.5	(83.2-222.1)	Female	6	4.1	147.2	(53.8-320.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	4.0	nc	(nc-nc)	Male	10	7.3	136.3	(65.3-250.7)
Female	1	1.0	nc	(nc-nc)	Female	5	5.8	85.6	(27.6-199.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	67	51.3	130.6	(101.2-165.9)
Female	0	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.8	nc	(nc-nc)
Male	5	8.7	57.2	(18.4-133.5)	Female	1	1.9	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.1	nc	(nc-nc)
Male	0	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	5	3.0	169.0	(54.5-394.5)
<b><u>Leukemia</u></b>					Female	5	6.9	72.4	(23.3-168.9)
Male	13	7.1	183.7	(97.7-314.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	4.4	nc	(nc-nc)	Female	6	12.7	47.2	(17.2-102.6)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.2	81.0	(26.1-189.0)	Male	200	208.5	95.9	(83.1-110.2)
Female	4	2.1	nc	(nc-nc)	Female	168	183.1	91.8	(78.4-106.7)
<b><u>Lung and Bronchus</u></b>									
Male	16	28.2	56.8	(32.5-92.3)					
Female	15	27.5	54.5	(30.5-89.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	25.6	93.9	(60.2-139.7)	Male	16	16.7	95.6	(54.6-155.2)
Female	5	8.1	61.9	(20.0-144.5)	Female	15	11.1	134.9	(75.4-222.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.7	149.0	(59.7-307.1)	Male	7	6.0	117.3	(47.0-241.7)
Female	2	3.5	nc	(nc-nc)	Female	1	4.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	20	15.3	131.1	(80.1-202.5)
Female	73	91.3	80.0	(62.7-100.5)	Female	8	11.5	69.8	(30.0-137.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.6	nc	(nc-nc)	Male	8	12.2	65.8	(28.3-129.6)
<b><u>Colon / Rectum</u></b>					Female	8	4.8	168.3	(72.4-331.6)
Male	21	23.6	89.2	(55.2-136.3)	<b><u>Ovary</u></b>				
Female	19	20.4	93.2	(56.1-145.6)	Female	7	6.7	104.2	(41.7-214.7)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.4	124.2	(53.5-244.7)	Male	16	11.5	139.3	(79.6-226.2)
Female	3	1.7	nc	(nc-nc)	Female	13	9.6	134.8	(71.7-230.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	100	85.2	117.4	(95.5-142.8)
Female	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	5.9	118.3	(47.4-243.8)
Male	14	14.2	98.7	(53.9-165.5)	Female	1	3.1	nc	(nc-nc)
Female	8	7.3	109.4	(47.1-215.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	1.9	nc	(nc-nc)
Male	4	3.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	9	4.9	182.8	(83.4-347.1)
<b><u>Leukemia</u></b>					Female	10	11.6	86.4	(41.4-158.9)
Male	15	10.9	137.9	(77.1-227.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	11	7.1	155.0	(77.3-277.4)	Female	26	21.4	121.3	(79.2-177.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	13	9.9	130.7	(69.5-223.6)	Male	353	331.7	106.4	(95.6-118.1)
Female	3	3.5	nc	(nc-nc)	Female	288	303.9	94.8	(84.2-106.4)
<b><u>Lung and Bronchus</u></b>									
Male	33	44.6	74.0	(50.9-104.0)					
Female	46	46.9	98.1	(71.9-130.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	19.8	80.8	(46.2-131.2)	Male	24	13.0	184.3	(118.0-274.2)
Female	5	7.1	69.9	(22.5-163.2)	Female	16	9.5	167.9	(95.9-272.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.7	134.4	(43.3-313.7)	Male	3	4.5	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	11	11.8	93.2	(46.4-166.7)
Female	91	75.9	119.9	(96.5-147.2)	Female	13	9.8	132.2	(70.3-226.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.2	nc	(nc-nc)	Male	6	9.5	63.5	(23.2-138.2)
<b><u>Colon / Rectum</u></b>					Female	6	4.1	146.8	(53.6-319.4)
Male	14	18.7	74.7	(40.8-125.3)	<b><u>Ovary</u></b>				
Female	29	18.7	155.1	(103.9-222.8)	Female	3	5.7	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	3	4.9	nc	(nc-nc)	Male	7	8.9	79.0	(31.6-162.7)
Female	2	1.5	nc	(nc-nc)	Female	7	8.5	82.7	(33.1-170.3)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	74	62.9	117.6	(92.3-147.6)
Female	2	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	4.6	109.1	(35.2-254.6)
Male	3	10.9	nc	(nc-nc)	Female	7	2.8	249.4	(99.9-514.0)
Female	5	6.2	80.8	(26.1-188.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	1.5	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	10	9.7	103.6	(49.6-190.6)
Male	7	8.6	81.2	(32.5-167.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	6.3	142.2	(64.9-270.0)	Female	13	17.3	75.2	(40.0-128.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	7.5	nc	(nc-nc)	Male	239	253.9	94.1	(82.6-106.9)
Female	4	3.0	nc	(nc-nc)	Female	291	258.2	112.7	(100.1-126.4)
<b><u>Lung and Bronchus</u></b>									
Male	22	33.4	65.8	(41.2-99.7)					
Female	35	38.8	90.3	(62.9-125.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	73	59.5	122.7	(96.2-154.3)	Male	61	41.6	146.6	(112.1-188.3)
Female	20	22.5	89.0	(54.3-137.4)	Female	64	33.5	190.8	(146.9-243.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	17	13.0	131.2	(76.4-210.1)	Male	11	14.4	76.4	(38.1-136.6)
Female	10	10.7	93.4	(44.7-171.8)	Female	13	11.8	110.1	(58.6-188.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	2.4	nc	(nc-nc)	Male	43	38.2	112.5	(81.4-151.5)
Female	283	273.0	103.7	(91.9-116.5)	Female	39	33.1	118.0	(83.9-161.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	8.8	68.3	(24.9-148.7)	Male	45	32.1	140.4	(102.4-187.9)
<b><u>Colon / Rectum</u></b>					Female	21	13.9	150.8	(93.3-230.5)
Male	76	60.2	126.2	(99.4-158.0)	<b><u>Ovary</u></b>				
Female	76	59.2	128.3	(101.1-160.6)	Female	22	20.0	110.0	(68.9-166.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	30	15.7	191.3	(129.0-273.1)	Male	32	27.7	115.5	(79.0-163.0)
Female	4	4.8	nc	(nc-nc)	Female	35	26.8	130.5	(90.9-181.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	8	4.4	181.2	(78.0-357.1)	Male	183	211.8	86.4	(74.3-99.9)
Female	3	3.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	15	14.6	102.5	(57.3-169.1)
Male	43	36.9	116.6	(84.3-157.0)	Female	9	9.1	99.4	(45.4-188.7)
Female	31	21.4	144.5	(98.2-205.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	13	7.3	177.6	(94.5-303.7)
Male	14	8.7	160.3	(87.5-268.9)	<b><u>Thyroid</u></b>				
Female	4	2.3	nc	(nc-nc)	Male	15	14.4	103.8	(58.1-171.2)
<b><u>Leukemia</u></b>					Female	37	39.2	94.5	(66.5-130.2)
Male	29	27.5	105.5	(70.6-151.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	23	20.7	111.3	(70.6-167.1)	Female	76	63.0	120.7	(95.1-151.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	26	24.9	104.5	(68.2-153.1)	Male	963	825.5	116.7	(109.4-124.3)
Female	17	9.9	171.6	(99.9-274.8)	Female	1055	890.2	118.5	(111.5-125.9)
<b><u>Lung and Bronchus</u></b>									
Male	147	105.1	139.9	(118.2-164.4)					
Female	186	129.5	143.7	(123.8-165.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	7	8.2	85.2	(34.1-175.5)	Female	0	1.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	8.2	61.3	(19.7-143.0)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.1	nc	(nc-nc)
Male	3	1.0	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.6	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	18	30.0	60.1	(35.6-95.0)
Female	0	0.3	nc	(nc-nc)	Female	17	27.1	62.7	(36.5-100.4)
<b><u>Lung and Bronchus</u></b>									
Male	1	3.9	nc	(nc-nc)					
Female	3	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	13.2	182.2	(116.7-271.1)	Male	4	9.6	nc	(nc-nc)
Female	5	4.7	106.5	(34.3-248.5)	Female	10	7.8	128.9	(61.7-237.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	5	2.6	193.8	(62.5-452.3)	Female	2	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	8	9.0	88.9	(38.3-175.3)
Female	76	64.5	117.9	(92.9-147.6)	Female	6	7.4	81.6	(29.8-177.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.2	nc	(nc-nc)	Male	12	7.7	155.4	(80.2-271.5)
<b><u>Colon / Rectum</u></b>					Female	6	3.2	190.1	(69.4-413.8)
Male	17	14.3	119.3	(69.4-191.0)	<b><u>Ovary</u></b>				
Female	15	12.8	117.2	(65.5-193.3)	Female	10	4.7	214.8	(102.8-395.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	8	6.3	127.0	(54.7-250.3)
Female	2	1.0	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	49	49.6	98.8	(73.1-130.6)
Female	2	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	3.4	nc	(nc-nc)
Male	5	8.9	56.4	(18.2-131.7)	Female	2	2.0	nc	(nc-nc)
Female	12	4.9	243.8	(125.8-425.8)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.1	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	10.0	110.2	(54.9-197.2)
Male	5	6.5	76.9	(24.8-179.4)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	4.6	nc	(nc-nc)	Female	12	14.8	81.3	(42.0-142.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	5.8	137.7	(59.3-271.4)	Male	226	192.8	117.2	(102.5-133.6)
Female	2	2.2	nc	(nc-nc)	Female	256	203.0	126.1	(111.1-142.5)
<b><u>Lung and Bronchus</u></b>									
Male	37	23.8	155.3	(109.3-214.1)					
Female	45	28.4	158.6	(115.7-212.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	23	20.4	112.5	(71.3-168.8)	Male	12	13.4	89.4	(46.1-156.2)
Female	3	7.3	nc	(nc-nc)	Female	6	9.8	61.1	(22.3-133.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.8	132.4	(42.7-309.0)	Male	4	4.7	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	13	12.2	106.7	(56.8-182.5)
Female	93	78.8	118.0	(95.3-144.6)	Female	15	10.1	148.4	(83.0-244.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.3	nc	(nc-nc)	Male	1	9.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	6	4.2	142.5	(52.0-310.1)
Male	17	19.0	89.4	(52.1-143.2)	<b><u>Ovary</u></b>				
Female	19	18.6	102.0	(61.4-159.2)	Female	7	5.9	118.9	(47.6-245.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	5.1	98.0	(31.6-228.7)	Male	12	9.2	130.9	(67.5-228.6)
Female	2	1.5	nc	(nc-nc)	Female	8	8.6	92.9	(40.0-183.0)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.2	nc	(nc-nc)	Male	57	66.9	85.2	(64.5-110.4)
Female	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	6	4.7	127.0	(46.4-276.5)
Male	15	11.3	133.2	(74.5-219.7)	Female	0	2.8	nc	(nc-nc)
Female	4	6.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.5	nc	(nc-nc)
Male	2	2.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	4	10.0	nc	(nc-nc)
Male	10	8.8	114.0	(54.6-209.7)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	6	6.4	93.9	(34.3-204.4)	Female	22	18.4	119.7	(75.0-181.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	6	7.9	75.8	(27.7-165.0)	Male	245	264.0	92.8	(81.6-105.2)
Female	0	3.1	nc	(nc-nc)	Female	259	266.3	97.3	(85.8-109.9)
<b><u>Lung and Bronchus</u></b>									
Male	33	35.1	94.0	(64.7-132.0)					
Female	35	40.5	86.5	(60.2-120.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	20	15.0	133.3	(81.4-205.9)	Female	2	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	5	1.7	287.9	(92.8-672.0)
<b><u>Colon / Rectum</u></b>					Female	0	0.8	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	5	3.2	158.4	(51.1-369.7)	Female	0	1.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	16	12.2	130.6	(74.6-212.2)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	0.8	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	1.9	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	1.1	450.8	(145.3-1051.9)	Female	4	3.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	56	45.2	123.8	(93.5-160.8)
Female	0	0.6	nc	(nc-nc)	Female	59	48.8	120.8	(92.0-155.8)
<b><u>Lung and Bronchus</u></b>									
Male	11	5.9	186.6	(93.0-333.8)					
Female	7	7.4	94.7	(37.9-195.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	10.5	114.2	(58.9-199.5)	Male	6	6.5	92.5	(33.8-201.4)
Female	5	3.8	131.3	(42.3-306.5)	Female	5	4.7	106.5	(34.3-248.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	4	1.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	5.9	101.7	(37.1-221.4)
Female	35	36.0	97.3	(67.7-135.3)	Female	7	5.1	137.9	(55.3-284.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.0	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	4	2.0	nc	(nc-nc)
Male	8	8.9	90.2	(38.9-177.8)	<b><u>Ovary</u></b>				
Female	7	9.3	75.0	(30.0-154.5)	Female	3	2.8	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	1	2.4	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	6	4.5	133.6	(48.8-290.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	35	30.5	114.7	(79.8-159.5)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	4	2.3	nc	(nc-nc)
Male	7	5.0	139.6	(55.9-287.7)	Female	1	1.4	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	0.9	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	1	4.4	nc	(nc-nc)
Male	3	4.3	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	3.3	nc	(nc-nc)	Female	8	8.5	94.1	(40.5-185.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	2	3.6	nc	(nc-nc)	Male	131	125.8	104.1	(87.1-123.6)
Female	1	1.6	nc	(nc-nc)	Female	116	129.1	89.9	(74.3-107.8)
<b><u>Lung and Bronchus</u></b>									
Male	18	17.4	103.7	(61.4-163.9)					
Female	13	20.8	62.5	(33.3-106.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	24	25.4	94.3	(60.4-140.4)	Male	18	17.9	100.8	(59.7-159.3)
Female	10	8.6	116.4	(55.7-214.1)	Female	9	13.2	68.1	(31.1-129.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	5.6	107.7	(39.3-234.5)	Male	4	6.1	nc	(nc-nc)
Female	8	4.3	187.3	(80.6-369.1)	Female	9	4.5	198.7	(90.7-377.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	20	16.4	121.9	(74.4-188.2)
Female	104	107.2	97.0	(79.3-117.6)	Female	14	12.8	109.6	(59.9-184.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.5	nc	(nc-nc)	Male	13	13.9	93.8	(49.9-160.4)
<b><u>Colon / Rectum</u></b>					Female	3	5.4	nc	(nc-nc)
Male	24	26.1	92.0	(58.9-136.9)	<b><u>Ovary</u></b>				
Female	25	23.3	107.2	(69.4-158.3)	Female	8	7.9	101.8	(43.8-200.6)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.7	119.2	(51.3-235.0)	Male	14	11.9	118.0	(64.4-197.9)
Female	4	1.9	nc	(nc-nc)	Female	7	10.3	68.2	(27.3-140.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	74	90.0	82.2	(64.6-103.2)
Female	0	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	5	6.3	79.6	(25.6-185.7)
Male	22	15.8	138.8	(87.0-210.2)	Female	1	3.5	nc	(nc-nc)
Female	14	8.4	167.5	(91.5-281.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	3.0	nc	(nc-nc)
Male	3	3.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	7	6.1	113.9	(45.6-234.6)
<b><u>Leukemia</u></b>					Female	14	15.9	88.3	(48.2-148.2)
Male	9	11.9	75.8	(34.6-144.0)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	4	8.1	nc	(nc-nc)	Female	14	24.5	57.1	(31.2-95.9)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	10.7	46.9	(15.1-109.3)	Male	324	353.3	91.7	(82.0-102.3)
Female	4	3.8	nc	(nc-nc)	Female	331	346.8	95.4	(85.4-106.3)
<b><u>Lung and Bronchus</u></b>									
Male	39	44.7	87.2	(62.0-119.3)					
Female	48	49.0	98.1	(72.3-130.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	5	10.4	48.2	(15.5-112.6)	Male	6	7.5	80.4	(29.3-174.9)
Female	4	3.4	nc	(nc-nc)	Female	3	5.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.4	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.9	101.2	(40.5-208.4)
Female	57	44.3	128.7	(97.5-166.7)	Female	5	5.2	96.9	(31.2-226.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.5	nc	(nc-nc)	Male	7	6.0	117.4	(47.0-241.8)
<b><u>Colon / Rectum</u></b>					Female	0	2.2	nc	(nc-nc)
Male	21	10.9	192.8	(119.3-294.7)	<b><u>Ovary</u></b>				
Female	23	9.0	254.9	(161.5-382.4)	Female	2	3.2	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	2.8	211.9	(77.4-461.3)	Male	6	4.9	121.8	(44.5-265.0)
Female	1	0.7	nc	(nc-nc)	Female	6	4.0	148.9	(54.4-324.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	30	38.9	77.2	(52.1-110.2)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	3	2.6	nc	(nc-nc)
Male	5	6.8	73.9	(23.8-172.4)	Female	1	1.4	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	1	1.5	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	5	2.7	182.0	(58.7-424.8)
<b><u>Leukemia</u></b>					Female	7	6.7	104.1	(41.7-214.5)
Male	9	5.0	180.7	(82.5-343.1)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	3	3.2	nc	(nc-nc)	Female	5	10.2	49.0	(15.8-114.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	9	4.6	197.7	(90.2-375.4)	Male	166	149.6	111.0	(94.7-129.2)
Female	0	1.5	nc	(nc-nc)	Female	157	141.1	111.2	(94.5-130.1)
<b><u>Lung and Bronchus</u></b>									
Male	28	18.7	150.0	(99.7-216.8)					
Female	23	20.0	114.9	(72.8-172.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	24.8	52.3	(27.8-89.5)	Male	21	17.0	123.7	(76.5-189.0)
Female	5	9.2	54.4	(17.5-127.0)	Female	15	12.9	115.9	(64.8-191.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.2	96.0	(30.9-224.1)	Male	5	5.9	84.9	(27.4-198.2)
Female	5	4.2	119.7	(38.6-279.3)	Female	3	4.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.0	nc	(nc-nc)	Male	14	15.6	89.9	(49.1-150.9)
Female	108	104.6	103.3	(84.7-124.7)	Female	10	13.0	76.9	(36.8-141.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	3.3	nc	(nc-nc)	Male	12	12.8	93.6	(48.3-163.5)
<b><u>Colon / Rectum</u></b>					Female	9	5.4	165.3	(75.4-313.8)
Male	16	24.7	64.7	(37.0-105.1)	<b><u>Ovary</u></b>				
Female	19	24.6	77.3	(46.5-120.7)	Female	6	7.7	77.8	(28.4-169.4)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	5	6.4	78.4	(25.3-183.0)	Male	11	11.4	96.7	(48.2-173.0)
Female	3	1.9	nc	(nc-nc)	Female	15	10.9	137.4	(76.8-226.6)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	74	83.9	88.2	(69.2-110.7)
Female	4	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	6.0	133.7	(57.6-263.5)
Male	8	14.8	54.0	(23.3-106.4)	Female	1	3.7	nc	(nc-nc)
Female	2	8.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	4	2.4	nc	(nc-nc)
Male	4	3.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	9	5.5	163.0	(74.4-309.5)
<b><u>Leukemia</u></b>					Female	10	14.2	70.5	(33.8-129.7)
Male	8	11.4	70.4	(30.3-138.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	9	8.4	107.0	(48.8-203.2)	Female	15	23.5	63.9	(35.7-105.4)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	10.0	50.1	(16.1-116.9)	Male	268	334.1	80.2	(70.9-90.4)
Female	1	3.9	nc	(nc-nc)	Female	294	346.9	84.8	(75.3-95.0)
<b><u>Lung and Bronchus</u></b>									
Male	17	43.0	39.5	(23.0-63.3)					
Female	32	50.2	63.7	(43.6-89.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Windsor

## Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	4	4.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.5	90.2	(29.1-210.5)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.3	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	2	0.6	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	16	19.7	81.4	(46.5-132.1)
Female	0	0.2	nc	(nc-nc)	Female	13	14.5	89.9	(47.8-153.8)
<b><u>Lung and Bronchus</u></b>									
Male	4	2.6	nc	(nc-nc)					
Female	0	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	23.8	121.7	(81.5-174.8)	Male	21	16.3	128.7	(79.6-196.7)
Female	8	8.2	97.6	(42.0-192.3)	Female	19	12.0	158.1	(95.1-246.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.9	nc	(nc-nc)	Male	2	5.7	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	7	4.4	160.2	(64.2-330.0)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.0	nc	(nc-nc)	Male	12	14.9	80.5	(41.5-140.6)
Female	97	99.4	97.6	(79.1-119.0)	Female	12	12.0	99.9	(51.5-174.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.0	nc	(nc-nc)	Male	12	12.4	96.9	(50.0-169.2)
<b><u>Colon / Rectum</u></b>					Female	4	5.1	nc	(nc-nc)
Male	26	23.3	111.4	(72.8-163.3)	<b><u>Ovary</u></b>				
Female	25	21.1	118.7	(76.8-175.3)	Female	5	7.3	68.7	(22.1-160.3)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	7	6.2	112.7	(45.2-232.3)	Male	12	11.0	109.1	(56.3-190.6)
Female	0	1.8	nc	(nc-nc)	Female	8	9.8	81.6	(35.1-160.8)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	51	83.9	60.8	(45.2-79.9)
Female	4	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	8	5.8	139.1	(59.9-274.0)
Male	13	14.3	91.0	(48.4-155.7)	Female	4	3.2	nc	(nc-nc)
Female	13	7.9	165.3	(87.9-282.7)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	2.5	nc	(nc-nc)
Male	2	3.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	8	5.4	149.0	(64.2-293.7)
<b><u>Leukemia</u></b>					Female	14	13.4	104.8	(57.2-175.8)
Male	8	10.7	75.0	(32.3-147.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	7.4	94.7	(37.9-195.1)	Female	23	23.6	97.6	(61.9-146.5)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	8	9.8	81.6	(35.1-160.7)	Male	296	324.3	91.3	(81.2-102.3)
Female	3	3.7	nc	(nc-nc)	Female	335	323.8	103.5	(92.7-115.1)
<b><u>Lung and Bronchus</u></b>									
Male	57	42.1	135.5	(102.7-175.6)					
Female	50	48.5	103.1	(76.5-135.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	45	43.5	103.4	(75.4-138.4)	Male	27	30.2	89.3	(58.8-129.9)
Female	14	16.9	82.6	(45.1-138.7)	Female	23	24.2	95.1	(60.2-142.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	13	9.4	138.9	(73.9-237.5)	Male	13	10.3	126.2	(67.1-215.8)
Female	14	7.7	182.6	(99.8-306.5)	Female	6	8.5	70.6	(25.8-153.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	18	27.6	65.2	(38.6-103.0)
Female	165	190.0	86.8	(74.1-101.1)	Female	32	24.1	132.7	(90.7-187.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	6.2	80.4	(25.9-187.7)	Male	24	22.4	107.0	(68.5-159.2)
<b><u>Colon / Rectum</u></b>					Female	7	10.1	69.5	(27.9-143.3)
Male	37	43.5	85.1	(59.9-117.3)	<b><u>Ovary</u></b>				
Female	44	44.6	98.7	(71.7-132.5)	Female	14	14.2	98.6	(53.9-165.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	13	11.1	116.6	(62.0-199.4)	Male	26	19.9	130.3	(85.1-191.0)
Female	7	3.6	194.7	(78.0-401.3)	Female	19	20.1	94.5	(56.8-147.5)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	3.3	nc	(nc-nc)	Male	124	146.9	84.4	(70.2-100.7)
Female	2	2.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	11	10.5	104.6	(52.2-187.2)
Male	36	26.1	138.1	(96.7-191.2)	Female	7	6.8	103.7	(41.5-213.6)
Female	13	15.3	85.0	(45.2-145.3)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	8	5.9	136.6	(58.8-269.2)
Male	6	6.1	97.8	(35.7-212.9)	<b><u>Thyroid</u></b>				
Female	0	1.6	nc	(nc-nc)	Male	8	10.5	76.4	(32.9-150.5)
<b><u>Leukemia</u></b>					Female	33	27.5	120.0	(82.6-168.6)
Male	16	19.9	80.2	(45.8-130.3)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	13	15.4	84.6	(45.0-144.7)	Female	50	43.3	115.5	(85.7-152.3)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	20	17.5	114.2	(69.7-176.3)	Male	567	589.6	96.2	(88.4-104.4)
Female	14	7.2	194.8	(106.4-326.9)	Female	630	638.7	98.6	(91.1-106.7)
<b><u>Lung and Bronchus</u></b>									
Male	85	75.2	113.0	(90.3-139.7)					
Female	92	93.5	98.4	(79.3-120.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	155	153.4	101.0	(85.7-118.2)	Male	83	110.9	74.8	(59.6-92.8)
Female	65	55.6	116.8	(90.1-148.9)	Female	84	89.0	94.3	(75.3-116.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	45	38.0	118.3	(86.3-158.3)	Male	49	37.5	130.5	(96.5-172.5)
Female	22	30.1	73.2	(45.8-110.8)	Female	35	29.0	120.6	(84.0-167.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	4	6.4	nc	(nc-nc)	Male	106	103.4	102.6	(84.0-124.0)
Female	686	697.2	98.4	(91.2-106.0)	Female	89	84.4	105.4	(84.7-129.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	42	25.1	167.4	(120.6-226.2)	Male	105	85.4	122.9	(100.5-148.8)
<b><u>Colon / Rectum</u></b>					Female	43	35.6	120.9	(87.5-162.9)
Male	152	161.8	93.9	(79.6-110.1)	<b><u>Ovary</u></b>				
Female	157	152.6	102.9	(87.4-120.3)	Female	52	51.9	100.2	(74.9-131.5)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	41	40.7	100.7	(72.2-136.6)	Male	84	72.1	116.5	(93.0-144.3)
Female	13	11.9	108.8	(57.9-186.1)	Female	69	66.5	103.8	(80.8-131.4)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	13	15.8	82.3	(43.8-140.8)	Male	586	548.8	106.8	(98.3-115.8)
Female	12	13.3	90.0	(46.4-157.1)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	40	38.6	103.6	(74.0-141.1)
Male	107	99.2	107.9	(88.4-130.4)	Female	25	23.1	108.0	(69.9-159.4)
Female	67	54.5	122.9	(95.2-156.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	20	28.4	70.5	(43.0-108.9)
Male	26	22.9	113.7	(74.2-166.6)	<b><u>Thyroid</u></b>				
Female	10	5.7	174.6	(83.6-321.0)	Male	43	43.1	99.9	(72.3-134.5)
<b><u>Leukemia</u></b>					Female	122	117.0	104.3	(86.6-124.6)
Male	64	75.8	84.4	(65.0-107.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	59	54.5	108.2	(82.4-139.6)	Female	199	155.7	127.8	(110.6-146.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	119	65.0	183.0	(151.6-218.9)	Male	2370	2192.6	108.1	(103.8-112.5)
Female	41	24.6	166.6	(119.6-226.1)	Female	2512	2280.5	110.2	(105.9-114.5)
<b><u>Lung and Bronchus</u></b>									
Male	352	270.4	130.2	(116.9-144.5)					
Female	394	315.2	125.0	(113.0-138.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	5	7.0	71.6	(23.1-167.1)	Female	2	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.4	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	2	1.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.8	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	2	0.5	nc	(nc-nc)	Female	5	1.8	283.6	(91.4-661.7)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	17	26.1	65.0	(37.9-104.1)
Female	1	0.3	nc	(nc-nc)	Female	23	22.7	101.5	(64.3-152.3)
<b><u>Lung and Bronchus</u></b>									
Male	3	3.4	nc	(nc-nc)					
Female	3	3.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	12.7	70.8	(32.3-134.4)	Male	13	8.9	145.5	(77.4-248.8)
Female	5	4.7	107.3	(34.6-250.3)	Female	8	6.7	118.8	(51.2-234.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	2.8	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	7	8.3	84.8	(34.0-174.7)
Female	60	54.6	109.9	(83.9-141.5)	Female	7	6.7	104.7	(42.0-215.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	8	7.2	111.3	(47.9-219.3)
<b><u>Colon / Rectum</u></b>					Female	1	2.8	nc	(nc-nc)
Male	16	13.1	122.0	(69.7-198.1)	<b><u>Ovary</u></b>				
Female	9	12.4	72.6	(33.1-137.9)	Female	5	4.0	123.8	(39.9-289.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	6	3.4	174.6	(63.7-380.0)	Male	6	6.0	99.4	(36.3-216.5)
Female	0	1.0	nc	(nc-nc)	Female	7	5.5	126.1	(50.5-259.9)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	50	47.5	105.2	(78.1-138.7)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	2	3.2	nc	(nc-nc)
Male	9	8.1	110.8	(50.5-210.3)	Female	1	1.9	nc	(nc-nc)
Female	7	4.3	161.6	(64.7-332.9)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	1.3	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	6	3.1	194.9	(71.2-424.3)
<b><u>Leukemia</u></b>					Female	8	7.5	107.1	(46.1-211.0)
Male	6	5.9	101.3	(37.0-220.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	5	4.2	117.9	(38.0-275.1)	Female	14	12.6	110.9	(60.6-186.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	5.5	nc	(nc-nc)	Male	181	180.3	100.4	(86.3-116.1)
Female	1	2.0	nc	(nc-nc)	Female	181	179.7	100.7	(86.6-116.5)
<b><u>Lung and Bronchus</u></b>									
Male	11	22.8	48.3	(24.1-86.4)					
Female	27	26.1	103.6	(68.2-150.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2016-2020

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	56	44.1	126.9	(95.8-164.8)	Male	58	27.5	210.6	(159.9-272.3)
Female	11	16.0	68.5	(34.2-122.7)	Female	28	19.9	141.0	(93.7-203.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	7.2	111.5	(48.0-219.7)	Male	10	9.7	102.9	(49.3-189.2)
Female	8	6.0	132.4	(57.0-260.8)	Female	5	8.0	62.6	(20.2-146.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	22	24.7	89.0	(55.7-134.7)
Female	196	158.9	123.3	(106.7-141.9)	Female	27	21.6	125.1	(82.4-182.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.1	145.6	(53.2-316.8)	Male	24	18.3	131.0	(83.9-194.9)
<b><u>Colon / Rectum</u></b>					Female	12	8.8	137.0	(70.7-239.4)
Male	37	37.7	98.3	(69.2-135.5)	<b><u>Ovary</u></b>				
Female	37	38.6	95.9	(67.5-132.2)	Female	11	12.0	91.7	(45.7-164.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	12	10.4	115.1	(59.4-201.1)	Male	22	19.0	115.5	(72.4-174.9)
Female	7	3.3	210.2	(84.2-433.2)	Female	20	19.0	105.0	(64.1-162.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	158	132.3	119.4	(101.5-139.5)
Female	1	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	9.6	93.4	(42.6-177.3)
Male	23	21.8	105.5	(66.9-158.3)	Female	1	6.0	nc	(nc-nc)
Female	15	13.3	112.4	(62.9-185.5)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	2.6	nc	(nc-nc)
Male	2	5.3	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	4	1.4	nc	(nc-nc)	Male	8	7.1	112.8	(48.6-222.3)
<b><u>Leukemia</u></b>					Female	9	17.6	51.1	(23.3-97.0)
Male	25	17.8	140.1	(90.7-206.9)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	14	13.5	103.9	(56.8-174.4)	Female	30	38.2	78.5	(53.0-112.1)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	17	15.7	108.0	(62.9-172.9)	Male	592	534.0	110.9	(102.1-120.2)
Female	4	6.7	nc	(nc-nc)	Female	586	555.2	105.5	(97.2-114.4)
<b><u>Lung and Bronchus</u></b>									
Male	51	74.2	68.7	(51.1-90.3)					
Female	98	91.1	107.6	(87.4-131.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# **APPENDICES**

## APPENDIX I: SELECTED RESOURCES FOR INFORMATION ON CANCER

This Appendix contains a listing of selected resources for cancer information. Cancers are complex diseases, and many may have multiple factors contributing to their development.

For information on cancer risk factors or prevention, you may wish to contact the following:

Cancer Information Service (National Cancer Institute): 1-800-4-CANCER (1-800-422-6237)

Cancer Response Line (American Cancer Society): 1-800-ACS-2345 (1-800-227-2345)

In addition, the following selected Internet websites provide information on cancer. Many of these also provide links to other sites (not listed) which may be of interest.

**Massachusetts Department of Public Health:** <http://www.mass.gov/dph>

**American Cancer Society:** <http://www.cancer.org>

### **Centers for Disease Control and Prevention**

Home Page: <http://www.cdc.gov>

Cancer Prevention and Control Program: <http://www.cdc.gov/cancer>

Fruits and Veggies More Matters™ Campaign (nutrition – formerly 5-A-Day Program):  
<http://www.fruitsandveggiesmorematters.org/>

### **National Cancer Institute**

Information: <http://www.cancer.gov>

Cancer Literature in PubMed:

[https://www.ncbi.nlm.nih.gov/pubmed?cmd=current=Limits&pmfilter\\_Subsets=Cancer](https://www.ncbi.nlm.nih.gov/pubmed?cmd=current=Limits&pmfilter_Subsets=Cancer)

Surveillance, Epidemiology, and End Results (SEER) Program data: <http://seer.cancer.gov>

**Your Cancer Risk** (Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; formerly at Harvard Center for Cancer Prevention):

<http://www.yourdiseaserisk.wustl.edu>

**Oncolink** (Abramson Cancer Center of the University of Pennsylvania):

<http://www.oncolink.org>

**Cancerquest** (Emory University – Winship Cancer Institute): [www.cancerquest.org](http://www.cancerquest.org)

**National Coalition for Cancer Survivorship:** <http://www.canceradvocacy.org>



## APPENDIX II: MDPH CANCER PREVENTION AND CONTROL INITIATIVES

The Massachusetts Department of Public Health is working to reduce the incidence and mortality of cancer in the Commonwealth. Partnerships between MDPH programs, researchers, healthcare providers, and nonprofit organizations collect cancer information, lead quality improvement projects, coordinate evidenced-based workshops for managing living with chronic disease (including cancer), provide education for health professionals, and bring shared messages to the public. Our collaborated efforts focus on reducing cancer risk, incidence, and mortality through healthy lifestyles, early diagnosis, and increased access to care. The Department's programs address the impact of tobacco, alcohol, nutrition, and physical activity on cancer prevention, along with environmental and occupational hazards for cancer. Throughout, there is an emphasis on our efforts; we emphasize reducing disparate health outcomes and unequal access to cancer care.

### MDPH Bureaus and Programs:

Bureau of Climate and Environmental Health, [www.mass.gov/dph/environmental\\_health](http://www.mass.gov/dph/environmental_health)  
Bureau of Substance Abuse Services, [www.mass.gov/dph/bsas](http://www.mass.gov/dph/bsas)  
Comprehensive Cancer Control Program: [www.mass.gov/comprehensive-cancer-control-program](http://www.mass.gov/comprehensive-cancer-control-program)  
Massachusetts Breast and Cervical Cancer Program: [www.mass.gov/massachusetts-breast-and-cervical-cancer-program-mbccp](http://www.mass.gov/massachusetts-breast-and-cervical-cancer-program-mbccp)  
Tobacco Cessation and Prevention Program, [www.mass.gov/dph/mtcp](http://www.mass.gov/dph/mtcp)  
Occupational Health Surveillance Program, [www.mass.gov/dph/ohsp](http://www.mass.gov/dph/ohsp)  
Office of Elder Affairs: [www.mass.gov/elders/](http://www.mass.gov/elders/)  
Office of Oral Health: <https://www.mass.gov/orgs/office-of-oral-health>  
Division of Prevention and Wellness: [www.mass.gov/dph/healthpromotion](http://www.mass.gov/dph/healthpromotion)

MDPH cancer prevention and screening publications are available at the Massachusetts Health Promotion Clearinghouse, [www.maclearinghouse.com](http://www.maclearinghouse.com).

Massachusetts Cancer Registry Publications are available through the Massachusetts Cancer Registry website at [www.mass.gov/dph/mcr](http://www.mass.gov/dph/mcr).

